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Protein-sphingolipid interactions and their role in immunity and disease, Maria Shamin 
 
Sphingolipids are a diverse class of lipids involved in fundamental cellular processes. In addition to 
their role in membrane architecture, sphingolipids can act as bioactive molecules, regulate membrane 
protein function and be presented to the immune system as lipid antigens by CD1 family molecules. 
The critical importance of sphingolipids for cell function is highlighted by the catastrophic diseases 
that result from defects in sphingolipid metabolism.  
 
Lipid loading onto CD1d is facilitated by the lysosomal lipid transfer protein Saposin B, but the lipid 
loading mechanism is unknown. I used a range of highly sensitive biochemical assays to probe the 
interaction between CD1d and SapB. Interestingly, no direct interaction was detectable. Importantly, 
this suggests that additional proteins may promote their interaction. 
 
In addition to their role as antigens, sphingolipids have roles in immunity by regulating the trafficking 
and function of immune receptors. Krabbe disease, a neurodegenerative disease caused by loss of 
function of the lysosomal sphingolipid hydrolase GALC, is accompanied by immune defects possibly 
driven by phagocytic cell dysfunction. I investigated how GALC deficiency alters the phenotype and 
function of the phagocytic cell line THP-1. This study was compromised by substantial off-target 
effects caused by genetic manipulation of THP-1 cells. Characterising these off-target changes 
identified perturbations in sphingolipid metabolism pathways, confirming that these cell lines are not 
appropriate for further studies.  
 
The lysosomal enzyme acid ceramidase (AC) hydrolyses ceramide to sphingosine, thus regulating the 
levels of pro-apoptotic and pro-survival lipids. This role in apoptosis means that regulation of AC 
activity is of interest for cancer treatment. Although the structure of AC was recently determined, it is 
still unclear how it accesses membrane-embedded lipid substrates. I attempted to co-crystallise AC 
with Saposin A lipoprotein nanodiscs to understand this process. Although this system did not prove 
suitable for this project, I was able to determine the crystal structure of a new saposin oligomer 
highlighting even greater diversity of tertiary arrangement of these important lipid transfer proteins. 
I next asked whether AC processes galactosylceramide to psychosine, the cytotoxic GALC substrate 
accumulating in Krabbe disease, contributing to Krabbe disease pathology by increasing 
oligodendrocyte cell death. Surprisingly, I found that GALC knockout oligodendrocytes were not more 
 iv 
susceptible to cell death than wild-type oligodendrocytes, calling into question whether psychosine 
accumulation is the direct cause of oligodendrocyte cell death and demyelination in Krabbe disease.  
The sphingolipid-interacting adhesion protein PTPRM is lost at the surface of GALC-deficient 
oligodendrocytes, suggesting that specific sphingolipid-PTPRM interactions cause the mistrafficking of 
this adhesion protein in Krabbe disease oligodendrocytes, potentially contributing to demyelination. I 
probed the interaction of PTPRM with sphingolipids through X-ray crystallography studies and 
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1.1 Sphingolipids in normal cell function 
Sphingolipids are a very diverse class of lipids and an essential component of all eukaryotic cell 
membranes. Ceramide, the building block for complex sphingolipids, consists of a sphingoid backbone 
N-acylated with fatty acid (Fig. 1.1A). Complex sphingolipid species are formed by addition of various 
polar groups to the C1-hydroxyl position of ceramide (Fig. 1.1B). The major classes of complex 
sphingolipids are sphingomyelin, formed by addition of a phosphorylcholine head group; 
glycosphingolipids, formed by addition of mono-, di- or oligosaccharides to ceramide; and 
gangliosides, formed by addition of sialic acid residues to the carbohydrate head groups of 
glycosphingolipids. The diversity of sphingolipid species is further enhanced by differences in the 
length and degree of saturation the fatty acyl backbone, as well as variations in the sphingoid 
backbone1,2. These variations determine the biological functions of sphingolipids, underscoring the 
diversity of their roles. An additional layer of complexity is added by the compartmentalisation and 
dynamic regulation of individual sphingolipid species. 
 
 
Figure 1.1. Sphingolipid structure 
A. Skeletal formula of ceramide highlighting the sphingosine backbone and fatty acyl group. B. 
Skeletal formula of galactosylceramide. 
 
1.1.1 The lipid raft concept: organisation of proteins and lipids into membrane 
microdomains 
The primary function of lipids is to form a physical barrier between individual cells and their 
environment and segregate organelles from the cytosol. Sphingolipids contribute to this fundamental 
function and modulate the biophysical properties of membranes3. The majority of membrane lipids 
have kinked unsaturated hydrocarbon chains, adopting liquid-disordered membrane phase behaviour 
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characterised by low order and high fluidity. Sphingolipids have long, saturated or trans-
monounsaturated hydrocarbon chains forming a tall and narrow cylinder shape with polar head 
groups capable of forming hydrogen bonds. These properties allow sphingolipids to pack together at 
higher densities than unsaturated membrane lipids and adopt an ordered, gel-like phase in 
membranes. Complex sphingolipids such as sphingomyelin and glycosphingolipids are enriched in the 
outer leaflet of the plasma membrane and favourably interact with cholesterol, which fluidises the 
gel-like phase to form a liquid-ordered phase characterised by dense packing, high order and high 
fluidity3. These properties give the plasma membrane resistance to mechanical stress3. The favourable 
interaction of cholesterol with complex sphingolipids is explained by the “umbrella model”. The 
hydroxyl polar head group of cholesterol is too small to shield the bulky, hydrophobic sterol rings from 
water. Tight packing of cholesterol with complex sphingolipids covers the sterol rings under the 
"umbrella" formed by large polar head groups4. 
 
The preferential interaction between cholesterol and saturated glycolipids including complex 
sphingolipids has been hypothesised to promote the formation of tightly packed membrane domains 
with distinct lipid and protein compositions from the bulk membrane, named lipid rafts5. The "raft 
hypothesis" has generated considerable controversy since its formulation because these domains 
were initially observed in model membranes and systems, including detergent-insoluble membrane 
fractions posited to be lipid rafts, but these could not be visualised in live cells6. However, 
accumulating evidence for the existence of membrane rafts in cells comes from recent studies using 
fluorescent lipid and protein probes in live cell super-resolution microscopy experiments combined 
with studies on membrane blebs with a lipid and protein composition similar to the plasma 
membrane, known as giant plasma membrane vesicles. These studies show that segregated 
membrane domains enriched in cholesterol, sphingolipids and specific proteins exist but these are 
highly dynamic and very small (tens of nanometres), making direct observation challenging7.  
 
Lipid rafts appear to facilitate the recruitment of specific proteins and the exclusion of others. Several 
factors targeting proteins to lipid rafts have been identified: post-translational modifications such as 
glycosylphosphatidylinositol (GPI) anchoring and palmitoylation (reversible covalent attachment of 
GPI or a fatty acid molecule, respectively), as well as transmembrane domain length and surface area7-
9. Lipid rafts were originally thought to serve as a platform for cargo protein sorting and initiation of 
vesicular transport from the trans Golgi network to the plasma membrane10. The evidence for a central 
role of lipid rafts for this process is still inconclusive11. However, lipid rafts have been implicated in 
protein recycling from endosomes to the plasma membrane. The evidence supporting this is that 
 3 
shortening of the transmembrane domain of a plasma membrane lipid raft protein is sufficient to 
exclude it from lipid rafts and results in its mistargeting to the lysosome12.  
 
A well-documented role for lipid rafts is the assembly of cell signalling platforms facilitating signal 
transduction. A number of transmembrane receptors, and in particular immune receptors, have been 
shown to associate with lipid rafts upon activation. Super-resolution microscopy of live B-cells showed 
that clustering of the B-cell receptor facilitates the stabilisation of an ordered lipid domain, thereby 
bringing antigen-bound B-cell receptors in close proximity with raft-associated activating signalling 
proteins and away from raft-excluded inhibitory regulators, resulting in downstream B-cell receptor 
signalling13. Evidence suggests that innate pattern recognition receptors of the Toll-like receptor (TLR) 
family also localise to lipid rafts upon stimulation. TLR4 is activated by bacterial lipopolysaccharide 
(LPS) binding to the TLR4 co-receptor MD-2. LPS is initially extracted by LPS-binding protein (LBP) and 
is transferred to the raft-associated, GPI-anchored protein CD14. Upon LPS binding, CD14 has been 
shown to recruit TLR4 to lipid rafts, transferring LPS to the TLR4:MD-2 complex and bringing TLR4 in 
proximity to activator proteins14,15. Reduction of cholesterol, sphingomyelin or glucosylceramide 
(GluCer) levels reduced the response of macrophages to LPS, indicating that these lipids are necessary 
for LPS-induced TLR signalling14,16-18. Köberlin et al. observed that perturbations to sphingolipid 
metabolism led to changes in TLR4 internalisation after LPS stimulation19. Accumulation of cholesterol 
in macrophages causes enhanced signalling of TLR4 but also TLR2, TLR7 and TLR9, suggesting the 
function of these receptors may also be regulated by cholesterol-enriched lipid rafts20.  
 
A distinction has been made between lipid rafts and ceramide enriched lipid domains, named 
ceramide-rich platforms. The head group of sphingomyelin can be cleaved by sphingomyelinases to 
form ceramide within lipid rafts at the plasma membrane. Sphingomyelinases can be activated by a 
number of stimuli such as the engagement of TNF receptor superfamily members including TNF-α 
receptor 1, the T-cell co-stimulatory receptor CD40 and the death receptors Fas and CD95, as well as 
stress stimuli including ultraviolet light and oxidative stress21,22. Ceramide has distinct biophysical 
properties from sphingomyelin and glycosphingolipids. Due to its small polar head group, ceramide is 
thought to displace cholesterol from lipid rafts, thereby decreasing membrane fluidity within lipid rafts 
and potentially modifying their protein content21,23. Ceramide is known to increase membrane 
permeability and introduce negative curvature21. It is also unique among sphingolipids in its capacity 
to spontaneously translocate to the inner leaflet of the plasma membrane, where it can interact with 
cytosolic proteins21. Finally, ceramide promotes the clustering of small nanodomains to form larger 
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microdomains in model membranes24. This facilitates the clustering of receptors and signalling 
molecules25-27.  
 
It is unclear if distinct receptors preferentially associate with sphingolipid domains of different 
composition. Considering the huge variety of sphingolipids, lipid rafts are likely to be heterogeneous 
and serve different functions. Our understanding of the roles of individual sphingolipid species and 
other glycolipid classes in lipid rafts is still very limited due to the lack of appropriate tools to study 
these differences.  
 
1.1.2 The ceramide/sphingosine-1-phosphate cell death rheostat 
Ceramide, sphingosine and their phosphorylated derivatives sphingosine-1-phosphate (S1P) and 
ceramide-1-phosphate (C1P) are interconvertible sphingolipid species regulating a cell death rheostat 
(Fig. 1.2). Ceramide has a well-documented role in mediating cell death. Although the molecular 
mechanisms of ceramide-mediated cell death are not fully understood, they are thought to involve 
mitochondrial membrane perturbation and/or triggering of cell death signalling in a cell-type, cellular 
compartment and ceramide species-dependent manner2,28. Cell death signalling may be promoted by 
the formation of ceramide-rich platforms activating signal transduction by death receptors as well as 
spontaneous flipping of ceramide to the cytoplasmic leaflet where it can initiate cell death signalling 
cascades21. Ceramide phosphorylation by ceramide kinase produces C1P, a pro-inflammatory and pro-
survival lipid2. 
 
Ceramide catabolism forms sphingosine, which also possesses pro-apoptotic properties28. Sphingosine 
can in turn be converted to S1P by sphingosine kinases. S1P is an anti-apoptotic immune signalling 
molecule which promotes cell survival and migration via its action on G protein-coupled S1P receptors 
(S1PR). S1P is produced intracellularly and exported to the outer leaflet of the plasma membrane by 
transporters including ATP-binding cassette transporters and spinster homolog 2 (SPNS2)29, resulting 
in autocrine activation of S1PRs on the same cell. Structural evidence indicates that S1P accesses the 
binding site of S1PR1 by lateral diffusion within the plasma membrane30. Additionally, S1P can be 
extracted from the plasma membrane by lipid transfer proteins such as Apolipoprotein M. Lipoprotein 
complexes can then diffuse in the extracellular environment for autocrine and paracrine action31. S1P 
is more hydrophilic than other sphingolipids and has therefore been proposed to diffuse freely in the 
aqueous environment32; however, the majority of plasma S1P is associated with lipoproteins33. S1PR-
independent intracellular actions of S1P have also been documented but their physiological relevance 




Figure 1.2. The sphingolipid cell death rheostat 
Cell death and survival is regulated by the levels of pro-apoptotic ceramide and sphingosine and 
anti-apoptotic ceramide-1-phosphate (C1P) and sphingosine-1-phosphate (S1P). The interconversion 
of these sphingolipids is mediated by the action of ceramidases, ceramide synthases, kinases and 
phosphatases.  
 
The levels of ceramide, sphingosine, C1P and S1P controlling the cell death rheostat is dynamically 
regulated by the action of sphingomyelinases, ceramide synthases, ceramidases, sphingosine and 
ceramide kinases, phosphatases and S1P lyases (Fig. 1.2). One of these players, acid ceramidase, will 
be described further in section 1.6. 
 
1.1.3 Specific interactions between proteins and sphingolipids 
An emerging concept in the field is that membrane-embedded sphingolipids can directly interact with 
membrane proteins. The first example of a sequence-specific interaction is the sphingolipid-binding 
motif VXXTLXXIY in the transmembrane helix of the vesicular transport protein p24. This motif 
mediates specific binding to a single species of sphingomyelin (d18:1/18:0) via binding of the 
transmembrane helix of p24 to both the lipid head group and the hydrocarbon chains of 
sphingomyelin. Sphingomyelin binding promotes the homodimerisation of p24 and regulates vesicular 
trafficking34. Subsequently, several transmembrane receptors containing a similar motif were 
confirmed to bind sphingolipids35,36. Among these, the lysosomal ceramide exporter Lysosome 
Associated Protein Transmembrane 4B (LAPTM4B) was found to bind ceramide. Ceramide binding 
induces a conformational change in the transmembrane region of LAPTM4B and promotes its 
dimerisation with the leucine transporter 4F2hc/LAT1, resulting in mTORC activation37. Sequence 
analysis also indicates that TLR3 and TLR5 possess a sphingolipid-binding motif within their 
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transmembrane domain38, although whether it mediates specific binding to sphingolipids and the 
functional consequences of sphingolipid binding have not yet been investigated.  
 
Sphingolipids, and in particular gangliosides, have been found to modulate the function of G protein-
coupled receptors (GPCRs) through specific interactions. The ganglioside GM1 is thought to modulate 
the function of the serotonin1A receptor through binding to a sphingolipid-binding motif39,40. The 
epidermal growth factor receptor (EGFR) is maintained in its resting state in the absence of ligand by 
two separate lateral interactions with the head group of the ganglioside GM3: the first through a 
membrane-proximal lysine residue41, and the second through terminal N-acetylglucosamine residues 
on EGFR N-linked glycans42, demonstrating that protein glycosylation can contribute to sphingolipid 
binding. Besides regulating transmembrane protein oligomerisation and function, it is conceivable 
that specific interactions with sphingolipids may regulate the stability of transmembrane proteins or 
target them to lipid rafts, although these mechanisms have not yet been demonstrated. 
 
Sphingolipid-protein interactions can also mediate intercellular binding. Circulating phagocytes exit 
the bloodstream and access inflammatory sites in tissues by a complex process involving binding of 
surface sialofucosylated glycans attached to proteins and lipids including gangliosides to the protein 
E-selectin expressed on the surface of endothelial cells43. In the nervous system, the myelin-associated 
glycoprotein facilitates the wrapping of the myelin sheath around neuronal axons by specifically 
binding to the gangliosides GD1a and GT1b on the apposed neuronal membrane44. Moreover, 
sulfatide exposed on the surface of apoptotic cells facilitates their phagocytosis by macrophages, 
probably via an interaction between a macrophage scavenger receptor and the sulfatide head group45. 
Several pathogens exploit sphingolipids as cellular entry receptors. For example, the human 
immunodeficiency virus envelope protein gp120 can bind galactosylceramide (GalCer) and 
globotriaosylceramide (Gb3) for viral entry46 and Shigella targets activated CD4+ T-cells through 
binding of the gangliosides GM1 and GM3 on the activated T-cell surface47. 
 
1.2 Sphingolipid synthesis and transport to the plasma membrane 
The synthesis of sphingolipids is a complex stepwise and compartmentalised process, involving 
regulated sphingolipid transport and numerous synthetic enzymes working in a sequential manner. 
While the sphingolipid synthetic pathway is well understood, our understanding of sphingolipid 
trafficking pathways is still being refined. De novo synthesis of sphingolipids begins with formation of 
ceramide through a series of reactions on the cytosolic face of the endoplasmic reticulum (ER). 
Ceramide can translocate to the ER lumen, where it is used to synthesise GalCer by UDP-
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galactose:ceramide galactosyltransferase 8 (UGT8)48. GalCer is transported to the Golgi apparatus by 
vesicular transport, where it can be sulfated to form sulfatide. Alternatively, ceramide is transported 
to the Golgi apparatus, where it is converted to sphingomyelin or GluCer. Ceramide transport from 
the ER to the trans Golgi network for sphingomyelin synthesis is effected through the action of 
ceramide transport protein (CERT). The C-terminal START domain of CERT extracts ceramide from ER 
membranes and transports it to trans Golgi regions at ER–Golgi membrane contact sites49,50. Ceramide 
is also thought to be transported to the cis Golgi network by vesicular transport for GluCer synthesis51. 
GluCer is then transported to the trans Golgi by the lipid transfer protein 4-phosphate adaptor protein 
2 (FAPP2) for synthesis of complex glycosphingolipids and subsequent vesicular transport to the 
plasma membrane52.  
 
1.3 Sphingolipid degradation 
Sphingolipid degradation and recycling is essential for the maintenance of sphingolipid homeostasis. 
The major sphingolipid degradative pathway occurs in the lysosome, where sphingolipids are 
subjected to sequential degradation by lysosomal sphingolipid hydrolases with the help of the lipid 
transfer proteins GM2 activator (GM2A) and saposins. Sphingolipids are trafficked to lysosomal 
compartments through vesicular trafficking pathways including endocytic, phagocytic and autophagic 
pathways53,54. The limiting membrane of the lysosome is protected from hydrolysis by the glycocalyx, 
a dense layer of oligosaccharides on the luminal side of lysosomal membrane glycoproteins55. The 
generation of sphingolipid-enriched intraluminal vesicles by inner budding of endosomal membranes 
renders these lipids accessible to lysosomal hydrolases53. Intraluminal vesicle membranes have high 
curvature, high concentration of the anionic phospholipid bis(monoacylglycero)phosphate (BMP) and 
low concentration of cholesterol. These conditions, combined with the low pH of the lysosome, 
promote the activity of sphingolipid hydrolases and saposins53. 
 
Sphingosine, the final product of sphingolipid catabolism, can exit the lysosome and enter the 
sphingolipid salvage pathway by re-acylation of sphingosine to form ceramide on the cytosolic face of 
the ER. The salvage pathway contributes to 50% to 90% of sphingolipid biosynthesis56. The 
mechanisms of sphingosine efflux from the lysosome and delivery to the ER have not yet been 
identified. The lysosomal cholesterol exporter NPC1 has been proposed to function as a sphingosine 
exporter57.  
 
In addition to the lysosomal sphingolipid degradation pathway, sphingolipid degrading enzymes are 
present in numerous cellular compartments, including the plasma membrane, ER, Golgi, nucleus and 
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mitochondria. Several of these enzymes, for example sphingomyelinases, are known to be responsive 
to various stimuli, thus dynamically regulating the levels of individual sphingolipid species in a localised 
manner1. 
 
1.3.1 Defective sphingolipid degradation: sphingolipidoses 
Defective sphingolipid degradation due to loss-of-function mutations in lysosomal sphingolipid 
hydrolases or their respective helper proteins causes a subset of lysosomal storage diseases called 
sphingolipidoses (Fig. 1.3). These are severe and currently incurable autosomal recessive disorders. 
Loss of enzyme function results in the accumulation of primary sphingolipid substrates and/or their 
derivatives in specific cell types and tissues. The accumulation of undigested substrate is primarily 
lysosomal, but their accumulation has been observed throughout the cell, including at the plasma 
membrane58,59. While each sphingolipidosis is associated with unique pathologies, several pathogenic 
cascades are shared by lysosomal storage diseases, including altered cellular trafficking and 
degradation, oxidative stress, calcium homeostasis, inflammation and activation of cell death 
pathways60,61. The precise mechanism by which sphingolipids initiate cellular dysfunction remains 
unclear, but may include disruption of membrane integrity, architecture, and functional domains. In 
addition to the primary substrate, deacylated forms of the accumulated sphingolipid accumulate in a 
number of sphingolipidoses62. These lysolipids have detergent-like properties and are thought to 




Figure 1.3. Lysosomal storage diseases caused by defective glycosphingolipid catabolism 
Hereditary diseases (red) caused by genetic defects of individual hydrolase enzymes (blue) or 
activator proteins (green) in the glycosphingolipid and ganglioside degradation pathway. 
Abbreviations: N-Acetyl-β-D-galactosamine (β-GalNAc); α-N-acetylneuraminic acid (α-NeuNAc); 
lactosylceramide (LacCer); glucosylceramide (GlcCer), galactosylceramide (GalCer), 
digalactosylceramide (Gal2Cer); sphingomyelin (SM); β-galactosidase (GLB); β-hexosaminidase (β-
Hex); α-galactosidase (GLA); arylsulfatase A(ARSA); glucosylceramidase (GCase); β-






Lipids are embedded within membranes63 and thus are not directly accessible to soluble sphingolipid 
degrading enzymes. Lysosomal lipid transfer proteins, namely saposins and GM2A provide 
sphingolipid hydrolases access to their substrates. There are four saposin proteins named Saposin A, 
B, C, D (SapA-D). Each saposin functions in conjunction with specific hydrolases to facilitate the 
degradation of different sphingolipids and the loss of saposin function phenotypically resembles the 
loss of the associated hydrolases64-69 (Fig. 1.3). Saposins are expressed ubiquitously and conserved 
across vertebrates70. All four saposins are the products of the proteolytic cleavage of a single precursor 
glycoprotein, prosaposin (PSAP). PSAP is folded and glycosylated in the ER and transported to 
endolysosomal compartments by the sorting receptor Sortilin71. Sortilin also delivers acid aspartyl 
protease cathepsin D72, which cleaves PSAP to form SapA, SapB, SapC and SapD in the lysosome73.  
 
Several lysosomal lipid transfer proteins have been identified besides saposins. Interestingly, acid 
sphingomyelinase (SMPD1) does not require an external lipid transfer protein but possesses an N-
terminal saposin homology domain that allows it to directly access its substrate sphingomyelin74. 
GM2A is the essential co-factor for the degradation of the ganglioside GM2 by β-hexosaminidase 
A75,76. Finally, Niemann–Pick C2 (NPC2) solubilises cholesterol for transfer to the lysosomal cholesterol 
exporter Niemann-Pick C1 (NPC1)77. These additional lipid transfer proteins will not be discussed 
further since my work has focused on the saposins. 
 
1.4.1 Structural features of saposins 
Saposins are small (approximately 80 amino acids, 8-12 kDa) non-enzymatic proteins. Each saposin 
possesses 6 conserved cysteines and a conserved N-glycosylation site at the same position78. Although 
individual saposins have low sequence identity (< 35%), they adopt a common fold consisting of four 
amphipathic α-helices (Fig. 1.4A). The N- and C-terminal α-helices α1 and α4 form a stem stabilised by 
two disulfide bonds. The central α-helices α2 and α3 form a hairpin motif maintained by a single 
disulphide bond. Two flexible hinge loops separate the stem and hairpin motifs, allowing saposins to 
open and close in a jack-knife manner. The internal face of saposins is hydrophobic, allowing for lipid 
binding (Fig. 1.4B). Several X-ray crystallography and nuclear magnetic resonance (NMR) structures 
demonstrating different conformational states are available for each saposin79-86 (Fig. 1.4C-K). Saposin 
monomers can adopt a closed, globular conformation to shield the internal hydrophobic surface from 
the aqueous environment (Fig. 1.4C, G and J). In their open form, saposins can dimerise, enclosing a 
hydrophobic cavity (Fig. 1.4D, F, H, K). This cavity can be used to solubilise lipids, as illustrated by a 
crystal structure of SapB enclosing the hydrophobic moiety of a lipid molecule (Fig. 1.4F). SapA also 
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presents lipids substrates to its cognate enzyme as a dimer, although these dimers possess different 
conformations (Fig. 1.4D). Although the precise mechanism of lipid extraction from membranes is not 
known, the interaction of saposins with membranes is likely to require opening of the saposins to 
expose the internal hydrophobic face, as observed in an NMR structure of detergent micelle-
associated SapC in its open conformation (Fig. 1.4I). 
 
1.4.2 The liftase and solubiliser models of saposin function 
There are two proposed mechanisms for how saposins assist in lipid presentation to hydrolases. In the 
solubiliser model, saposins extract lipids from membranes and present them as soluble protein-lipid 
complexes to cognate enzymes in solution (Fig. 1.5A). The liftase model proposes that saposins bind 
to membranes and destabilise them, thereby providing membrane-associated enzymes access to lipid 
substrates (Fig. 1.5B). SapA and SapB are thought to be solubilisers, whereas SapC and SapD are 
proposed to function as liftases. The solubiliser model has been demonstrated by a crystal structure 
of SapA in complex with its soluble cognate enzyme obtained by our group80. SapB is also proposed to 
function as a solubiliser, based on its capacity to extract radiolabelled lipids from liposomes87 and a 
crystal structure of SapB enclosing a single lipid molecule82 (Fig. 1.4F). The liftase mechanism has been 
observed for SapC. Atomic force microscopy combined with fluorescence microscopy and Förster 
resonance energy transfer microscopy showed that SapC binds and remodels lipid bilayers, recruiting 
its cognate enzyme glucosylceramidase (GCase) and promoting its activity and/or access to 
substrate88,89. Similarly, SapD associates with membranes and enhances the activity of its cognate 
enzyme at the membrane interface90. In vitro studies have showed that SapD increases the 
permeability of large unilamellar vesicles91 and breaks down large lipid vesicles into smaller vesicles 
at very high concentrations92. The physiological relevance and implications of these findings are still 




Figure 1.4. Structure of saposins 
A. Topology diagram of the saposin fold. Disulphide bonds are shown in yellow. B. Ribbon and 
transparent surface representation of an open SapA monomer (PDB ID: 4DDJ) with the surface 
coloured based on residue hydrophobicity. (C-K) Ribbon representation of published saposin 
structures. C. Crystal structure of a closed human SapA monomer (PDB ID: 2DOB). D. Crystal 
structure of GALC and LDAO-bound murine SapA (PDB ID: 5NXB). E. Crystal structure of a human 
SapA-LDAO nanodisc (PDB ID: 4DDJ). Detergent molecules are shown in stick representation in 
yellow. F. Crystal structure of phosphatidylethanolamine (PE)-bound human SapB (PDB ID: 1N69). PE 
is shown in stick representation in yellow. G. Crystal structure of a closed human SapC monomer 
(PDB ID: 2GTG). H. Crystal structure of a human SapC dimer (PDB ID: 2QYP). I. NMR structure of 
human SapC in the presence of SDS micelles (PDB ID: 1SN6). J. Crystal structure of a closed human 




Figure 1.5. Solubiliser and liftase models of saposin function 
A. Schematic diagram illustrating the solubiliser model of saposin function. SapA (pink) extracts 
GalCer (yellow) and presents it to the hydrolase GALC (purple) in solution. Adapted figure, courtesy 
of Dr Janet Deane. B. Schematic diagram illustrating the liftase model of saposin function. SapC 
(green) binds and perturbs lipid bilayers to promote the activity of glucosylceramidase (GCase; sky 
blue) on its substrate glucosylceramide (GluCer; dark blue) at the membrane surface. 
 
1.4.3 Saposin nanodiscs for structural studies 
The lipid binding properties of saposins have been employed to form stable and uniform lipoprotein 
nanodiscs suitable for NMR93 and electron microscopy94 studies of membrane proteins (Fig. 1.4E). 
SapA has been found to assemble with a very wide range of lipids to form nanodiscs95. Interestingly, 
all saposins can form nanodiscs95, regardless of whether they are thought to function according to the 
solubiliser or liftase model. This suggests that each saposin has a specific mode of action when 
presenting substrates to its cognate enzyme, but all saposins also share the ability to form lipoprotein 
discs in vitro. It is unknown whether lipoprotein disc formation occurs at physiological concentrations 
in the lysosome.  
 
1.5 β-galactocerebrosidase (GALC)  
The lysosomal enzyme β-galactocerebrosidase, also known as β-galactosylceramidase (GALC) is 
essential for the normal catabolism and recycling of galactosphingolipids. GALC cleaves the terminal 
galactose head group of glycosphingolipids, catalysing the catabolism of GalCer to ceramide and 
galactose, psychosine (galactosylsphingosine) to sphingosine and galactose, and lactosylceramide to 
GluCer and galactose (Fig. 1.6A). Access to these substrates is provided by SapA (Fig. 1.6B and 1.5A)80. 
GALC is particularly important for myelin maintenance, and loss-of-function mutations in GALC or 




Figure 1.6. GALC hydrolyses galactosphingolipids 
A. Skeletal formulae of GALC substrates and lipid products. GALC converts galactosylceramide to 
ceramide, psychosine to sphingosine and lactosylceramide to glucosylceramide. B. Figure courtesy of 
Dr Janet Deane. The mechanism of GALC function is illustrated by a cross-section through the GALC-
SapA structure (PDB ID: 5NXB) revealing an open channel stretching from the GALC active site into 
the SapA hydrophobic cavity. The GALC surface and cut-through is shown in cyan and the SapA 
dimer surface is shown in yellow and orange. For clarity, the second GALC monomer is not shown. 
Substrate binding to the active site pocket is modelled based on the previously determined GalCer 
analogue-bound GALC structure (PDB ID: 4CCC). The illustration of the hydrophobic cavity (green) 
shows that the substrate GalCer (stick representation, in pink) can fit into this cavity, bridging the 
channel from the GALC active site to hydrophobic SapA core.  
1.5.1 Krabbe disease  
Krabbe disease, also known as globoid cell leukodystrophy, is a sphingolipidosis caused by loss-of-
function mutations in GALC. Krabbe disease is characterised by demyelination of neurons in the 
central and peripheral nervous system (CNS and PNS), resulting in neurodegeneration and death. 
Krabbe disease is an autosomal recessive disorder with a prevalence of 1 in 100,000, although this 
varies between countries and communities. Approximately 250 pathogenic mutations in GALC have 
been identified; the most common is a 30 kilobase (kb) gene deletion. In the majority of cases, 
symptoms appear before 12 months of age (infantile-onset disease) and results in death in the first 
two years of life. A minority of patients develop a less severe form of Krabbe disease with late or adult 
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onset and slower disease progression96. Hematopoietic stem cell transplantation administered prior 
to the onset of symptoms is currently the only treatment extending the lifespan and reducing the 
symptoms of Krabbe disease patients97. There are several animal models of Krabbe disease, including 
the Twitcher mouse phenotypically resembling human Krabbe disease due to a spontaneously 
occurring mutation in GALC98. Canine99, feline100, primate101 and ovine102 models of Krabbe disease are 
also available.  
 
1.5.2 Krabbe disease pathogenesis 
Myelin is formed by tight wrapping of myelinating cell membranes to form an insulating, multilayered 
myelin sheath around neuronal axons. Oligodendrocytes are the myelinating cells of the CNS; 
Schwann cells perform this function in the PNS. The myelin sheath is primarily composed of lipids (70-
80% lipids, 15-30% proteins by weight) and is particularly enriched in the sphingolipid species 
sphingomyelin, GalCer, and its sulfated derivative sulfatide103. The formation and stability of myelin is 
dependent on close packing and tight regulation of interactions between neurons and the myelin 
sheath, as well as between myelin layers104. These interactions include protein-protein interactions, 
such as between oligodendrocyte neurofascin and the axonal proteins contactin-1 and Caspr105; 
protein-lipid interactions, for example between myelin-expressed Myelin-associated glycoprotein and 
the gangliosides GD1a and GT1b in the neuronal membrane44; as well as potential trans interactions 
between GalCer and sulfatide head groups on apposed myelin sheath surfaces106,107. The mechanisms 
leading to demyelination in Krabbe disease have not yet been fully elucidated. The primary substrate 
of GALC, GalCer, does not accumulate at high levels in Krabbe disease. Instead, psychosine, the 
deacylated form of GalCer (Fig. 1.6A), has been found to accumulate in the brain, liver and kidney of 
Krabbe disease patients. Psychosine is a cytotoxic lysolipid normally undetectable in the tissues of 
healthy patents. The cytotoxic properties of psychosine prompted the formulation of the "psychosine 
hypothesis" proposing that accumulation of psychosine in myelinating cells causes their death and 
subsequent demyelination and neurodegeneration108-110. Multiple mechanisms of psychosine 
cytotoxicity have been proposed, including disruption of membrane domains and membrane 
integrity111 and direct activation of cell stress and death signalling pathways112. Unfortunately, many 
of the studies on the cytotoxic activity of psychosine have relied on exogenous feeding of psychosine, 
which may not accurately reflect the localisation and concentration of psychosine in the disease state. 




1.5.3 Immune dysfunction in Krabbe disease 
Krabbe disease is accompanied by immune dysregulation. A hallmark of Krabbe disease is the 
formation of giant, multinucleated phagocytic cells called globoid cells in the brain. Globoid cells are 
thought to be derived from microglia, the brain-resident macrophages, and/or infiltrating peripheral 
macrophages. Globoid cell formation has been hypothesized to be driven by chronic inflammation 
caused by myelin damage or storage of undigested GALC substrates following phagocytosis of myelin 
debris113. However, globoid cells have been reported in the spinal cord of foetuses with Krabbe disease 
prior to demyelination114,115, and globoid cells and neuroinflammation have been found in the absence 
of demyelination in a mouse model of Krabbe disease116, suggesting that globoid cell formation may 
be an early event directly caused by the loss of GALC and galactosphingolipid accumulation in 
phagocytic cells. 
 
Furthermore, elevated levels of pro-inflammatory cytokines including TNF-α have been observed in 
the brain of the Twitcher mouse model and rhesus macaques with Krabbe disease117,118. An intriguing 
hypothesis is that globoid cells or aberrantly activated immune cells drive Krabbe disease 
pathogenesis by producing pro-inflammatory cytokines such as TNF-α, which can cause 
oligodendrocyte cell death119,120. Peripheral blood mononuclear cells (PBMCs) isolated from Krabbe 
disease patients have been found to produce higher levels of TNF-α than healthy controls121, 
suggesting that peripheral immune cells may be abnormally activated in Krabbe disease. A major type 
of PBMC involved in TNF-α production are monocytes. These are circulating phagocytic cells that can 
differentiate to macrophages122.  
 
Thus, some evidence suggests that loss of GALC in Krabbe disease may affect phagocytic cell function, 
potentially through abnormal accumulation of galactosphingolipids in these cells. As discussed in 
section 1.1, the importance of sphingolipids for immune receptor function is becoming increasingly 
appreciated. GluCer, lactosylceramide, GM3 and (iso)Gb3 have been found to be abundant in 
monocyte/macrophages123, but the presence of GalCer has not been previously reported in these cells. 
However, quantification of GalCer by lipidomics is particularly challenging because GalCer is an 
isobaric structural isomer of GluCer, requiring additional procedures for the separation of these lipid 
species prior to mass spectrometry. It is therefore possible that GalCer is present in these cells but 
indistinguishable from GluCer using conventional glycosphingolipid analysis techniques. Even small 
amounts of a lipid species may still be functionally relevant, especially if concentrated in functional 
domains. Whether galactosphingolipids are present and important in phagocytic cells has not yet been 
directly investigated. This question is explored in Chapter 4. 
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1.6 Acid ceramidase (AC) 
Acid ceramidase (AC; ASAH1) catalyses the final step of sphingolipid degradation, the hydrolysis of 
ceramide to sphingosine in lysosomal compartments. This role makes AC a key enzyme for the 
maintenance of sphingolipid homeostasis. Loss-of-function mutations in ASAH1 result in ceramide 
accumulation, causing the lysosomal storage disease Farber disease. AC also plays a key role in 
apoptosis by regulating the balance between pro-apoptotic ceramide and anti-apoptotic S1P 
(discussed in section 1.1.2), and up-regulation of AC expression has been implicated in several cancers. 
Furthermore, AC is essential for embryonic development, as demonstrated by the fact that AC 
knockout in mice leads to early embryonic death at the 4-cell stage124,125.  
 
AC is a glycoprotein synthesised in the ER and modified by N-linked glycosylation at five sites126. AC is 
transported from the trans Golgi network to endosomal compartments by mannose-6-phosphate 
receptor-dependent trafficking126. AC activity is restricted to endolysosomal compartments through 
several mechanisms. Formation of catalytically active, mature AC requires autoproteolysis of the 
peptide bond between Cys143 and Ile142, forming a disulfide-bonded heterodimer composed of two 
subunits. This autoproteolysis event is triggered by the low pH of endolysosomal compartments127,128. 
Moreover, the optimal pH for AC catalytic activity is pH 4.5. AC is a soluble enzyme and its interaction 
with substrate-containing membranes is promoted by low pH, the presence of the anionic lipid BMP 
and the high membrane curvature associated with intraluminal vesicles90. Interestingly, AC is also 
capable of reverse activity in vitro, converting fatty acid and sphingosine to ceramide129,130. The 
forward and reverse activity are regulated by differences in optimal pH and lipid environment, 
suggesting that AC may be recruited to different compartments for ceramide synthesis under certain 
conditions130.  
 
1.6.1 Role of saposins in AC function 
SapD has been shown to enhance the activity of AC90,131,132. SapD does not promote the recruitment 
of AC to membranes, but appears to stimulate its activity at the membrane interface90, supporting the 
hypothesis that SapD functions as a liftase to promote AC activity. However, it is unclear whether AC 
is entirely dependent on SapD to access lipids. In vitro activity assays show reduced activity (3-
20%)90,128 of AC on liposome-embedded ceramide in the absence of SapD. Loss-of-function mutations 
in SapD have not been identified in humans, but a SapD knock-out mouse model is viable. SapD knock-
out mice do not present Farber disease symptoms or massive accumulation of ceramide as seen in 
Farber disease patients, and show no phenotypic abnormalities until adulthood133. This could be 
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because SapA and SapC, which have been shown to enhance AC activity on liposome-embedded 
ceramide to a lesser extent than SapD90, are able to help AC in vivo. Alternatively, AC could be able to 
function without the help of saposins, albeit less efficiently.  
 
1.6.2 Structural features of AC 
Previous work by our group led to the determination of a low-resolution crystal structure of AC 
showing negatively charged loops around the active site of AC likely to be necessary for its interaction 
with membranes and activity on membrane-embedded substrate. In the course of the project 
described in Chapter 5, a crystal structure of AC was published by Gebai et al.128. This structure allowed 
the authors to propose a catalytic mechanism of AC based on molecular docking of the substrate 
ceramide and confirmed the presence of hydrophobic patches necessary for AC function around the 
deep active site (Fig. 1.7). However, many questions on the mechanism of AC function remained 
unanswered. It is unclear how substrates access the active site of AC from a lipid bilayer. This process 
may require conformational changes triggered by interactions with the membrane and partial 
penetration of the hydrophobic loops of AC into the lipid bilayer (Fig. 1.8A). Moreover, the exact 
mechanism by which SapD, and perhaps other saposins promote AC activity needs to be clarified (Fig. 
1.8B). The interaction of AC with membranes is explored in Chapter 5.  
 
 
Figure 1.7. The activity of AC is dependent on hydrophobic loops around its active site 
Surface representation of the structure of AC (PDB ID: 5U7Z) coloured by hydrophobicity, showing 
that the active site of AC (circled with red dashes) is surrounded by hydrophobic loops. The view in 




Figure 1.8. The mechanism of ceramide access to the active site of AC is unknown 
Schematic representations of potential mechanisms of substrate access to the active site of AC. A. 
The association of AC with membranes may drive partial insertion of AC (red) into the lipid bilayer 
and induce conformational changes facilitating ceramide (pink) access to the active site of AC. B. 
SapD promotes AC activity at the membrane interface. This may be done by association of SapD 
(yellow) with the lipid bilayer, perturbing the membrane surface to facilitate access of ceramide to 
the active site of AC. 
 
1.6.3 Farber disease  
Loss-of-function mutations in ASAH1, the gene encoding AC, cause Farber disease, a lysosomal storage 
disease characterised by ceramide accumulation in multiple tissues. This causes destructive 
inflammation resulting in subcutaneous nodules, joint contractures, and voice hoarseness, often 
accompanied by neurological and respiratory complications and spleen and liver enlargement. Farber 
disease is extremely rare, with only 200 reported cases and a predicted prevalence of less than 1 in 
1,000,000. There are approximately 60 known pathologic loss-of-function mutations in ASAH1134. 
Severe cases of Farber disease result in death before the age of 2-3 years. Patients with mild and 
attenuated forms of Farber disease have an increased lifespan but suffer from similar symptoms. 
There is little correlation between residual AC activity, disease severity and response to treatment. 
Furthermore, a very small number of people have been diagnosed with distinct symptoms 
corresponding to a separate disease named spinal muscular atrophy with progressive myoclonic 
epilepsy (SMA-PME). It is not clear what differentiates SMA-PME from Farber disease, especially since 
patients sharing the same mutation can present different diseases134. There is currently no cure for 
AC deficiency. Hematopoietic stem cell transplantation extends the lifespan of patients and resolves 
inflammation, alleviating peripheral symptoms but not neurological symptoms135. Enzyme 
replacement therapy and gene therapy are currently being investigated as therapeutic approaches for 
AC deficiencies 134.  
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1.6.4 Involvement of AC in cancer 
AC up-regulation is associated with several types of cancers, and in particular with prostate cancer 
where it has been found to be overexpressed in 40-80% of tumours136. Radiation-induced AC 
expression is also associated with resistance to radiation therapy137,138. It is therefore actively 
investigated as a target for cancer therapy139. The non-competitive AC inhibitor carmofur is used 
clinically but is associated with severe toxicity140. Recently published structures of AC128 as well as 
carmofur-bound AC141 give hope for structure-based design of improved AC inhibitors.  
 
1.6.5 Involvement of AC in other sphingolipidoses 
Recent evidence points to an involvement of AC in sphingolipidoses besides Farber disease. Gaucher 
disease is caused by loss of GCase and subsequent accumulation of GluCer and its deacylated form 
glucosylsphingosine in macrophages and neurons. Recent studies indicate that AC can deacylate 
accumulated GluCer to glucosylsphingosine in cells deficient in GCase (Fig. 1.9A). Irreversible inhibition 
of GCase142 or GCase knock-out143 causes a massive accumulation of glucosylsphingosine, and this 
accumulation is prevented by inhibition of AC with carmofur. Moreover, AC deficient fibroblasts from 
Farber disease patients do not accumulate glucosylsphingosine upon GCase inhibition142,144, and 
glucosylsphingosine accumulation returns following transfection of AC142. Similarly, Fabry disease 
fibroblasts deficient in the enzyme α-galactosidase A accumulate lyso-Gb3, the deacylated form of the 
main α-galactosidase A substrate Gb3 (Fig. 1.9B), and this accumulation is prevented by inhibition of 
AC by carmofur142. This indicates that AC can accommodate the large head groups of 
glycosphingolipids and catalyse their deacylation. I investigated whether AC can convert GalCer to 
psychosine (Fig. 1.9C), thus contributing to the pathogenesis of Krabbe disease in Chapter 5.  
 21 
 
Figure 1.9. AC may deacylate glycosphingolipid substrates 
Skeletal formulae of potential AC glycosphingolipid substrates and products. A. Evidence suggests 
that AC can deacylate glucosylceramide to glucosylsphingosine. B. Evidence suggests that AC may 
also deacylate Gb3 to lyso-Gb3. C. AC may deacylate galactosylceramide to psychosine. 
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1.7 Sphingolipid presentation to the immune system 
1.7.1 CD1 molecules 
In an analogous way to peptide presentation by MHC molecules, endogenous and microbial lipids are 
presented to the immune system by CD1 molecules and recognised by specialised T-cells. This allows 
the immune system to detect and respond to the lipidome of cells in states of homeostasis, infection 
or under stress. CD1 molecules are primarily expressed on antigen-presenting cells145,146 and have 
structural similarity to MHC class-I, including association with β-2-microglobulin (β2m), but unlike MHC 
molecules, CD1 molecules are non-polymorphic and the antigen-binding grooves of CD1 molecules 
are hydrophobic, allowing the binding of most classes of lipids including sphingolipids, phospholipids, 
glycerolipids and lysolipids147. There are five CD1 isoforms expressed in humans, named CD1a, CD1b, 
CD1c, CD1d and CD1e. CD1 molecules are synthesised in the ER, where they associate with β2m and 
endogenous ER lipids before trafficking to the plasma membrane via the secretory pathway. Each 
isoform then samples different environments for lipids. CD1a remains predominantly at the cell 
surface. CD1c and CD1d recycle between the plasma membrane and the early and late endocytic 
compartments via interactions with adaptor protein-2, whereas CD1b cycles between the plasma 
membrane and late endosomal/lysosomal compartments via adaptor protein-3-dependent 
trafficking148. CD1e is cleaved in the lysosome to form a soluble isoform that does not present lipids 
to T-cells but may function as a lipid transfer protein to promote loading of lipids onto other CD1 
molecules149. CD1 isoforms differ in their expression profile, lipid-binding cavity size, their lipid binding 
profile and the T-cell subsets recognising them. Of the five CD1 family members, CD1d is best 
characterised and is the only CD1 isoform present in mice. CD1d is recognised by the T-cell receptor 
(TCR) of natural killer T (NKT) cells.  
 
 
Figure 1.10. Skeletal formula of the NKT cell agonist α-galactosylceramide 
 
1.7.2 NKT cells  
NKT cells recognising CD1d are divided into two groups: invariant NKT (iNKT) cells with a semi-invariant 
T cell receptor recognising the synthetic lipid α-Galactosylceramide (α-GalCer), and more diverse type 
II NKT cells. α-GalCer is a synthetic saturated glycosphingolipid derived from a marine sponge (Fig. 
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1.10). The α-glycosidic linkage between the galactose head group and the ceramide moiety of α-
GalCer is found in bacteria150 but not in humans, where GalCer is synthesised with a β-glycosidic 
linkage (Fig. 1.1B). 
 
iNKT cells have been well characterised due to the availability of α-GalCer/CD1d tetramers as a tool 
to identify and isolate α-GalCer-responsive cells. iNKT cells are innate-like T-cells involved in the 
orchestration of immune responses151. These cells possess NK cell markers such as NK1.1 and are able 
to rapidly produce large quantities of various cytokines including interleukin (IL)-4 and interferon γ 
(IFN-γ) in response to TCR stimulation. Alternatively, iNKT cells can be activated by stimulation by pro-
inflammatory cytokines such as IL-12 even in the absence of TCR stimulation. These responsive 
properties allow iNKT cells to initiate, coordinate and suppress immune responses151,152. iNKT cells are 
important in response to infection by pathogens such as Streptococcus pneumoniae153. The 
importance of CD1d-dependent NKT cell activation in response to viral infection is highlighted by the 
fact that CD1d expression is down-regulated by a number of viruses including herpes simplex virus 
type 1 and human immunodeficiency virus154. iNKT cells also play a critical role in autoimmune disease, 
transplant immunology, and cancer and are therefore the subject of extensive research to understand 
and modulate their function for therapeutic purposes.  
 
Despite being more numerous than iNKT cells in humans, type II NKT cells are less well characterised 
due to their diversity and the lack of tools to identify, isolate and study these cells. However, they are 
also known to play important roles in various pathological contexts including infection, cancer and 
autoimmunity. For example, sulfatide-reactive NKT cells play a protective role in a mouse model of 
multiple sclerosis155.  
 
1.7.3 Structural features of CD1d 
Over one hundred structures of CD1d have been deposited. CD1d has a similar structure to MHC 
molecules, with an antigen-binding groove formed by two α-helices lying over an antiparallel β-sheet 
(Fig. 1.11A). The antigen-binding groove of CD1d is highly hydrophobic to accommodate a lipid 
molecule, enclosing it away from the solvent and allowing the polar head group to protrude for TCR 
recognition (Fig. 1.11B). Molecular dynamics simulations show that the portal to the lipid binding 





Figure 1.11. CD1d possesses a tight hydrophobic lipid-binding groove 
A. Ribbon representation of a crystal structure of human CD1d-β2m with the lipid α-GalCer in stick 
representation in yellow (PDB ID: 1ZT4). The view in the bottom panel is rotated by 60° about the 
horizontal axis. B. Surface representation of the structure shown in A, coloured by hydrophobicity, 
showing that the hydrocarbon tails of α-GalCer are enclosed within a tight hydrophobic groove.  
 
1.7.4 Role of lipid transfer proteins 
Lipids are embedded within membranes and thus are not directly accessible to the lumenal lipid-
binding groove of CD1 molecules. The loading of lipid antigen onto CD1 molecules therefore requires 
the action of lipid transfer proteins for efficient antigen presentation. The loading of lipids onto CD1d 
can occur in the ER, at the cell surface and in endocytic compartments. Relatively little is known about 
how lipid specificity is determined, and studies using secreted or recycling, surface-cleavable human 
CD1d found differences in the lipid repertoire bound to CD1d, reflecting the lipids present in the 
compartments through which it had trafficked157-159. Different lipid transfer proteins are present in the 
different cellular locations where lipid antigen loading occurs and are likely to determine the lipid 
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repertoire bound to CD1 molecules160. Interestingly, the late endocytic/lysosomal compartment is the 
site of both glycolipid catabolism and lipid loading of CD1d and the resident lipid transfer proteins 
function in both these processes. Importantly, the antigenicity of glycolipids can be regulated by 
processing of their glycan head goups prior to presentation to T-cells, highlighting the complex 
interplay between these two pathways161,162.  
 
The evidence for saposin-mediated lipid loading of CD1 molecules comes from animal knockout 
studies, cell-based assays and in vitro assays. Knockout of the saposin precursor PSAP in mice results 
in the dramatic loss of presentation of endogenous iNKT cell ligands by CD1d163. The presentation of 
exogenous lipid antigens, such as α-GalCer, is impaired in PSAP knockout or knockdown cells163-166. In 
vitro assays have identified that all the saposins, as well as the other lysosomal lipid transfer proteins, 
GM2A and NPC2, are capable of transferring lipids onto CD1 molecules163,167. However, some lipid 
transfer proteins appear to be more efficient than others at loading specific lipid antigens onto 
different CD1 molecules165,168,169. Specificity within the saposin family in this process has been explored 
via in vitro assays identifying SapB as the dominant saposin for the loading of lipid antigens onto CD1d. 
Specifically, incubation of CD1d with SapB and α-GalCer has been shown to enhance the stimulation 
of iNKT cells165,166 and SapB can mediate lipid binding to CD1d in T-cell independent assays165 
suggesting a direct role for this specific saposin in lipid loading of CD1d. The ability of SapB to facilitate 
and enhance lipid exchange on CD1d has also been monitored in vitro via iNKT TCR binding to CD1d 
following incubation with lipids alone or lipids plus SapB166. These in vitro assays implicate SapB as a 
“lipid editor” that facilitates the loading and unloading of lipid antigens onto CD1d. The 
liftase/solubiliser models are relevant for the proposed mechanisms by which saposins load lipids onto 
CD1 molecules169. SapB is thought to behave as a solubiliser, forming protein-lipid complexes that 
enhance lipid loading of CD1d, while SapC appears to recruit CD1c to membranes and facilitate lipid 
loading of CD1c at the membrane surface.  
 
Due to the hydrophobic properties of lipids, their exposure to aqueous solutions is thermodynamically 
unfavourable. Therefore, lipid transfer between hydrophobic lipid-binding cavities of proteins 
requires direct interaction of the protein components to provide continuous shielding of the lipid from 
the aqueous phase170. This hypothesis is supported by the fact that other known lipid transfer proteins 
directly interact with the protein receiving the lipid77,171,172. SapB and CD1d are thus expected to 
participate in a direct interaction facilitating lipid transfer from one protein to the other. This 




The interaction of proteins with sphingolipid molecules and membrane domains is emerging as an 
understudied fundamental mechanism regulating protein and cell function. Although a number of 
these interactions have come to light in recent years, our understanding of the molecular basis of 
these interactions is still limited. Expanding our knowledge of these interactions is essential in order 
to design therapies, manipulate cellular pathways and make predictions about processes involving 
sphingolipids. In this study, I aimed to explore protein-sphingolipid interactions critical for immunity 
and disease. Specifically, I aimed to: 
 
1. Understand how SapB mediates lipid loading onto CD1d.  
Using structural and biochemical methods, I aimed to characterise the interaction between CD1d and 
SapB facilitating the transfer of lipids between these two proteins. 
2. Explore the impact of GALC deficiency on the membrane proteome of phagocytic cells. 
I aimed to investigate the effect of GALC knockout in a monocytic cell line using CRISPR-Cas9. I set out 
to use proteomics and RNA sequencing approaches to determine whether the expression, localisation 
and trafficking of plasma membrane proteins were affected by loss of GALC and subsequent 
accumulation of galactosphingolipids in monocytes.  
3. Understand the mechanism of AC function and its role in Krabbe disease. 
Using structural, biochemical and cell biology methods, I aimed to understand how AC accesses 
membrane-embedded substrates and whether it processes GalCer to psychosine, the cytotoxic lipid 
accumulating in Krabbe disease, thus contributing to the pathogenesis of Krabbe disease.  
4. Investigate whether protein-sphingolipid interactions contribute to the loss of an adhesion 
protein down-regulated at the surface of GALC-deficient oligodendrocytes. 
Following on previous work in our lab, I aimed to use structural methods to probe the interaction of 
Protein Tyrosine Phosphatase Receptor Type M with sulfatide. 
 27 
2 Methods 
2.1 Molecular biology 
2.1.1 DNA amplification by PCR 
Primer stocks were diluted in water to a working concentration of 5 μM. Template DNA was diluted 
to 10 ng/μL in water. PCR reactions were assembled as in Table 2.1. A hot-start PCR protocol was 
executed using a thermal cycler; 95 °C for 2 minutes, followed by 30 cycles of denaturation (95 °C, 20 
seconds), annealing (55 °C, 10 seconds) and extension (70 °C, 20 seconds/kb). PCR products were 
visualised by agarose gel electrophoresis (section 2.1.2). Excess primers, template and dNTPs were 
removed using a Monarch PCR & DNA Cleanup Kit (NEB) according to manufacturer’s instructions. 
 
Table 2.1. PCR components for DNA amplification 
Component  Volume (μL) 
10x KOD buffer (Novagen) 5  
MgSO4 (25 mM) 3  
dNTPs (2.5 mM)   5  
Template DNA (10 ng/μL)   1 
Forward primer (5 μM)   4 
Reverse primer (5 μM)   4 
MQW   27.6 
KOD hot-start DNA polymerase (Novagen) 0.4  
 
2.1.2 Analysis of DNA by agarose gel electrophoresis 
1% agarose gels were made by melting 1 g of agarose powder in 100 mL of 1X Tris-Borate EDTA (TBE) 
buffer by microwave heating prior to the addition of 10 μL SYBR Safe DNA stain (Invitrogen). DNA 
samples were mixed with 6X DNA loading dye (NEB) before being resolved by horizontal 
electrophoresis in TBE buffer (70V, 140 mA). DNA was then visualised with visible blue light. 
 
2.1.3 Restriction digestion of DNA 
Insert and vector DNA were digested with enzymes and buffers supplied by NEB. Per 50 μL reaction, 
1 μg DNA was incubated with 1 μL of each enzyme in CutSmart buffer (NEB) at 37 °C for 5-15 minutes 
(Time-Saver qualified enzymes) or 60 minutes. 1 μL alkaline phosphatase (Promega) was added to 
vector reactions and incubated at 37 °C for 1 hour.  Cut vector DNA was analysed by agarose gel 
electrophoresis (section 2.1.2) and extracted from excised gel slices using a Monarch DNA Gel 
Extraction Kit (NEB), as directed by the manufacturer. 20 units of DpnI was added to digested inserts 
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and incubated at 37 °C for 1 hour followed by PCR clean-up purification using a Monarch PCR & DNA 
Cleanup Kit (NEB) as directed by the manufacturer.  
 
2.1.4 DNA ligation 
Cut DNA fragments were mixed in a 6:1 molar ratio of insert to vector (~100 ng total DNA), combined 
with 0.5 μL T4 DNA ligase in T4 ligase buffer (NEB) in a total volume of 10 μL. Control reactions without 
insert or vector were always performed. Ligation reactions were incubated at room temperature for 
2 hours or overnight at 16 °C. 2 μL of the ligation reaction were then transformed into chemically 
competent E. coli cells (section 2.1.6). 200 μL of transformed cells were plated and plasmid DNA 
prepared as in section 2.1.7. Each construct was sequenced in full by Sanger sequencing (GENEWIZ, 
Cambridge). 
 
2.1.5 Preparation of chemically competent E. coli cells 
Liquid cultures (100 mL) of E. coli were grown to an optical density at 600 nm of 0.25 to 0.3 and chilled 
on ice for 15 minutes. Cells were pelleted by centrifugation (4000g, 4 °C, 10 minutes), resuspended in 
30 mL sterile ice-cold 0.1 M CaCl2 and incubated on ice for a further 30 minutes. Cells were then 
pelleted again and resuspended in 5 mL sterile 0.1 M CaCl2 with 15% v/v glycerol. Chemically 
competent cells were stored at -80 °C in 50 μL aliquots until required. 
 
2.1.6 Transformation of chemically competent E. coli cells with plasmid DNA 
DH5α competent E. coli cells were used for transformation of most constructs. Aliquots of chemically 
competent cells were thawed on ice. 100 ng plasmid DNA was added to cells, incubated on ice for 30 
minutes then heat-shocked (50 seconds, 42 °C). Cells were chilled on ice for 2 minutes and recovered 
in 400 μL SOC medium in a shaking incubator (37 °C, 1 hour, 230 rpm). After recovery, selection was 
applied by plating 50-200 μL of transformed cells on LB agar supplemented with the appropriate 
antibiotic and incubated overnight at 37 °C. Lentiviral expression vectors were transformed into Stbl3 
competent E. coli cells (Thermo Fisher Scientific). Transformation was performed as described above, 
however, recovery and plate incubation were performed at 30 °C. 
 
2.1.7 Preparation of plasmid DNA 
Single colonies of transformed cells were picked and grown overnight in 2XTY in the presence of 
appropriate antibiotic, at 37 °C for DH5α cells or 30 °C for Stbl3 (230 rpm). Bacterial cultures were 
pelleted by centrifugation (4 000g, 10 minutes) and plasmid DNA prepared using commercially 
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available variations of the alkaline lysis method. For small scale preparations of <20 μg DNA, a PureLink 
HiPure Miniprep kit (Invitrogen) was used to isolate plasmid DNA from 5 mL overnight cultures of E. 
coli. For large scale preparations, a PureLink HiPure plasmid Midiprep kit (Invitrogen) was used to 
isolate plasmid DNA from 100 mL overnight cultures of E.coli. Plasmid DNA was stored at -20°C. 
 
2.2 Plasmid construction, cloning and mutagenesis  
2.2.1 Cloning of CD1d and β2m into PB-T-H6 
The vector PB-T-PAF was kindly provided by Prof James Rini (University of Toronto)173. In this vector, 
a tetracycline response element controls the expression of the target protein construct with an ER 
secretion peptide (eventually cleaved from the secreted protein) and an N-terminal Protein A tag. A 
modified version of this vector retaining the N-terminal secretion signal but with the Protein A fusion 
removed was constructed by Dr Janet Deane. Codon-optimised cDNA was synthesized (GeneArt) 
encoding human β2m (residues 21-119, Uniprot P61769) and the extracellular domain of human CD1d 
(residues 20-301, Uniprot P15813) with a C-terminal hexahistiding tag (CD1d-H6). CD1d DNA was 
amplified with the following primers: 
forward 5’-GCACTAGTGAAGTTCCCCAGAGACTGTTCC-3’;  
reverse 5’- CGGGCGCGCCTCAGTGATGGTGATGGTGGTGCTTGC-3’.  
β2m DNA was amplified with the following primers:  
forward 5’- GCACTAGTATCCAGCGGACCCCTAAGATC-3’; 
reverse 5’-CAGGCGCGCCTCACATGTCGCGGTCCCAC-3’.  
Both inserts were digested with SpeI-HF and AscI (NEB) and individually ligated to digested PB-T-PAF 
vector, to produce PB-T-CD1d-H6 and untagged PB-T-β2m. 
 
2.2.2 Cloning of SapB into pHLsec 
SapB cloning into the bacterial expression vector pET-15b was done by Dr Janet Deane. Codon-
optimised cDNA was synthesized (GeneArt) encoding the segment of human PSAP corresponding to 
SapB (residues 195-274, Uniprot P07602) and subcloned into pET-15b using NcoI and XhoI restriction 
endonuclease sites to produce untagged protein.  
 
For subcloning of SapB into the mammalian expression vector pHLsec-H6, SapB was amplified by PCR 
using the following primers: forward 5’-GAAACCGGTGATGTTTGTCAGGATTG-3’, reverse 5’-
GTTTTTGTGATGAAGTGGGTACCAAGC-3’, introducing AgeI and KpnI restriction enzyme sites for 
restriction cloning into pHLsec-H6.  
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2.2.3 Cloning of CD1d and HLA-A2 into pEGFP-N1 
CD1d and HLA-A2 were cloned into the pEGFP-N1 expression vector (a kind gift from Dr Stephen 
Graham) by Gibson assembly cloning. DNA encoding full-length CD1d preceded by a Kozak sequence 
was optimised for expression in mammalian cells and synthesised by GeneArt with 20 bp overlaps 
corresponding to the pEGFP-N1 vector. DNA encoding full-length HLA-A2 was generously provided by 
Louise Boyle. 20 bp overlaps corresponding to the pEGFP-N1 vector were added by PCR using primers 
designed with the NEBuilder assembly tool. Gibson assembly was performed using the NEBuilder HiFi 
DNA Assembly Master Mix (NEB, E2621S). 
 
2.2.4 Cloning of AC-H6 and AC-BAP-H6  
A construct encoding human AC without its secretion sequence (residues 22-395) was cloned from 
cDNA by Samantha Spratley. The sequence encoding AC was amplified using the following primers:  
forward: 5’-GAAACTAGTCAGCACGCGCCGCCGTGG-3’; 
reverse 5’-GTGCTTAAGCCAACCTATACAAGGGTCAGGGC-3’.  
Amplified insert DNA encoding AC and the vectors PB-T-H6 and PB-T-BAP-H6 was digested with SpeI-
HF (NEB) and BfrI (Roche). AC was ligated to PB-T-H6 and PB-T-BAP-H6 as described in section 2.1.4. 
 
2.2.5 Cloning of AC27 into PB-T-PAF 
AC (residues 27-295) was cloned into the vector PB-T-PAF173 (described in section 2.2.1) by Dr Janet 
Deane, forming the construct encoding ProtA-AC27. 
 
2.2.6 Cloning of guide RNAs targeting GALC into a lentiviral vector 
In order to clone the guide RNA (gRNA) target sequences into the lentiviral vector pKLV-U6gRNA-
EF(BbsI)-PGKpuro2ABFP (a kind gift from the Lehner lab), the following DNA oligos pairs were used: 
gRNA1 top: 5’-CACCGAAAGTGGAAATAGGTGGTGA-3’; 
gRNA1 bottom: 5’-AAACTCACCACCTATTTCCACTTTC-3’;  
gRNA2 top: 5’-CACCGGTGGTGATGGGCAGACAAC-3’; 
gRNA2 bottom: 5’-AAACGTTGTCTGCCCATCACCACC-3’. 
DNA oligo pairs were phosphorylated and annealed as follows. 1 µL top oligo (100 µM), 1 µL bottom 
oligo (100 µM) and 5 units (U) T4 PNK (NEB) were incubated in T4 Ligation Buffer (NEB) at 37 °C for 30 
min, followed by 5 min at 95 °C and gradual cooling to 25 °C at 5 °C/min. The annealed oligos were 
diluted 250-fold and cloned into the backbone vector with the following digestion-ligation reaction: 
100 ng vector was incubated with 2 µL diluted oligo duplex, 1 µL BpiI and 0.5 µL T7 ligase in Tango 
buffer with 500 µM dithiothreitol (DTT) and 500 µM ATP in a 20 µL reaction. The reaction was cycled 
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six times through the following steps: 37 °C for 5 min, 23 °C for 5 min. 11 µL of the ligation product 
was treated with 1.5 µL PlasmidSafe exonuclease (Lucigen) in PlasmidSafe Buffer with 1 mM ATP at 
37 °C for 30 min. 1 µL of the final product was transformed into Stable Competent E. coli (NEB) as 
described in section 2.1.6. Plasmid DNA was isolated and sequenced as described in section 2.1.7. The 
insertion of the gRNA target sequence into the vector was verified by sequencing using a sequencing 
primer for the U6 promoter (5’-GACTATCATATGCTTACCGT-3’).    
 
2.2.7 Cloning of GALC rescue vectors 
The GALC gene was introduced into a puromycin-resistant lentiviral pCW57 vector for rescue of GALC 
protein expression in GALC KO MO3.13 cells by Dr Stuart Fawke. For GALC expression in GALC KO THP-
1 cells, silent mutations were introduced into GALC to escape gRNA targeting, and GALC mutant inserts 
were cloned into neomycin-resistant pCW57. pCW57-MCS1-P2A-MCS2 (Neo) was a gift from Adam 
Karpf (Addgene plasmid # 89180 ; http://n2t.net/addgene:89180 ; RRID:Addgene_89180). 
Mutagenesis was performed by PCR-driven overlap extension following a published protocol174. For 
each rescue GALC construct, overlapping segments of the GALC gene are amplified from template 
GALC plasmid using two flanking primers (named A and D) marking the 5' ends of both strands and 
two internal primers (B and C) introducing the mutations of interest creating overlapping nucleotide 
sequences. AB and CD products are amplified in a first PCR reaction, then used as template in a second 
PCR reaction, where denatured products hybridize and full-length mutant GALC is amplified. For GALC 
Rescue 1, the DNA sequence 5'-GAA ATA GGT GGT-3' was mutated to 5'-GAG ATC GGC GGC-3'. The 
following primers were used:  
A: 5'-CAGGGACAGCAGAGATCCACTTTGGC-3' 
B: 5'-GCCATCTGTTGTCTGCCCATCGCCGCCGATCTCCACTTTTAAAATATGCAAAGAGG-3'  
C: 5'-CCTCTTTGCATATTTTAAAAGTGGAGATCGGCGGCGATGGGCAGACAACAGATGGC-3'  
D: CGTTTCCCGGAACCACGCCCAG-3'  
For the GALC Rescue 2 construct, the DNA sequence 5'-GAT GGG CAG ACA-3' was mutated to 5'-GAC 
GGC CAA ACC-3'. The following primers were used:  
A: 5'-CAGGGACAGCAGAGATCCACTTTGGC-3' 
B: 5'-GCTCAGTGCCATCTGTGGTTTGGCCGTCACCACCTATTTCCACTTTTAAAATATGC-3'  
C: 5'-GCATATTTTAAAAGTGGAAATAGGTGGTGACGGCCAAACCACAGATGGCACTGAGC-3' 
D: 5'-CGTTTCCCGGAACCACGCCCAG-3' 
PCR reactions were performed with KOD following the protocol detailed in section 2.1.1 with an 
annealing temperature gradient between 47 °C and 61 °C. Amplification products were gel extracted 
(section 2.1.3) and diluted to 40 ng/µL. AB and CD fragments were combined and used as template 
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(80 ng) in a standard KOD PCR reaction with primers A and D. Amplified hybridisation products AD 
were gel extracted and purified. These products and the target vector pcW57(Neo) were digested with 
SalI-HF and NheI-HF (NEB) and ligated with a 5:1 molar ratio of insert to vector as described in section 
2.1.4. Ligation products were transformed into Stbl3 E. coli and verified by sequencing (sections 2.1.6-
7).  
 
2.3 Mammalian cell culture 
2.3.1 HEK293F cells 
2.3.1.1 Maintenance 
HEK293F cells were maintained in FreeStyle 293 media (Gibco) in polycarbonate flasks (125 mL flask 
for cultures up to 40 mL, 500 mL flasks for 150 mL cultures, and 1 L flasks for 300 mL cultures) in an 
incubation shaker (37 °C, 8% CO2, 130 rpm) and passaged at a confluency of 2x106 cells/mL (every 2-3 
days). Viable cells were counted after Trypan blue staining using a haemocytometer. The appropriate 
volume of culture was removed, and cells were diluted to a concentration of 0.2x106 cells/mL in fresh 
media. 
 
2.3.1.2 Cell freezing 
60x106 cells were spun down (60g, 5 min) and resuspended in 6 mL Freestyle293 media supplemented 
with 10% dimethyl sulfoxide (DMSO). 1 mL aliquots, each containing 10x106 cells, were dispensed into 
sterile cryovials quickly transferred to a CoolCell LX freezing container (BioCision) for cooling to -80 °C 
at 1 °C/min. Frozen cells were stored in liquid nitrogen. 
 
2.3.1.3 Cell thawing 
Cryovials containing 10x106 cells in 1 mL were thawed in a water bath at 37°C and quickly diluted in 
30 mL warm FreeStyle293 media in a polycarbonate flask. 
 
2.3.2 THP-1 cells 
2.3.2.1 Maintenance 
THP-1 cells were maintained in THP-1 medium: RPMI-1640 Medium with L-glutamine and sodium 
bicarbonate (Sigma, R8758), supplemented with 10% fetal bovine serum (FBS) and 50 µM 2-
mercaptoethanol. Cells were maintained in T25, T75 or T175 flasks lying in a horizontal position at 37 
°C in humidified air with 5% CO2. The absence of mycoplasma contamination in THP-1 cell cultures was 
regularly verified using the MycoAlert Mycoplasma Detection Kit (Lonza).  
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THP-1 cells were passaged before they reached a density of 0.8x106 cells/mL (every 2-3 days). Cells 
were thoroughly resuspended, and a cell suspension aliquot was mixed 1:1 with Trypan blue (Sigma) 
to assess cell viability. Viable cells were counted using a haemocytometer. A fraction of the cell 
suspension was removed from the flask, and the cell suspension was supplemented with fresh THP-1 
medium for a cell density of 0.1-0.2x106 cells/mL. 
 
2.3.2.2 Cell freezing  
For long-term cell storage, THP-1 cells were frozen in aliquots of 2.5x106 cells. Cells were pelleted by 
centrifugation (125g, 5 min), the culture medium was removed by aspiration and replaced with 500 
µL THP-1 freezing medium (90% (v/v) FBS, 10% (v/v) DMSO). Cells were rapidly transferred to a sterile 
cryovial, which was slowly cooled to -80 °C at the rate of -1 °C/minute using a CoolCell freezing 
container (BioCision). Frozen cells were then transferred to liquid nitrogen within 24 hours. 
 
2.3.2.3 Cell thawing 
Frozen aliquots of THP-1 cells were warmed with agitation using a water bath at 37 °C. Once defrosted, 
cells were rapidly transferred to a 15 mL Falcon tube containing 10 mL THP-1 recovery medium (RPMI-
1640 Medium with L-glutamine and sodium bicarbonate supplemented with 20% FBS and 50 µM 2-
mercaptoethanol). Cells were pelleted by centrifugation (125g, 5 min) and the medium containing 
DMSO was aspirated and replaced with 5 mL THP-1 recovery medium. The cell suspension was then 
transferred to a T25 flask and incubated at 37 °C. Cell density was monitored every day until cells 
started doubling every 24 hours. Cells were then split with THP-1 medium (containing 10% FBS).  
 
2.3.2.4 Differentiation 
THP-1 cells were differentiated by addition of 25 nM phorbol 12-myristate 13-acetate (PMA) to THP-
1 medium175. For activity assays, cells were seeded at 0.4x106 cells/mL in a T75 flask. For 
immunofluorescence microscopy, 0.5x106 WT cells or 0.012x106 Cas9, mixed population EV and GALC 
KO cells were seeded on glass coverslips in a 24-well plate. Cells were exposed to PMA for 48 hours. 
The medium was then removed and replaced with THP-1 medium without PMA for a recovery period 
of 24 hours. Differentiated cells were then used in subsequent experiments. 
 
2.3.2.5 LPS stimulation 
Differentiated THP-1 cells were stimulated with lipopolysaccharide (LPS) from E. coli O111:B4 (Sigma). 
Differentiated THP-1 cells were incubated with LPS at 100 ng/mL in THP-1 medium overnight.  
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2.3.3 HEK-293T cells 
2.3.3.1 Maintenance 
HEK293T cells were maintained in HEK293T medium: Dulbecco’s Modified Eagle Medium (DMEM; 
Sigma) with 10% FBS and 2 mM L-glutamine. Cells were maintained at 37°C in humidified air with 5% 
CO2. 
 
HEK293T cells were passaged before 100% confluency was reached (approximately every 2-3 days). 
For cell passage, the medium was aspirated, cells washed in phosphate-buffered saline (PBS) and 
detached with trypsin-EDTA (Sigma). On cell detachment, trypsin was deactivated with 4 volume 
equivalents of HEK293T medium and the cell suspension split and transferred to a new flask containing 
HEK293T medium. For example, for confluent HEK293T cells in a T75 flask, 2 mL of trypsin was applied 
to washed cells for 2 minutes at 37 °C and deactivated with 8 ml of HEK293T medium. The cell 
suspension was then split 1:8 into a new T75 flask and made up to 10 mL with HEK293T medium. 
 
2.3.3.2 Lentivirus production 
7x106 HEK293T cells were seeded in 30 mL HEK293T medium in a 150 mm dish. The following day, the 
media was changed to 8 mL OptiMEM (Gibco) and cells were transfected using FuGENE 6 (Promega). 
60 µL FuGENE 6 was added to 1 mL OptiMEM, mixed by brief vortexing, and incubated for 5 min at 
room temperature. 6.5 µg pCMV-dR8.91, 3.5 µg pMD-VSVG and 10 µg of the lentiviral vector of 
interest (20 ng DNA in total) were then combined with FuGENE 6. The solution was briefly vortexed 
and incubated for 20 minutes at room temperature to allow complex formation before dropwise 
addition to the cells. 6 hours after transfection, the medium was replaced with 30 mL fresh HEK293T 
medium. Lentivirus-containing medium was harvested 48 hours post-transfection, filtered through a 
0.45 µm membrane, and used immediately for viral transduction or stored in 1 mL aliquots at -80 °C.   
 
2.3.4 Oligodendrocyte cells 
2.3.4.1 Maintenance 
Undifferentiated MO3.13 were maintained in DMEM with 10% FBS and 4 mM L-glutamine. Cells were 
maintained in T75 flasks at 37 °C in humidified air with 5% CO2. Cells were passaged before they 
reached 80% confluency (every 2-4 days). Cells were washed twice with 5 mL PBS. 2 mL trypsin-EDTA 
(Gibco) was added to the cells and incubated for 5 minutes. Trypsin was neutralised with 8 mL DMEM 




MO3.13 oligodendrocytes were differentiated by changing the media to differentiation media 
(DMEM, 1% FBS, 100 nM PMA) one day after seeding. Cells were grown in this differentiation media 
for 3 or 7 days before being used in subsequent assays. 
 
2.4 Protein expression, purification and preparation 
2.4.1 Stable H6-tagged CD1d-β2m expression in HEK293F cells 
2.4.1.1 Transfection 
For production of an inducible, stable co-expression cell line, HEK293F cells were grown to a density 
of 1x106 cells/mL in 30 mL and quadruple-transfected with the following plasmids. One plasmid 
contains a neomycin resistance gene and a transposon encoding the tetracycline transactivator 
inducer (PB-RN, 5 µg), a helper plasmid (PBase, 5 µg) transiently expresses the PB transposase which 
integrates the transposons into the host cell genome, and two plasmids containing a transposon 
encoding the target proteins CD1d-H6 and β2m under the control of a tetracycline response element 
(PB-T-CD1d-H6 and PB-T-β2m, 12.5 µg each). All plasmids were added to 0.6 mL OptiProSFM (Thermo 
Fisher Scientific). 35 µL FreeStyle MAX transfection reagent (Thermo Fisher Scientific) was added to 
0.6 mL OptiProSFM in a separate tube. DNA and transfection reagent mixtures were mixed and 
incubated at room temperature for 10 min before dropwise addition to the cells. Cells were grown for 
2 days before starting antibiotic selection. 
 
2.4.1.2 Antibiotic selection 
Cells were maintained in 30 mL FreeStyle media supplemented with 500 µg/mL geneticin (neomycin 
analogue). Every 2-3 days, cells were pelleted (60g, 5 minutes) and media was replaced by fresh media 
with geneticin. Drug selection was stopped after two weeks. Cultures were expanded to 150 mL (cell 
density was always maintained above 0.2x106 cells/mL) and aliquots were frozen. 
 
2.4.1.3 Induction of protein expression 
Cells were diluted to a density of 0.5x106 cells/mL in 150 mL FreeStyle293 media. Recombinant protein 
expression was induced by adding doxycycline at 2 µg/mL. 
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2.4.1.4 Protein harvest 
Expression media containing secreted recombinant protein was collected over a 2-month period from 
the start of induction. Every 2-3 days, one third of the culture volume was harvested and cells were 
pelleted (60g, 5 min). Supernatant containing protein was retained. The pellet was resuspended in the 
same volume of fresh media with 2 µg/mL doxycycline and returned to the culture flask. After one 
week, the culture volume was expanded to 300 mL. Subsequently, the cell pellet was discarded after 
harvesting the media. Media containing protein was cleared by centrifugation (4000g, 10 min), then 
filtered through a 0.2 µm filter and stored at 4°C. When harvested media was to be stored for longer 
than two weeks, it was supplemented with 0.02% sodium azide to prevent microbial growth and 
filtered through a 0.2 µm filter a second time immediately prior to purification. 
 
2.4.2 Purification of H6-tagged CD1d-β2m 
2.4.2.1 Nickel affinity purification 
CD1d-H6 was purified from conditioned media by nickel affinity chromatography. Conditioned media 
was incubated with 1 mL washed Ni-NTA agarose beads (Qiagen) per 100 mL media on an end-over-
end rotator for 1 hour at 4 °C. The beads were then applied to a gravity column and washed in 20 
column volumes (CV) PBS pH 7.4. CD1d-H6 was eluted using PBS containing 300 mM imidazole in 500 
µL fractions. Imidazole was diluted out from the protein buffer by multiple cycles of dilution in PBS 
and concentration in a centrifugal concentrator (10K molecular weight cut-off (MWCO); Amicon) until 
the imidazole concentration was below 10 mM.  
 
2.4.2.2 Size exclusion chromatography 
CD1d-β2m was further purified by size exclusion chromatography on a Superdex 200 column (GE 
Healthcare). The column was equilibrated in SEC buffer (150 mM NaCl, 50 mM Tris pH 7.4) for 
crystallisation experiments or cross-linking buffer (20 mM HEPES pH 7.0, 150 mM NaCl) for interaction 
assays. CD1d-β2m was concentrated to 2 mg/mL and stored at 4 °C for up to one month.  
 
2.4.3 Expression of deglycosylated H6-tagged CD1d-β2m 
CD1d-β2m expressing cells were treated with the α-mannosidase I inhibitor kifunensine to produce 
protein with high mannose glycans readily cleaved by Endoglycosidase H (Endo H). 1 mM kifunensine 
stock (Cayman chemicals, 10009437) was prepared in warm, sterile water, filtered and stored at 4 °C 
for up to 3 weeks. 5 μM kifunensine was added to cells at the same time as protein expression was 
induced with doxycycline. When media was replaced, fresh media was supplemented with 5 μM 
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kifunensine as well as 2 µg/mL doxycycline. Cells were discarded after 3 weeks of kifunensine 
treatment because there was significant cell death after this point. 
 
2.4.4 Purification of deglycosylated H6-tagged CD1d-β2m 
CD1d-β2m expressed in cells treated with kifunensine was purified by nickel affinity purification with 
Ni-NTA agarose (Qiagen) and eluted with 100 mM citrate pH 4. CD1d-β2m protein was buffer 
exchanged into 100 mM citrate pH 5.5 using repeated rounds of dilution and concentration in a 
centrifugal concentrator and concentrated to 2 mg/mL.  
 
For small-scale optimisation of Endo H treatment, 20 µg CD1d-β2m was incubated with a dilution series 
of Endo H (1000-62.5 units, NEB, P0702L) at room temperature or 37 °C, for 3 hours or overnight. As 
a positive control, CD1d-β2m was denatured by incubation with 0.5% SDS, 40 mM DTT at 100 °C for 10 
minutes prior to Endo H treatment at 37 °C overnight. After Endo H treatment, all samples were 
analysed by SDS-PAGE on a Coomassie-stained 4-12% Bis-Tris gel run in MOPS buffer. For preparative 
Endo H treatment, CD1d-β2m (at 2 mg/mL in 100 mM citrate pH 5.5) was incubated with 6.25 µL (3125 
NEB units) Endo H per milligram of CD1d for 3 hours at room temperature. A 20 µL sample was taken 
for SDS-PAGE analysis. Precipitate was removed by centrifugation (13 000g, 2 min), and 20 µL samples 
of the cleared solution and pellet were taken for SDS-PAGE analysis. Soluble CD1d-β2m was further 
purified and separated from Endo H by size exclusion chromatography on a Superdex 200 10/300 
column (GE Healthcare) equilibrated with 20 mM citrate pH 6, 150 mM NaCl and fractions containing 
CD1d-β2m only were pooled, concentrated and used in crystallisation trials. 
 
2.4.5 Expression of untagged saposins in E. coli 
pET15b expression plasmids encoding untagged human SapB or mouse SapA were transformed into 
chemically competent ORIGAMI E. coli cells following the protocol detailed in section 2.1.6. Ampicillin 
and Tetracycline selection was maintained at all times. A single transformant colony was used to 
inoculate a 5 mL 2 x TY starter culture incubated overnight (37 °C, 200 rpm). The next day, 1 L of 2 x 
TY medium was inoculated with the starter culture and incubated (37 °C, 200 rpm) until it reached an 
absorbance at 600 nm of 0.6-0.8. Protein expression was induced by addition of 1 mM isopropyl β-D-
1- thiogalactopyranoside. Following induction, incubation continued at 21 °C with shaking at 200 rpm 
overnight, prior to pelleting cells by centrifugation (5 000g, 30 min, 4 °C). Bacterial pellets were used 
immediately or stored at -20 °C. 
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2.4.6 Purification of untagged saposins 
2.4.6.1 Mechanical lysis of bacterial cells 
Bacterial pellets from 1 L of culture were fully resuspended in 30 mL ice-cold anion-exchange buffer 
(50 mM Tris pH 7.4, 25 mM NaCl) and lysed by passing twice through a hydraulic cell disruptor 
(Constant Systems TS) at 25 kpsi pressure, 8 °C. Insoluble cell wall and membrane fractions were 
pelleted by centrifugation (40 000g, 30 min, 4 °C) and discarded. 
 
2.4.6.2 Heat treatment of bacterial lysate 
Cleared lysate was heat-treated in a boiling water bath (100 °C, 5 min, repeated four times) to 
precipitate heat-sensitive proteins. Denatured, precipitated E. coli proteins were pelleted by 
centrifugation (40 000g, 30 min, 10 °C) and discarded. The supernatant contained heat-resistant 
proteins including saposins. The supernatant was supplemented with 20 μg/mL DNAse I, 2.5 mM 
MgCl2, and 0.5 mM CaCl2 to digest contaminating DNA. The solution was dialysed against 5 L of anion-
exchange buffer using SnakeSkin dialysis tubing (3500 MWCO; Thermo Scientific).  
 
2.4.6.3 Anion-exchange (AEX) chromatography 
A 5 mL HiTrap Q Sepharose column (GE) was equilibrated with 10 CV anion exchange buffer (50 mM 
Tris pH 7.4, 25 mM NaCl) before loading the crude saposin extract using a peristaltic pump at 5 
mL/min. The column was then washed with 10 CV anion exchange buffer A and connected to an FPLC 
(ÄKTÄ purifier, GE) for elution of bound proteins with a 0-50% gradient of 50 mM Tris pH 7.4, 1 M NaCl 
over 20 CV. 2 mL fractions were collected and A280 was continuously recorded during elution. 
Fractions corresponding to A280 peaks were analysed using 4-12% gradient Bis-Tris SDS-PAGE (section 
2.6.2.2). All fractions containing saposins were pooled and concentrated to a volume of 5 mL using 
Vivaspin 20 centrifugal concentrators (3 000 MWCO, Sartorius). 
 
2.4.6.4 Size exclusion chromatography 
A HiLoad 16/600 Superdex 75 column (GE) was equilibrated with 1.5 CV size exclusion buffer (50 mM 
Tris pH 7.4, 150 mM NaCl) prior to injection of 5 mL concentrated AEX elution. Isocratic elution with 
size exclusion buffer was performed at 1 mL/min over 1.2 CV. 2 mL fractions were collected and A280 
was continuously recorded during elution. Fractions corresponding to the main A280 peak were 
pooled and concentrated to 15-20 mg/mL using Vivaspin 20 centrifugal concentrators (3 000 MWCO, 
Sartorius). Purity was assessed by 4-12% gradient Bis-Tris SDS-PAGE (section 2.6.2.2). Purified saposins 
were stored at 4 °C and stable for at least six months. 
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2.4.7 Loading of proteins with α-GalCer 
Endogenous lipids co-purified with CD1d and SapB were exchanged for the lipid α-GalCer (Avanti 
Lipids) based on a protocol used to obtain crystal structures of α-GalCer-loaded CD1d176,177. α-GalCer 
was resuspended in DMSO at 1 mg/mL and dissolved by heating the solution at 80 °C for 10 min, with 
brief sonication and vortexing every 3 minutes. CD1d-β2m and SapB were incubated with a 3-fold 
molar excess of α-GalCer in PBS overnight at room temperature, in a volume such that the DMSO 
concentration did not exceed 1%. DMSO was then diluted out of the buffer by several cycles of dilution 
and concentration using centrifugal concentrators prior to concentration of the proteins for size 
exclusion chromatography. α-GalCer-loaded proteins were separated from free α-GalCer by size 
exclusion chromatography with a Superdex 200 10/300 column equilibrated in 20 mM HEPES pH 7.0, 
150 mM NaCl. α-GalCer-loaded proteins were used within 24 hours after size exclusion 
chromatography to avoid significant hydrolysis of the lipid.  
 
2.4.8 SapA nanodisc preparation 
The protocol for SapA nanodisc preparation was adapted from Frauenfeld et al.94 and Chien et al.93. 
Egg phosphatidylcholine (PC), 14:0 bis(monomyristoylglycero)phosphate (S,R) (BMP) and cholesterol 
(Chol) from ovine wool were purchased from Avanti Polar Lipids. The appropriate quantity of lipids in 
chloroform was mixed in a 2 mL glass vial and dried under an argon stream to form a lipid film. The 
lipid film was resuspended by vortexing vigorously in 104 mM citrate pH 4.0, 156 mM NaCl to make a 
solution with 5 mg/mL lipids. The lipid solution was incubated in a water bath at 37 °C for one hour, 
with vigorous vortexing every 15 min. This was followed by 10 cycles sonication in a sonicating water 
bath for 30 s and vortexing for 15 s. n-Dodecyl-beta-Maltoside (DDM) from a 5% (w/v) stock was then 
added for a final concentration of 0.2% DDM, 100 mM citrate pH 4, 150 mM NaCl, and mixed by 
pipetting. The solution remained cloudy. 385 µg mouse SapA was added for each milligram of lipid 
and mixed by pipetting. The solution was incubated at 37 °C for one hour, with mixing every 15 min. 
AC buffer (100 mM citrate pH 4.0, 150 mM NaCl) was added to make a final volume of 550 µL. The 
solution was incubated at room temperature for a further 10 min, then spin-filtered and loaded onto 
a Superdex 200 10/300 column (GE Healthcare) equilibrated with AC buffer. Fractions containing 
nanodiscs were concentrated in centrifugal concentrators (4 mL 3K MWCO, then 500 µL 5K MWCO; 
Amicon and Vivaspin). Nanodiscs were used in experiments within 24 hours. 1 mg lipids yielded 
approximately 400-600 µg nanodiscs. 
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2.4.9 Expression of H6-tagged SapB in HEK293F cells 
H6-tagged SapB was expressed in HEK293F cells by polyethylenimine (PEI)-based transient 
transfection. 300 μg DNA encoding SapB-H6 was diluted in 5 mL sterile PBS and mixed by brief 
vortexing. 450 μg PEI was added and the solution was mixed by brief vortexing. The mixture was 
incubated at room temperature for 20 minutes, then added dropwise to 300 mL HEK293F cells at a 
density of 1x106 cells/mL. The cells were then incubated with shaking (37 °C, 8% CO2, 130 rpm). After 
4 days, the media was harvested as described in section 2.4.1.4.  
 
2.4.10 Purification of SapB-H6 
SapB-H6 was purified from conditioned media by nickel affinity purification followed by elution with 
300 mM imidazole in PBS as described in section 2.4.2.1. SapB-H6 was further purified by size exclusion 
chromatography with a Superdex 75 column (GE Healthcare) in cross-linking buffer (20 mM HEPES pH 
7.0, 150 mM NaCl).  
 
2.4.11 SapB-H6 tag removal 
Prior to crystallisation trials (but not cross-linking assays), the tag of SapB-H6 was removed by 
incubation of SapB (1 mg/mL) with washed Carboxypeptidase A-agarose beads (1.2 U/mL; Sigma 
C1261) at 25 °C for 3 hours or overnight with shaking at 170 rpm. This was followed by incubation with 
washed Ni-NTA resin (Qiagen) on an end-over-end rotator to remove tagged protein (30 min, 4 °C). 
The supernatant containing untagged SapB was separated from Carboxypeptidase A-agarose and Ni-
NTA agarose by passing through a gravity flow column and washing the beads several times with 250 
μL cross-linking buffer. Remaining tagged SapB was eluted from Ni-NTA agarose with 300 mM 
imidazole in PBS. Flow-through, wash and eluted fractions were analysed by SDS-PAGE on a 4-12% Bis-
Tris gel in MOPS-SDS running buffer. Flow-through and wash fractions containing pure untagged SapB 
in cross-linking buffer were pooled and concentrated in a centrifugal concentrator (3K MWCO; 
Sartorius).  
 
2.4.12 Stable AC-H6 and AC-BAP-H6 expression in HEK293F cells 
Production of inducible cell lines stably expressing AC-H6 and AC-BAP-H6 was performed as described 
in section 2.4.1, except that HEK293F cells were co-transfected with only 3 plasmids: PB-RN (5 µg), 
PBase (5 µg), and PB-T-AC-H6 or PB-T-AC-BAP-H6  (25 µg). 
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2.4.13 Purification of H6-tagged AC 
H6-tagged AC (AC-H6 and AC-BAP-H6) was purified by nickel affinity purification with Ni-NTA agarose 
(Qiagen) and eluted with 100 mM citrate pH 4. Purified AC-BAP-H6 was then buffer exchanged into 
PBS for subsequent biotinylation (section 2.4.15). Alternatively, AC-BAP-H6 was eluted with 300 mM 
imidazole in PBS and imidiazole was diluted out by multiple cycles of dilution in PBS and concentration 
in a centrifugal concentrator (10K MWCO; Amicon). 
 
AC-H6 and AC-BAP-H6 were concentrated to 2 mg/mL and stored at 4 °C in 100 mM citrate pH 4 and 
PBS, respectively. AC is a lysosomal protein and is therefore very resistant to proteolysis, remaining 
stable for several months at 4 °C.  
 
2.4.14 AC-H6 tag removal 
The hexahistidine tag on the C-terminus of AC-H6 was removed with Carboxypeptidase A in 20 mM 
Tris pH 7.4, 300 mM NaCl following the protocol described in section 2.4.11.   
 
2.4.15 AC-BAP-H6 biotinylation 
AC-BAP-H6 was biotinylated following a published method178. 40 µM (2 mg/mL) AC-BAP-H6 was mixed 
with 5 µM MgCl2, 2 mM ATP, 1 µM GST-BirA (previously purified by Dr Janet Deane) and 150 µM D-
Biotin in 1 mL PBS. The sample was incubated on a gently shaking platform (30 °C, 2 h). The same 
amount of GST-BirA andD-Biotin were added to the sample for further incubation (30 °C, 2 h). GST-
BirA was removed by incubating the sample with 25 µL glutathione sepharose 4B resin (GE Healthcare) 
with mixing (room temperature, 30 min). Beads were removed by centrifugation (4000g, 3 min). Biotin 
and ATP were diluted 200-fold by multiple cycles of dilution and concentration. 
 
2.4.15.1 Gel-shift assay 
The extent of biotinylation was measured by a gel-shift assay. Two samples with 5 µL of 10 µM (0.5 
mg/mL) AC and a control sample of 5 µL PBS were mixed with 10 µL 2X SDS-PAGE loading buffer and 
heated at 95 °C for 5 minutes in a PCR bloc. The samples were cooled to room temperature. 5 µL of 
1.75 mg/mL streptavidin in PBS were added to one AC sample and the control sample, leaving a control 
AC sample without streptavidin. Streptavidin was provided in excess, so that all biotinylated AC would 
bind streptavidin. After incubating at room temperature for 5 min, the samples were run on a 12% 
SDS-PAGE gel. The gel was stained with Coomassie stain and imaged with Odyssey (LI-COR 
Biosciences). The unbiotinylated α subunit of AC was used as a loading control. The intensity of the 
bands was calculated with Image Studio Lite (LI-COR Biosciences). The proportion of biotinylated AC 
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was calculated by dividing the ratio of unbiotinylated β subunit to α subunit in the sample mixed with 
streptavidin by the ratio of total β to α in the sample without streptavidin.  
 
2.4.16 Purification of ProtA-AC27 
The cell line stably expressing ProtA-AC27 was established by Dr Janet Deane using the PiggyBac 
system described in section 2.4.1. 
 
2.4.16.1 Small-scale optimisation 
ProtA-AC27 was captured from 3 mL conditioned media by incubation with 75 µL IgG Sepharose 6 Fast 
Flow beads (GE Healthcare, 17-0969-01) for 2 hours at 4 °C. Beads were spun down (500g, 2 min), the 
flow-through was removed and beads were washed twice with 1 mL TEV reaction buffer (50 mM Tris 
pH 7.4, 150 mM NaCl). After protein capture and wash, five different conditions for TEV protease 
digestion were tested in small scale experiments. 15 µL of protein-loaded beads were transferred to 
four PCR tubes. For the last test experiment, 1 mL of optimal TEV cleavage buffer (50 mM Tris pH 8, 
0.1 M NaCl) was added to 15 µL loaded beads. The beads were spun down (500g, 2 min) and excess 
media was removed. The 50% bead slurry in optimal TEV cleavage buffer was transferred to a PCR 
tube. EZCut TEV Protease (BioVision, 7847-1000) was added to each tube for a final concentration of 
0.1 or 0.2 mg/mL. The reaction was incubated at 37 °C or 4 °C for 2 hours or overnight. The 
supernatant, containing untagged AC27, was then separated from the beads by centrifugation (1000g, 
1 min) through a Pierce microspin column (Thermo Scientific), then beads were washed four times 
with 50 µL TEV reaction buffer. 
 
2.4.16.2 Large-scale preparation 
ProtA-AC27 was captured from 500 mL conditioned media by incubation with 2.75 mL IgG Sepharose 
6 Fast Flow beads. After ProtA-AC27 capture, IgG beads were washed with 5 CV TEV reaction buffer 
(50 mM Tris pH 7.4, 10 mM NaCl). TEV was then added to a 50% bead slurry for a final TEV 
concentration of 0.1 mg/mL, with 0.02% sodium azide to prevent bacterial growth. The mixture was 
incubated with gentle shaking (80 rpm) overnight at 34 °C. The supernatant containing untagged AC27 
was separated from the beads using a gravity column. The beads were washed until all protein was 
eluted, as indicated by null absorbance at 280 nm of the wash fractions. Flow-through and wash 
fractions were combined, then H6-tagged TEV was separated from AC27 by incubation with 1 mg Ni-
NTA resin for 1 hour at room temperature. The flow-through was collected. Beads were washed with 
30 mM imidazole in PBS. Flow-through and wash fractions, containing AC27, were combined, 
concentrated and the buffer was exchanged to AC buffer (100 mM citrate pH 4, 150 mM NaCl) by 
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several cycles of dilution and concentration in a centrifugal concentrator (10K MWCO; Amicon). AC27 
was further purified by size exclusion chromatography using a Superdex 200 16/600 column 
equilibrated in AC buffer.  
 
2.4.17 AC autoproteolysis 
To allow autoproteolysis of AC into its active, mature form, AC was incubated in AC buffer (100 mM 
citrate pH 4, 150 mM NaCl) at 37 °C for 27 hours. 
 
2.4.18 Transient expression of PTPRM Fn3-4-H6 in HEK293F cells 
PTPRM Fn3-4 (residues 478-723) was cloned into the pHLsec vector with a C-terminal H6 tag by Eve 
Caroe and recombinantly expressed in HEK293F cells by transient transfection with PEI. 300 μg DNA 
encoding PTPRM Fn3-4-H6 was diluted in 5 mL sterile PBS and mixed by brief vortexing. 450 μg PEI was 
added and the solution was mixed by brief vortexing. The mixture was incubated at room temperature 
for 20 minutes, then added dropwise to 300 mL HEK293F cells at a density of 1x106 cells/mL. The cells 
were then incubated with shaking (37 °C, 8% CO2, 130 rpm). After 4 days, the media was harvested as 
described in section 2.4.1.4. 
 
2.4.19 Purification of H6-tagged PTPRM Fn3-4 
H6-tagged PTPRM Fn3-4 was purified from conditioned media by nickel affinity purification as 
described in section 2.4.2.1, but using 20 mM imidazole in TBS, pH 7.4 as wash buffer and 300 mM 
imidazole in TBS, pH 7.4 as elution buffer. PTPRM Fn3-4 was further purified by size exclusion 
chromatography with a Superdex 75 16/600 column (GE Healthcare) in 20 mM Tris pH 7.4, 150 mM 
NaCl. 
 
2.5 X-ray crystallography: protein structure determination and analysis 
2.5.1 Protein crystallisation 
Proteins were concentrated with Corning Spin-X UF centrifugal concentrators. Crystallization 
experiments were set up using a Mosquito LCP robot (LCP Labtech) in 96-well nanolitre-scale sitting 
drops (200 nL protein plus 200 nL of precipitant) equilibrated at 20 °C against 80 μL reservoirs of 
precipitant. For most crystallisation experiments, the following crystallisation screens were set up: 
Morpheus (Molecular Dimensions), JCSG-plus (Molecular Dimensions), PACT Premier (Molecular 





Glycosylated CD1d, unglycosylated CD1d and α-GalCer loaded glycosylated CD1d was mixed with 
unglycosyated SapB, α-GalCer loaded unglycosylated SapB or glycosylated SapB at various 
concentrations and molar ratios detailed in Chapter 3. Co-crystallisation trials were set up immediately 
after mixing of the two components. 
 
2.5.1.2 AC and nanodiscs 
AC-H6 (4.5 mg/mL) and SapA-PC nanodiscs (3.5 mg/mL) were mixed in equimolar quantities and 
immediately used to set up crystal trays, or incubated at room temperature for 75 minutes, then 
concentrated further to the solubility limit of the mixture prior to setting up co-crystallisation trials. 
 
320 μL AC27 (4.1 mg/mL, 100 μM) was incubated with 320 μL psychosine (2 mM) in the same buffer 
(100 mM citrate pH 4, 150 mM NaCl) for one hour. The mixture was concentrated until AC27 was at a 
concentration of 4.1 mg/mL based on protein absorbance at 280 nm prior to setting up co-
crystallisation trials. 
 
2.5.1.3 PTPRM Fn3-4 
All crystallisation experiments were set up with PTPRM Fn3-4 at 11.5 mg/mL unless indicated 
otherwise. Co-crystallisation experiments with galactose were performed by adding a 5-fold molar 
excess of galactose (2 mM) to concentrated PTPRM from a 0.1 M stock of galactose in water 
immediately prior to setting up co-crystallisation trials.  
 
2.5.2 Optimisation of crystallisation conditions 
When crystals, microcrystals, or microcrystalline precipitate were obtained, a grid search strategy was 
undertaken to optimise these crystals by manually setting up 96-well optimisation plates centred 
around the successful crystallisation condition with incremental changes in precipitant concentration, 
pH and/or additive concentration in the reservoir solution in each well. 
 
2.5.3 Crystal microseeding 
Microseeding of PTPRM Fn3-4 crystals was performed following a published protocol179. A stabilising 
solution was made with 50% original crystallisation condition (20% PEG 3350, 0.2 M ammonium 
nitrate), 35% water, 15% PTPRM Fn3-4 protein solution (at 9.1 mg/mL).  Microcrystals were grown by 
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Eve Caroe in a drop containing 400 nL PTPRM Fn3-4 at 11.3 mg/mL with 200 nL reservoir solution 
containing 22% PEG 3350, 0.22 M ammonium nitrate. These microcrystals were resuspended in 50 uL 
stabilising solution. Seed stock was made by vortexing the microcrystal solution with a Teflon bead 
(Seed Bead, Hampton research) for 90 s. The seed solution was serially diluted 1 in 4 in stabilising 
solution to obtain a range of seeding solution concentrations. A 96-well crystallisation plate was set 
up with dilutions of the original reservoir solution (50%-72% dilution of 20% PEG 3350, 0.2 M 
ammonium nitrate) across columns. Drops were dispensed with 200 nL PTPRM Fn3-4 at 9.1 mg/mL 
and 200 nL seed stock with different dilutions of seed stock dispensed on each row. 
 
2.5.4 Crystal soaks 
PTPRM Fn3-4 crystals were soaked with galactosphingolipid headgroup analogues prior to harvest. 0.5 
M stocks were made with galactose or D-Galactose 4-sulfate (Gal-4S) sodium salt (Sigma 90572) in 
water. A soak solution was made with 10 mM galactose or Gal-4S in reservoir solution. Crystals were 
transferred to a drop of soak solution and incubated for 10 to 30 minutes. Non-cryoprotective 
conditions were supplemented with 20% glycerol in soak solution prior to harvest. Crystals were then 
harvested using nylon loops and flash frozen in liquid nitrogen. 
 
2.5.5 SDS-PAGE analysis of crystals 
Crystal contents were analysed by SDS-PAGE analysis of crystals. Several crystals were harvested from 
the crystallisation drop and washed by transferring to a drop of reservoir solution to remove 
uncrystallised protein components. Crystals were then transferred to a second drop of reservoir 
solution and dissolved in SDS-PAGE loading buffer. Alternatively, large crystals from which data had 
been collected at the synchrotron were recovered into SDS-PAGE loading buffer from the crystal-
mounting loop. Individual crystal components were analysed by SDS-PAGE followed by Coomassie 
staining. 
 
2.5.6 X-ray data collection 
Crystals were cryoprotected in reservoir solution supplemented with 20% v/v glycerol (unless the 
crystallisation condition was already cryprotective, as is the case in the Morpheus screen) and flash-
cooled by plunging into liquid nitrogen. Diffraction data were recorded at Diamond Light Source on 
beamlines I03, I04 and I04-1. Diffraction data were indexed and integrated using the automated data 
processing pipelines at Diamond Light Source180 implementing XIA2 DIALS181, XIA2 3dii, autoPROC or 
autoPROC and STARANISO182 depending on the extent of anisotropic diffraction, then scaled and 
merged using AIMLESS183.  
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2.5.7 Molecular replacement 
2.5.7.1 CD1d 
The model for molecular replacement was generated using the published structure of CD1d-β2m 
bound to lysophosphatidylcholine184 (PDB ID: 3U0P, chains A and B), using phenix.sculptor185,186 to 
remove the lipid ligand from the model and revert the glycosylation site mutations present in this 
structure. Molecular replacement was performed with Phaser-MR187 and was followed by rigid body 
refinement using phenix.refine188. Molecular replacement into the highly anisotropic data (crystal 
form (iii) described in Table 3.2) was carried out using both the isotropic and anisotropically processed 
data, resulting in the same solution. Maps were inspected using Coot189.  
 
2.5.7.2 SapA assembly 
The molecular replacement model for the SapA assembly structure was the open human SapA 
monomer (PDB ID: 4DDJ). The protein chain was extracted from the deposited model and the 
anisotropic B-factors of this high-resolution structure were converted to isotropic factors (B-factors = 
30) using the PDB file editor in phenix185. The SapA assembly structure was solved by molecular 
replacement using four copies of the SapA model using Phaser-MR187. The resulting model was 
partially incorrect, so the fourth SapA chain was deleted from this solution using the PDB file editor in 
phenix185 and re-placed manually by symmetry with the other 3 chains with the Secondary Structure 
Matching (SSM) superpose tool in Coot189, with kind help from Randy Read.  
 
2.5.7.3 PTPRM Fn3-4 
The PTPRM Fn3-4 structure was solved by molecular replacement with four copies of the unpublished 
PTPRM Fn3-4 structure (chain A) previously obtained by Eve Caroe, Dr Stephen Graham and Dr Janet 
Deane using Phaser-MR187. 
 
2.5.8 Structure refinement 
2.5.8.1 SapA assembly 
The model was refined by rigid body refinement with phenix.refine188. Mismatches in the mouse vs 
human SapA sequence were mutated manually in Coot189. The model was further refined by XYZ 
coordinate refinement in reciprocal space with non-crystallographic symmetry and reference model 
restraints to minimise over-fitting of the data. The model was then refined by molecular dynamics 
simulation and structure manipulation in ISOLDE190. Where possible, obvious Ramachandran outliers, 
 47 
rotamers outliers and non-Proline cis peptide bonds were corrected in ISOLDE. The model was then 
refined in phenix.refine. This cycle was repeated once. Model geometry was evaluated with 
MolProbity191 and ISOLDE validation tools throughout the refinement process. 
 
2.5.8.2 PTPRM Fn3-4 
After molecular replacement, PTPRM Fn3-4 was refined in phenix.refine188. The first round of rigid 
body refinement corrected the erroneously assigned space group P 31 2 1 to P 32 2 1. Missing parts of 
the model were built in Coot189. The model was refined by multiple cycles of molecular dynamics 
simulation and structure manipulation in ISOLDE190 followed by refinement in phenix.refine. 
Ramachandran outliers, rotamer outliers and non-Proline cis peptide bonds were corrected in ISOLDE. 
The following settings were used for refinement in phenix.refine: XYZ coordinate refinement in 
reciprocal space with individual B-factors and occupancies refinement, non-crystallographic symmetry 
restraints, X-ray/stereochemistry weight and X-ray/ADP weight optimisation and Ramachandran 
restraints. N-linked glycans were built in Coot using the carbohydrate building tool192. Model geometry 
was evaluated with MolProbity191 and ISOLDE validation tools throughout the refinement process.  
 
2.5.9 Structure analysis 
Structure alignments were performed with the Matchmaker tool in ChimeraX193. Potential hydrogen 
bonds were identified in ChimeraX. Potential hydrophobic interactions were determined by 
identifying pairs of hydrophobic residues closer than 0.4 Å (Wan der Waals radius overlap ≥ -0.4 Å) 
with the Contacts tool in ChimeraX. Structural figures were rendered with ChimeraX. Surface residue 
hydrophobicity colouring was performed using the Molecular lipophilicity potential tool194,195. 
Structure colouring by conservation was done in Chimera196.  
 
2.5.10 Protein sequence alignment 
Profile-profile alignment was performed using the Fold and Function Assignment System (FFAS) 
server197 and structure based-alignment using the Dali server198. Furin cleavage sites were found using 
the ELM server199. Multiple sequence alignments were performed using MULTALIN200 and visualised 
with Jalview201.  
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2.6 Protein biochemistry 
2.6.1 Protein quantification 
2.6.1.1 Measuring UV absorbance at 280 nm (A280) 
Concentrations of purified proteins containing at least one tyrosine or tryptophan were determined 
by measuring the A280 of a 1.5 μL sample using a NanoDrop One spectrophotometer (Thermo). Prior 
to measurement the instrument was blanked in appropriate buffer. Concentration was calculated by 
using the theoretical extinction coefficient at 280 nm and optical density provided by ExPASy 
protparam. 
 
2.6.1.2 BCA microplate assay 
A blank solution (lysis buffer diluted 1/5) and a set of BSA concentration standards (2000, 1000, 500, 
250, 125, 62.5 μg/mL) in blank solution were prepared. Cell lysates were diluted 1/5 prior to analysis. 
25 μL of each standard and diluted sample were transferred to a 96-well flat bottom transparent 
microplate in duplicate. 200 μL of Pierce BCA protein assay working reagent (Thermo Fisher) was 
added to each well using a dispensing pipette and the plate was incubated at 37   ̊C for 30 min prior 
to measuring the absorbance at 570 nm using a Spectramax M5 plate reader. Concentrations of 
protein samples were calculated from the BSA standard curve using a quadratic fit. 
 
2.6.2 Analysis of proteins by polyacrylamide gel electrophoresis 
2.6.2.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Gels were poured using Mini-PROTEAN glass plates and casting equipment (Bio-Rad). Gel composition 
is described in Table 2.2. Protein samples were denatured by heating (95   ̊C, 5 min) in SDS-PAGE 
loading buffer (20 mM DTT, 40 mM Tris, 2 % w/v SDS, 4% glycerol, 0.01% w/v bromophenol blue) prior 
to separation in SDS running buffer (20 mM Tris-HCl, 154 mM glycine, 0.1% w/v SDS) using a BioRad 
Mini-PROTEAN electrophoresis cell at room temperature (40 mA/gel, 200 V, < 30 W, 50 min). 
 
2.6.2.2 Gradient Bis-Tris polyacrylamide gel electrophoresis 
Pre-cast 4-12% Bis-Tris polyacrylamide gradient gels (NuPAGE) were also used for protein 
electrophoresis with 1X MES-SDS running buffer (NuPAGE) or, where indicated, 1X MOPS-SDS running 
buffer (NuPAGE) as directed by the manufacturer (125 mA/gel, 200 V, < 30 W, 35 min). Protein was 
denatured and reduced as above prior to separation. 
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2.6.2.3 Visualising separated proteins 
SDS-PAGE gels were incubated at room temperature overnight with 10 mL InstantBlue Coomassie 
based reagent (Expedeon) on a rocking platform. Before scanning, gels were rinsed in water to remove 
excess stain. Gels were scanned as uncompressed TIF files, 600 dpi. 
 










Water 3.80 mL 3.20 mL 2.20 mL 2.04 mL 
30% Acrylamide solution 3.40 mL 4.00 mL 5.00 mL 510 μL 
Resolving gel buffer (1.5 M Tris-HCl, 
pH 8.8) 2.60 mL - 
Stacking gel buffer (1 M Tris-HCl, 
pH 6.8) - 390 μL 
20% SDS 50 μL 15 μL 
Tetramethylethylenediamine 20 μL 10 μL 
10% Ammonium persulfate  100 μL 30 μL 
 
2.6.2.4 SYPRO Ruby staining 
For sensitive protein detection, 1.5 mm 4-12% Bis-Tris gels were stained with SYPRO Ruby (Thermo 
Fisher) after SDS-PAGE electrophoresis, following the rapid protocol described in the product manual: 
the gel was fixed twice in 150 mL of fix solution (50% methanol, 7% acetic acid) with agitation on an 
orbital shaker at room temperature for 15 min each time. The fix solution was replaced with 90 mL 
SYPRO Ruby stain. The gel was microwaved for 45 s at full power, agitated for 30 s, microwaved for 45 
s and incubated with shaking at room temperature for 5 min. The gel was then reheated for 45 s in 
the microwave then agitated at room temperature for 23 min, for a total stain time of 30 min. The gel 
was transferred to a clean container and washed in 150 mL of wash solution (10% methanol, 7% acetic 
acid) with agitation at room temperature for 30 min. The gel was then rinsed in MQW for 5 min twice 
prior to imaging using a G:BOX imaging system (Syngene). 
 
2.6.3 Western blot  
2.6.3.1 Cell lysis  
For analysis of TNF-α in THP-1 cells, 3x106 cells were washed in PBS 3 times, lysed in 300 μL RIPA buffer 
(50 mM Tris HCl, PH 7.4, 150 mM NaCl, 1% Triton X-100 (TX-100), 0.5% Sodium deoxycholate, 0.1% 
SDS, 1 mM EDTA, Complete protease inhibitor cocktail (Roche), 1 mM phenylmethylsulfonyl fluoride 
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(PMSF)) and incubated at 4 °C for 30 min on a rotating wheel. The lysate was cleared by centrifugation 
(12 000g, 20 min). Protein concentration was determined by BCA assay as described in section 2.6.1.2 
and protein concentration was equalised across samples. 
 
For analysis of cleaved Caspase-3 (Casp-3) in WT and GALC KO MO3.13 oligodendrocytes, cells were 
seeded in 6 well plates and differentiated on the next day. As a positive control, WT oligodendrocytes 
were treated with 2 µM staurosporine (Cell Guidance Systems) for 24 hours before cell lysis. 3 or 7 
days after differentiation, cells were washed twice in PBS, lysed in 100 µL lysis buffer (10 mM Tris pH 
8, 1 mM EDTA, 1% TX-100, 140 mM NaCl, 1 mM PMSF) and incubated at 4 °C for one hour on a rotating 
wheel. The lysate was cleared by centrifugation (12 000g, 10 min). Protein concentration was 
determined by BCA assay as described in section 2.6.1.2 and protein concentration was equalised 
across samples. 
 
2.6.3.2 Electrophoretic separation and transfer of proteins 
Protein was denatured in SDS-PAGE loading buffer and 60 μL of protein lysate were loaded onto a gel 
for protein separation by SDS-PAGE as described in section 2.6.2.1, alongside 5 μL of PageRuler Plus 
pre-stained protein ladder (Thermo Scientific). Proteins were transferred onto a nitrocellulose 
membrane in wet transfer buffer (25 mM Tris, 192 mM glycine, 20% v/v ethanol) in a Mini Trans-Blot 
Electrophoretic Transfer Cell (Bio-Rad) at 100 V for 1 hour. 
 
2.6.3.3 Immunoblotting 
Antibodies used for immunoblotting are documented in Table 2.3. All antibodies were diluted in 5% 
w/v dried milk powder in PBST (PBS, 0.1% v/v Tween-20). All incubation steps were performed on a 
rocking platform. Wash steps were performed with 5% w/v milk in PBST. For Western blot analysis of 
cleaved Casp-3, PBS was replaced by TBS in all steps. 
 
Membranes were blocked for one hour in 5% w/v milk in PBS at room temperature. Membranes were 
then incubated with primary antibody overnight at 4 °C and washed (5 min, 3 times) prior to incubation 
with infrared fluorophore–conjugated secondary antibody on a rocking platform (1 hour, room 
temperature). Membranes were washed with 5% milk in PBST (5 minutes, twice), then washed once 
in PBST (15 min), rinsed in PBS and dried. Immuno-reactive bands were visualised with an Odyssey CL-
x infrared imager (LI-COR Biosciences). Band intensities were quantified using Image Studio-Lite (LI-
COR Biosciences).  
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Table 2.3. Antibodies used for Western blot experiments 
Target Source Dilution Provider and ID 
Primary Antibodies 
β2m Rabbit polyclonal 1:10000 Dako A0072 (provided by Louise Boyle) 
GFP Rabbit polyclonal 1:5000 Sigma G1544 
TNF-α Mouse monoclonal 1:500 R&D Systems MAB610 
TNF-α Rabbit polyclonal 1:1000 Cell Signalling Technology 3707S 
Cleaved Casp-3 Rabbit polyclonal 1:1000 Cell Signalling Technology 9661 
GAPDH Mouse monoclonal 1:1000 Ambion AM43000 
Secondary Antibodies 
Mouse IgG IRdye800  Goat polyclonal 1:10000 Li-COR Biosciences 
Rabbit IgG IRdye680 Goat polyclonal 1:10000 Li-COR Biosciences 
 
2.6.4 Equilibrium binding assay  
Ni-NTA agarose beads were loaded with a saturating amount of CD1d-β2m, and complete capture of 
CD1d-β2m was verified by measuring the absorbance of the supernatant at 280 nm. Saturated beads 
were washed three times in equilibrium assay buffer (50 mM HEPES pH 7.0, 150 mM NaCl, 0.05% 
digitonin, 2.5 mM CaCl2, 2.5 mM MgCl2). Serial dilutions (1:1) of CD1d-β2m-saturated beads were made 
in equilibrium assay buffer supplemented with unloaded Ni-NTA beads to equalize the bead volume 
across all samples. SapB was added at a final concentration of 680 nM in equilibrium assay buffer. The 
reaction was incubated with shaking at room temperature for 1 hour. The supernatant containing 
unbound SapB was separated from the beads by centrifugation (800g, 2 min) followed by separation 
with a Micro-Spin column (Pierce) (800g, 2 min) to remove all beads. The supernatant was analysed 
by SDS-PAGE followed by staining with SYPRO Ruby (Life Technologies) as described in section 2.6.2.4. 
For analysis of bead samples, these were boiled in SDS-PAGE loading dye, separated by SDS-PAGE and 
detected by Coomassie staining.  
 
2.6.5 Cross-linking assay  
Amine-reactive cross-linking agents disuccinimidyl sulfoxide (DSSO) and PEGylated 
bis(sulfosuccinimidyl)suberate (BS(PEG)5) were dissolved in DMSO and added to 10 μM CD1d-β2m 
alone, 20 μM SapB alone or 10 μM CD1d + 20 μM SapB with final cross-linker concentrations of 0, 200 
μM or 1 mM in cross-linking buffer. The reaction was incubated for 30 min at room temperature and 
terminated by incubation with 20 mM Tris pH 8 for 15 min. The reaction products were analysed by 
SDS-PAGE on a 4-12% Bis-Tris gradient gel followed by Coomassie staining.  
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2.6.6 GFP co-immunoprecipitation 
2.6.6.1 Expression of GFP-tagged constructs 
80% confluent HeLa cells in 12 mL media in a 100 mm dish were transfected with 12 μg vector (pEGFP-
N1 empty vector, CD1d-EGFP or HLA-A2-EGFP) pre-mixed with 36 μL FuGene 6 in Opti-MEM. 15 hours 
after transfection, the media was replaced with fresh media containing 200 U/mL interferon γ (IFN-γ; 
a kind gift from Louise Boyle). 48 hours after IFN-γ stimulation, cells were scraped into a falcon tube 
and washed 3 times by centrifugation (220g, 5 min, 4 °C) and resuspension in PBS.  
 
2.6.6.2 Cell lysis 
Cells were lysed for 30 minutes in 1 mL ice cold lysis buffer (50 mM citrate pH 6, 150 mM NaCl, 0.5 
mM EDTA, 0.5% NP-40, 1x Pierce protease inhibitor tablet (Pierce, A32963)) by pipetting cells up and 
down every 10 minutes. The lysate was cleared by centrifugation (20 000g, 10 min, 4 °C). Total protein 
concentration in the supernatant was measured by BCA assay as described in section 2.6.1.2 and 
protein concentration was equalized across samples.  
 
2.6.6.3 Immunoprecipitation 
20 μL GFP-Trap_A (ChromoTek, gta-20) slurry pre-washed 3 times in wash buffer (50 mM citrate pH 6, 
150 mM NaCl, 0.5 mM EDTA) were added to lysates. The lysates were incubated with resin on an end-
over-end rotator for 30 min at 4 °C. Beads were pelleted by centrifugation (2500g, 4 °C, 2 min) and 
washed twice with 1 mL wash buffer. Beads were resuspended in 45 µL 2x SDS-PAGE loading buffer 
and boiled at 95 °C for 5 min. Beads were pelleted by centrifugation (20 000 g, room temperature, 2 
min) and discarded. The supernatant was stored at -20 °C prior to WB (section 2.6.3) or mass 
spectrometry (section 2.9.8) experiments. 
 
2.6.7 SEC-MALS analysis of SapA nanodiscs 
Size exclusion chromatography - multi-angle light scattering (SEC-MALS) was performed at room 
temperature. 100 μL of SapA-PC nanodiscs was injected onto a Superdex 200 increase 10/300 GL 
column (GE Healthcare) pre-equilibrated in 100 mM citrate pH 4, 150 mM NaCl at a flow rate of 0.5 
mL/min. The static light scattering, differential refractive index, and the UV absorbance at 280 nm 
were measured in-line by DAWN 8+ (Wyatt Technology), Optilab T-rEX (Wyatt Technology), and 
Agilent 1260 UV (Agilent Technologies) detectors. The molar mass was calculated using ASTRA 6 
software (Wyatt Technology). 
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2.6.8 Nanodisc pull-down assay with biotinylated AC 
10 µL of Pierce high capacity strepatividin agarose beads were washed twice by resuspending in 1 mL 
PBS and spinning at (500g, 5 min). 50 µg of biotinylated AC in 150 µL PBS was bound to the beads by 
incubating on a rotating wheel at room temperature for 1 hour. The beads were spun down (500g, 2 
min) and washed twice with 150 µL pull-down buffer (50 mM citrate pH 4.0, 20 mM NaCl). 150 µL pull-
down buffer, 160 µg SapA in 150 µL pull-down buffer, or nanodiscs containing 160 µg SapA (after 
buffer exchange into 150 µL pull-down buffer) were then added to the beads and incubated on a 
rotating wheel at room temperature for 1 hour. Beads were spun down (2500g, 1 min) and washed 3 
times with 150 µL pull-down buffer. AC was eluted by boiling the beads in 20 µL 1X SDS-PAGE buffer. 
Eluted protein was run on a 15% SDS-PAGE gel and protein was stained with Coomassie stain.  
 
2.7 Enzyme activity assays 
2.7.1 GALC activity assay 
2.7.1.1 Lysate preparation 
4-10x106 THP-1 cells were pelleted by centrifugation (300g, 5 min, 4 °C) and washed twice with ice-
cold PBS. Alternatively, adherent MO3.13 cells or differentiated THP-1 in a confluent T75 flask were 
gently washed three times with ice-cold PBS. For suspension cells, cell pellets were resuspended in 1 
mL ice-cold lysis buffer (10 mM Tris pH 8, 1 mM EDTA, 1% TX-100, 140 mM NaCl, 1 mM PMSF). For 
adherent cells, 1 mL ice-cold lysis buffer was added to the cells and cells were scraped into an 
Eppendorf tube. Lysates were incubated for 1 hour at 4 °C on an end-over-end rotator, then cleared 
by centrifugation (12 000g, 10 min) and cleared lysates were transferred to a new Eppendorf tube. 
Protein concentration in each sample was determined with a bicinchoninic acid assay (Pierce) and 
protein concentration was equalised across samples. For each sample, two tubes containing 300-1000 
µg protein in 1 mL lysate were aliquoted, to obtain one experimental sample and one “no antibody” 
control sample. 
 
2.7.1.2 GALC immunoprecipitation 
Lysate components non-specifically interacting with protein A resin were pre-cleared by incubation of 
the lysate with 40 µL washed Protein A slurry on an end-over-end rotator for 1 hour at 4 °C. Protein A 
beads and non-specifically bound proteins were removed by centrifugation (12 000g, 5 min, 4 °C). Pre-
cleared lysate was incubated with 50 µL monoclonal antibody against GALC and 40 µL washed Protein 
A slurry overnight at 4 °C. GALC antibody was omitted from the “no antibody” control samples. This 
antibody was previously generated via a collaboration with Dr Karsten Skjødt, validated by our lab and 
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published in Spratley et al.202. Beads were pelleted by centrifugation (1000g, 5 min) and the 
supernatant was discarded. Beads were washed with 500 µL lysis buffer three times.  
 
2.7.1.3 Activity assay 
Beads were incubated with 400 µL pre-warmed activity assay buffer (20 mM sodium acetate, 150 mM 
NaCl, 0.1% NP-40, pH 4.6) with 0.3 mM 4-Methylumbelliferyl-β-D-galactopyranoside (4MβDG) at 37 
°C, protected from light in an Infors shaker (210 rpm). At three time points, 110 µL of fully resuspended 
sample was mixed with 27.5 µL Stopping Buffer (2.4 M NaOH, 1.9 M Glycine, pH 13.6). Beads were 
pelleted by centrifugation (20 000g, 5 mins) and 125 µL of supernatant was transferred to a black half-
volume 96-well plate. Fluorescence was measured using a Clariostar Plus (BMG) or SpectraMax M5 
(Molecular Devices) microplate reader with excitation at 365 nm and emission at 445 nm. 
 
2.7.2 AC Activity assay 
2.7.2.1 Ceramide solubilisation 
Several detergent mixtures were tested for ceramide solubilisation. Dried ceramide was resuspended 
by vigorous vortexing in 20 mM citrate pH 4, 150 mM NaCl. Various detergents were then added. The 
following detergent compositions used in published assays were tested:  
 - 0.125% TX-100 + 0.05% Tween 20 + 0.2% Sodium cholate203; 
 - 0.5% TX-100 + 0.2 % Tween 20 + 0.2 % NP-40 + 0.8 % Na Cholate204; 
 - 1% Na Cholate205; 
 - 1% TX-100. 
The mixture was sonicated in a sonicating water bath for 5 min. Solubilisation efficiency was visually 
assessed based on the cloudiness of the ceramide solution after this process. 
 
2.7.2.2 Activity assay with AC after H6 tag removal 
C12 ceramide (d18:1) (Avanti, 860512P) and lauric acid (Sigma W261416) stocks were made in 
chloroform, aliquoted and dried under an argon stream to form a lipid film for storage. 50 nmoles (24 
µg) of dried ceramide was resuspended in activity assay buffer without detergent (20 mM citrate pH 
4, 150 mM NaCl) by vortexing, incubated at 37 °C for 1 hour with vortexing every 15 minutes, and 
liposomes were formed by 10 cycles of sonication for 1 min in a sonicator bath and vortexing for 10 s. 
TX-100 was then added for a final concentration of 1% (v/v). The lipid mixture was vortexed for 1 min 
and sonicated for 5 min. 0.65 nmoles (30 µg) AC was added to the lipids and mixed by pipetting gently. 
The activity assay reaction contained 4.8 µM AC, 370 µM ceramide and 1% (v/v) TX-100 in a final 
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volume of 135 µL. AC buffer (100 mM citrate pH 4) was added to the negative control instead of AC. 
The reaction was incubated at 37 °C for 4 hours and stopped by addition of 1 mL 2:1 
chloroform/methanol. The chloroform phase was transferred to a fresh vial and dried under an argon 
stream. Lipids were resuspended in 30 µL chloroform. 
 
2.7.2.3 Activity assay with AC27 
50 nmoles (24 µg) of dried ceramide was resuspended in activity assay buffer with detergent 
(20 mM citrate pH 4, 150 mM NaCl, 1% (v/v) TX-100), and subjected to 4 cycles of heating in a water 
bath at 85 °C for 30 s, sonication for 30 s and vortexing for 10 s. The lipid solution was cooled prior to 
the addition of 0.6 nmoles (25 µg) AC27, mixed by pipetting gently. The activity assay reaction 
contained 3 µM AC, 250 µM ceramide and 1% (v/v) TX-100 in a final volume of 200 µL. Besides these 
differences, the assay was performed as described above. 
 
2.7.2.4 Thin layer chromatography (TLC) 
Silica-coated glass plates (Sigma, Z185310) or polyester plates (Sigma, Z122777) were developed in 
80:10:1 (v/v/v) chloroform:methanol:water. The plate was pre-washed by developing the blank plate 
and air-dried for 5 min before running the samples. In order to maximise saturation of the chamber 
with solvent, the tank was lined with filter paper and resealed swiftly after opening. Lipids extracted 
from the activity assay reaction (30 µL) were manually spotted on the TLC plate using a 10 µL Hamilton 
syringe, alongside 10 µg of lipid standards. 
 
2.7.2.5 Lipid detection 
After chromatogram development, plates were air-dried for 5 min, sprayed with 10% cupric sulfate in 
8% phosphoric acid and allowed to dry for 30 minutes. Plates were charred in an oven (150 °C, 15 min) 
and imaged within 30 minutes using the epi-white setting on a ChemiDoc (Biorad) system.  
 
2.8 Generation of GALC knockout and rescue THP-1 cell lines 
2.8.1 Guide RNA design 
Target sequences for GALC gene editing by CRISPR/Cas9 were selected by Dr Janet Deane and Dr Stuart 
Fawke using the Dharmacon CRISPR Design Tool. No off-target effects were predicted for the 20-
nucleotide sequences targeted by gRNA1 (5’-AAAGTGGAAATAGGTGGTGA-3’) and gRNA2 (5’-
GGTGGTGATGGGCAGACAAC-3’). These target sequences were cloned into the pSpCas9 BB vector 




THP-1 cells were electroporated with pSpCas9 BB vectors encoding Cas9 and gRNA targeting GALC 
following a protocol provided by Leah Hunter and Colin Crump (Department of Pathology, University 
of Cambridge). 2x106 WT THP-1 cells were pelleted (1000g, 5 min) and resuspended in ice-cold THP-1 
media. 400 µL of cell suspension at 5x106 cells/mL was transferred to a 0.4 cm Gene Pulser cuvette 
(Bio-Rad). Cells were electroporated with 2.5 µg pSpCas9 BB vector in a Gene Pulser XCell system (Bio-
Rad) at 250 V, 1000 µF. Immediately after electroporation, 500 µL warm THP-1 media was added to 
the cuvette. Cells were then transferred to a 6-well plate and supplemented with 2 mL warm media. 
After 24 h, cells were pelleted (1000g, 5 min) and resuspended in fresh media with 2 µg/mL puromycin 
for antibiotic selection. After two days, the media was changed to puromycin-free media and cells 
were allowed to recover for 2 weeks.   
 
2.8.3 Lentiviral transduction of THP-1-Cas9 cells with gRNAs 
THP-1 cells stably expressing FLAG-tagged Streptococcus pyogenes Cas9 (Cas9 THP-1) were a gift from 
the Lehner lab. This cell line was created using a lentiviral vector with Blasticidin resistance followed 
by clonal selection. Lentivirus stocks of the vectors encoding gRNA1 and gRNA2 (section 2.2.6) were 
produced as described in section 2.3.3.2. For lentiviral transduction of gRNAs, 0.5x106 Cas9 THP-1 cells 
were seeded in THP-1 media into each well of three separate 24-well plates. As the lentivirus 
concentration was unknown, a range of volumes (0.025 to 1 mL) of each lentivirus stock (gRNA1, 
gRNA2 and EV) was added across each plate. THP-1 media was added to the wells for a final volume 
of 1.25 mL per well. Two additional wells were seeded as untransduced controls. The plates were 
centrifuged at 230g for 20 minutes to sediment lentivirus particles, then incubated at 37 °C in 
humidified air with 5% CO2 for 24 hours. 
 
2.8.4 Antibiotic selection 
Cells from each plate were split 1:1 into two 24-well plates. The volume in each well was adjusted to 
1.25 mL with THP-1 media. 2 µg/mL puromycin was added to each well of the second plate. Cells were 
incubated at 37 °C for 3 days. Successful antibiotic selection was confirmed by the death of puromycin-
treated untransduced cells, as assessed by trypan blue staining.  
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2.8.5 Assessment of transduction efficiency 
To determine which virus concentration results in the infection of 30% of cells, expression of the Blue 
Fluorescent Protein (BFP) fluorescent marker from lentiviral vectors was analysed by flow cytometry 
in cells grown in the absence of antibiotic selection. To this end, cells in suspension were pooled with 
any adhered cells detached by incubation with 200 µL trypsin for 5 min. Cells were pelleted (350g, 5 
min), resuspended in 1 mL PBS and transferred to a polystyrene tube. Cells were analysed on a BD 
LSRFortessa cell analyser (20 000 events per sample, medium speed). BFP expression was detected 
using a 405 450/50 filter and cell autofluorescence was detected using a 488 530/30 filter. The 
lentivirus concentration yielding 30% infection in unselected cells was determined, and puromycin-
selected cells transduced with this virus concentration were carried forward. Suspension cells were 
pooled with adherent cells detached with trypsin, pelleted (125g, 5 min) and washed with PBS three 
times. These mixed knockout cell populations were expanded, frozen and stored in liquid nitrogen.  
 
2.8.6 Clonal selection 
Clonal selection was done by limiting dilution. For each mixed population, suspension and detached 
adherent cells were pooled, counted, pelleted (200g, 5 min) and diluted to 5 cells/mL in fresh THP-1 
media supplemented 1:1 with conditioned media from the flask of origin. 100 µL of diluted cells were 
distributed to each well of a 96-well plate. Clonal cell populations were then gradually expanded to 20 
mL. Four clones per sample were frozen and carried forward for knockout validation.  
 
2.8.7 Assessment of GALC gene editing 
Genomic DNA was extracted from 5x106 cells from each clonal population using a Pure Link Genomic 
DNA Mini Kit following the manufacturer’s instructions. A region of DNA (862 bp) including the GALC 
editing site was amplified by PCR using the following primers:  
forward: 5’-GCCCTACTTGCCCAATGATTGGCACAGAAAG-3’; 
reverse: 5’-CAAAACTGTCCCTATGCTCTGTCCTGTATATATAG-3’.  
A 50 µL reaction containing 250-500 ng genomic DNA, 500 nM forward primer, 500 nM reverse primer 
and 0.25 µL GoTaq polymerase in GoTaq buffer with 200 µM dNTPs was incubated at 95°C for 5 
minutes followed by 30 cycles of denaturation (95 °C, 30 s), annealing (64.7 °C, 30 s), and extension 
(72 °C, 1 min) and a final extension (72 °C, 5 min). The PCR product was purified using the QIAquick 
PCR Purification Kit (Qiagen). Sanger sequencing was done by GENEWIZ using the sequencing primer 
5’-CACCATAGAATTTATTAGCCTCA-3’. Assessment of GALC gene editing was done by sequencing trace 
decomposition using the online tool TIDE (https://tide.nki.nl/)206. EV was used as a control. Indel size 
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range was set to the maximum (0-50). TIDE analysis was performed on two independent samples from 
each cell line.  
 
2.8.8 Generation of GALC rescue cell lines 
Lentivirus stocks encoding GALC Rescue 1 and GALC Rescue 2 recombinant constructs (section 2.2.7) 
were produced as in section 2.3.3.2. GALC KO1 and GALC KO2 THP-1 cells were seeded in 6-well plates 
for a final cell density of 0.2x106 cells per well in 2 mL THP-1 media. 0-800 µL GALC Rescue 1 or GALC 
Rescue 2 lentivirus stock, respectively, was added to each well. After 48 h, geneticin was added to 
each well for a final concentration of 400 μg/mL. Cells were maintained under antibiotic selection for 
4 days and cultures were expanded as cell density increased. Some untransduced control cells 
remained alive after 4 days of antibiotic selection, therefore antibiotic dosage was increased to 800 
μg/mL geneticin for 4 days, at which point all untransduced cells were dead. The number of infection 
events was approximated based on the number of geneticin-resistant cells after 10 days, assuming a 
doubling rate of 24 hours. The culture produced by transduction of 5-10% of cells was selected as the 
rescue cell line. 
 
2.8.9 Rescue GALC expression 
Rescue GALC expression was induced by addition of 25-1000 μg/L doxycycline in the culture media. 
Cells were maintained in media with doxycycline for a minimum of 6 days prior to validation of GALC 
rescue by GALC activity assays (section 2.7.1) and downstream qPCR experiments. 
 
2.8.10 Transduction of WT THP-1 cells with an empty lentiviral control vector 
Viral stocks of unmodified puromycin-resistant pCW57 empty lentiviral vector were made by Dr Stuart 
Fawke. WT THP-1 cells were transduced with this vector as described in section 2.8.8. 72 hours after 
transduction, transduced cells were selected with 2 μg/mL puromycin for 72 hours. Cells were allowed 
to recover in THP-1 media without antibiotic for 7 days.  
 
2.9 Proteomics 
All chemicals were of AR grade or better and purchased from Merck/Sigma unless otherwise stated. 
 
2.9.1 Cell culture 
Proteomics analysis was performed on three independent biological replicates. EV, KO1 and KO2 cells 
were seeded at 0.25x106 cells/mL in 30 mL THP-1 media in 150 mm dishes to harvest 11.5x107 cells at 
 59 
a cell density of 0.5x106 cells/mL the next day. Cells were pelleted (300g, 5 min), washed in 15 mL PBS 
and transferred to a clean 15 mL falcon, pelleted and washed once more, then resuspended in 1.15 
mL PBS. 1 mL of resuspended cells (1x107 cells) was transferred to a low bind Eppendorf tube for 
plasma membrane profiling, and 150 µL (1.5x106 cells) were transferred to a Bioruptor microtube 
(Diagenode) for whole cell proteomics and stored at -80 °C until processing (section 2.9.3). Cells were 
pelleted and the supernatant was discarded. 
 
2.9.2 Sample preparation for plasma membrane profiling 
2.9.2.1 Biotinylation of plasma membrane proteins 
Surface sialic acid residues were oxidized with sodium meta-periodate and biotinylated using 
aminooxy-biotin, a reaction catalyzed by aniline. The oxidation/biotinylation mix (1 mM sodium meta-
periodate (Pierce, 20504), 100 mM aminooxy-biotin (Insight biotech, 90113), 10 mM aniline (Sigma, 
242284) in ice-cold PBS pH 6.7) was freshly prepared and mixed by vortexing. Aniline was added 
immediately prior to use. Cells were thoroughly resuspended in 1 mL oxidation/biotinylation mix and 
incubated at 4 °C for 30 min with end-over-end rotation in the dark. The oxidation reaction was 
quenched by addition of glycerol to a final concentration of 1 mM. Cells were washed three times with 
PBS and pelleted by centrifugation (300g, 5 min). The cell pellet was stored at -80 °C until samples 
from all three replicates were harvested. Downstream processing was performed at the same time for 
all samples.  
 
2.9.2.2 Cell lysis 
Biotinylated cell pellets were thawed on ice. Cells were lysed in 1 mL lysis buffer (10 mM Tris pH 7.4, 
1% TX-100, 150 mM NaCl, 1× complete protease inhibitor without EDTA (Roche)) on an end-over-end 
rotator at 4 °C for 30 min. Lysates were clarified by centrifugation (13 000g, 4 °C, 10 mins) and the 
supernatant was transferred to a fresh tube. The clarification step was repeated a second time. 
Biotinylated proteins were enriched by incubation with 50 µL of washed high capacity neutravidin 
agarose bead slurry (Thermo Fisher Scientific, 29202) at 4 °C for 2 hours with end-over-end rotation.   
 
2.9.2.3 Preparation of peptides for mass spectrometry 
Extensive washing of beads was performed using a vacuum manifold and SnapCap filter columns 
(Pierce, 69725). Beads were washed 20 times with 400 µL Lysis buffer, followed by 20 washes with 0.5 
% SDS in PBS (pH 7.4), then 10 washes with freshly made Urea buffer (50 mM triethylammonium 
bicarbonate buffer (TEAB), 6 M urea, pH 8.5). Columns were removed from the vacuum manifold and 
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capped, and beads were incubated with 400 µL reduction/alkylation solution (10mM Tris(2-
carboxyethyl)phosphine (Sigma 646547), 20mM iodoacetamide in Urea buffer) in the dark with mixing 
in a thermomixer (1300 rpm, 30 min). The reduction/alkylation solution was removed using the 
vacuum manifold, and beads were washed 10 times with Urea buffer, followed by 5 washes with 50 
mM TEAB. Beads were resuspended in 400 µL 50 mM TEAB and transferred to a low bind Eppendorf 
tube. Beads were pelleted (500g, 2 min) and supernatant was removed using a fine gel loading tip 
with a constricted end. Beads were resuspended in 50 µL of 50 mM TEAB with 0.5 µg trypsin and 
incubated at 37 °C for 6 hours in a thermomixer (1500 rpm). Beads were pelleted (500g, 3 min) and 
supernatant was transferred to a new tube. Beads were resuspended with a further 50 µL of 50 mM 
TEAB, pelleted by centrifugation and the supernatant was added to the same tube for full recovery of 
peptides. Samples were dried in a vacuum centrifuge before proceeding with Tandem mass tag (TMT) 
labelling (section 2.9.4).  
 
2.9.3 Sample preparation for whole cell proteomics 
The methods described in section 2.9.3 were carried out by Dr James Williamson as part of an 
established collaboration with the lab of Prof Paul Lehner (Cambridge Institute for Therapeutic 
Immunology & Infectious Disease, University of Cambridge) and are included here for completeness. 
 
2.9.3.1 Lysis and protein quantification 
Cell pellets obtained in section 2.9.1 were resuspended in 50 µL resuspension buffer (76 mM HEPES 
pH 7.55, 6 mM MgCl2, Benzonase (1400 U/mL) and 15 mM TCEP) by pipetting. 18.75 µL 20% lithium 
dodecyl sulfate was then immediately added to the cell suspension using a low retention pipette tip 
(RPT, StarLab) and pipetted to mix. Nucleic acids were fragmented by 30 s on/30 s off sonication in a 
Bioruptor Pico sonicator (Diagenode) for 10 minutes at 4°C. Samples were then incubated for 15 
minutes at 37 °C to ensure complete reduction. Samples were alkylated by adding 6 µL of 187.5 mM 
methyl methanethiosulfonate (final concentration 15 mM) and incubating at room temperature for 
15 minutes. 5 µL aliquots of each sample were diluted 2x in water and compared to a standard curve 
of BSA in the same buffer using a reducing agent-compatible BCA assay (Thermo Fisher). 25 µg of each 
sample was taken and the volumes of each lysate were equalised using resuspension buffer with 5% 
lithium dodecyl sulfate. 
 
2.9.3.2 S-trap digestion 
To each sample a 10% volume of 12% phosphoric acid was added to acidify samples to ~pH 2, 
completing denaturation. 6x volumes of wash buffer (100 mM HEPES pH 7.1, 90% methanol) was then 
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added and the resulting solution is loaded onto a S-trap (Protifi) using a positive pressure manifold 
(Tecan M10), adding not more than 150 µL of sample at a time (~80 PSI). In-house fabricated adaptors 
were used to permit the use of S-traps with the manifold. Samples were then washed 4x with 150 µL 
wash buffer. To remove any remaining wash buffer S-traps were centrifuged at 4000g for 2 minutes. 
To each S-trap, 30 uL of digestion solution (50 mM HEPES pH 8, 0.1% sodium deoxycholate) containing 
1 µg Trypsin/lysC mix (Promega) was added. S-Traps were then loosely capped and placed in low 
adhesion 1.5 mL microfuge tubes in a ThermoMixer C (Eppendorf) with a heated lid and incubated at 
37 °C for 6 hours. Where digestion was carried out overnight the Thermomixer was set to 4 °C after 6 
hours. Peptides were recovered by adding 40 µL digestion buffer to each trap and incubating at room 
temperature for 15 minutes before slowly eluting with positive pressure (2-3 PSI). Traps were 
subsequently eluted with 40 µL 0.2% formic acid and 40 µL 0.2% formic acid, 50% acetonitrile in the 
same manner. Eluted samples were then dried in a vacuum centrifuge equipped with a cold trap prior 
to TMT labelling (section 2.9.4). 
 
2.9.4 TMT labelling and clean-up 
The methods described in section 2.9.4 to 2.9.7 were carried out by Dr James Williamson as part of an 
established collaboration with the lab of Prof Paul Lehner (Cambridge Institute for Therapeutic 
Immunology & Infectious Disease, University of Cambridge) and are included here for completeness. 
 
Dried samples were resuspended in 21 µL 100 mM TEAB pH 8.5. After warming to room temperature, 
0.5 µg TMTpro/0.2 µg TMT reagents (Thermo Fisher) were resuspended in 9 µL anhydrous acetonitrile 
which was added to the respective samples and incubated at room temperature for 1 h. A 3 µL aliquot 
of each sample was taken and pooled to check TMT labelling efficiency and equality of loading by 
liquid chromatography-mass spectrometry (LC-MS). Samples were stored at -80 °C in the interim. After 
checking each sample was at least 98% TMT labelled, total reporter ion intensities were used to 
normalise the pooling of the remaining samples such that the final pool should be as close to a 1:1 
ratio of total peptide content between samples as possible. This final pool was then dried in a vacuum 
centrifuge. The sample was acidified to a final 0.1% trifluoracetic acid (~200 µL volume) and formic 
acid was added until the sodium deoxycholate visibly precipitated. 4 volumes of ethyl acetate were 
then added and the sample vortexed vigorously for 10 s. The sample was then centrifuged at 15 000g 
for 5 min at room temperature to effect phase separation. A gel loading pipette tip was used to 
withdraw the lower (aqueous) phase to a fresh low adhesion microfuge tube. If any obvious sodium 
deoxycholate contamination remained, the two-phase extraction with ethyl acetate was repeated. 
The sample was then partially dried in a vacuum centrifuge and brought up to a final volume of 1 mL 
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with 0.1% trifluoracetic acid. Formic acid was added until the pH was < 2, confirmed by spotting onto 
pH paper. The sample was then cleaned up by solid-phase extraction using a 50 mg tC18 SepPak 
cartridge (Waters) and a positive pressure manifold. The cartridge was wetted with 1 mL 100% 
Methanol followed by 1 mL acetonitrile, equilibrated with 1 mL 0.1% trifluoracetic acid and the sample 
was loaded slowly. The sample was passed twice over the cartridge. The cartridge was washed 3x with 
1 mL 0.1% trifluoracetic acid before eluting sequentially with 250 µL 40% acetonitrile, 70% acetonitrile 
and 80% acetonitrile and dried in a vacuum centrifuge. 
 
2.9.5 Basic pH reversed phase fractionation 
Samples were resuspended in 40 µL 200 mM ammonium formate pH 10 and transferred to a glass 
HPLC vial. Basic pH reversed-phase fractionation was conducted on an Ultimate 3000 UHPLC system 
(Thermo Scientific) equipped with a 2.1 mm × 15 cm, 1.7 µm Kinetex EVO column (Phenomenex). 
Solvent A was 3% acetonitrile, Solvent B was 100% acetonitrile, solvent C was 200 mM ammonium 
formate (pH 10). Throughout the analysis solvent C was kept at a constant 10%. The flow rate was 500 
µL/min and UV was monitored at 280 nm. Samples were loaded in 90% A for 10 min before a gradient 
elution of 0–10% B over 10 min, 10-34% B over 21 min, 34-50% B over 5 mins followed by a 10 min 
wash with 90% B. 15 s (100 µL) fractions were collected throughout the run. Fractions containing 
peptide (as determined by absorbance at 280 nm) were recombined across the gradient to preserve 
orthogonality with on-line low pH reversed-phase separation. For example, fractions 1, 25, 49, 73, 97 
are combined and dried in a vacuum centrifuge and stored at -20 °C until LC-MS analysis. For whole 
cell proteome samples or plasma membrane enriched samples 24 / 12 fractions respectively are 
generated in this way. 
 
2.9.6 Mass spectrometry 
Samples were analysed on an Orbitrap Fusion instrument on-line with an Ultimate 3000 RSLC nano 
UHPLC system (Thermo Fisher). Samples were resuspended in 10 µL 5% DMSO/1% trifluoracetic acid. 
5 µL of each fraction was injected. Trapping solvent was 0.1% trifluoracetic acid, analytical solvent A 
was 0.1% formic acid, solvent B was acetonitrile with 0.1% formic acid. Samples were loaded onto a 
trapping column (300 µm x 5 mm PepMap cartridge trap; Thermo Fisher) at 10 µL/min for 5 minutes. 
Samples were then separated on a 75 cm x 75 µm, 2 µm particle size PepMap C18 column (Thermo 
Fisher). The gradient was 3-10% B over 10 min, 10-35% B over 155 min, 35-45% B over 9 min followed 
by a wash at 95% B for 5 min and re-equilibration at 3% B. Eluted peptides were introduced by 
electrospray to the mass spectrometer by applying 2.1 kV to a stainless steel emitter (5 cm x 30 µm; 
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PepSep). During the gradient elution, mass spectra were acquired using Tune v3.3 and Xcalibur v4.3 
(Thermo Fisher). 
 
2.9.7 Data processing 
Data were processed with PeaksX+, v10.5 (Bioinfor). Briefly, .raw files were searched iteratively in 
three rounds, with unmatched DeNovo spectra (at 0.1% PSM FDR) from the previous search used as 
the input for the next. The three iterations were as follows: 1) Swissprot Human (27/03/2020) + 
common contaminants; 2) the same databases as search 1 but permitting semi-specific cleavage; 3) 
trEMBL Human (27/03/2020), with specific cleavage rules. Identified proteins and their abundances 
were output to .csv, imported to R and submitted to statistical analysis using LIMMA, a moderated t-
test available through the Bioconductor package207-209. LIMMA p-values were corrected for multiple 
hypothesis testing using the Benjamini-Hochberg method to generate a false discovery rate-adjusted 
p-value (q-value) for each comparison. 
 
2.9.8 Mass spectrometry analysis for the GFP co-immunoprecipitation experiment 
GFP co-immunoprecipitation samples were prepared as detailed in section 2.6.6. Mass spectrometry 
was performed by Dr Robin Antrobus and Dr Jack Houghton in the CIMR proteomics facility. Samples 
were resolved approximately 1 cm into a pre-cast 4-12% Bis-Tris polyacrylamide gel. The lanes were 
excised and cut in 4 equal chunks and the proteins reduced, alkylated and digested in-gel. The resulting 
tryptic peptides were analysed by LC-MS/MS using a Q Exactive coupled to an RSLCnano3000 (Thermo 
Scientific). Peptides were resolved on a 50 cm EASY-spray column (Thermo Scientific) with MS/MS 
data acquired in data-dependent acquisition mode. 
 
Label-free quantitation values were obtained by processing raw files with MaxQuant (version 1.6.6.0) 
with the following parameters: specific trypsin digestion; Human database (UniProt reference 
proteome downloaded 03 Dec 2018 containing 21066 proteins); oxidation (M) and N terminal 
acetylation as variable modifications; carbamidomethylation (C) as a fixed modification; label-free 
quantification enabled; Match between runs enabled. Post-processing was carried out using R with 
bespoke scripts incorporating the “limma” statistical package. 
 
2.9.9 Gene Ontology and pathway enrichment analysis 
Gene Ontology and pathway enrichment was performed with the tool DAVID 6.8210. DAVID analysis 
was performed on lists of genes significantly up- and down-regulated (q-value < 0.05) against a 
background list of all genes detected in the experiment. 
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2.10 RNA sequencing 
2.10.1 Cell culture  
RNA sequencing (RNAseq) was performed on four technical replicates for each cell line (EV, KO1, KO2). 
For each cell line, cells were seeded at 0.25x106 cells/mL in in 20 mL THP-1 media in four separate T75 
flasks to harvest 1x107 cells at a density of 0.5x106 cells/mL the next day. 
 
2.10.2 Cell lysis 
Cells were pelleted (1000g, 5 min) and washed with 1 mL PBS. The cell pellet was thoroughly 
resuspended in 400 µL freshly prepared lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM 
MgCl2, 1 mM DTT, 1% TX-100, 25 U/mL Turbo DNAse I (Invitrogen)) and incubated on ice for 20 
minutes. Lysates were cleared by centrifugation (13 000g, 20 min, 4˚C) and the supernatant 
transferred to a fresh Eppendorf tube (low bind Eppendorf tubes were used throughout this 
experiment). Clarified lysates were aliquoted and stored at -70 ˚C.  
 
2.10.3 RNA extraction 
100 µL lysate was thawed and incubated with 200 µL freshly prepared proteinase K buffer (10 mM 
Tris-Cl pH 7.5, 1.5% SDS, 0.5 µg/mL Proteinase K) at 42 ˚C for 30 min. Samples and acidic phenol-
chloroform were pre-warmed to 65 ˚C. 300 µL acidic phenol-chloroform was then added to each 
sample. Samples were vortexed thoroughly at high speed (10 s) and heated at 65 ˚C for 5 mins with 
occasional vortexing. Samples were then placed on ice for 5 minutes and the aqueous phase was 
separated by centrifugation (13 000g, 5 min, 4 ˚C). The upper aqueous phase was carefully collected 
into a fresh tube and 300 µL TE-buffered chloroform was added to each sample. Samples were 
thoroughly vortexed (30 s) and centrifuged (13 000g, 2 min, room temperature). The upper aqueous 
phase was carefully collected into a fresh tube.  
 
2.10.4 Ethanol precipitation 
RNA was mixed with 3 M sodium acetate pH 4.8 and 100% ethanol (1:0.1:3 v/v/v) and 30 µg GlycoBlue 
co-precipitant (Thermo Fisher Scientific) by vortexing thoroughly for 10 s. RNA was precipitated at -70 
˚C for 30 min. After centrifugation (13 000g, 15 min, 4 ˚C), the supernatant was removed using a fine 
gel loading tip. The RNA pellet was washed with 150 uL 95% ethanol, vortexed thoroughly, and 
centrifuged (13 000g, 2 min, room temperature). The supernatant was discarded, and the pellet was 
dried in a vacuum chamber for 5 minutes. RNA was resuspended in 20 µL water by vortexing. 
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2.10.5 Ribosomal RNA depletion 
Ribosomal RNA was depleted from 5 µg of total RNA using a Ribo-Zero Gold rRNA Removal Kit 
(Illumina)211 following the manufacturer’s instructions. Depleted RNA was diluted in water for a 
volume of 180 µL, purified by ethanol precipitation and resuspended in 12 µL 10 mM Tris pH 7.5. Half 
of each depleted RNA sample was stored at -70 ˚C as a back-up and the second half carried forward 
for RNA fragmentation.  
 
2.10.6 RNA fragmentation by alkaline hydrolysis 
RNA was fragmented by alkaline hydrolysis in a 20 µL reaction containing depleted RNA, 5 mM Na2CO3, 
45 mM NaHCO3 and 1 mM EDTA and incubated at 95˚C for 15 min. The reaction was stopped by 
addition of 280 µL stop/precipitation solution (300 mM NaOAc pH 5.5, 50 µg/mL GlycoBlue) and 
fragmented RNA was recovered by ethanol precipitation and resuspended in 4 µL water.  
 
2.10.6.1 RNA gel extraction  
RNA was incubated with 6 µL denaturing gel loading buffer (Ambion) at 80 ˚C for 3 mins then cooled 
on ice prior to loading on a 15% (w/v) denaturing acrylamide gel (46% (w/v) urea, 14.25% 
acrylamide/0.75% bisacrylamide (Accugel), TBE) alongside a 10 bp DNA ladder and 28 and 34 
nucleotide primers. The gel was run at 15 W for 40 min, then stained with SYBR Gold nucleic acid stain 
(Thermo Fisher Scientific) in TBE for 4 min. RNA fragments migrating between 28 and 34 nucleotides 
were excised from the gel using separate clean scalpels and eluted by addition of 600 µL RNA gel 
extraction buffer (300 mM NaOAc pH 5.5, 1 mM EDTA, 0.25% SDS) and overnight incubation at 4˚C on 
a rotating wheel. Eluted RNA was transferred to low bind Eppendorf tubes, washed by ethanol 
precipitation and resuspended in 15 µL 10 mM Tris pH 7.5. 
 
2.10.7 Generation of RNA libraries 
2.10.7.1 Removal of 3’-phosphates 
RNA fragments were denatured at 80˚C for 2 min and cooled on ice. 3’-phosphates were removed in 
a 20 µL reaction with 20 U T4 Polynucleotide Kinase (NEB) and 20 U SUPERase-In RNase inhibitor 
(Thermo Fisher Scientific) in T4 Polynucleotide Kinase buffer without ATP. The reaction was incubated 
at 37˚C for 2 hours and heat-inactivated at 65˚C for 10 min. RNA was diluted in water for a volume of 
100 µL, washed by ethanol precipitation and resuspended in 7 µL 10 mM Tris pH 7.5.  
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2.10.7.2 Ligation with 3’-adaptor 
The RNA was ligated to a 3ʹ-adaptor primer (5ʹ-pNNNNNNNTGGAATTCTCGGGTGCCAAGG-3ʹ) pre-
adenylated using a 5ʹ DNA adenylation kit (NEB) following the manufacturer's instructions. 
Dephosphorylated RNA was mixed with 50 pmoles adenylated 3’-adaptor, denatured at 80˚C for 2 
mins and cooled to room temperature. The ligation was performed with 400 U T4 RNA Ligase 2 
truncated K227Q (NEB) in T4 RNA Ligase Reaction Buffer (without ATP) with 20 U SUPERase-In and 
15% (w/v) PEG 8000 in a 20 µL reaction incubated at 14˚C overnight. RNA was washed by ethanol 
precipitation and resuspended in 4 µL 10 mM Tris pH 7.5. Ligated RNA fragments (56-62 nucleotides) 
were purified from a 15% denaturing gel as described above and dissolved in 10 µL 10 mM Tris pH 7.5. 
 
2.10.7.3 3’ adaptor-ligated product phosphorylation 
3’ adaptor-ligated products were phosphorylated with 20 U T4 Polynucleotide Kinase (NEB) in T4 
Polynucleotide Kinase buffer with 1 mM ATP and 20 U SUPERase-In in a 20 µL reaction incubated at 
37 ˚C for 2 hours and heat-inactivated at 65˚C for 10 min. Phosphorylated RNA was washed by ethanol 
precipitation and resuspended in 10 µL 10 mM Tris pH 7.5. 
 
2.10.7.4 Ligation with 5’-RNA adaptor 
RNA was ligated to the 5’-RNA adaptor (5’-GUUCAGAGUUCUACAGUCCGACGAUCNNNNNNN-3’; 100 
pmoles) with 20 U T4 RNA ligase in T4 RNA ligase buffer with 20 U SUPERase-In in a 20 µL incubated 
at 14˚C overnight. The fully adapted RNA was washed by ethanol precipitation and resuspended in 6 
µL 10 mM Tris pH 7.5. 
 
2.10.7.5 Reverse transcription 
3 µL fully adapted RNA was annealed to 50 pmoles reverse transcription primer (5'-
GCCTTGGCACCCGAGAATTCCA-3’) in a 4.5 µL reaction with 12.5 nmoles dNTP incubated at 65˚C for 5 
min. RNA was subsequently reverse transcribed with 200 U Superscript III (Invitrogen) in first strand 
buffer (Invitrogen) with 2.5 mM MgCl2, 10 mM DTT, 20 U SUPERase-In in a 20 µL reaction incubated 
at 55 °C for 50 min, followed by heat inactivation at 85 °C for 5 min. 
 
2.10.8 PCR amplification and barcode addition 
Standard PCR reactions were used to prepare amplicons using forward primer RP1 (5ʹ-
AATGATACGGCGACCACCGAGATCTACACGTTCAGAGTTCTACAGTCCGA-3ʹ) and reverse primer 5ʹ-
CAAGCAGAAGACGGCATACGAGATN6GTGACTGGAGTTCCTTGGCACCGAGAATTCCA-3ʹ (RPIX), where X is 
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primer number (1-12) and N6 the reverse complement of the respective hexanucleotide index 
sequence detected during Illumina sequencing. (TruSeq Small RNA Library Prep Kit, indexes 1-12). 
Phusion High-Fidelity DNA polymerase mastermix (NEB) was used for amplification of 1 µL cDNA with 
4 pmoles of each primer in a 20 µL reaction with the following cycling parameters: initial denaturation 
at 98˚C for 30 s, followed by 16 cycles of denaturation (98˚C, 10 sec), annealing (60˚C, 30 sec) and 
extension (72˚C, 15 sec), with a final extension step (72˚C, 10 min). The PCR product was purified with 
a QIAquick PCR purification kit (Quiagen) following the manufacturer’s instructions and eluted with 
30 µL water. The PCR was mixed with 10 µL loading dye (bromophenol blue in 30% sterile glycerol) 
and loaded onto a 10% w/v non-denaturing polyacrylamide gel (9.5% acrylamide/0.5% bisacrylamide 
(Accugel) in TBE) alongside a 10 bp ladder. The gel was run at 200 V for 35 min. Products with an 
approximate length of 163 bp were excised from the gel and eluted by addition of 600 µL DNA gel 
extraction buffer (300 mM NaCl, 10 mM Tris–HCl pH 8 and 1 mM EDTA) and incubation at 4 °C 
overnight on an end-over-end rotator. The amplicon libraries were purified by ethanol precipitation 
and resuspended in 15 µL 10 mM Tris pH 8. DNA concentration in each sample was determined using 
a Qubit fluorometer (Thermo Fisher Scientific). A pooled 2.11 nM library (20 µL, 0.41 ng per sample) 
was sequenced on a NextSeq 500 system (Illumina) at Cambridge Genomic Services (Department of 
Pathology, University of Cambridge). 
 
2.10.9 RNAseq data analysis 
Data analysis was performed by Dr Katy Brown (Department of Pathology, University of Cambridge). 
Log2 fold changes were analysed with DESeq2 and corrected with lfcShrink212. False discovery rate 
adjusted q-values were calculated using fdrtool in R213 for every combination of conditions. 
 
2.11 Quantitative PCR 
2.11.1 RNA extraction and reverse transcription 
RNA was extracted from 5x105 cells using a PureLink RNA micro kit (Invitrogen) following the 
manufacturer’s instructions and stored at -80 °C. Reverse transcription was performed from 2 µg RNA 
using a High yield RNA-to-cDNA kit (Applied Biosystems, 4387406) following the manufacturer’s 
instructions. A “no reverse transcriptase” control was produced by omitting the addition of reverse 
transcriptase enzyme and buffer to one sample from each batch to monitor genomic DNA 




qPCR experiments were performed for three technical replicates per sample using the TaqMan FAM 
dye-labeled MGB probes (Thermo Fisher Scientific) listed in Table 2.4 and TaqMan Fast Advanced 
Master Mix following the manufacturer’s instructions. 10-100 ng cDNA was added to each 20 µL 
reaction. Lack of genomic DNA contamination was confirmed by performing qPCR on the “no reverse 
transcriptase” control and ensuring that no amplification was detected or that the control Ct value 
was over 10 cycles higher than sample Ct values. Reactions were set up in white 96 well-plates (Bio-
Rad) and executed on a CFX96 real-time thermal cycler (Bio-Rad) with the following cycle parameters: 
polymerase activation at 95 °C for 10 minutes, then 40 cycles of denaturation (95 °C, 15s) and 
annealing/extension (60 °C, 1 min). 
 
Table 2.4. TaqMan gene expression assays used in qPCR experiments 













SLC4A4  Hs00186798_m1  
MDFIC  Hs04177766_g1  
PLXNC1  Hs00194968_m1  
TRHDE  Hs01072025_m1  
SDK1  Hs01010140_m1  
2.11.3 Housekeeping gene validation 
The stable expression of several housekeeping control genes (ACTB, CASC3 and HMBS) was assessed 
by quantifying the expression of these genes in WT, EV1, KO1 and KO2 THP-1 cells and calculating the 
average pairwise variation of each control gene with the remaining control genes using the GeNorm 
algorithm209 in qBase+ software (Biogazelle, Zwijnaarde, Belgium - www.qbaseplus.com).  
 
2.11.4 qPCR data analysis 
qPCR experiments were performed independently with at least three biological replicates. The 
expression of each gene relative to control was determined using the ΔΔCt method. Ct values for each 
biological replicate were calculated as the mean Ct of three technical replicates. ACTB was used as the 
housekeeping control gene in all qPCR experiments. ΔCt was calculated as: 
ΔCt = Cthousekeeping gene − Ctgene of interest 
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Log2 fold change in gene expression relative to control (ΔΔCt) was calculated by subtracting the mean 
ΔCtcontrol value of the control sample across all biological replicates from the sample ΔCtsample value for 
each biological replicate: 
ΔΔCtsample = ΔCtsample - mean(ΔCtcontrol) 
The statistical significance of gene expression changes was determined by ordinary one-way ANOVA 
on ΔΔCt values, followed by Tukey’s multiple comparison test in GraphPad Prism 8. The assumptions 
of independence of observations, normality of distributions and equality of variance between groups 
required for these statistical tests were met. 
 
2.12 Microscopy 
2.12.1 Brightfield microscopy on undifferentiated THP-1 cells 
5x104 undifferentiated THP-1 cells were pelleted (125g, 5 min) and washed twice with PBS. Cells were 
incubated in 5 µg/mL Hoechst 33342 (H1399, Thermo Fisher Scientific) in PBS away from light at room 
temperature for 5 minutes. Cells were then imaged on an EVOS FL microscope (Thermo Fisher 
Scientific) with 40x magnification. 
 
2.12.2 Immunofluorescence microscopy 
2.12.2.1 Cell seeding 
13 mm round glass coverslips were sterilised in 70% ethanol then washed in PBS in 24-well tissue 
culture plates. Adherent cells were seeded onto the glass coverslips as required.  
 
2.12.2.2 Cell fixing 
The culture medium was removed from the cells and cells were washed once in ice-cold PBS. Cells 
were fixed with 250 μL ice-cold, freshly prepared 4% formaldehyde in 250 mM HEPES, pH 7.4 for 10 
minutes on ice. A second fixation step was performed with 250 μL 8% formaldehyde in 250 mM HEPES, 
pH 7.5 for 20 min at room temperature. Cells were washed twice with 500 μL PBS. Residual 
formaldehyde was quenched with 250 μL 50 mM NH4Cl for 5 min. Cells were washed twice with 500 
μL PBS and stored in PBS at 4 °C until the next step (for long term storage, 0.02% azide was added).  
 
2.12.2.3 Cell permeabilisation and staining 
Cells were permeabilised with 250 μL 0.1% saponin in PBS on a rocking platform (15-30 min, room 
temperature). Cells were then incubated with 250 μL blocking buffer (0.1% saponin, 5% FBS in PBS) 
with rocking (15-30 min, room temperature). Primary antibodies (Table 2.5) were diluted in blocking 
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buffer. Using tweezers and a bent needle, coverslips were placed cell-side down onto 30 μL drops of 
antibody solution on parafilm and incubated for 2 hours in a humidified chamber. Coverslips were 
then placed in a 24 well-plate and washed 5 times with 250 μL blocking buffer on a rocking platform 
(5 min per wash, room temperature). Coverslips were then placed onto 30 μL drops of secondary 
antibodies (Table 2.5) in blocking buffer and incubated for 1 hour in a humidified chamber. Cells were 
washed 5 times with 250 μL blocking buffer (5 min, room temperature), then briefly rinsed 3 times 
with 250 μL 0.1% saponin in PBS, followed by 3 rinses with 250 μL PBS. Coverslips were briefly rinsed 
in MQW, excess water was blotted off and coverslips were mounted cell-side down onto a 15 μL drop 
of mounting medium (10% w/v Mowiol 4-88, 0.66 μg/mL DAPI, 25% v/v glycerol, 0.1 M Tris pH 8.5) on 
a microscopy slide. Mounted samples were dried at room temperature overnight and visualised on an 
Axioimager Z2 widefield microscope (Carl Zeiss). 
 
Table 2.5. Antibodies used for immunofluorescence experiments 
Target Source Dilution Provider and ID 
Primary Antibodies 
LAMP-1 Rabbit polyclonal  1 in 1000  Abcam ab24170  
EEA-1 Mouse monoclonal 1 in 500  BD Biosciences 610456 
Secondary Antibodies 
Rabbit IgG 
AlexaFluor555 Donkey polyclonal 
1:200 
Life Technologies  
Mouse IgG 
AlexaFluor488  Donkey polyclonal 
1:200 
Life Technologies  
 
2.12.3 Retention Using Selective Hooks (RUSH) assay 
HeLa cells stably expressing the Strep-KDEL sequence and the target protein expression vector 
pDCGx15 encoding a signal peptide, Streptavidin-binding peptide (SBP) at the N-terminus and a GFP-
SPOT double tag at the C-terminus were generously provided by Dr David Gershlick (Cambridge 
Institute for Medical Research). Full-length PTPRM (residues 21-1451), the Fn3-4 domain (residues 
478-768), and the extracellular domain (residues 21-768) of PTPRM were cloned into pDCGx15 by Eve 
Caroe.  
Cells were seeded on sterilised coverslips in 24 well plates at 5 000 cells per well (Strep-KDEL HeLa 
cell line) or 10 000 cells per well (MO3.13 cell line) in DMEM with 10% FBS. Individual plates were 
seeded for each time point to prevent changes in temperature while processing samples for 
separate time points.  
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Cells were transfected on the next day with 250 ng pDCGx15 vector expressing PTPRM truncations 
pre-mixed in 25 μL OptiMEM with 0.75 μL FuGene 6 (as detailed in section 2.6.6.1). 4 hours after 
transfection, the transfection reagent was removed and 500 μL fresh media added to the cells.  
A 585 mM biotin (B4501, Sigma) stock solution in DMSO was prepared with mixing at 37 °C, then 
aliquoted and stored at -20 °C. The day after transfection, a 2X biotin working solution (2.4 mM) was 
prepared by diluting the stock solution 1:250 in culture media and mixing thoroughly to dissolve any 
precipitate, then pre-warmed to 37 °C. At t=0, 500 μL of 2X biotin working solution was added onto 
the cells in 500 μL culture media for a final biotin concentration of 1.2 mM. At each time point, cells 
were placed on ice, fixed and mounted onto microscopy slides with Mowiol with DAPI following the 
protocol described in section 2.12.2. Cells were then imaged on an Axioimager Z2 widefield 
microscope (Carl Zeiss). 
2.13 Cell-based assays 
2.13.1 Cytokine array 
0.45x106 cells were pelleted by centrifugation (200g, 5 min), washed in PBS, resuspended in 1.5 mL 
serum-free medium (RPMI-1640 medium with L-glutamine and sodium bicarbonate) and transferred 
to a 12-well plate. Conditioned media was harvested after 24 hours, cells and debris were pelleted by 
centrifugation (1000g, 5 min) and the supernatant was incubated with the antibody-based Human 
Cytokine Array C5 (RayBiotech) following the manufacturer’s instructions. The array was imaged using 
a G:BOX imaging system (Syngene). Spot intensity calculation and background subtraction were 
performed in Image Studio Lite (LI-COR). Intensity fold change for each cytokine was calculated from 
raw intensity data.  
 
2.13.2 Reactive oxygen species assay 
Reactive oxygen species (ROS) were detected using the membrane permeable fluorogenic dye 2',7'-
dichlorodihydrofluorescein diacetate (H2-DCF-DA; D399, Invitrogen). The dye was stored under dry N2 
and a 5000x working stock (5 mM) was made in anhydrous DMSO before use. EV1, KO1 and KO2 cells 
were pelleted (125g, 5 min) and washed in PBS twice. Cells were resuspended in Dulbecco's 
phosphate-buffered saline (DPBS) with 1 µM H2-DCF-DA at a cell density of 0.5x106 cells/mL. 100 µL 
were transferred to a black lidded 96-well plate (655086, Greiner) in triplicate and the plate was 
incubated at 37 °C, 5% CO2 for 15 minutes. Fluorescence was measured using a Spark CM (Tecan) or 
Clariostar Plus (BMG) plate reader (Excitation: 492–495 nm, Emission: 517–527 nm). 
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2.13.3 Apoptosis assays 
2.13.3.1 TUNEL assay 
The APO-BrdU TUNEL Assay Kit (ThermoFisher) was used to detect apoptosis. 0.6x106 WT and GALC 
KO oligodendrocytes were seeded in T75 flasks and differentiated on the next day. The differentiation 
media was changed after 4 days. The media of the staurosporine-treated control cells was replaced 
by differentiation media containing 2 µM staurosporine 24 hours before sample processing. 7 days 
after differentiation, floating cells were pooled with adherent cells detached by trypsinisation. 1x106 
cells were then labelled and stained with Alexa Fluor 488 following the kit protocol. Samples were 
analysed on the LSRFortessa cell analyser (BD Biosciences). The BrdU-conjugated fluorophore 
AlexaFluor 488 was excited with a 488 nm laser? with the 515/20 emission filter. 5x103, 5x103 and 
8x103 events were recorded for WT, staurosporine-treated and GALC KO samples, respectively, with 
a detector voltage of 291 V. 1x103 events were analysed for the unstained WT sample, with a higher 
detector voltage of 421 V. Data was analysed with FlowJo. 
 
2.13.3.2 DNA laddering assay 
DNA fragmentation was assessed following a published protocol214. 140x103 WT and GALC KO MO3.13 
were seeded into 6 cm dishes. On the next day, cells were differentiated. One dish was kept as an 
undifferentiated sample. Dishes with WT and GALC oligodendrocytes were then processed 1, 2, 3, 6 
and 7 days after differentiation as described below. The media of the dishes processed on day 6 and 
7 was changed with fresh differentiation media 3 days after differentiation was initiated. One WT 
sample was treated with 2 µM staurosporine for 24 hours before harvesting at day 7 post-
differentiation. Adherent cells were detached with trypsin and pooled with detached cells. Cells were 
washed once with PBS and spun down (200g, 5 min). The pellet was resuspended in 50 µL hypotonic 
buffer and kept on ice for 10 min. The lysate was centrifuged (4500g, 4 °C, 5 min). In a fresh tube, the 
supernatant was supplemented with SDS (1% final concentration). RNase A was added (2.5 mg/mL) 
and the sample was incubated for 2 hours at 55 °C. Proteinase K was added (2.5 mg/mL) and the 
sample was incubated for 2 hours at 37 °C. 100 µL 10 M ammonium acetate and 1 mL chilled absolute 
ethanol were added to the sample, and the sample was stored at -20 °C for 1-8 days. All samples were 
then centrifuged (13000g, 10 min). The pellet was washed with 500 µL 70% ethanol and spun down 
(13000g, 10 min). The pellet was air-dried and resuspended in 20 µL TE buffer. Samples were mixed 
with 10 µL of 6X DNA loading dye (NEB) and analysed by agarose gel electrophoresis (1.5% agarose 
gel, 35 V, 3.5 h).  
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3 CD1d-Saposin B interaction studies 
 
This chapter has been expanded and reworked from a published article “The lipid transfer protein 




As described in section 1.7.4, the lysosomal lipid transfer protein SapB has been shown to facilitate 
lipid exchange on the lipid antigen presenting molecule CD1d165,166,169. However, the mechanism of 
lipid transfer has not yet been elucidated. SapB is thought to act as a lipid solubiliser, extracting the 
lipid from a lipid bilayer, encapsulating it in its hydrophobic core and presenting it to lipid-interacting 
proteins in solution. Due to the hydrophobic property of lipids, their exposure to aqueous solutions is 
thermodynamically unfavourable. Therefore, lipid transfer between SapB and the hydrophobic lipid-
binding groove of CD1d must require direct interaction between these proteins, as well as structural 
rearrangements for continuous shielding of the lipid from the aqueous phase. To gain an insight into 
the mechanism of CD1d lipid loading by SapB, I attempted structural studies of CD1d in complex with 
SapB. CD1d did not co-crystallise with SapB, calling into question whether SapB directly interacts with 
CD1d. This was addressed using biochemical assays to probe the interaction between CD1d and SapB.  
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3.1 Purification of CD1d-β2m complex from a human cell line 
Several strategies have been developed previously for the purification of CD1d including refolding 
from E. coli inclusion bodies216, baculovirus-insect cell expression184 and mammalian expression 
systems217. An important consideration for CD1d protein expression and purification is the inclusion 
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of the essential partner protein β2m. In a manner similar to the heavy chain of MHC class I, CD1d non-
covalently associates with β2m and this association is required for maturation of its four glycan 
chains218. In order to obtain high quality, near-native CD1d protein for in vitro studies, I co-expressed 
human CD1d with β2m in the mammalian suspension cell line HEK293F as this would confer correct 
folding, native post-translational modification and full glycosylation of CD1d. Initial trials using 
polyethylenimine (PEI)-based transient co-transfection of CD1d and β2m resulted in very low yields 
(0.1 mg protein per 100 mL media). Thus I used a piggyBac expression system173 (detailed in section 
2.4.1) to establish stable and inducible co-expression of full-length, untagged β2m with the 
ectodomain of CD1d possessing a C-terminal hexahistidine (H6) tag (Fig. 3.1A). Although the piggyBac 
expression system had been previously used in our lab, this was the first attempt at co-expression of 
two proteins using this system. Both proteins were expressed with an N-terminal secretion signal 
sequence targeting synthesis to the endoplasmic reticulum, resulting in protein secretion into the 
media. This expression strategy results in CD1d molecules that are bound to endogenous human lipids 
acquired during folding in the endoplasmic reticulum and trafficking through the Golgi apparatus157. 
CD1d-H6 was purified from conditioned media by nickel affinity chromatography (Fig. 3.1B) followed 
by size exclusion chromatography (Fig. 3.1C-D). Untagged β2m co-purified with CD1d, indicating that 
both proteins are correctly folded and form a stable complex. Although some CD1d alone was purified, 
I was able to separate this from CD1d-β2m following size exclusion chromatography (Fig. 3.1C-D). 
Intriguingly, CD1d alone elutes earlier from the size exclusion column than the CD1d-β2m complex, 
which is unexpected given that CD1d alone is expected to be smaller and therefore elute later. There 
are two possible explanations for this elution profile. The glycans on β2m-associated CD1d may non-
specifically interact with the column, retarding its elution. However, I would expect tailing of the 
elution peak in this case. Alternatively, CD1d may adopt a conformation with a larger hydrodynamic 
radius in the absence of β2m, accelerating its elution. 
 
Using this expression system, I obtained a high yield (1 mg protein per 100 mL media) of >95% pure 
CD1d-β2m protein. The yield was 10 times higher than that obtained with transient co-transfection in 




Figure 3.1. Human CD1d-β2m expression and purification from mammalian cells 
A. A hexahistidine (H6)-tagged construct encoding the extracellular domain of CD1d (CD1d-H6) was 
co-expressed with untagged full-length β2m in mammalian cells. Both proteins were secreted into 
the media. B. CD1d-H6 was captured from the media with Ni-NTA agarose and eluted with 300 mM 
imidazole in PBS. Fractions were analysed on a Coomassie-stained 4-12% Bis-tris SDS-PAGE gel, 
showing co-purification of untagged β2m with CD1d-H6. C. Eluted fractions were pooled, 
concentrated, and CD1d-H6 -β2m was further purified by size exclusion chromatography (SEC) using a 
Superdex 200 10/300 column. D. SEC elution fractions were analysed on a Coomassie-stained 4-12% 
Bis-tris SDS-PAGE gel. The indicated fractions were pooled, concentrated, and used in downstream 
experiments. 
 
3.2 Purification of SapB 
The four saposin proteins (SapA-D) are produced from the proteolytic cleavage of the precursor 
protein PSAP which normally occurs upon delivery to the lysosome. To produce recombinant SapB 
alone, the segment of human PSAP corresponding to SapB (Fig. 3.2A) was expressed in E. coli. 
Untagged SapB was purified following a well-established protocol219 that exploits the remarkable heat 
stability of saposins conferred by the presence of three disulphide bonds stabilising each saposin 
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monomer. A large fraction of contaminants was precipitated and removed by boiling of E. coli lysates. 
SapB was further purified by anion exchange chromatography (Fig. 3.2B-C) followed by size exclusion 
chromatography (Fig. 3.2D-E), which allows the separation of SapB from contaminating E. coli proteins 
and DNA. This protocol yields 50 mg pure SapB per litre of culture. Previous structural studies with E. 
coli-expressed SapB identified that it exists as a tight dimer that co-purifies with E. coli 
phosphatidylethanolamine82. 
 
Figure 3.2. Human SapB expression and purification from E. coli 
A. Untagged human SapB (residues 195-274 of the precursor protein PSAP) was recombinantly 
expressed in E. coli. B. SapB was purified by anion exchange chromatography using a 5 mL HiTrap 
QSepharose column. C. Eluted fractions were analysed on a Coomassie-stained 4-12% Bis-Tris SDS-
PAGE gel. The indicated fractions were pooled and concentrated for further purification. D. SapB was 
further purified by size exclusion chromatography using a Superdex 75 16/600 column. Large 
amounts of contaminating DNA characterised by high absorbance at 260 nm elute around 90 mL. 
The first elution peak contains purified SapB. E. Eluted fractions corresponding to the first peak were 
analysed on a Coomassie-stained 4-12% Bis-Tris SDS-PAGE gel. The indicated fractions were pooled, 
concentrated and used in downstream experiments. 
 77 
3.3 Co-crystallisation trials of CD1d and SapB  
Previously published work strongly supported that SapB directly loads lipids onto CD1d, a process that 
would require a direct interaction between these two proteins in order to facilitate lipid exchange. 
Therefore, I attempted to co-crystallise CD1d with SapB to get structural insight into their interaction 
and the mechanism of CD1d lipid loading by SapB.  
 
3.3.1 Initial co-crystallisation experiments 
Using highly pure protein described in sections 3.1 and 3.2, I set up sitting-drop vapour diffusion 
crystallisation trials with CD1d and SapB in a 1:2 molar ratio, taking into account the fact that SapB 
functions as a dimer. Both proteins were purified in the same buffer (150 mM NaCl, 50 mM Tris pH 
7.4). Crystallisation trials were set up with CD1d at 12.7 mg/mL and SapB at 4.5 mg/mL (Fig. 3.3A). 
Low-resolution diffraction quality crystals grew against a reservoir containing 20% v/v PEG 
monomethylether 550, 10% w/v PEG 20 000, 20 mM 1,6-hexanediol, 20 mM 1-butanol, 20 mM 1,2-
propanediol, 20 mM 2-propanol, 20 mM 1,4-butanediol, 20 mM 1,3-propanediol, 0.1 M bicine/Trizma 
base pH 8.5 (Fig. 3.3B). Crystallisation conditions were optimized by screening around the pH, alcohol 
and precipitant concentration. To test whether these crystals contained both CD1d and SapB, I 
harvested several crystals, washed them in reservoir solution to remove residual uncrystallised 
components, then separated proteins contained in the crystal by SDS-PAGE followed by detection 
using Coomassie staining (Fig. 3.3C). CD1d and β2m are visible on the gel, but SapB is not. These 
crystals composed of CD1d-β2m alone were therefore not pursued further. 
 
Crystals also grew as bunches of needle crystals against several related reservoir solutions containing 
20% w/v PEG 6000 and divalent cations at pH 6 and 7 (Fig. 3.3D). These crystals did not diffract. 
Therefore, I washed several of these crystals and analysed them by SDS-PAGE, showing that these 
crystals were composed of SapB only (Fig. 3.3E).  
 
I set up additional trials with a 1:3 molar ratio of CD1d to SapB, with SapB in excess in order to drive 
complex formation. Some non-crystalline protein aggregates were formed, but these could not be 
harvested for SDS-PAGE analysis, even after optimisation of crystallisation conditions.  
 
The formation of crystals composed of CD1d-β2m alone or SapB alone shows that the proteins used in 
this study are pure and crystallisable. However, no crystal containing both CD1d and SapB was grown. 
This suggests that the conditions in which these protein constructs crystallize are not conducive to 
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their interaction, or that a key component necessary for their interaction may be missing. In the next 
experiments, I have attempted to address these issues.  
 
 
Figure 3.3. Crystallisation trials of CD1d-β2m and SapB. 
A. Coomassie-stained SDS-PAGE of the purified protein sample containing CD1d-β2m and a 2-fold 
molar excess of SapB used in crystallisation trials. B. Crystals grown by sitting drop vapour diffusion 
against a reservoir containing 20% v/v PEG MME 550, 10% w/v PEG 20 000, 20 mM 1,6-hexanediol, 
20 mM 1-butanol, 20 mM 1,2-propanediol, 20 mM 2-propanol, 20 mM 1,4-butanediol, 20 mM 1,3-
propanediol, 0.1 M bicine/Trizma base pH 8.5. A condenser lens was used to image these thin 
crystals. C. Coomassie-stained SDS-PAGE of harvested and washed crystals shown in panel B. D. 
Crystals grown by sitting drop vapour diffusion against a reservoir of 20% w/v PEG 6000, 0.2 M 
calcium chloride and 0.1 M HEPES pH 7. E. Coomassie-stained SDS-PAGE of harvested and washed 
crystals shown in panel D. The scale bar represents 100 μm. 
 
3.3.2 CD1d deglycosylation 
CD1d possesses four N-glycosylation sites. Glycans have a high chemical and conformational 
heterogeneity and can therefore limit protein crystallisation. To facilitate CD1d crystallisation in 
different crystallisation conditions and improve crystal quality, I produced deglycosylated CD1d 
protein for crystallisation trials. Deglycosylated protein can be produced from mammalian cells by 
inhibiting α-mannosidase I with kifunensine220 during protein expression. This permits normal protein 
folding and initial glycosylation, but glycan processing is limited so that glycans are sensitive to 
cleavage by Endoglycosidase H (Endo H) after protein purification221. Endo H treatment leaves a single 
N-Acetylglucosamine residue at each glycosylation site.  
 
The expression of CD1d-β2m from the cell line produced in section 3.1 is inducible. From the time of 
induction of protein expression, cells were treated with kifunensine throughout protein expression. 
CD1d was purified from the media of kifunensine-treated cells by nickel affinity purification and eluted 
with 100 mM citrate pH 4 (Fig. 3.4A). A low pH elution buffer was chosen because Endo H has a low 
pH optimum (pH 5.5). CD1d is likely to remain correctly folded and stable at low pH since it normally 
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localizes to late endosomal compartments. Indeed, using this purification protocol, the yield remained 
similar to that obtained with imidazole elution (section 3.1). 
 
 
Figure 3.4. Optimisation of CD1d-β2m deglycosylation 
CD1d-β2m was expressed in HEK293F cells in the presence of kifunensine to produce protein with 
high-mannose glycans susceptible to Endo H cleavage. A. Nickel affinity purification of CD1d-β2m 
from the media of kifunensine-treated cells. B. Small-scale optimisation of conditions for Endo H 
treatment of CD1d-β2m, analysed by Coomassie-stained 4-12% SDS-PAGE Bis-Tris gel. As a positive 
control, CD1d-β2m was denatured prior to treatment with Endo H. Abbreviations: g: glycosylated; 
CD1dg: deglycosylated. 
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I first optimised the experimental conditions for Endo H treatment of CD1d in a small-scale experiment 
by varying the following factors: amount of Endo H added (a range of 1000 to 62.5 units was tested by 
serial dilution), time (3 hours or overnight) and temperature (room temperature or 37 °C). As a positive 
control, CD1d was denatured prior to treatment with Endo H. All conditions resulted in complete 
deglycosylation of CD1d as assessed by comparison with the positive control (Fig. 3.4B). Consequently, 
for large scale CD1d deglycosylation, CD1d was incubated with the smallest concentration of Endo H 
tested (3125 units per mg of CD1d) for 3 hours at room temperature. I observed the formation of 
precipitate in the sample during incubation with Endo H. After Endo H treatment, I pelleted the 
precipitate by centrifugation and analysed it by SDS-PAGE (Fig. 3.5A). This revealed that the precipitate 
is composed of deglycosylated CD1d without β2m. This instability of deglycosylated CD1d without β2m 
is advantageous since its loss by precipitation increases the homogeneity of the sample. 
Deglycosylated CD1d-β2m was further purified by size exclusion chromatography to remove Endo H 
(Fig. 3.5B). Unfortunately, it was not possible to fully separate Endo H from deglycosylated CD1d by 
size exclusion chromatography due to their similar size, therefore only fractions containing CD1d were 
pooled and used in crystallisation experiments (Fig. 3.5C). A second peak with high absorbance at 280 
nm was visible on the size exclusion trace. This did not correspond to protein as assessed by Coomassie 
staining. Although the content of this peak is unclear, this unknown component was well separated 
from the CD1d sample. 
 
3.3.3 Co-crystallisation trials of deglycosylated CD1d and SapB  
Co-crystallisation trials were set up with deglycosylated CD1d (6.5 mg/mL) and SapB (2.3 mg/mL) at a 
molar ratio of 1:2 in 100 mM citrate pH 6.0, 150 mM NaCl (Fig. 3.6A). Crystals grew in many 
crystallisation conditions, suggesting that deglycosylated CD1d is more readily crystallisable than 
glycosylated CD1d. A crystal was grown against a reservoir containing 20% w/v PEG 3350, 0.1 M bis-
Tris propane pH 7.5 and 0.2 M di-sodium malonate (Fig. 3.6B) and a 2.52 Å diffraction dataset was 
collected from this crystal (Table 3.1, crystal (i)). The structure was solved by molecular replacement 
using a published structure of CD1d-β2m (PDB ID: 3U0P) as a search model. Rigid-body refinement of 
this solution showed unbiased Fo-Fc difference density correctly indicating the presence of N-
Acetylglucosamine (remaining after Endo H cleavage) on each molecule on residues Asn20 and Asn42 
or Asn163 (Fig. 3.6C), absent in the search model, confirming the validity of the molecular replacement 
solution. Additional unmodelled density near the lipid-binding groove was evident that likely 
corresponds to the lipid head group (Fig. 3.6C). No additional positive difference density 
corresponding to SapB molecules was observed.  
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Figure 3.5. Large scale CD1d-β2m deglycosylation 
A. Large scale deglycosylation of CD1d-β2m by Endo H treatment. After Endo H treatment, 
precipitate was formed and the contents of the mixture, soluble fraction and precipitate were 
analysed by SDS-PAGE on a 12% acrylamide gel. B. Soluble deglycosylated CD1d-β2m was further 
purified by size exclusion chromatography on a Superdex 200 10/300 column. C. Size exclusion 
chromatography fractions were analysed by SDS-PAGE on a 12% acrylamide gel, showing incomplete 
separation between CD1d-β2m and Endo H. The indicated fractions containing CD1d-β2m only were 




Figure 3.6. Crystallisation trials of deglycosylated CD1d-β2m with SapB. 
A. Coomassie-stained SDS-PAGE of the purified protein sample containing deglycosylated CD1d-β2m 
and a 2-fold molar excess of SapB used in crystallisation trials. B. Crystal grown by sitting drop 
vapour diffusion against a reservoir containing 20% w/v PEG 3350, 0.1 M bis-Tris propane pH 7.5 and 
0.2 M di-sodium malonate. A condenser lens was used to image this thin crystal. C. Electron density 
(2Fo-Fc, in blue) and difference density (Fo-Fc, in green for positive and red for negative) maps of the 
structure solved from the crystal shown in panel B. The lipid-binding groove of CD1d is seen from 
above (CD1d peptide backbone in pink). Unmodelled density corresponding to the lipid headgroup 
protruding from the CD1d lipid-binding groove, and residual N-Acetylglucosamine (GlcNAc) on 
Asparagine 163 is indicated by green arrows. D. Crystals grown by sitting drop vapour diffusion 
against a reservoir containing 16% v/v PEG 500 monomethylether, 8% w/v PEG 20000, 0.1 M 
bicine/Trizma base pH 8.5, 30 mM sodium nitrate, 30 mM sodium phosphate dibasic and 30 mM 
ammonium sulfate. E. Coomassie-stained SDS-PAGE of harvested and washed crystals shown in 
panel D. F. Coomassie-stained SDS-PAGE of crystals grown in various crystallisation conditions 
containing deglycosylated CD1d-β2m and a 2-fold molar excess of SapB. Scale bar represents 100 
μm. Abbreviations: dg: deglycosylated; GlcNAc: N-Acetylglucosamine. 
 
Screening of many other crystals grown in conditions containing deglycosylated CD1d and SapB 
showed that they had the same space group and cell dimensions as the crystal described above, 
signifying that they have the same content. However, a crystal belonging to a different space group 
grew against a reservoir containing 20% v/v PEG 550 monomethylether, 10% w/v PEG 20000, 0.1 M 
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bicine/Trizma base pH 8.5, 30 mM sodium nitrate, 30 mM sodium phosphate dibasic and 30 mM 
ammonium sulfate and diffracted to 7 Å. This crystal was optimised by screening around the pH and 
precipitant concentration and increasing protein concentration (to 13.3 mg/mL CD1d-β2m and 4.7 
mg/mL SapB). This improved the resolution of a crystal grown in optimised crystallisation conditions 
(16% v/v PEG 500 monomethylether, 8% w/v PEG 20000, 0.1 M bicine/Trizma base pH 8.5, 30 mM 
sodium nitrate, 30 mM sodium phosphate dibasic and 30 mM ammonium sulfate; Fig. 3.6D) to 3.49 Å 
(Table 3.1, crystal (ii)). The structure was solved by molecular replacement and refined by rigid body 
refinement. The validity of the solution was confirmed by the presence of N-Acetylglucosamine at 
expected positions (Asn40, 42 and 163) on each of the six molecules in the asymmetric unit. No 
unmodelled density corresponding to SapB was observed, indicating that the crystal contained only 
CD1d. This was confirmed by SDS-PAGE analysis of optimised crystals (Fig. 3.6E). Similarly, crystals 
from a number of additional crystallisation conditions containing deglycosylated CD1d and SapB were 
analysed by SDS-PAGE and found to contain deglycosylated CD1d alone (Fig. 3.6F). 
 




Data collection   Crystal (i) Crystal (ii) 
Beamline  I03 I04-1 
Wavelength (Å)  0.9793 0.9159 
Processing package  XIA2 DIALS XIA2 3dii 
Space group   C 2 P 21 
Cell dimensions  
 
 
   a,b,c (Å)   186.2, 57.1, 129.2 123.8, 122.9, 159.9 
   α,β,γ (°)   90, 100, 90 90, 95, 90 
Resolution (Å)   54.53 – 2.52 
(2.56 – 2.52) 
123.27 – 3.49 
(3.55 – 3.49) 
Rmerge   0.072 (2.438) 0.161 (1.572) 
Rpim  0.031 (1.028) 0.067 (0.663) 
CC1/2  0.999 (0.813) 0.992 (0.714) 
I/sI   10.9 (0.8) 6.9 (1.0) 
Completeness (%)   99.8 (98.0) 99.8 (99.9) 
Redundancy   6.7 (6.6) 6.9 (6.6) 
     
Molecular replacement 
CD1d-β2m molecules per 
asymmetric unit 2 6 
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In summary, deglycosylated CD1d crystallises readily in a wide range of crystallisation conditions. The 
use of deglycosylated protein improved the quality of the crystals, allowing determination of the 
structure of CD1d to 2.52 Å. However, none of the crystals grown with these reagents contained both 
CD1d and SapB. This suggests that a key component necessary for their interaction may be missing. 
 
3.3.1 Co-crystallisation trials of CD1d and SapB loaded with the lipid α-GalCer 
Previous studies have shown that the ectodomain of CD1d co-purifies with a broad range of cellular 
lipids following synthesis and trafficking through the secretory pathway, but is likely to be primarily 
loaded with sphingomyelin157-159. SapB co-purifies with E. coli phosphatidylethanolamine82, a lipid 
species that has also been shown to bind CD1d222. Although it seems likely that this lipid composition 
for SapB and CD1d should be compatible with protein-protein interactions required for lipid exchange, 
lipid loading onto CD1d has only been formally demonstrated in vitro for a few lipids, and in particular 
α-GalCer165,166. Therefore, both proteins were pre-loaded with α-GalCer for co-crystallisation trials. 
Lipid loading was performed based on a protocol used to obtain crystal structures of α-GalCer-loaded 
CD1d177,222. CD1d and SapB were incubated with a 3-fold excess of lipid in PBS overnight. α-GalCer-
loaded proteins were then separated from free α-GalCer by size exclusion chromatography. Lipid 
exchange did not cause changes in the elution profile of CD1d (Fig. 3.7A-B) and SapB (Fig. 3.7C-D), 
suggesting that both proteins remained correctly folded and did not degrade over the course of lipid 
exchange. 
 
I set up co-crystallisation trials with α-GalCer-loaded CD1d and SapB at a molar ratio of 1:2 and 1:3 in 
50 mM Tris pH 7.4, 150 mM NaCl (CD1d at 11.9 mg/mL and SapB at 4.2 or 6.3 mg/mL; Fig. 3.8A). 
Crystals grew against a reservoir containing 0.1 M sodium acetate pH 5.0, 20% w/v PEG 6000 and 0.2 
M ammonium chloride (Fig. 3.8B) and a diffraction dataset was collected (Table 3.2, crystal (iii)). The 
structure was solved by molecular replacement and refined by rigid body refinement as in section 
3.3.3. For each of the four CD1d molecules in the asymmetric unit, unbiased Fo-Fc difference density 
indicated the presence of the expected N-Acetylglucosamine on residues Asp2, Asp42 and/or Asp 163, 
confirming the validity of the molecular replacement solution. Unmodelled density near the lipid 
binding groove corresponding to α-GalCer was also observed (Fig. 3.8C). No additional positive 
difference density corresponding to SapB molecules was observed. The absence of SapB was 
confirmed by SDS-PAGE analysis of the crystal (Fig. 3.8D). The harvested crystal was directly dissolved 
in SDS-PAGE buffer after data collection. 
 
Other crystals grew against a reservoir containing 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% 
v/v 2-methyl-2,4-pentanediol, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium 
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iodide, 0.1 M bicine/Trizma base pH 8.5 (Fig. 3.8E). These crystals did not diffract, so I analysed the 
contents of remaining crystals by SDS-PAGE analysis. This showed that this crystal was also 
composed of CD1d only (Fig. 3.8F). 
 
 
Figure 3.7. Re-purification of CD1d and SapB after loading with the lipid α-GalCer 
Purified CD1d and SapB protein were loaded with the lipid α-GalCer by overnight incubation with a 
3-fold molar excess of the lipid. Size exclusion chromatography of CD1d and SapB with a Superdex 
200 10/300 column was used to separate lipid-loaded proteins from lipids in solution. A. Size 
exclusion chromatogram of α-GalCer-loaded CD1d. B. Eluted fractions were analysed on a 
Coomassie-stained 15% SDS-PAGE gel. C. Size exclusion chromatogram of α-GalCer-loaded SapB. D. 






Figure 3.8. Crystallisation trials of α-GalCer-loaded CD1d and SapB 
A. Coomassie-stained SDS-PAGE of the purified protein samples containing α-GalCer-loaded CD1d-
β2m and a 2- or 3-fold molar excess of α-GalCer-loaded SapB used in crystallisation trials. B. Crystal 
grown by sitting drop vapour diffusion against a reservoir containing 0.1 M sodium acetate pH 5.0, 
20% w/v PEG 6000 and 0.2 M ammonium chloride. C. Electron density (2Fo-Fc, in blue) and 
difference density (Fo-Fc, in green for positive and red for negative) maps of the structure solved 
from the crystal shown in panel B. The lipid-binding groove of CD1d is seen from above (CD1d 
peptide backbone in yellow). Unmodelled density corresponding to α-GalCer in the CD1d lipid-
binding groove, and residual N-Acetylglucosamine (GlcNAc) on Asparagine 163 is indicated by green 
arrows. D. Coomassie-stained SDS-PAGE of harvested crystal shown in panel B. E. Crystals grown by 
sitting drop vapour diffusion against a reservoir containing 12.5% w/v PEG 1000, 12.5% w/v PEG 
3350, 12.5% v/v 2-methyl-2,4-pentanediol, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M 
sodium iodide, 0.1 M bicine/Trizma base pH 8.5. F. Coomassie-stained SDS-PAGE of harvested crystal 





Table 3.2. Data collection statistics for CD1d crystal (iii). Values in parentheses are for the highest-
resolution shell. 
Data collection   Crystal (iii) 
Beamline  I04 
Wavelength (Å)  0.9999 
Processing package  STARANISO 
Space group   C 2 
Cell dimensions  
 
   a,b,c (Å)   273.3, 88.0, 127.9 
   α,β,γ (°)   90, 114, 90 
  Isotropic Anisotropic 
Resolution (Å)   124.71 – 4.97 
(5.05 – 4.97) 
124.71 – 4.55 
(4.99 – 4.55) 
Rmerge   0.438 (2.187) 0.198 (0.507) 
Rpim  0.279 (1.366) 0.127 (0.323) 
CC1/2  0.967 (0.322) 0.987 (0.704) 
I/sI   1.9 (0.5) 3.4 (1.8) 
Completeness (%)   99.8 (99.8) e* 80.0 (56.7) 
s* 39.2 (8.1) 
Redundancy   3.4 (3.5) 3.4 (3.4) 
    
Molecular replacement 
CD1d-β2m molecules per asymmetric unit 4 
 
3.3.2 Co-crystallisation trials of glycosylated CD1d with glycosylated SapB  
SapB possesses one N-linked glycosylation site on residue Asn21, which remains unglycosylated when 
expressed in E. coli. Although unglycosylated SapB loads lipids onto CD1d165,166, it is possible that this 
glycan on SapB may increase its affinity for CD1d. Therefore, I expressed H6-tagged SapB (SapB-H6) in 
mammalian cells, enabling the purification of glycosylated protein. SapB-H6 was expressed using the 
pHLsec vector transfected into HEK293F cells using transient PEI-based transfection. SapB-H6 was 
purified by nickel affinity chromatography from the media (Fig. 3.9A), followed by size exclusion 
chromatography (Fig. 3.9B-C). Following purification, two SapB-H6 species were present, with 
apparent molecular weights of 12 and 15 kDa (Fig. 3.9B). This tagged SapB construct has a predicted 
molecular weight of 10 kDa, therefore these two species are likely to be SapB-H6 protein modified 
with glycans of different sizes. The lack of separation of these two species by size exclusion 





Figure 3.9. Purification of glycosylated SapB from mammalian cells 
Secreted, hexahistidine-tagged full-length SapB (SapB-H6) was expressed in mammalian HEK293F 
cells to enable purification of glycosylated SapB. A. SapB-H6  was captured from the media with Ni-
NTA agarose and eluted with 300 mM imidazole in PBS. Fractions were analysed on a Coomassie-
stained 4-12% Bis-Tris SDS-PAGE gel. Two SapB species are present, likely reflecting the 
heterogeneity of glycan modifications. B. Eluted fractions were pooled, concentrated, and CD1d-H6 -
β2m was further purified by size exclusion chromatography (SEC) using a Superdex 200 10/300 
column. SEC elution fractions were analysed on a Coomassie-stained 4-12% Bis-tris SDS-PAGE gel. All 
fractions were pooled. C. SEC chromatogram. D-E. The C-terminal His-tag of SapB was removed by 
incubation with carboxypeptidase A-agarose beads for 3 hours (D) or overnight (E). After this 
treatment, untagged SapB was separated from SapB-H6 and free histidine by nickel affinity 
chromatography with Ni-NTA beads. Flow-through (FT) and wash fractions containing untagged 
SapB, and elution fractions containing SapB-H6 were visualised on a Coomassie-stained 15% SDS-
PAGE gel. 
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Because of the small size and compact conformation of SapB dimers, the addition of a His6 tag may 
affect SapB folding and function. Therefore, I removed the tag by treatment of SapB-H6 with 
carboxypeptidase A, which hydrolyses peptide bonds of C-terminal residues up to the lysine residue 
preceding the His tag. SapB-H6 was incubated with carboxypeptidase A-agarose beads for 3 hours or 
overnight, then untagged SapB was separated from cleaved His and His-tagged SapB by affinity 
purification with Ni-NTA agarose. Tag removal efficiency was assessed by SDS-PAGE analysis of flow-
through and wash fractions containing untagged SapB, and eluted fractions containing His-tagged 
SapB (Fig. 3.9D-E). Carboxypeptidase A digestion for 3 hours was found to be insufficient (Fig. 3.9D). 
After overnight digestion (Fig. 3.9E), a large fraction of SapB appeared untagged and this protocol was 
used to generate untagged glycosylated SapB for the next experiments. Approximately 0.5-1 mg 
untagged SapB was obtained from a 300 mL HEK293F culture. I noted that SapB bands appeared 
smeary, indicating some heterogeneity that may have been caused by excessive digestion of SapB by 
Carboxypeptidase A. However, due to the relatively small quantity of degraded SapB, this sample was 
carried through for crystallisation experiments. 
 
I set up co-crystallisation trials with glycosylated CD1d (12.4 mg/mL) and glycosylated, untagged SapB 
(4.3 mg/mL) at a molar ratio of 1:2 in 20 mM HEPES pH 7.0, 150 mM NaCl (Fig. 3.10A). Crystals grew 
against a reservoir containing 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v 2-methyl-2,4-
pentanediol, 20 mM 1,6-hexanediol, 20 mM 1-butanol, 20 mM 1,2-propanediol, 20 mM 2-propanol, 
20 mM 1,4-butanediol, 20 mM 1,3-propanediol and 0.1 M bicine/Trizma base pH 8.5 (Fig. 3.10B). 
However, SDS-PAGE analysis of these crystals showed that they were composed of CD1d only (Fig. 
3.10C). 
 
Crystals also grew against a reservoir containing 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v 
2-methyl-2,4-pentanediol, 20 mM D-glucose, 20 mM D-mannose, 20 mM D-galactose, 20 mM L-
fucose, 20 mM D-xylose, 20 mM N-acetyl-D-glucosamine, 0.1 M MOPS/HEPES-Na pH 7.5 (Fig. 3.10D). 
These crystals were analysed by SDS-PAGE and were once again found to contain CD1d only (Fig. 
3.10E). (Note that although glycosylated SapB runs at around the same size as β2m, separation of SapB 
and β2m is clearly visible by SDS-PAGE analysis using 4-12% Bis-Tris gradient gels, as seen in Fig. 3.14).  
 
No crystal containing glycosylated SapB was found. This may be because the sample heterogeneity 




Figure 3.10. Crystallisation trials of CD1d and glycosylated SapB 
A. Coomassie-stained SDS-PAGE of the purified protein samples containing CD1d-β2m and a 2-fold 
molar excess of glycosylated SapB used in crystallisation trials. B. Crystal grown by sitting drop 
vapour diffusion against a reservoir containing 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v 
2-methyl-2,4-pentanediol, 20 mM 1,6-hexanediol, 20 mM 1-butanol, 20 mM 1,2-propanediol, 20 
mM 2-propanol, 20 mM 1,4-butanediol, 20 mM 1,3-propanediol and 0.1 M bicine/Trizma base pH 
8.5. C Coomassie-stained SDS-PAGE of harvested crystals shown in panel B. D. Crystals grown by 
sitting drop vapour diffusion against a reservoir containing 12.5% w/v PEG 1000, 12.5% w/v PEG 
3350, 12.5% v/v 2-methyl-2,4-pentanediol, 20 mM D-glucose, 20 mM D-mannose, 20 mM D-
galactose, 20 mM L-fucose, 20 mM D-xylose, 20 mM N-acetyl-D-glucosamine, 0.1 M MOPS/HEPES-
Na pH 7.5. E. Coomassie-stained SDS-PAGE of harvested crystal shown in panel D. Scale bar 
represents 100 μm.  
 
3.3.3 Summary of co-crystallisation experiments 
I have performed extensive co-crystallisation trials of CD1d and SapB. I have identified several factors 
that may affect this interaction as well as protein crystallisation. I have used different molar ratios of 
CD1d to SapB, fully glycosylated or deglycosylated protein, and protein loaded with endogenous lipids 
or with α-GalCer (Table 3.3). Several crystals were obtained in each of these experiments, confirming 
the protein samples were of high quality and crystallisable, with the exception of glycosylated SapB. 
However, each of these crystals was found to contain CD1d or SapB only, indicating that they do not 
form a stable, crystallisable complex.  
 
In a crystallisation experiment, the drop containing protein and precipitant gradually equilibrates with 
the reservoir, generally resulting in reduced drop volume and the progressive increase in 
concentration of the drop components. In this way, the protein components are steadily concentrated 
together. High concentrations of individual components can drive the formation of a protein complex 
even for weakly interacting proteins223. The absence of a co-crystal containing both CD1d and SapB 
suggests one of two things. (1) CD1d and SapB may interact in solution, but their complex is not 
crystallisable. Crystallisation is the process of formation of a regular array of macromolecules; if 
CD1d:SapB complexes cannot self-organise into such an array, no crystal can be formed. (2) CD1d and 
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SapB may not directly interact together. Although there is strong evidence that SapB directly loads 
lipids onto CD1d, a direct interaction has not yet been demonstrated. In fact, several publications 
report a failure to detect a direct interaction between saposins and human CD1d160,165,166. 
Unfortunately, these reports do not show any data or detail the approaches used to monitor binding, 
and the implication is that these interactions exist but are weak or transitory. 
 
Table 3.3. Summary of co-crystallisation trials 
CD1d SapB 
Molar ratio of CD1d 
to SapB 
Glycosylated CD1d Unglycosylated SapB 
1:2 
1:3 
α-GalCer loaded glycosylated CD1d α-GalCer loaded unglycosylated SapB 
1:2 
1:3 
Deglycosylated CD1d Unglycosylated SapB 1:2 
Glycosylated CD1d Glycosylated SapB 1:2 
 
3.4 In vitro CD1d-SapB interaction assays 
The fact that CD1d and SapB do not form a crystallisation complex cast doubt on the established idea 
that SapB directly interacts with CD1d. Therefore, I aimed to determine whether CD1d interacts with 
SapB using biochemical techniques adapted for weak and transient interactions. 
 
3.4.1 Equilibrium binding assays of CD1d and SapB 
Classical pull-down experiments involve the capture and immobilisation onto resin of a tagged bait 
protein followed by incubation with prey protein. Subsequent wash steps remove unbound protein, 
leaving behind protein complexes for detection. However, as the concentration of free prey protein is 
reduced at each wash, the equilibrium is pushed towards complex dissociation, meaning this method 
is not well suited for the capture of weak or transient interactions. Using this approach, no interaction 
was detectable between immobilised CD1d-β2m and SapB. Therefore, an alternative approach was 
adopted to overcome the limitations of prey depletion by using an in vitro equilibrium binding assay 
(Fig. 3.11A). In this assay, the bait is bound to beads at a range of concentrations and the prey is added 
at a low, limiting concentration. Following incubation, and no wash steps, the supernatant is separated 
from the beads and unbound prey is detected using the sensitive protein dye SYPRO Ruby. Monitoring 
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the depletion of prey from the supernatant by the large excess of bait protein, rather than monitoring 
complex formation directly, represents a more sensitive measure of binding and thus is optimised for 
weak or transient interactions224. Equilibrium binding assays were carried out using CD1d-β2m as bait 
at a concentration range of 0-40 μM and with SapB as the prey at 680 nM. Previous in vitro studies 
have identified that SapB can load α-GalCer onto CD1d at a pH range between 5 and 8165. Although 
this exchange appears to be most efficient at pH 6, this pH causes partial dissociation of the CD1d H6-
tag from the Ni-NTA resin. Therefore, the equilibrium binding assay was performed at pH 7. Previous 
work and preliminary experiments showed that β2m dissociates from CD1d in the presence of 
detergent225. However, the gentle detergent digitonin was found to cause minimal disruption of the 
CD1d-β2m complex225 and was used in this assay. Despite the use of this optimised approach, no 
binding of SapB to CD1d could be detected (Fig. 3.11B). In these conditions, at high CD1d-β2m 
concentrations, a small amount of β2m is detectable in the supernatant due to dissociation from CD1d 
(Fig. 3.11B). By comparing how little appears to be lost based on the Coomassie-stained bead samples 
this highlights the sensitivity of this technique and of the SYPRO Ruby stain for protein detection. 
 
 
Figure 3.11. Equilibrium binding assay of CD1d-β2m and SapB 
A. Schematic diagram illustrating the equilibrium binding assay protocol. B. Increasing 
concentrations of CD1d-β2m were bound to beads and detected by Coomassie-stained SDS-PAGE. 
After incubation with SapB, unbound SapB was detected in supernatants by SYPRO Ruby-stained 
SDS-PAGE. The lipids bound to CD1d-β2m and SapB in this experiment are the endogenous lipids 
they co-purify with following expression in human cells and E. coli. 
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As discussed in section 3.3.4, it is possible that the lipids associated with CD1d and SapB may 
contribute to protein-protein interactions. Therefore, I performed the equilibrium binding assay with 
both proteins pre-loaded with α-GalCer, a lipid that has been shown to be loaded onto CD1d by SapB. 
α-GalCer lipid loading was done as described in section 3.3.4 prior to the experiment. However, this 
variation also did not result in a detectable interaction between SapB and CD1d (Fig. 3.12A). To 
exclude the possibility that a strong interaction between CD1d and SapB only occurs when SapB 
exchanges a lower affinity antigen for α-GalCer, I repeated the equilibrium binding assay where SapB 
was pre-loaded with α-GalCer while CD1d retained the co-purified endogenous lipids (Fig. 3.12B). 
Again, there was no substantial depletion of SapB from the supernatant in this assay. Taken together, 
these results strongly suggest that CD1d and SapB do not directly interact in vitro, or that their 
interaction is extremely weak with a Kd > 40 μM. 
 
 
Figure 3.12. Equilibrium binding assay of α-GalCer-loaded CD1d-β2m and SapB 
An equilibrium binding assay was performed as using α-GalCer-loaded proteins. A. Increasing 
concentrations of α-GalCer-loaded CD1d-β2m were bound to beads and detected by Coomassie-
stained SDS-PAGE. After incubation with α-GalCer-loaded SapB, unbound SapB was detected in 
supernatants by SYPRO Ruby-stained SDS-PAGE. B. As for panel A but with SapB alone pre-loaded 
with the lipid α-GalCer. CD1d-β2m is bound to endogenous lipids co-purified following expression in 
human cells.  
 
3.4.2 In vitro cross-linking assays of CD1d and SapB 
Cross-linking of proteins using short chemical tethers that react with surface-exposed lysine side-
chains can be used to capture transient or weak interactions. Both CD1d and SapB have several 
surface-exposed lysines, and of particular importance, lysine residues are present near the lipid-
binding groove of CD1d where SapB is predicted to bind (Fig. 3.13A-B). Therefore, it is possible that 
CD1d and SapB interact in a way that is amenable to intermolecular cross-linking of surface lysines by 
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amine-reactive cross-linkers. I used cross-linkers of different lengths to maximise the chances of 
capturing an interaction: DSSO, with a 10.3 Å spacer arm, and BS(PEG)5, with a 21.7 Å spacer arm. 
CD1d-β2m and SapB were incubated with these cross-linkers either alone or following mixing (Fig. 
3.13C). For the CD1d-β2m samples alone, cross-linking between CD1d and β2m is clearly evident, as 
expected. There is also some evidence of additional higher order oligomers, probably due to the large 
number of surface lysines on both CD1d and β2m. However, no additional cross-linking products were 
observed when CD1d-β2m and SapB were incubated together with the cross-linkers.  
 
Although unglycosylated SapB loads lipids onto CD1d165,166, it is possible that the N-linked glycan on 
Asn21 on SapB (Fig. 3.13B) may increase its affinity for CD1d. Therefore, I purified glycosylated SapB-
H6 (section 3.3.5) for use in a cross-linking experiment. This time, I did not remove the His6 tag, as to 
do so would result in smearing of the bands corresponding to SapB on a gel, as discussed in section 
3.3.5, and make SDS-PAGE analysis difficult. 
 
I carried out a cross-linking experiment using glycosylated SapB-H6 and glycosylated CD1d (Fig. 3.14). 
Once again, I did not observe formation of any additional cross-linked products when CD1d-β2m was 
incubated with glycosylated SapB-H6. I noted that although the same amount of unglycosylated SapB 
(Fig. 3.13C) and glycosylated SapB-H6 (Fig. 3.14) were used in cross-linking assays, the Coomassie-
stained bands corresponding to glycosylated SapB appear much stronger. This increased staining may 
be due to the additional histidine residues in the affinity tag increasing the amount of Coomassie 
reagent binding to this small protein. These results indicate that CD1d-β2m and SapB do not interact 
together in a conformation that is amenable to cross-linking. 
 
In summary, no direct interaction between CD1d and SapB has been detected using several sensitive 




Figure 3.13. In vitro cross-linking of CD1d-β2m and SapB 
A. Ribbon diagram of the structure of CD1d (beige) and β2m (pink) (PDB ID 3U0P) with the lipid 
antigen groove labelled (arrow). Surface-accessible lysine residues available for cross-linking are 
highlighted (red sticks). B. Ribbon diagram of the structure of a SapB dimer (yellow and orange, PDB 
ID 1N69) with bound lipid (in gray). Lysine residues are highlighted as in panel A. The N-linked 
glycosylation site of SapB is highlighted (blue sticks). C. Coomassie-stained SDS-PAGE of CD1d-β2m 
and unglycosylated SapB samples following incubation with cross-linkers of different lengths: DSSO 
(10.3 Å) or BS(PEG)5 (21.7 Å).  
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Figure 3.14. In vitro cross-linking of CD1d-β2m and glycosylated SapB 
Coomassie-stained SDS-PAGE of CD1d-β2m and glycosylated SapB (gSapB) samples following 
incubation with cross-linkers of different lengths: DSSO (10.3 Å) or BS(PEG)5 (21.7 Å).  
 
3.5 CD1d co-immunoprecipitation/mass spectrometry 
The lack of a detectable interaction between CD1d and SapB in vitro suggests that SapB may require 
a cellular co-factor to interact with CD1d. To test whether CD1d interacts indirectly with SapB inside 
cells and identify potential protein partners that may facilitate this interaction, I performed a co-
immunoprecipitation experiment followed by mass spectrometry, using CD1d as bait. This experiment 
was performed in HeLa cells due to the ease of transfection of this cell line and the presence of key 
proteins. Saposins are ubiquitously expressed and present in HeLa cells226, and β2m expression can be 
induced in HeLa cells by treatment with interferon-γ (IFN-γ)(Louise Boyle, personal communication). I 
transiently expressed recombinant, full-length CD1d with a C-terminal green fluorescent protein (GFP) 
tag (CD1d-GFP) (Fig. 3.15A) in HeLa cells. Alternatively, as negative controls, I expressed the 
transmembrane MHC class I antigen HLA-A2 with a C-terminal GFP tag (HLA-A2-GFP) or soluble, 
cytosolic GFP alone. In the same manner as CD1d, HLA-A2 forms a stable interaction with β2m 
necessary for its correct folding. β2m expression was induced in all transfected cells by treatment with 
IFN-γ. This was done 15 hours after transfection to avoid reducing transfection efficiency. 48 hours 
after IFN-γ treatment, GFP-tagged bait was immunoprecipitated from the lysate at endososomal pH 
(pH 6).  
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As a preliminary experiment, I performed GFP immunoprecipitation followed by Western blotting for 
GFP to ensure that all constructs are expressed and immunoprecipitated at pH 6 (Fig. 3.15B). All three 
constructs were successfully expressed and captured. However, expression levels were unequal. GFP 
was expressed at a much higher level than CD1d, and HLA-A2 expression was lower than CD1d. This 
may affect pull-down results, since a larger amount of bait protein can pull-down larger amounts of 
interaction partners. I envisaged optimising transfection protocols for each construct to equalize 
expression levels, however, this would result in different levels of cell stress and may cause changes 
in protein expression, post-translational modification and interactions across samples. Therefore, I 
chose to maintain this protocol for the co-immunoprecipitation/mass spectrometry experiment, 
keeping in mind this caveat. I performed a Western blot for β2m to verify that CD1d and HLA-A2 are 
correctly folded and able to form an interaction with this protein partner (Fig. 3.15B). β2m does not 
co-immunoprecipitate with GFP, but co-immunoprecipitates with CD1d and to a lesser extent with 
HLA-A2, which is expected due to lower expression of HLA-A2. This indicates that CD1d and HLA-A2 
are correctly folded and an interaction with the known partner β2m can be detected. 
 
 
Figure 3.15. CD1d co-immunoprecipitation in HeLa cells 
A. HeLa cells were transiently transfected with full-length CD1d with a C-terminal GFP tag, or, as 
negative controls, full-length HLA-A2 with a C-terminal GFP tag or GFP alone. Both CD1d and HLA-A2 
are known to form a stable interaction with β2m. B. GFP was immunoprecipitated from transfected 
lysates at endolysosomal pH (pH 6). Successful expression and capture of all protein constructs and 
co-immunoprecipitation of the CD1d and HLA-A2 partner protein β2m was verified by Western 
blotting for GFP and β2m. 
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I then performed the co-immunoprecipitation experiment followed by mass spectrometry in three 
biological replicates. Proteins interacting with CD1d were compared to proteins interacting with GFP 
(Fig. 3.16A) and HLA-A2 (Fig. 3.16B). The only protein significantly enriched by co-immunoprecipitation 
with CD1d was CD1d itself. No peptide corresponding to SapB co-immunoprecipitating with CD1d was 
detected by mass spectrometry. Two overlapping peptides mapped to the saposin SapC 
(NVIPALELVEPIK and NVIPALELVEPIKK) were detected after CD1d co-immunoprecipitation in two 
replicates, but this enrichment was not found to be significant.  
 
 
Figure 3.16. CD1d co-immunoprecipitation-mass spectrometry 
CD1d-GFP or the negative controls GFP or HLA-A2-GFP were transiently expressed in HeLa cells and 
immunoprecipitated. Co-immunoprecipitated interacting proteins were quantified by mass 
spectrometry. A. Volcano plot showing pairwise comparison between the proteins pulled down by 
CD1d-GFP and GFP control. Each dot represents a single protein. Proteins significantly changed (q > 
0.05) are coloured in blue. B. Volcano plot showing pairwise comparison between the proteins 
pulled down by CD1d-GFP and HLA-A2 control. 
 
There is no significant enrichment of any CD1d-interacting proteins, including β2m. HLA-A2 binds β2m, 
therefore it is not expected that it should be significantly enriched by CD1d co-immunoprecipitation 
when compared with HLA-A2. However, β2m does not interact with GFP, therefore it should be 
enriched by co-immunoprecipitation with CD1d. In this experiment, β2m enrichment by CD1d co-
immunoprecipitation is not significant and lesser than expected (2-fold change; Fig. 3.16A). The fact 
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that the known stable interaction partner of CD1d was not identified in this experiment suggests that 
these experimental conditions were suboptimal, for example due to misfolding of a large fraction of 
overexpressed CD1d causing non-specific interactions and therefore high variability between samples. 
Therefore, this assay is not suitable for the identification of transient interactions. Technical difficulties 
caused by protein over-expression may be overcome by endogenous co-immunoprecipitation 
experiments using an antibody recognising CD1d. However, the interaction between CD1d, SapB and 
unidentified proteins potentially facilitating their interaction may be hindered by antibody binding. 
Although alternative strategies could be used to pursue the aim of identifying CD1d interaction 
partners, it was decided at this point to cease work on this project. 
 
3.6 Discussion 
I attempted to obtain a snapshot of the lipid transfer mechanism between CD1d and SapB using X-ray 
crystallography. Despite extensive testing of various combinations of highly pure and crystallisable 
protein components, CD1d and SapB did not co-crystallise. Furthermore, I have been unable to 
identify a direct interaction between CD1d-β2m and SapB in vitro. In addition to co-crystallisation 
trials, several biochemical approaches that have the capacity to capture weak and transient 
interactions were implemented, including equilibrium binding assays and protein cross-linking. 
Various factors that may influence the strength or specificity of these interactions were tested, 
including different pH and buffer systems, exchange of the lipids loaded onto both protein 
components, and changing the glycosylation state of each protein. None of these variants resulted in 
the detection of a direct interaction. Previous work in our lab studying saposin interactions with 
lysosomal hydrolases showed that although these interactions are sensitive to pH and salt 
concentrations, they were always detectable, and while detergent/lipid was required, neither the 
nature of the lipid/detergent nor the glycosylation state mattered80. 
 
Direct protein-protein interactions are crucial for several different lipid transfer pathways. The 
lipopolysaccharide (LPS) transfer cascade resulting in Toll-like receptor 4 (TLR4) activation involves 
several lipid transfer steps. LPS binding protein (LBP) extracts LPS and transfers it onto the receptor 
CD14. CD14 then transfers LPS to the TLR4 co-receptor MD-2. A direct, high affinity (Kd = 5.52 nM) 
interaction between LBP and CD14 is necessary for lipid transfer, and lipid transfer promotes rapid 
dissociation of CD14:LPS from LBP. Similarly, a direct interaction between CD14 and the TLR4:MD-2 
complex is required for lipid transfer171. The transfer of lipids between proteins is also seen in the 
formation of Apolipoprotein B-containing lipoproteins. Microsomal Triglyceride Transfer protein 
assists this process by binding to Apolipoprotein B with high affinity (Kd = 10-30 nM)227 and transferring 
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lipids onto Apolipoprotein B through an unknown mechanism. Both functions are required for 
lipoprotein assembly172. As another example, Niemann–Pick C1 (NPC1) and Niemann–Pick C2 (NPC2) 
proteins collaborate to export cholesterol from the lysosome. Soluble NPC2 binds cholesterol in the 
lysosomal lumen, interacts with the middle lumenal domain of the multipass transmembrane protein 
NPC1 and transfers cholesterol to NPC1 via a transfer tunnel linking the cholesterol-binding pockets 
of both proteins. The interaction between NPC2 and NPC1 (Kd = 0.4-2 μM) is required for cholesterol 
export77. In all cases, a high-to-medium affinity direct interaction between proteins engaged in lipid 
transfer is detectable. In this study, we were unable to detect a direct interaction between CD1d and 
SapB despite the assays being capable of detecting very weak interactions. Specifically, the equilibrium 
assay used in this study can detect protein interactions where the dissociation constant is as weak as 
40 μM. In the absence of avidity effects, interactions weaker than 40 μM are unlikely to be 
physiologically relevant. Furthermore, the cross-linking assay can detect short-lived, transient 
interactions and the co-crystallography technique uses very high concentrations of protein 
components allowing for the detection of very weak interactions. It therefore seems unlikely that an 
interaction that is undetectable by these methods could permit direct lipid exchange between SapB 
and CD1d.  
 
The study of lipid loading of CD1 molecules is technically challenging as biochemical methods often 
require the inclusion of detergents, which may interfere with lipid solubilisation and binding. Also, the 
detection of changes to CD1d-lipid complexes is limited by available reagents including specific 
antibodies and iNKT cell receptors. However, the inability to identify a direct interaction between 
CD1d and SapB raises a number of important questions regarding the role of saposins in lipid antigen 
presentation.  
 
It is well established that knockout of the saposin precursor protein PSAP results in impaired 
presentation of lipid antigens by CD1d. Due to the dual role of saposins in lipid loading and lipid 
processing, the absence of PSAP will not only alter CD1d lipid loading, but will also significantly alter 
the composition of the lysosomal lipidome. Indeed, the loss of a single saposin results in the cellular 
accumulation of multiple, different GSLs. For example, loss of SapB alone, in mice or in humans, results 
in the accumulation of sulfatide, globotriaosylceramide, and lactosylceramide228,229. Therefore, in 
saposin knockout and rescue models, the effects on antigen processing and the changes to local lipid 
concentrations may have indirect and unpredictable effects on CD1d loading in the lysosome. 
Similarly, cell-based assays that involve recognition of CD1d-lipid complexes by NKT cells are made 
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complicated by the requirement of some glycolipid headgroups to be processed by lysosomal 
hydrolases161, a process that is itself dependent upon saposins. 
 
In vitro assays testing the role of different saposins in facilitating lysosomal hydrolase activity identify 
some of the difficulties in determining specificity of saposin-lipid binding. For example, in vitro assays 
have identified that SapC and SapA are both able to enhance the activity of β-galactosylceramidase 
(GALC) to promote degradation of galactosphingolipids230,231. However, this does not reflect the 
specificity of saposins in whole organisms as loss of SapA causes Krabbe disease, similar to that of loss 
of GALC, while mutations in SapC do not64,65,67-69. Why these in vitro assays do not recapitulate the 
specificity of saposins in a whole organism remains unclear but may suggest a non-specific detergent-
like effect of saposins when present at relatively high concentrations. It is unclear whether a similar 
effect may be partially confounding the interpretation of SapB’s influence on CD1d lipid loading. While 
in vitro studies demonstrating the ability of SapB to enhance CD1d stimulation of iNKT cells or binding 
to iNKT cell receptors are very compelling regarding the importance of SapB in this process, these do 
represent an indirect way of monitoring how SapB may be involved in lipid exchange165,166. In light of 
our data showing no detectable interaction between CD1d and SapB, the question remains: how can 
SapB facilitate lipid editing without directly binding CD1d? Modelling of how SapB might facilitate lipid 
exchange identified a role for SapB in enhancing the kinetics of lipid exchange in a manner similar to 
that of Tapasin in peptide exchange on MHC class-I molecules166. In order for Tapasin to carry out this 
role, it does bind directly to MHC class-I but as part of a larger complex including additional 
proteins232,233. Although the in vitro assays demonstrating the importance of SapB for CD1d lipid 
presentation did not require other proteins, it is possible that there may be additional factors involved 
in enhancing the affinity of SapB for CD1d in cells. A co-immunoprecipitation-mass spectrometry 
approach to identify CD1d binding partners was not technically successful, most likely due to issues 
with recombinant CD1d expression. The detection of protein interactions within the lumen of 
endolysosomal compartments presents many challenges. The low pH of endolysosomal 
compartments is not conducive to proximity labelling approaches such as Bio-ID and APEX, which rely 
on a biotinylation reaction requiring pH > 7. The presence of proteases can result in cleavage of 
recombinant protein tags, posing difficulties for tag-based approaches including Förster resonant 
energy transfer as well as proximity labelling. Overcoming these challenges for the identification of 
CD1d binding partners will be essential to clarify the mechanism of CD1d lipid loading. 
 
Additional factors may influence the efficiency of lipid loading onto CD1d in cells. For example, the 
relative abundance of different lipid transfer proteins in the lysosome may influence the lysosomal 
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lipid composition, altering exchange kinetics. Therefore, it may be important that SapA-D exist in 
equimolar concentrations in the endolysosome, as ensured by their production from a common 
precursor. If this is the case, studies involving individual saposins or partial PSAP rescues will be 
difficult to interpret, potentially explaining some experimental inconsistencies. The lysosomal 
lipidome is not only influenced by the activity of saposins and sphingolipid processing hydrolases but 
also by the careful balance of other membrane components such as cholesterol and 
bis(monoacylglycero)phosphate. Lipid loading of CD1 in endolysosomal compartments is highly 
complex, requiring the delicate interplay of lipid binding, lipid processing and lipid exchange. For now, 
the mechanism of transfer of lipids onto CD1 molecules, as well as the molecular determinants of lipid 
transfer protein binding specificity, remains unclear. 
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Krabbe disease is accompanied by immune dysfunction. The hallmark of Krabbe disease which gives 
this disorder its alternative name, globoid cell leukodystrophy, is the presence of globoid cells in the 
brain. These are large multinucleated globular cells of unelucidated phagocytic origin113. Moreover, 
elevated levels of pro-inflammatory IL-6 and TNF-α have been observed in the brain of a mouse 
disease model117. The causes of these immune pathologies are unknown. The phagocytic origin of 
globoid cells and the central role of phagocytes in secreting pro-inflammatory cytokines have led me 
to hypothesise that immune dysfunction is driven by phagocytic cell dysfunction due to loss of GALC. 
Loss of the lysosomal enzyme GALC leads to the accumulation of its substrates GalCer and psychosine. 
Perturbation of glycosphingolipid degradation leads to substrate accumulation in the lysosome, but 
also throughout the cell, including at the plasma membrane58,59. As discussed in section 1.1, it is 
becoming increasingly appreciated that the correct lipid environment is crucial for the function, 
signalling and localisation of plasma membrane proteins, and in particular of immune signalling 
complexes. Notably, defects in sphingolipid metabolism result in dysregulation of Toll-like receptor 
(TLR) signalling and trafficking16-19. This suggests that GALC may play a role in normal phagocyte 
function. In this study, I explored how loss of GALC affects phagocytic cells and the proteins expressed 
on their surface. The phagocytic monocyte-like THP-1 cell line234 was chosen as a model to study how 
sphingolipid imbalances affect phagocyte phenotype and function. Krabbe disease patients have 
extremely low GALC activity levels, and even small amounts of residual enzyme activity can be 
sufficient to prevent substrate accumulation. This is demonstrated by the fact that loss of up to 90% 
of enzyme activity can be asymptomatic235. A knockdown approach may not sufficiently reduce GALC 
levels. Therefore, I used CRISPR/Cas9 to generate GALC knockout (KO) THP-1 cell lines. Unfortunately, 
the results of this study were compromised by off-target effects of genetic manipulation in parental 
and control cell lines. The implications of these findings for the design of gene knockout strategies are 
discussed.  
 
Statement of collaboration 
 
Several collaborations have been essential to the work described in this chapter. The Lehner lab 
(Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge) kindly 
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provided the THP-1 Cas9 cell line and Dr Lidia Duncan provided the protocols for CRISPR/Cas9 
knockout in these cells. Dr James Williamson generously trained me in sample preparation for plasma 
membrane profiling and performed mass spectrometry analysis of these samples. He also performed 
the sample processing and mass spectrometry analysis of whole cell lysates. The datasets generated 
through this collaboration are presented in sections 4.4.1, 4.4.5 and 4.4.7. Prof Ian Brierley 
(Department of Pathology, University of Cambridge) supervised and significantly aided sample 
preparation for RNA sequencing. RNA sequencing was done by Cambridge Genomic Services 
(Department of Pathology, University of Cambridge) and Dr Katy Brown (Department of Pathology, 
University of Cambridge) performed the data analysis, generating the data presented in section 4.4.3. 
 
4.1 THP-1 cells possess high levels of GALC activity 
GALC is known to be expressed in oligodendrocytes, where its importance is well established. 
However, GALC expression and function in other cell types has been scarcely investigated. 
Transcription profiling studies have shown that GALC is expressed in primary human phagocytic cells, 
including monocytes236,237. I tested whether there is detectable GALC activity in the monocyte-like 
THP-1 cell line using a GALC activity assay previously developed by our group. In this assay, 
endogenous GALC is enriched from cell lysates by immunoprecipitation using a specific monoclonal 
antibody. GALC-bound beads are then washed and incubated with the fluorogenic GALC substrate 4-
methylumbelliferyl β-D-galactopyranoside (4MβDG) and the generation of fluorescent product is 
monitored over time238. The activity of GALC was higher in THP-1 cells than in the MO3.13 
oligodendrocyte-like cell line (Fig. 4.1). This suggests that GALC has an important role in regulating 
galactosphingolipid turnover in THP-1 cells, indicating that THP-1 cells are an appropriate phagocytic 
cell line to monitor the effects of GALC loss. Endogenous GALC protein levels are too low to be 
detectable by Western blot in MO3.13 cells, and GALC detection by Western blot was similarly 




Figure 4.1. GALC activity in THP-1 cells 
GALC activity assay on THP-1 and MO3.13 cell lysates. GALC was immunoprecipitated from cell 
lysates and incubated with the fluorogenic substrate 4MβDG. GALC activity is reported as the change 
of fluorescence in relative fluorescence units (RFU) over time. Background activity was measured in 
a control sample where no GALC antibody was added for the immunoprecipitation step (“No Ab”). 
This data is representative of three independent experiments.  
 
THP-1 monocytes can be differentiated by phorbol 12-myristate 13-acetate (PMA) into a macrophage-
like cell more responsive to lipopolysaccharide (LPS) stimulation175. THP-1 cells grow in suspension 
when undifferentiated and become adherent upon differentiation. I observed that GALC activity is 
tuned down by differentiation, and further reduced by stimulation of differentiated cells with the TLR2 
agonist lipopolysaccharide (LPS) (Fig. 4.2A). Quantitative PCR (qPCR) indicates that GALC gene 
expression is significantly up-regulated by differentiation of THP-1 cells, and LPS stimulation of 
differentiated cells significantly down-regulates GALC gene expression (Fig. 4.2B). This is in agreement 
with previous transcription profiling studies showing differential GALC expression in primary human 
monocytes and macrophages236,237. Changes in total GALC activity are not correlated with changes in 
GALC gene expression, suggesting that GALC activity is also regulated by protein degradation or 
changes in RNA stability. GalCer levels are regulated by the complex interplay of GALC-mediated 
GalCer degradation, GalCer formation through the catabolism of complex galactosphingolipids and 
GalCer synthesis by UDP-galactose:ceramide galactosyltransferase 8 (UGT8). qPCR analysis showed 
that UGT8 gene expression was significantly down-regulated in LPS-stimulated differentiated THP-1 
cells compared to undifferentiated cells (Fig. 4.2C). Unfortunately, no reliable antibodies against UGT8 
were available, therefore the presence of UGT8 protein could not be confirmed and quantified. 
However, down-regulation of UGT8 at the mRNA and protein level upon stimulation of macrophages 
with LPS and a TLR7/8 agonist has been previously reported239. Altogether, this data supports the 
hypothesis that galactosphingolipid levels are dynamically regulated in THP-1 cells to facilitate 
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processes such as immune signalling, phagocytosis and adhesion specific to each state. In the rest of 
this study, I focused on the role of GALC in undifferentiated monocyte-like THP-1 cells. 
 
Figure 4.2. GALC expression is modulated by THP-1 differentiation and LPS stimulation 
A. GALC activity assay in undifferentiated, differentiated and LPS-stimulated THP-1 cells. GALC was 
immunoprecipitated from cell lysates and incubated with the fluorogenic substrate 4MBDG. GALC 
activity is reported as the change of fluorescence in relative fluorescence units (RFU) over time. 
Background activity was measured in a control sample where no GALC antibody was added for the 
immunoprecipitation step (“No Ab”). This data is representative of two independent experiments. B-
C. qPCR quantification of GALC (B) and UGT8 (C) gene expression relative to ACTB in undifferentiated 
(undiff), differentiated (diff) and differentiated WT THP-1 cells stimulated with LPS (Diff + LPS). Gene 
expression was normalised to undifferentiated cells. p-values were calculated by one-way ANOVA 
followed by Tukey’s multiple comparison test. Error bars represent the 95% confidence interval. ns: 
not significant (p-value > 0.05); *: p ≤ 0.05.; **: p ≤ 0.01. 
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4.2 CRISPR/Cas9-mediated knockout of GALC in THP-1 cells 
To investigate the effect of GALC loss in phagocytes, I knocked out GALC in THP-1 cells using 
CRISPR/Cas9240. Expressing Cas9 and guide RNA (gRNA) targeting GALC in this cell line was challenging, 
because phagocytes are inherently resistant to transfection. A first attempt to transiently express Cas9 
and gRNAs by electroporation of a co-expression plasmid into THP-1 cells was unsuccessful. No viable 
cells expressing this plasmid were obtained due to the low cell viability and low transfection efficiency 
using this technique. Subsequently, I used a THP-1 cell line stably expressing Cas9 (THP-1 Cas9) 
provided by a collaborator and delivered gRNAs targeting GALC or an empty vector (EV) gRNA by 
lentiviral transduction of this cell line (Fig. 4.3A). I used two different gRNAs (gRNA1 and gRNA2) 
targeting different parts of exon 3 (residues 73-93) of GALC (Fig. 4.3B). These gRNAs were previously 
successfully used in our lab to knock out GALC in MO3.13 oligodendrocytes. Generating two different 
knockout cell lines using distinct gRNAs allows to discriminate between on-target effects caused by 
loss of GALC, and potential off-target effects caused by non-specific binding of each gRNA. Cas9 THP-
1 cells were infected with lentivirus vectors at a concentration such that 30% of cells were infected, 
as determined by flow cytometry using the lentiviral BFP marker. This ensures that the majority of 
transduced cells are infected by a single virus particle and only one insertion event takes place in each 
cell, minimising the risk of insertional mutagenesis. Loss of GALC may cause changes in the expression 
of adhesion molecules on the surface of THP-1 cells, which may result in adhesion of THP-1 cells 
normally growing in suspension. Therefore, after lentiviral transduction, I carried forward both 
suspension cells and any adherent cells detached with trypsin for the next steps. l selected transduced 
cells with puromycin and isolated single clones by limiting dilution, generating monoclonal 
populations labelled empty vector control clone 1 (EV1), knockout clone 1 (KO1) and knockout clone 
2 (KO2) (Fig. 4.3A). These clones remained in suspension. I expanded and froze aliquots of these cell 
lines. Cas9 and gRNAs are stably expressed in these cell lines and pose a risk of spurious gene editing 
over time. Therefore, I ensured that all experiments were performed within 12 passages after thawing 





Figure 4.3. CRISPR/Cas9-mediated knockout of GALC in THP-1 cells 
A. Graphical summary of the CRISPR/Cas9 knock-out protocol. B. DNA sequence of GALC exon 3. The 
arrows labelled gRNA1 and gRNA2 indicate the target DNA sequence for these gRNAs. Exon 3 
encodes residues 73 to 93 of GALC. 
 
4.2.1 GALC KO validation 
To determine whether GALC gene editing by CRISPR/Cas9 successfully introduced insertions or 
deletions (indels), I isolated genomic DNA from individual clones and amplified the region of DNA 
encompassing the genetic lesion for Sanger sequencing (Fig. 4.4A-B). Indels were identified by TIDE 
analysis206(Fig. 4.4C-D). For KO1, there is clear GALC gene editing across the gRNA1 site, however, TIDE 
analysis identifies three potential sequence traces instead of the expected two corresponding to each 
GALC allele (Fig. 4.4A). In accord with this, TIDE analysis identifies three deletions (-4, -10 and -21; Fig. 
4.4C). The same result was obtained after sequencing a fresh batch of cells from this clone. This 
puzzling result may be explained by the presence of two clones in this cell population. Both clones 
may have a shared mutation on one allele and a divergent mutation on the second allele. Alternatively, 
the DNA region normally corresponding to GALC may have failed to amplify due to a large deletion in 
one allele. Although this suggests that KO1 may not be a monoclonal population, it is clear that the 
GALC gene is edited in this population with two missense deletions and one in-frame deletion. For 
KO2, there are two deletions identified in the sequence trace (Fig. 4.4B) and confirmed by TIDE 




Figure 4.4. Analysis of GALC gene editing 
A. Sanger sequencing chromatogram of GALC KO1 compared with EV1 control. Genomic DNA was 
extracted from cells and the DNA region corresponding to GALC was amplified by PCR prior to 
Sanger sequencing. The DNA sequence targeted by gRNA1 is highlighted. The arrow indicates the 
site where the sequence begins to differ from WT. B. Sanger sequencing chromatogram of GALC KO2 
compared with EV1 control. The DNA sequence targeted by gRNA2 is highlighted. The arrow 
indicates the site where the sequence begins to differ from WT. C. TIDE analysis of gene editing 
across the GALC guide site 1 in GALC KO1 cells. D. TIDE analysis of gene editing across the GALC 
guide site 2 in GALC KO2 cells. 
 110
 
It is possible that in-frame deletions in one GALC allele in each clone still permit synthesis of small 
amounts of a deletion mutant GALC. However, these deletions affect a buried loop containing the 
residue Thr93 contributing to the substrate-binding pocket of GALC241. Therefore, these mutations are 
likely to result in GALC instability and misfolding, resulting in its degradation, and crucially, dysfunction 
of GALC due to substantial changes to the substrate binding site. I verified that GALC activity was lost 
in GALC KO cell lines using the highly sensitive GALC activity assays described above. GALC activity was 
virtually abolished in both GALC KO clones (Fig. 4.5). Residual GALC activity below 10% is a good mimic 
of the disease state and thus is likely to result in accumulation of GALC substrates235. I noted that GALC 
activity was 2 to 3-fold lower in the Cas9 THP-1 cell line and in the EV1 control cell line than in WT 
THP-1 cells.  
 
 
Figure 4.5. GALC KO validation with a GALC activity assay 
A. GALC activity assay in WT, Cas9, EV1 and GALC KO1 and KO2 cell lysates. GALC was 
immunoprecipitated from cell lysates and incubated with the fluorogenic substrate 4MβDG. GALC 
activity is reported as the change of fluorescence in relative fluorescence units (RFU) over time. 
Background activity was measured in a control sample where no GALC antibody was added for the 
immunoprecipitation step (“No Ab”). This data is representative of three independent experiments. 
 
4.3 Investigating the phenotype of GALC KO THP-1 cells 
Due to the role of glycosphingolipids in plasma membrane integrity, I next investigated whether loss 
of GALC leads to notable changes in cell viability and morphology in THP-1 cells. Regular monitoring 
of cell density and viability by trypan blue staining followed by cell counting indicated that loss of GALC 
did not alter the growth rate nor viability of THP-1 cells. 
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Previous studies have found that mimicking Krabbe disease by treating cells with the GALC substrate 
psychosine induces multinucleation in several cell types242,243. I monitored changes to nuclear 
morphology by Hoechst 33342 staining of GALC KO THP-1 cells, but no multinucleation was observed 
in undifferentiated GALC KO cells (Fig. 4.6). This suggests that loss of GALC in THP-1 cells is not 
sufficient to trigger this phenotype. This effect may be cell type dependent, or triggered by additional 




Figure 4.6. Loss of GALC does not trigger multinucleation of THP-1 cells. 
A. Undifferentiated WT, Cas9, KO1 and KO2 THP-1 cells in suspension were stained with the nuclear 
stain Hoechst 33342 and visualised by brightfield and fluorescence microscopy. Scale bar: 20 μm. 
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A key function of phagocytic cells is the orchestration of inflammation and immune responses through 
the secretion of cytokines. To explore whether loss of GALC causes significant changes to the cytokines 
secreted by THP-1 cells, I used an antibody-based cytokine array to analyse the levels of 80 cytokines 
in the media of EV1, KO1 and KO2 cells (Fig. 4.7A-C). No cytokine had an abundance altered more than 
two-fold in both knockout clones. This indicates that loss of GALC does not lead to substantial loss or 
overexpression of cytokines in unstimulated THP-1 cells.  
 
 
Figure 4.7. Quantification of cytokines secreted by GALC KO THP-1 cells 
A. Antibody-based cytokine arrays incubated with media from EV1 and KO1 cells. B. Antibody-based 
cytokine arrays incubated with media from EV1 and KO2 cells. C. Relative quantification of cytokines 
secreted by GALC KO cells normalized to EV1. Fold change in KO1 cells is represented in pink, and 
fold-change in KO2 cells in purple. The raw intensity data from the cytokine array was used for this 
quantification. The dashed lines correspond to the chosen threshold of a fold change > 2. 
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4.4 Investigating protein changes at the plasma membrane 
4.4.1 Plasma membrane profiling and whole cell proteomics 
The dependence of immune receptors on their lipid environment, combined with the immune 
dysregulation seen in Krabbe disease patients, prompted the hypothesis that loss of GALC and 
subsequent accumulation of galactosphingolipids alters the proteins present at the plasma membrane 
through changes in protein stability, trafficking and/or gene expression. I used complementary 
unbiased approaches to detect such changes in protein abundance at the plasma membrane.  
 
I performed plasma membrane profiling (PMP) in collaboration with Dr James Williamson. PMP allows 
the relative quantification of plasma membrane proteins by mass spectrometry. Proteins on the 
surface of intact cells are enriched by biotinylation of surface sialic acid residues followed by cell lysis 
and binding to streptavidin beads. After thorough washing of the beads, plasma membrane proteins 
are subjected to tryptic digestion, and peptides from individual samples are labelled with a unique 
Tandem mass tag (TMT) that allows relative quantification of each protein by mass spectrometry (Fig. 
4.8). The proteome on the surface of GALC KO1 and KO2 cells was compared to EV1 control cells. Mass 
spectrometry was simultaneously performed on 3 biological replicates for each cell line. Each sample 
was harvested at the same cell density of 0.5x106 cells/mL to avoid confounding effects caused by 
differences in cell density. Indeed, THP-1 cells have been shown to differentiate into distinct 
populations with different properties depending on cell density244. All the experiments that follow 
have been performed at the same cell density unless otherwise indicated.  
 
PMP showed large and significant changes in the abundance of many proteins on the cell surface of 
GALC KO cells compared to EV1 control (Fig. 4.9, Appendix II). Changes in protein abundance at the 
plasma membrane may be caused by several mechanisms differentially affecting each protein. 
Changes in the lipid environment may drive changes in transmembrane protein folding and stability. 
Lipid imbalances may also lead to changes in gene expression. These two classes of mechanisms would 
affect protein levels in the whole cell. Alternatively, overall protein levels may be unchanged in the 
cell, but hindered trafficking to the plasma membrane or aberrant retention at the cell surface may 




Figure 4.8. Graphical summary of the plasma membrane profiling protocol 
Plasma membrane (PM) proteins were labelled with biotin on the surface of intact cells and pulled 
down by streptavidin (SA) beads after cell lysis. Plasma membrane proteins were then washed and 
digested with trypsin. Peptides from each sample (3 biological replicates per cell line) were then 





Figure 4.9. Plasma membrane profiling of GALC KO cells 
A. Volcano plots showing pairwise comparison between the proteome at the surface of GALC KO 
cells and EV1 control THP-1 cells. Each dot represents a single protein. Proteins significantly changed 
(q < 0.05) more than two-fold are coloured in blue. Proteins significantly changed in the same 
direction in both GALC KO1 and KO2 are coloured in dark blue. 
 
To discriminate between the potential mechanisms driving changes in protein abundance at the 
plasma membrane, I investigated cellular changes in protein levels by proteomics on whole cell lysates 
(WCP) in collaboration with Dr James Williamson in parallel with PMP. Both experiments were 
performed on the same cell samples. This permits direct comparison between the plasma membrane 
and whole cell proteomes, to distinguish between global changes caused by altered protein stability 
or gene expression and changes caused by protein mistrafficking and mislocalisation. A large number 
of significant changes in protein abundance in whole cell lysates of GALC KO cells compared to EV1 
control were observed (Fig. 4.10A and Appendix III). These changes are well-correlated with changes 
observed at the plasma membrane. The change in abundance of proteins observed in both datasets 
(averaged over both knockout clones) tends to be in the same direction at the plasma membrane and 
in the whole cell (Fig. 4.10B). These changes are particularly consistent for proteins significantly 
changed in both datasets. In particular, SLC7A11 is highly upregulated both at the plasma membrane 
and in the whole cell. This suggests that for the majority of proteins, changes in abundance at the 
plasma membrane is caused by differences in protein stability or gene expression. Off-diagonal data 
points correspond to proteins that are enriched or depleted in one dataset, but unchanged or 
anticorrelated in the other dataset. Such points are of particular interest because they may correspond  
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Figure 4.10. Whole cell proteomics of GALC KO cells 
A. Volcano plots showing pairwise comparison between the cellular proteome of GALC KO cells and 
EV1 control THP-1 cells. Each dot represents a single protein. Proteins significantly changed (q < 
0.05) more than two-fold are coloured in green. Proteins significantly changed in the same direction 
in both GALC KO1 and KO2 are coloured in dark green. B. Fold change in protein abundance at the 
plasma membrane vs. the whole cell. Fold change was calculated as the average fold change in KO1 
and KO2. Proteins significantly changed (q < 0.05) in both clones at the plasma membrane and in the 




to mistrafficked proteins. However, the most extreme off-diagonal points corresponding to OAS3, 
MMUT and CTSL (Fig. 4.10B) appear to represent unreliable measurements rather than mistrafficking. 
These three proteins are respectively nuclear, mitochondrial and lysosomal and are therefore not 
enriched in the PMP experiment. Only a single peptide has been detected for each of these proteins 
by plasma membrane profiling. Therefore, their quantification is unreliable. Thus, no protein 
mistrafficking or mislocalisation events were identified in GALC-deficient THP-1 cells. 
Loss of GALC appears to cause changes in protein stability or gene expression rather than protein 
localisation in THP-1 monocytes. I investigated mechanisms relevant to Krabbe disease pathology 
potentially driving these changes. 
 
4.4.2 Biologically relevant changes in protein abundance in GALC KO cells 
Krabbe disease is accompanied by elevated TNF-α levels117. Interestingly, several TNF-α-responsive 
genes are up-regulated in GALC KO THP-1 cells: the interleukin-18 receptor IL18R1245, the death 
receptor FAS245, the Notch ligand JAG1246 and the cystine/glutamate antiporter SLC7A11247(Fig. 4.9). I 
hypothesised that loss of GALC leads to aberrant TNF-α signalling in monocytes. This may be caused 
by down-regulation of the receptors LILRB4 and AXL (Fig. 4.9), two negative regulators of TNF-α 
expression248,249. This hypothesis is intriguing because TNF-α can directly cause oligodendrocyte 
death119,120. Both the transmembrane precursor form of TNF-α and cleaved soluble TNF-α are active250. 
However, GALC KO cells did not secrete more TNF-α than EV1 cells (Fig. 4.11A and 4.7) and precursor 
TNF-α was not detected by Western blot in EV1 or GALC KO cells using two different antibodies. TNF-
α was also not detected in proteomics experiments. Surprisingly, TNF gene expression appeared 
slightly down-regulated in GALC KO cells compared to EV control (Fig. 4.11B). Therefore, I did not find 
evidence that loss of GALC causes aberrant TNF-α signalling in monocytes. 
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Figure 4.11. TNF is not up-regulated in GALC KO cells 
A. Relative quantification of TNF-α secreted by GALC KO cells normalized to EV1, determined in the 
experiment shown in Figure 4.7. B. qPCR quantification of TNF gene expression relative to ACTB in 
GALC KO1 and KO2 cells normalised to EV1 control cells. p-values were calculated by one-way 
ANOVA followed by Tukey’s multiple comparison test. Error bars represent the 95% confidence 
interval. ns: not significant (p-value > 0.05); *: p ≤ 0.05.  
 
Krabbe disease is associated with oxidative stress and production of reactive oxygen species 
(ROS)214,251-254. Interestingly, several oxidative stress response genes are up-regulated in GALC KO THP-
1 cells. At the plasma membrane, SLC7A11 imports cystine essential for synthesis of the antioxidant 
glutathione255 and the iron exporter SLC40A1 protects cells from oxidative stress by maintaining iron 
homeostasis256 (Fig. 4.9). In the cytoplasm, the antioxidant repair enzyme methionine-R-sulfoxide 
reductase B3 (MSRB3) reduces methionine sulfoxide to methionine257, metallothionein-2A (MT2A) 
acts as a free radical scavenger258, and the oxidoreductase AKR1C2 reduces reactive carbonyl 
species259 (Fig. 4.10A). The expression of several of these genes can be regulated by the antioxidant 
transcriptional master regulator Nrf2260-262. Under non-stressed conditions, Nrf2 is repressed through 
sequestration in the cytoplasm and proteasomal degradation. In the context of oxidative stress, Nrf2 
accumulates and translocates to the nucleus263. Proteomics on whole cell lysates showed that Nrf2 
abundance is unchanged in GALC KO cells compared to EV1 control cells, indicating that upregulation 
of proteins involved in the oxidative stress response occurs through a different mechanism. I tested 
whether GALC KO THP-1 cells have increased levels of intracellular ROS with the fluorogenic dye 2',7'-
dichlorodihydrofluorescein diacetate (H2-DCF-DA)251,252. No differences in ROS levels were found 
between GALC KO and EV1 control cells using this assay (Fig. 4.12). It is possible that the observed 
upregulation of oxidative stress response proteins maintains redox homeostasis in GALC KO cells. 
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Figure 4.12. GALC KO cells do not have increased levels of reactive oxygen species 
EV1 control, GALC KO1 and KO2 cells were incubated with the fluorogenic ROS reporter dye H2-DCF-
DA. Fluorescence was measured and normalised to EV1 in three independent experiments.  
 
Although the upregulation of TNF-α-responsive proteins and oxidative stress response proteins in 
GALC-deficient THP-1 monocytes generated intriguing hypotheses linking the changes observed in 
these cells to Krabbe disease pathology, preliminary experiments did not support these hypotheses.  
 
4.4.3 RNA sequencing 
To identify whether changes in protein abundance in GALC KO THP-1 monocytes are caused by 
changes in gene expression or protein stability, I performed RNA sequencing (RNAseq) of GALC KO and 
EV1 control cells in collaboration with Prof Ian Brierley and Dr Katy Brown. RNA was extracted from 
four technical replicate samples for each cell line (EV1, KO1, KO2). Ribosomal RNA constitutes the 
majority of total RNA preparations and was depleted from RNA preparations to avoid wasting 
sequencing reads211. After enrichment of transcriptome RNA through depletion of ribosomal RNA, 
transcriptome RNA was fragmented and ligated to adaptors for deep sequencing. Unique indexing 
barcodes were added to each sample for relative RNA quantification. A large number of genes 
differentially expressed between GALC KO cells and EV1 control were identified (Fig. 4.13A and 
Appendix IV). There is strong overlap between differentially expressed proteins identified in PMP, 
WCP and RNAseq experiments (Fig. 4.13B), indicating that a large proportion of these changes are 
caused by differential gene expression. To identify the functional characteristics of differentially 
expressed genes, I performed Gene Ontology (GO) enrichment analysis with the DAVID functional 
annotation tool210. Biological Process GO terms264,265 over-represented in the lists of significantly 
down-regulated and up-regulated genes in GALC KO cells versus EV1 control are shown in Table 4.1. 
Genes involved in viral response were up-regulated, and genes involved in transcription and 
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translation were down-regulated in GALC KO cells versus EV1 control. These processes are not known 
to be dysregulated in Krabbe disease. This led to the concern that their dysregulation may be an off-
target effect of lentiviral transduction or off-target Cas9 activity in GALC KO or EV1 control cell lines.  
 
 
Figure 4.13. RNA sequencing of GALC KO THP-1 cells 
A. Volcano plots showing pairwise comparison between the transcriptome of GALC KO cells and EV1 
control THP-1 cells. Each dot represents a single gene. Significant gene expression changes (q < 0.05) 
are coloured in orange. Significant gene expression changes larger than 2-fold in both GALC KO1 and 
KO2 are coloured in brown. B. Venn diagram showing genes quantified in plasma membrane 
profiling (PMP), whole cell proteomics (WCP) and RNA sequencing (RNAseq) experiments.  
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Table 4.1. Enrichment analysis of genes differentially expressed in GALC KO cells. GO Biological 
Process terms enriched in differentially expressed genes in GALC KO1 and KO2 compared with EV1 
control, against a background of all genes detected in the RNAseq experiment. Benjamini-Hochberg 
adjusted q-values are indicated. Significantly enriched Biological process terms (q-value < 0.05) are 
shown. 
Biological processes enriched in up-regulated genes Count 
Fold 
Enrichment q-value 
defense response to virus 21 9.7 3.01E-11 
type I interferon signaling pathway 14 15.1 2.30E-09 
negative regulation of viral genome replication 10 15.8 3.04E-06 
response to virus 13 8.7 8.13E-06 
interferon-gamma-mediated signaling pathway 8 8.3 1.14E-02 
     
Biological processes enriched in down-regulated 
genes    
translational initiation 44 22.7 6.21E-45 
nuclear-transcribed mRNA catabolic process, 
nonsense-mediated decay 42 24.6 1.13E-44 
SRP-dependent cotranslational protein targeting to 
membrane 39 28.6 2.40E-44 
viral transcription 40 24.3 2.31E-42 
translation 44 12.7 1.53E-33 
rRNA processing 40 13.1 8.92E-31 
cytoplasmic translation 6 16.8 2.60E-03 
translational elongation 5 21.5 6.73E-03 
formation of translation preinitiation complex 5 14.7 2.95E-02 
 
4.4.4 Validation of gene expression changes by qPCR 
Due to technical limitations on the number of samples that can be processed in parallel with 
proteomics and RNAseq approaches, a single control cell line was used in the experiments described 
above. The clonal cell line EV1 derived from the mixed population of EV gRNA-transduced Cas9-
expressing THP-1 cells was chosen as a control for these experiments, because this cell line had been 
manipulated and grown in the same way as the GALC KO cell lines and therefore appeared to be the 
most appropriate control. However, reliance on a single clonal control cell line comes with the risk 
that differences in protein expression attributed to loss of GALC in the knockout cell line are in fact 
caused by abnormalities in the EV1 control cell line. Validation experiments testing the expression of 
shortlisted proteins in all parental control cell lines in addition to EV1, KO1 and KO2 cells were 
therefore required. Since a large proportion of changes observed in GALC KO cell lines were driven by 
gene expression changes, qPCR was used to validate these results. WT THP-1 cells, Cas9 THP-1 cells, 
and the mixed population of cells transduced with EV gRNA (mixed population EV) from which the EV1 
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clone was isolated were included in validation experiments. The choice of a housekeeping control 
gene that is stably expressed across samples is essential for the accuracy and reliability of qPCR 
experiments. The expression of several housekeeping genes was tested across WT, EV1, KO1 and KO2 
lines using the GeNorm algorithm266 (Fig. 4.14), and ACTB was found to be the most stable gene across 
these cell lines. ACTB was therefore used as a housekeeping gene for the experiments described in 
the rest of this chapter.  
 
Figure 4.14. Average expression stability of housekeeping genes 
The relative stability of several housekeeping genes (ACTB, CASC3 and HMBS) was assessed by qPCR 
in WT, EV1, KO1 and KO2 cells and quantified by GeNorm analysis. Low GeNorm M values indicate 
higher stability of gene expression across cell lines.  
 
The relative expression of several proteins shortlisted in section 4.4.2 (SLC7A11, FAS, AXL, LILRB4 and 
MSRB3; Fig. 4.9A and 4.10A) and TNF was measured by qPCR across all cell lines. Strikingly, SLC7A11 
was strongly down-regulated in the clonal EV1 control cell line but expressed at similar levels in mixed 
population EV and Cas9 control cells and KO1 and KO2 cells (Fig. 4.15A). Thus, SLC7A11 is not up-
regulated in KO cells due to loss of GALC, but its expression is abnormally low in EV1 control cells. The 
same pattern is observed for FAS and MSRB3 (Fig. 4.15B-C). AXL and LILRB4 also appear dysregulated 
in EV1 control cells (Fig. 4.15D-E). TNF gene expression was remarkably low in Cas9 THP-1 cells 
(approximately 60-fold lower than WT) and all derived cell lines (Fig. 4.15F), explaining why TNF-α 
could not be detected by Western blot in EV1, KO1 and KO2 cells. The expression of several quantified 
genes differed significantly between Cas9 and WT THP-1 cells, although to a lesser extent than TNF. 
The mixed population of THP-1 cells transduced with Cas9 from which the clonal Cas9 THP-1 cell line 
was isolated by our collaborators was not available, so I could not identify which point in the process 
of making this cell line resulted in TNF dysregulation. However, lentiviral transduction of WT THP-1 
cells with an empty lentiviral vector (pCW57) does not result in TNF down-regulation (Fig. 4.16), 
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indicating that TNF down-regulation in the Cas9 cell line is caused by insertional mutagenesis or off-
target Cas9 activity in this clonal cell line rather than a process inherent to lentiviral transduction of 
THP-1 cells.  
 
In summary, there are abnormalities in the EV1 clonal cell line used as a control in all experiments 
described so far in this chapter. Transduction with EV control gRNA may have introduced some off-
target effects amplified by clonal selection. Consequently, many or all of the changes in protein 
expression detected by proteomics and RNAseq are artefacts. It is clear that mixed population EV or 
THP-1 Cas9 cells would be more suitable controls for these experiments, because the expression level 
of all genes quantified by qPCR is consistent across these cell lines. The parental Cas9 THP-1 clonal cell 
line appears different from WT THP-1 cells, and in particular shows strong down-regulation of TNF 
expression. This may affect the biological relevance of this cell line as a monocyte model because TNF-
α production is one of the key roles of monocytes and TNF-α autocrine feedback loops regulate 
monocyte function122. With this caveat in mind, conclusions about fundamental cellular processes 




Figure 4.15. Validation of shortlisted genes by qPCR 
 125 
qPCR quantification of SLC7A11, FAS, MSRB3, AXL, LILRB4 and TNF gene expression relative to ACTB 
in WT, Cas9, EV mixed population and GALC KO1 and KO2 cell lines, normalised to EV mixed 
population control. p-values were calculated by one-way ANOVA followed by Tukey’s multiple 
comparison test. Error bars represent the 95% confidence interval. ns: not significant (p-value > 
0.05); *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001; ****: p ≤ 0.0001.  
 
Figure 4.16. TNF gene expression is not down-regulated by lentiviral transduction 
qPCR quantification of TNF gene expression relative to ACTB in WT THP-1 cells, a mixed population 
of THP-1 cells transduced with an empty lentiviral vector (pCW57) and the clonal THP-1 cell line 
stably expressing Cas9. The results of a single experiment performed with technical triplicates for 
each sample are shown. Error bars represent the standard deviation.  
 
4.4.5 Repeat of plasma membrane profiling with additional controls 
Newly available 16-plex TMT labelling probes for proteomics allowed for a repeat of the PMP and WCP 
experiments with additional controls. The relative abundance of proteins in WT, Cas9, EV mixed 
population, GALC KO1 and KO2 cell lines was quantified. The experiment was performed in 
collaboration with Dr James Williamson as described in section 4.4.1, with independent triplicate 
samples of each cell line. An additional single replicate of EV1 was also included for reference to the 
previous proteomics experiments. PMP results were obtained prior to WCP results. First, the plasma 
membrane proteome of control cell lines was compared to assess the best normalisation control for 
this experiment. Cas9 THP-1 cells appeared very different from WT cells (Fig. 4.17A). The abundance 
of 1347 plasma membrane proteins is significantly changed in Cas9 cells. This shows that the 
introduction of Cas9 by lentiviral transduction of WT THP-1 cells has introduced large and wide-
ranging changes to its expression profile, either through insertional mutagenesis or off-target Cas9 
activity in this clonal cell line. Consequently, Cas9 or mixed population EV cells are better 
normalisation controls than WT or clonal EV lines for assessing changes caused specifically by loss of 
GALC. There was no significant difference in the proteome at the surface of mixed population EV cells 
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compared to the Cas9 control cell line (Fig. 4.17B), indicating that the mixed population EV cell line is 
indeed a much better control than the clonal EV1 cell line. The mixed population EV cell line was 
therefore chosen as the normalisation control. Five proteins were significantly changed (q < 0.05) at 
the plasma membrane of GALC KO1 and KO2 cells compared to mixed population EV control cells (Fig. 
4.17C, Table 4.2). The relative abundance of each of these proteins is similar in Cas9 and mixed 
population EV control cell lines, but different in WT cells for all proteins except PLXNC1 (Fig. 4.18).  
 
Figure 4.17. Plasma membrane profiling of control and GALC KO cell lines 
A. Volcano plot showing pairwise comparison between the proteome at the surface of Cas9 and WT 
THP-1 cells. Proteins significantly changed (q < 0.05) more than 2-fold are coloured in cyan. B. 
Volcano plot showing pairwise comparison between the proteome at the surface of mixed 
population EV and Cas9 THP-1 cells. No significant differences were found. C. Volcano plots showing 
pairwise comparison between the proteome at the surface of GALC KO THP-1 cells and mixed 
population EV control cells. Each dot represents a single protein. Proteins significantly changed (q < 
0.05) are coloured in cyan. Proteins significantly changed in both GALC KO1 and KO2 are labelled and 
coloured in dark blue.  
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Table 4.2. Proteins significantly changed at the plasma membrane of GALC KO1 and KO2 vs EV1 
cells (Benjamini-Hochberg adjusted q-value < 0.05) 
Gene ID 
Log2 (fold change 
KO1/EV1) q-value 
Log2 (fold change 
KO2/EV1) q-value 
TRHDE 0.73 9.17E-03 0.90 2.25E-03 
SDK1 0.68 3.29E-02 0.81 8.27E-03 
PLXNC1 -1.81 8.91E-04 -1.34 1.09E-02 
MDFIC -1.81 4.03E-04 -1.73 5.76E-04 
SLC4A4 -2.61 2.45E-05 -2.87 2.61E-06 
 
 
Figure 4.18. Relative abundance of shortlisted proteins in each sample 
Relative abundance (shown on a linear scale) of shortlisted proteins quantified in WT, Cas9, EV 
mixed population (EVm), GALC KO1 and KO2 THP-1 cell lines by plasma membrane profiling-mass 
spectrometry. Error bars indicate the standard deviation across three independent biological 
replicates. A single replicate samples of the EV1 clonal cell line (EVcl) was analysed by mass 
spectrometry alongside these samples. 
 
4.4.6 Validation of plasma membrane profiling results 
To validate that the changes observed in GALC KO cells are specifically caused by loss of GALC, I created 
a GALC rescue cell line by transduction of GALC KO1 and KO2 THP-1 cells with a geneticin-resistant 
inducible lentiviral vector encoding GALC. Cas9 and gRNAs targeting GALC are stably expressed in the 
KO cell lines, therefore I introduced silent mutations into the GALC rescue construct sequence to 
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escape Cas9-mediated cleavage. The simplest way to achieve this is to abolish Cas9 binding by 
mutating the Protospacer adjacent motif (PAM) sequence (NGG) required for Cas9 binding to DNA, 
but it was not possible to introduce a silent mutation into the PAM site adjacent to the sequence 
targeted by gRNA1. After binding of the Cas9-gRNA complex to a PAM site, Cas9 only cleaves DNA if 
there is sufficient homology between the gRNA spacer sequence and the target DNA sequence. I 
therefore mutated the target DNA sequence of the GALC rescue construct. The sequence directly 
upstream of the PAM site has been found to be most sensitive to mismatches with the target 
sequence267, therefore four mutations were introduced into this region (Fig. 4.19A). Some nucleotide 
pair mismatches have been reported to be more costly than others for Cas9 activity268 and these 
nucleotide pair mismatches were introduced where possible. The PAM site adjacent to the gRNA2 
target site is part of an intron. The recombinant DNA sequence encoding rescue GALC does not include 
introns and the PAM site adjacent to the gRNA2 target site is therefore lost (Fig. 4.19B). Although this 
is sufficient to abolish Cas9 activity at this site, silent mutations disrupting gRNA2 binding were also 
introduced (Fig. 4.19B). Site-directed mutagenesis of GALC rescue vectors proved challenging due to 
the large size of the template GALC vector. A QuikChange mutagenesis protocol modified for large 
plasmids269 was attempted without success. Mutations were successfully introduced using a two-step 
protocol174 using PCR to generate overlapping GALC gene segments containing the mutations of 
interest, which are then used as template for a second PCR to form the full-length mutant product174 
(section 2.2.7).  
 
GALC KO1 and KO2 cells were transduced with the GALC gRNA1 escape mutant (Rescue 1) and gRNA2 
escape mutant (Rescue 2) constructs, respectively. Cells were infected with a concentration of 
lentivirus vectors such that only 5-10% of cells were transduced in order to minimise the number of 
lentiviral insertion events per cell. Successfully transduced cells were selected by antibiotic selection. 
To avoid amplification of insertional mutations by clonal selection, both cell lines were maintained as 
a mixed population. GALC expression was induced by addition of various concentrations of doxycycline 
to cell cultures for 6 days prior to GALC activity measurement. GALC activity was rescued in the KO1 
rescue cell line (KO1R; Fig. 4.20A) and the KO2 rescue cell line (KO2R; Fig. 4.20B). Cells induced with 
the lowest concentration of doxycycline tested (30 μg/L for KO1R and 25 μg/L for KO2R) showed 
partial rescue of GALC activity (Fig. 4.20C) and were chosen for subsequent experiments because 
partial rescue of GALC activity is likely to be sufficient to restore normal sphingolipid metabolism235, 
whereas GALC overexpression may introduce lipid imbalances. Importantly, although average GALC 
activity in rescue cell populations appears to be similar to endogenous levels, GALC expression is 
expected to be heterogeneous across individual cells because transgene expression depends on 
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whether it integrates into a transcriptionally active or repressed region, a phenomenon known as 
position-effect variegation270.  
 
 
Figure 4.19. GALC rescue construct 
A. Recombinant GALC rescue 1 construct transduced into the GALC KO1 cell line. Silent mutations 
(highlighted in red) were introduced in the gRNA1 target site to prevent genetic ablation of the 
rescue construct by Cas9 and gRNA1 stably expressed in this cell line. The PAM site recognised by 
Cas9 is highlighted in orange. The core gRNA sequence most sensitive to nucleotide pair mismatches 
is indicated in purple. B. Recombinant GALC rescue 2 construct transduced into the GALC KO2 cell 
line, annotated as A. In addition to the four silent mutations introduced in the gRNA2 target site, the 
adjacent PAM site (NGG) is lost in the recombinant GALC construct because this site is included in 
the intron of endogenous GALC. 
 
Relative gene expression of proteins changed at the plasma membrane of GALC KO cells was assessed 
by qPCR in WT, Cas9, mixed population EV, GALC KO1, KO2, and doxycycline-induced rescue KO1R and 
KO2R cell lines and normalised to EV mixed population (Fig. 4.21). The changes observed at the plasma 
membrane by PMP (Fig. 4.18) are replicated in this experiment, providing independent validation of 
these results and showing that each of these changes is driven by differential gene expression. Rescue 
of GALC expression rescued SLC4A4 (Fig. 4.21A) and MDFIC (Fig. 4.21B) gene expression to a limited 
extent but did not rescue PLXNC1, TRHDE and SDK1 gene expression. These results suggest that these 




Figure 4.20. Rescue of GALC activity 
GALC expression was induced in the KO1R and KO2R rescue cell lines by addition of various 
concentrations of doxycycline. GALC activity was assessed by activity assays after 6 days of 
doxycycline induction. A. Ratio of GALC activity in KO1R cells induced with various concentrations of 
doxycycline to GALC activity in WT THP-1 cells. B. Ratio of GALC activity in KO2R cells induced with 
various concentrations of doxycycline to GALC activity in WT cells. C. GALC activity in WT and GALC 
knockout THP-1 cells (KO1 and KO2) compared with KO1R cells induced with 30 μg/L doxycycline and 




Figure 4.21. Validation of proteins differentially expressed in GALC KO THP-1 cells 
 132
qPCR quantification of SLC4A4, MDFIC, PLXNC1, TRHDE and SDK1 gene expression relative to ACTB in 
WT, Cas9, EV mixed population, GALC KO1 and KO2, and GALC rescue KOR1 and KOR2 THP-1 cell 
lines, normalised to EV mixed population control. p-values were calculated by one-way ANOVA 
followed by Tukey’s multiple comparison test. Error bars represent the 95% confidence interval. ns: 
not significant (p-value > 0.05); *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001; ****: p ≤ 0.0001.  
 
4.4.7 Repeat of whole cell proteomics with additional controls 
WCP analysis of WT, Cas9, EV mixed population, GALC KO1 and KO2 cell lines showed that a striking 
total of 2680 proteins were significantly up-regulated and 2228 proteins were significantly down-
regulated in the Cas9 THP-1 cell line compared with the WT THP-1 cell line (Fig. 4.22A, Appendix V). I 
identified pathways dysregulated in these cells by pathway enrichment analysis with DAVID210, 
focusing on pathways from the KEGG database271. Pathways over-represented in the lists of 
significantly down-regulated and up-regulated genes in Cas9 THP-1 cells versus WT THP-1 cells are 
shown in Table 4.3. Notably, the DNA mismatch repair pathway is up-regulated, perhaps due to 
continuing off-target Cas9 activity in these cells. The phagosome and lysosome pathways are most 
significantly enriched in down-regulated genes. Importantly, many proteins involved in 
glycosphingolipid metabolism, including GALC (as observed in Figure 4.5), the saposin precursor PSAP 
and the enzymes immediately upstream and downstream of GALC in the galactosphingolipid 
degradation pathway (ARSA and AC, respectively; Fig. 1.3) are significantly down-regulated in the Cas9 
cell line (Table 4.4). The dysregulation of glycosphingolipid metabolism strongly suggests that this cell 
line is inappropriate to study the effects of GALC deficiency. Given the variety of dysregulated 
pathways, it is not possible to identify a single cause for these changes. It is possible that continuous 




Figure 4.22. Whole cell proteomics of control and GALC KO cell lines 
A. Volcano plot showing pairwise comparison between the cellular proteome of Cas9 and WT THP-1 
cells. Proteins significantly changed (q < 0.05) more than 2-fold are coloured in green. B. Volcano 
plot showing pairwise comparison between the cellular proteome of mixed population EV and Cas9 
THP-1 cells. No significant differences were found. C. Volcano plots showing pairwise comparison 
between the cellular proteome of GALC KO THP-1 cells and mixed population EV control cells. Each 
dot represents a single protein. Proteins significantly changed (q < 0.05) are coloured in green. 
Proteins significantly changed in the same direction in both GALC KO1 and KO2 are coloured in dark 
green.  
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Table 4.3. Pathways dysregulated in the Cas9 THP-1 cell line. KEGG pathways enriched in lists of 
significantly up-regulated and down-regulated proteins in Cas9 THP-1 cells compared to WT, against 
a background of all quantified proteins in the WCP experiment. Benjamini-Hochberg adjusted q-
values are indicated. Significantly enriched pathways with a q-value < 0.005 are shown. 
Pathways enriched in up-regulated proteins Count 
Fold 
enrichment q-value 
Leukocyte transendothelial migration 4 7.5 9.92E-01 
Pathogenic Escherichia coli infection 3 9.1 9.92E-01 
Focal adhesion 4 4.9 9.92E-01 
T cell receptor signaling pathway 3 5.7 1.00E+00 
Pathways enriched in down-regulated proteins    
Thyroid hormone synthesis 4 10.9 5.27E-01 
Morphine addiction 3 11.4 5.37E-01 
Bile secretion 3 10.9 5.37E-01 
Citrate cycle (TCA cycle) 3 10.1 5.37E-01 
Endocrine and other factor-regulated calcium 
reabsorption 3 9.4 5.37E-01 
Retrograde endocannabinoid signaling 3 8.7 5.37E-01 
Insulin secretion 3 8.5 5.37E-01 
Gastric acid secretion 3 8.2 5.37E-01 
Aldosterone synthesis and secretion 3 8.0 5.37E-01 
Salivary secretion 3 8.0 5.37E-01 
Glutamatergic synapse 3 6.2 7.49E-01 
 
Despite the concerns highlighted above, available WCP data was used to identify proteins significantly 
enriched in whole cell lysates of GALC KO1 and KO2 cells compared with mixed population EV control 
cells (Fig. 4.22C and Appendix VI). Although the abundance of 125 proteins was significantly changed 
in GALC KO cells, the amplitude of these changes was small and only MSRB3 was up-regulated more 
than 2-fold in both GALC KO clones. Although MSRB3 gene expression appears slightly higher in KO 
cells compared to mixed population EV (Fig. 4.15C), this increase is not significant, it is therefore 
unclear whether MRSB3 up-regulation is caused by changes in gene expression or increased MSRB3 
stability in GALC KO cells. Pathway enrichment analysis on proteins significantly up- and down-
regulated in GALC KO cells yielded non-significant results (Table 4.5). These pathways were not 






Table 4.4. Glycosphingolipid metabolism proteins down-regulated in Cas9 cells. Relative protein 
abundance of proteins described by the GO term "glycosphingolipid metabolic process" significantly 
down-regulated in whole cell lysates of Cas9 versus WT THP-1 cells. 
Gene ID Gene name 
Log2 (fold change 
Cas9/WT) q-value 
HEXB Beta-hexosaminidase subunit beta -1.47 1.04E-08 
ARSB Arylsulfatase B -1.44 6.22E-09 
ARSD Arylsulfatase D -1.25 4.63E-08 
SUMF1 Formylglycine-generating enzyme -0.93 1.08E-04 
GM2A Ganglioside GM2 activator -0.81 8.63E-07 
ARSA Arylsulfatase A -0.77 4.39E-05 
ASAH1 Acid ceramidase -0.75 1.66E-06 
HEXA Beta-hexosaminidase subunit alpha -0.64 3.40E-06 
GLB1 Beta-galactosidase -0.62 1.42E-05 
GALC Galactocerebrosidase -0.61 9.13E-03 
PSAP Prosaposin -0.53 1.15E-03 
GBA Lysosomal acid glucosylceramidase -0.53 1.54E-05 
CTSA Lysosomal protective protein -0.46 4.35E-06 
NEU1 Sialidase-1 -0.23 2.27E-02 
 
Table 4.5. Pathway enrichment analysis of genes differentially expressed in GALC KO cells. KEGG 
pathways enriched in lists of significantly up-regulated and down-regulated proteins in GALC KO1 
and KO2 compared to mixed population EV cells, against a background of all quantified proteins in 
the WCP experiment. Benjamini-Hochberg adjusted q-values are indicated. 
Pathways enriched in up-regulated proteins  
Count Fold enrichment q-value 
Leukocyte transendothelial migration 4 7.5 9.92E-01 
Pathogenic Escherichia coli infection 3 9.1 9.92E-01 
Focal adhesion 4 4.9 9.92E-01 
T cell receptor signaling pathway 3 5.7 1.00E+00 
Pathways enriched in down-regulated proteins    
Thyroid hormone synthesis 4 10.9 5.27E-01 
Morphine addiction 3 11.4 5.37E-01 
Bile secretion 3 10.9 5.37E-01 
Citrate cycle (TCA cycle) 3 10.1 5.37E-01 
Endocrine and other factor-regulated calcium 
reabsorption 3 9.4 5.37E-01 
Retrograde endocannabinoid signaling 3 8.7 5.37E-01 
Insulin secretion 3 8.5 5.37E-01 
Gastric acid secretion 3 8.2 5.37E-01 
Aldosterone synthesis and secretion 3 8.0 5.37E-01 
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4.5 Immunofluorescence microscopy of Cas9 THP-1 cells 
Endolysosomal proteins appear to be dysregulated or differentially regulated in the Cas9 cell line 
compared to WT THP-1 cells. I used immunofluorescence microscopy for the lysosomal marker LAMP-
1 and the early endosomal marker EEA-1 to assess changes to these compartments in cells stably 
expressing Cas9. To facilitate adhesion to microscopy slides, THP-1 cells were differentiated with PMA 
to form macrophage-like adherent cells (Fig. 4.23). The majority of differentiated WT cells maintained 
a rounded morphology, with only a few cells spreading out and forming processes. In contrast, most 
differentiated Cas9 cells spread over the surface and a large proportion of these cells formed 
processes. Differentiated KO1 and KO2 cells appeared similar to Cas9 cells.  
 
 
Figure 4.23. The morphology of differentiated Cas9-derived cell lines differs from WT 
WT, Cas9, KO1 and KO2 THP-1 cells were differentiated and visualised with a brightfield microscope.  
 
Nuclear staining showed a striking difference in the nucleus morphology of differentiated Cas9 cells 
compared to WT (Fig. 4.24). Monocytes and macrophages have the capacity to form multilobated 
nuclei, possibly to support cell passage through small gaps by providing flexibility to the nucleus272. In 
addition, macrophages can fuse to form giant multi-nucleated cells through a poorly understood 
process273. PMA-differentiated THP-1 cells have been previously observed to have heterogeneous cell 
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and nuclear morphology, with some evidence of multilobation and multinucleation274. Similarly, 
spontaneously activated THP-1 cells have been reported to form giant multinucleated cells with up to 
20 nuclei275. In this experiment, differentiated WT cells show some multilobated nuclei and some cells 
appear to have two nuclei (Fig. 4.24). In Cas9 cells and Cas9-derived cell lines, this phenotype is more 
pronounced, with a large number of multinucleated cells possessing more than two nuclei in a flower-
shaped arrangement (Fig. 4.24). Considering the marked propensity of the Cas9 THP-1 cell line to form 
multi-nucleated cells, this cell line is not a good model to study how loss of GALC triggers the formation 
of multinucleated globular cells characteristic of Krabbe disease. The lysosome and early endosome 
markers are concentrated at the centre of these flower-shaped multinuclei in Cas9-derived cell lines 
(Fig. 4.24). This suggests that the localisation and trafficking of endo-lysosomal compartments differs 
from WT in these cell lines. This poses additional concerns about endolysosomal function in these 
cells. No differences were observed between Cas9, mixed population EV control cell lines and GALC 
KO1 and KO2 cell lines. Loss of GALC and subsequent galactosphingolipid does not appear to cause 
substantial changes in the number or localisation of lysosomes in Cas9 THP-1 cells, although such 
effects may be masked by abnormal lysosome localisation in these cells. 
 
In conclusion, the parental THP-1 Cas9 clonal cell line used to generate GALC KO THP-1 cells shows 
dramatic and wide-ranging abnormalities. Although Cas9-derived cell lines appeared normal when 
undifferentiated, these cells show a different cell morphology and a higher propensity to form 
multinucleated cells upon differentiation than WT THP-1 cells. The abundance of approximately half 
of all quantified proteins is significantly different from WT in this cell line. The endolysosomal 
compartments and sphingolipid metabolic enzymes are particularly affected by these changes. This 
cell line is therefore inappropriate for the study of changes caused by disruption of glycosphingolipid 
metabolism. This chapter illustrates that genetic manipulation of cells can cause unexpected and wide-
reaching changes amplified by the selection of single cell clones. Future studies of lipid metabolism in 





Figure 4.24. Immunofluorescence microscopy of THP-1 cell lines 
WT, Cas9, mixed population EV (EVm), GALC KO1 and KO2 THP-1 cells were differentiated and 
stained with antibodies against the lysosomal marker LAMP-1 and the early endosome marker EEA-
1. Nuclei were stained with DAPI. The symbol * indicates multilobated nuclei; arrows indicate 
multinucleated cells. Scale bar: 20 μm. 
 
4.6 Discussion 
Disentangling the mechanisms of inflammation, demyelination and oligodendrocyte cell death in 
Krabbe disease has been a major challenge for understanding the pathogenic mechanisms driving this 
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disease. I asked whether loss of GALC in phagocytic cells causes them to acquire an activated, globoid 
cell phenotype using CRISPR/Cas9 KO in the THP-1 monocytic cell line. I found that loss of GALC in 
monocytes alone is not enough to promote globoid cell formation and an inflammatory phenotype. A 
recently published study by Weinstock et al.276 independently confirmed this observation. The authors 
performed a site-specific KO of GALC in peripheral macrophages of WT mice. They observed that these 
mice did not present globoid cell infiltration of peripheral nerves. Cultured bone marrow derived 
macrophages (BMDMs) appeared normal and expressed normal levels of the pro-inflammatory 
cytokines TNF-α and IL-1β. In contrast, in mice with a double knockout of GALC in macrophages and 
Schwann cells, the myelinating cells of the peripheral nervous system, they observed globoid cell 
infiltration of demyelinating peripheral nerves. Moreover, incubation of cultured GALC KO BMDMs 
with exogenous GalCer induced globoid cell formation and up-regulation of TNF-α, IL-1β and 
integrated stress response genes. Altogether, this study provides strong evidence that globoid cell 
formation is driven by phagocytosis of myelin debris and subsequent accumulation of undigested 
GALC substrates in GALC-deficient macrophages. This triggers a stressed, pro-inflammatory, 
multinucleated macrophage phenotype.  
 
The glycosphingolipid repertoire at the surface of immune cells is diverse, dynamic and only partially 
understood. Regulation of various glycosphingolipid metabolic enzymes upon immune cell 
differentiation and stimulation has been observed for several immune cell types including monocytes 
and macrophages123. I have found that the expression levels of the galactosphingolipid anabolic and 
catabolic enzymes UGT8 and GALC is modulated upon THP-1 cell differentiation and LPS stimulation. 
This is in agreement with previous reports finding changes in GALC expression upon differentiation of 
primary monocytes236 and down-regulation of UGT8 expression upon TLR stimulation of a mouse 
macrophage cell line239. The dynamic regulation of galactosphingolipid synthesis and degradation 
suggests that these lipid species have functional roles in monocytes and macrophages. Quantification 
of glycosphingolipids by lipidomics is very challenging and requires the implementation of specialised 
procedures to discriminate between GalCer- and glucosylceramide (GluCer)-based glycosphingolipids. 
Our lab is working on implementing such a technique through a collaboration, but we are currently 
unable to quantify galactosphingolipids in THP-1 cells. Weinstock et al. 276 did not detect any GalCer 
in WT or GALC KO mouse BMDM. However, very small amounts of psychosine were detected in WT 
macrophages and this was significantly increased in GALC KO macrophages276. Thus, the high 
expression levels of GALC in THP-1 cells may be primarily to aid with digestion of phagocytosed GalCer 
rather than recycling of large amounts of self-synthesised galactosphingolipids. It is possible that 
psychosine is functionally relevant for these cells, but endogenous psychosine accumulation does not 
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cause activation of macrophages. It should be noted that differences exist in the glycosphingolipid 
profile of mouse and human immune cells, and these differences have not yet been fully 
characterised123.  
 
I attempted to understand the potential roles of galactosphingolipids in monocytes by investigating 
the effect of galactosphingolipid accumulation on the proteome at the cell surface. Unfortunately, the 
dysregulation of sphingolipid metabolism and endolysosomal compartments in the parental Cas9 cell 
line may have masked any effects of GALC loss in the GALC KO cell line, limiting the amount of 
meaningful data that could be obtained from these cell lines. Loss of GALC in the Cas9 THP-1 cell line 
caused few changes in protein expression at the cell surface through changes in gene expression. 
Rescue of GALC expression in the KO cell lines only partially rescued the expression of the 
sodium/bicarbonate cotransporter SLC4A4 and the transcriptional regulator MDFIC, making clear 
interpretation of these results elusive. I did not observe any changes in the cytokine profile of GALC 
KO cells compared to the EV1 control cell line, nor any changes in morphology compared to the Cas9 
and mixed population EV cell lines. However, the issues encountered in these cell lines severely 
undermine confidence in these observations. 
 
The generation of GALC KO and control cell lines posed significant problems. Due to the inherent 
resistance of phagocytic cells to transfection, a lentiviral transduction strategy was used to generate 
these cell lines. Two of the control clonal cell lines showed large and wide-ranging changes in protein 
expression compared to the parental cell line. These changes may have been caused by a mutation 
caused by random insertion of the lentiviral vector into the genome (insertional mutagenesis) or Cas9 
off target effects277 caused by unintended cleavage of DNA at sites showing mismatches with the gRNA 
causing mutations and potentially large deletions and genomic rearrangements. Although lentiviral 
transduction and CRISPR/Cas9 KO are commonly employed for biological research, the possibility of 
such off-target effects warrants caution while using these tools. As illustrated in this study, the use of 
all parental cell lines in control experiments is crucial for the interpretation of results obtained through 
the genetic manipulation of cell lines. Thanks to recent advances in proteomics labelling, it is now 
possible to analyse up to 16 samples by quantitative proteomics. Several precautions can be taken 
when generating KO cell lines. Where possible, a mixed population of transduced cells should be used 
instead of a single cell clone. This prevents the amplification of off-target effects, as I observed by 
direct comparison of the proteome of the Cas9 THP-1 cell line and mixed population EV cells, showing 
no significant difference in protein expression. However, a homogeneous cell population is sometimes 
required. Homologous recombination into a "safe harbour" locus can be employed to generate a 
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homogeneous cell line and circumvent the issue of insertional mutagenesis. Safe harbour loci are 
validated sites which can be disrupted without any known adverse effects on the cell, and which can 
support robust transcription of the inserted gene in most cell types278. THP-1 cells genetically 
engineered to facilitate Zinc finger nuclease-mediated genomic integration into the adeno-associated 
virus site 1 safe harbour locus are commercially available. Using this strategy to insert a DNA sequence 
encoding Cas9 and gRNAs can eliminate lentivirus insertion-mediated off-target effects. Moreover, 
several strategies have been recently developed to minimise off-target effects of CRISPR/Cas9279. For 
example, Cas9 variants have been designed to reduce the efficiency of cleavage and thus increase its 
specificity. These strategies can be combined to generate reliable KO cell lines in phagocytic cells.  
 
To conclude, recent evidence suggests that immune dysfunction in Krabbe disease is caused by storage 
of undigested myelin debris in GALC-deficient phagocytic cells, triggering the formation of globoid 
cells and contributing to a pro-inflammatory environment276. Despite the secretion of pro-
inflammatory factors by activated globoid cells, macrophages appear to have an overall protective 
role in Krabbe disease by removing myelin debris and promoting remyelination, as demonstrated in a 
macrophage-deficient Krabbe mouse model280. Loss of GALC does not intrinsically activate phagocytic 
cells and does not drive the pathogenesis of Krabbe disease. However, the dynamic regulation of 
galactosphingolipid anabolic and catabolic enzymes suggests that these lipid species could play active 
roles in cellular and immune processes. Since endogenous galactosphingolipid accumulation in GALC 
KO macrophages does not appear to trigger a distinctive phenotype in this study and a previous 
report276, GALC KO may not be the most appropriate tool to study this role. Instead, abolishing the 
synthesis of galactosphingolipids by knocking out the anabolic enzyme UGT8 may be a better tool to 
uncover the role of these lipids in phagocytic cells.  
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The lysosomal enzyme acid ceramidase (AC) hydrolyses ceramide to sphingosine, thus regulating the 
levels of these ubiquitous bioactive lipids involved in many aspects of cell function, including apoptosis 
and inflammation. Dysregulation of AC activity has dire consequences. Loss-of-function mutations in 
AC cause Farber disease, a rare lysosomal storage disorder that causes a range of severe symptoms 
resulting in early death. In contrast, up-regulation of AC expression is associated with some cancers 
and resistance to cancer treatment. In addition, AC may contribute to the pathogenesis of several 
lysosomal storage diseases by hydrolysing aberrantly accumulated glycosphingolipids to form harmful 
lysosphingolipids. The first aim of my PhD had been to determine the structure of AC as there was 
substantial preliminary work already performed within the Deane lab. However, within the first month 
of my PhD this structure was published by another lab128 and so the focus and aims of this project 
were re-addressed. Specifically, the structure left several key aspects of AC function unknown. It is 
unclear how AC accesses its membrane-embedded substrate, and how it could process 
glycosphingolipids with bulky head groups that are not present on its known substrate ceramide. This 
chapter describes my attempts to investigate these aspects of AC function using structural, 
biochemical and cell-based methods.  
 
Statement of acknowledgement 
 
Dr Sam Spratley, a former PhD student in our group, performed preliminary work for this project, 
establishing a purification strategy for AC and solving a preliminary structure of AC with the help of Dr 
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with crystal manipulation and diffraction data collection described in this chapter. Prof Randy Read 
(CIMR, University of Cambridge) assisted with the molecular replacement solution for the SapA 
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5.1 Understanding the interaction of AC with lipid membranes 
AC is thought to interact with lysosomal membranes through a large hydrophobic patch participating 
in hydrophobic interactions with the lipid bilayer, as well as electrostatic interactions with negatively 
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charged lipid head groups90,128 (Fig. 1.7), but the molecular details of these interactions are unknown. 
It is also unclear how ceramide substrates leave the lipid bilayer to access the deep active site of AC 
and how this process is facilitated by saposin D (Fig. 1.8). I aimed to understand how AC interacts with 
lipid membranes by obtaining a crystal structure of AC in complex with a lipid-containing nanodiscs. 
Small discs of lipid bilayer can be enclosed by saposin A (SapA) molecules to form stable and uniform 
assemblies suitable for structural studies. These discs have been used to provide a native lipid 
environment for nuclear magnetic resonance93 and electron microscopy94 studies of transmembrane 
proteins. SapA nanodiscs are also appropriate for the study of lipid processing enzymes, as 
demonstrated by the fact that the enzyme Sialidase-3 can degrade its ganglioside substrate embedded 
in SapA nanodiscs281. 
 
5.1.1 Stable expression of human AC in mammalian cells 
I established a stable, inducible HEK293F cell line expressing hexahistidine (H6)-tagged AC using the 
PiggyBac system173 (Fig. 5.1A). AC was purified from the media following a protocol optimised by Dr 
Sam Spratley, consisting of a single nickel affinity chromatography step followed by elution with low 
pH buffer (100 mM citrate, pH 4; Fig. 5.1B). AC was subsequently stored in the elution buffer. The yield 
was high: 12 mg of pure protein were purified from 500 mL of media. SDS-PAGE analysis of the purified 
product reveals two forms of AC, as observed previously126,128. The immature, uncleaved form of AC 
can be detected as a single band at approximately 55 kDa while mature AC is cleaved into two 
subunits, α (16 kDa) and β (40 kDa), linked by a disulphide bond. Mature AC is the active form of AC 
formed by autoproteolysis of the peptide bond between Cys143 and Ile142, an event triggered by the 
low pH of the lysosome 127,128. The molecular weight of AC is higher than predicted from its sequence 
(47 kDa) because it is glycosylated at five sites on the β subunit126. 
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Figure 5.1. Nickel affinity purification of recombinant AC from mammalian cells 
A. Recombinant AC was expressed in HEK293F cells. The construct encoded full-length AC possessing 
an N-terminal cleaved secretion signal peptide and a C-terminal hexahistidine (H6) tag. B. AC was 
captured from the media with Ni-NTA beads and eluted in 1 mL fractions of 100 mM citrate pH 4. 
Fractions were analysed on a Coomassie-stained 12% SDS-PAGE gel. 
 
5.1.2 Preparation and characterisation of SapA lipoprotein nanodiscs 
I expressed untagged recombinant mouse SapA in E. coli. SapA was purified using the same 
purification protocol as for SapB (section 3.2). E. coli lysate was boiled to remove most proteins, except 
for heat-stable proteins including SapA. I then purified SapA by anion exchange chromatography (Fig. 
5.2A-B) and size exclusion chromatography (Fig. 5.2C), yielding 8 mg of pure SapA from 1 L of culture 
(Fig. 5.2D).  
 
As described in section 1.4, SapA can adopt a closed, globular monomeric conformation (Fig. 1.4C), or, 
in the presence of lipids or detergents, SapA can extend into an open conformation exposing its 
internal hydrophobic face and allowing SapA to assemble into oligomers enclosing lipid or detergent 
molecules (Fig. 1.4B, D, E). SapA-lipid nanodisc formation requires incubation of SapA and lipids at low 
pH (pH 4.8) or solubilisation of lipids with the gentle detergent n-Dodecyl-β-D-maltoside (DDM) prior 
to incubation with SapA at neutral pH93. SapA has been found to assemble with a very wide range of 
lipids to form nanodiscs95 but most studies of this system have employed phosphatidylcholine 
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(PC)81,93,95,281,282. PC is one of the most abundant lipids in lysosomal membranes and AC has been 
shown to interact with liposomes primarily composed of PC (80 mole % PC and 20 mole % cholesterol 
(Chol))90. Therefore, SapA-PC nanodiscs were a good initial system for this study. The number of SapA 
and lipid molecules included in the nanodisc, and overall nanodisc size depend on several factors, 
including the lipid to SapA molar ratio93 and the pH of the buffer282.  
 
 
Figure 5.2. Purification of untagged recombinant mouse SapA from E. coli 
Mouse SapA was purified by anion exchange chromatography followed by size exclusion 
chromatography. A. Anion exchange chromatogram. B. The first fractions of the peak were analysed 
on a Coomassie-stained 4-12% Bis-Tris SDS-PAGE gel. The indicated fractions were pooled and 
concentrated for size exclusion chromatography. C. SapA was further purified by size exclusion 
chromatography on a Superdex 75 16/600 column. The indicated fractions containing SapA were 
pooled and concentrated for future experiments. Large amounts of contaminating DNA (absorbing 
at 280 nm) elute around 100 mL. D. SDS-PAGE analysis of purified SapA. 
 
When preparing SapA-PC nanodiscs I adapted published protocols93,94 as follows. Although human 
SapA has been used to form nanodiscs in previous studies, here I used the mouse ortholog which 
possesses 79.5% sequence identity and 91.6% similarity to human SapA. The interaction of AC with 
lipid membranes has been shown to be pH-dependent and strongly enhanced at pH 490. Nanodiscs 
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were therefore prepared at pH 4 as it is similar to the low pH of 4.8 used to promote nanodisc 
formation in Chien et al.93. Previous publications reported complete solubilisation of dried lipids in 
aqueous buffer upon addition of the detergent DDM93,94. However, in my initial experiments lipid 
solubilisation was incomplete, resulting in a very low yield with less than 10% of SapA forming 
nanodiscs. I improved lipid solubilisation by making liposomes in aqueous buffer by 10 cycles of 
sonication and vortexing of the lipid solution prior to the addition of DDM. This greatly improved the 
final yield to over 70%. Solubilised lipids were then incubated with SapA following the protocol by 
Frauenfeld et al.94 with a molar ratio of PC to SapA of 30:1 as in Chien et al.93. The incorporation of 
lipids into SapA nanodiscs increases the molecule size, allowing separation from free SapA and 
detergent-solubilised lipids by size exclusion chromatography (Fig. 5.3A-B). SapA-PC nanodiscs eluted 
at 15.8 mL from a Superdex 200 10/300 column. This elution volume was consistent across several 
preparations. The elution volume is dependent on the hydrodynamic radius of a molecule, allowing 
comparison of eluted macromolecules across different experiments when the same size exclusion 
chromatography column is used. In order to evaluate the composition of the nanodiscs I had 
produced, I compared the size exclusion chromatography profile with that from Chien et al.93 (Fig. 
5.3C). While I used a lipid to SapA ratio of 30:1, which should have produced a large nanodisc assembly 
eluting at 13.3 mL, the elution volume of my nanodiscs more closely matched that of a smaller 
nanodisc assembly produced using a 1:5 ratio and eluting at 15.9 mL. Li et al. 282 showed that nanodiscs 
eluting at this volume contain two SapA and 23-29 PC molecules by mass spectrometry and size 




Figure 5.3. SapA-phosphatidylcholine nanodiscs preparation 
Lipoprotein nanodiscs were made by incubating SapA with detergent-solubilised 
phosphatidylcholine (PC). A. Size exclusion chromatography using a Superdex 200 10/300 column 
allows separation of PC-SapA nanodiscs (elution peak at 15.8 mL) from SapA, which elutes at 17.7 
mL. B. Coomassie-stained SDS-PAGE gel of PC-SapA nanodiscs. C. This panel is reprinted with 
permission from Chien et al.93. Size-exclusion chromatography on a Superdex 200 Increase 10/300 of 
SapA-PC nanodiscs made at pH 4.8 using the indicated SapA to lipid ratio (1:5, in blue and 1:30, in 
red) by Chien et al. The proposed SapA arrangement is indicated for each peak.  
 
I characterised the molecular weight, size and shape of the SapA-PC nanodiscs I produced by SEC-
MALS. This technique uses size exclusion chromatography to separate macromolecules based on their 
hydrodynamic radius, then measures the light scattering, differential refractive index and UV signal of 
the sample. This facilitates the calculation of the molecular mass, independent of shape, and therefore 
the determination of the oligomeric state of macromolecules in solution. The observed average 
molecular mass of SapA-PC assemblies at pH 4 was 37.1 ± 0.5 kDa (Fig. 5.4). However, the sample was 
heterogeneous, as indicated by a polydispersity value (Mw/Mn) of 1.010 and higher molecular masses 
observed at the beginning of the peak. This is likely due to variable amounts of PC (770 Da) and/or 
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DDM (511 Da) molecules contained within the SapA nanodiscs. For nanodiscs containing a SapA dimer 
with 23-29 PC molecules, Li et al.282 measured molecular masses ranging from approximately 35 to 50 
kDa, with an average MW of 40.9 ± 1.6 kDa by SEC-MALS. These values are similar to the molecular 
mass distribution observed in this experiment (Fig. 5.4). In conclusion, I made SapA-PC nanodiscs with 
a molecular mass closely resembling previously published data, suggesting that they are composed of 
a SapA dimer encapsulating approximately 20 to 30 PC molecules.  
 
 
Figure 5.4. SEC-MALS analysis of SapA-PC assemblies at pH 4 
The molecular mass distribution (pink line) is shown across the elution profile (normalized 
differential refractive index, dRI, red dotted line) when eluting from a Superdex 200 10/300 Increase 
column. The observed molecular mass is 37 kDa, with higher molecular masses observed in the start 
of the peak. 
 
5.1.3 Crystallisation of AC with SapA-PC nanodiscs 
To investigate how AC interacts with membranes, I attempted to co-crystallise AC with SapA-PC 
nanodiscs. Both AC and nanodiscs were purified in pH 4 buffer, the optimal pH for AC interaction with 
membranes. AC and nanodiscs were concentrated to their solubility limit (4.5 mg/mL and 3.5 mg/mL, 
respectively) and mixed in equimolar quantities. I set up a high-throughput sparse matrix 
crystallisation screen using this mixture. In parallel with this approach, concentrated AC and nanodiscs 
were mixed and incubated at room temperature for 75 minutes, then concentrated further to the 
solubility limit of the mixture and used to set up the same crystallisation screen for comparison. Good 
quality crystals grew in several conditions (Fig. 5.5A). There was no significant difference between the 
conditions obtained in the screens set up with fresh or pre-incubated mixture, so I used freshly mixed 
AC and nanodiscs for subsequent screens. I optimised crystallisation conditions by changing the pH, 
precipitant concentration, and presence/absence of the additives glycerol and MgCl2. 
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Crystals diffracted to a maximum resolution of 3.2 Å (Table 5.1). All crystals belonged to the space 
groups P 61, P 61 2 2 or P 62 2 2, with the same unit cell dimensions, indicating that the same crystal 
form with the same composition grew in different conditions. The best quality datasets (based on low 
resolution merging statistics) were assigned the space group P 61, suggesting that this is the most likely 
space group. I could not solve the phase problem by molecular replacement using the unpublished 
low-resolution structure of AC previously obtained by our group and/or two copies of human SapA in 
its open conformation (PDB ID: 4DDJ).  
 
 
Figure 5.5. Crystals grown in conditions containing AC and PC-SapA nanodiscs  
A. Crystals grew in several conditions containing AC and PC-SapA nanodiscs. B. All crystallisation 
conditions being equal (20.25% PEG 3.35K, 0.1 M Bis-Tris pH 5.11), crystals grew in drops containing 
both AC and PC-SapA nanodiscs, but not AC alone or PC-SapA nanodiscs alone. C. Coomassie-stained 
SDS-PAGE gel of washed crystals compared to the input mixture containing both AC and nanodiscs. 
Approximately 20 medium-sized crystals were washed in a drop containing reservoir solution. 
 
To test whether the crystals grown were composed of AC and nanodisc complexes rather than AC or 
nanodiscs alone, I set up crystallisation plates with optimised conditions and added either the AC-
nanodisc mix, AC alone supplemented with nanodisc buffer instead of nanodiscs, or nanodiscs alone 
supplemented with AC buffer instead of AC. Many crystals grew in drops containing both AC and 
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nanodiscs, while drops containing only one component contained precipitate but not crystals (Fig. 
5.5B). This was a good indication that crystals were composed of AC and nanodisc complexes. 
However, SDS-PAGE of washed crystals clearly showed that the crystals were in fact composed of 
nanodiscs only, since AC present in the input mixture was completely depleted in the crystals (Fig. 
5.5C).  
 
Table 5.1. Representative data collection statistics. Values in parentheses are for the highest-
resolution shell. 
Beamline i04  
Wavelength (Å) 0.97950  
Processing package autoPROC  
Space group  P 61  
Cell dimensions   
   a,b,c (Å)  48.9, 48.9, 317.9  
α,β,γ (°)  90.0 90.0 120.0  
Resolution (Å)  52.982 - 3.208  
(3.418 - 3.208)  
Rmerge  0.166 (2.673)  
Rpim 0.058 (1.027)  
CC1/2 0.996 (0.497)  
I/sI  10.2 (0.9)  
Completeness (%)  s* 82.1 (24.0)  
e* 89.7 (39.1)  
Redundancy  9.0 (7.8)  
 
5.1.4 Pull-down experiments of SapA nanodiscs by AC 
Since the crystals grown in presence of AC and nanodiscs contained only nanodiscs, I needed to 
establish whether AC could interact with a lipid bilayer enclosed by SapA by pull-down assays. The 
interaction of AC with membranes is strongly enhanced at pH 4, corresponding to lysosomal pH, and 
appears drastically reduced at pH 690. Pull-down experiments that reflect the conditions of the 
lysosome are complicated by the loss of interaction between many protein tags and their ligand, such 
as polyhistidine and Ni-NTA at low pH. The interaction between biotin and streptavidin, however, is 
stable up to pH 4, making it a useful tool for pull-downs. I cloned and expressed a new construct of AC 
with a C-terminal biotin acceptor peptide (BAP) followed by a H6 tag (AC-BAP-H6) (Fig. 5.6A) using the 
same stable mammalian expression system as in section 5.1.1, yielding 6 mg of pure protein from 500 
mL media (Fig. 5.6B). I biotinylated AC-BAP-H6 in vitro with recombinant BirA purified from E. coli178. 
The C-terminal BAP tag is on the β-subunit, therefore biotinylation can be observed on the β-subunit 
 151 
of mature AC and uncleaved AC. I assessed biotinylation efficiency by a gel-shift assay (Fig. 5.6C), 
showing a biotinylation efficiency up to 70%. There was a significant loss of protein by precipitation 
when the incubation time or the amount of BirA was increased, indicating that the protocol detailed 
in section 2.4.15 is optimal.  
 
The binding of AC to membranes is enhanced by negatively charged lipids, and in particular the 
negatively charged phospholipid bis(monoacylglycero)phosphate (BMP) enriched in endolysosomal 
compartments90. AC was shown to interact strongly with liposomes containing 55 mole % PC, 25 mole 
% BMP and 20 mole % Chol. This composition was chosen to make negatively charged nanodiscs 
following the same protocol as for PC nanodiscs (Fig. 5.7A) since SapA nanodiscs can be made with a 
number of lipids mixtures, including a very similar mixture (50 mole % PC, 25 mole % Chol, 20 mole % 
BMP, 5 mole % GalCer)81.  
 
For the nanodisc pull-down experiment, biotinylated AC was immobilised on streptavidin agarose 
beads. Bead-bound AC was incubated with an 8-fold molar excess of SapA, SapA-PC nanodiscs or SapA-
(PC+BMP+Chol) nanodiscs (Fig. 5.7B). After washing the beads to remove unbound protein, AC was 
eluted by boiling the beads in SDS-PAGE buffer and eluted protein was analysed by SDS-PAGE. No 
SapA-PC nanodiscs nor SapA-(PC+BMP+Chol) nanodiscs were bound to AC at pH 4 (Fig. 5.7C), 
indicating that AC does not form a stable interaction with lipid membranes enclosed within SapA 




Figure 5.6. Preparation of biotinylated AC 
A. Secreted AC with a C-terminal biotin acceptor peptide (BAP) followed by a hexahistidine tag was 
stably expressed in HEK293F cells. B. AC was captured from the media with Ni-NTA beads and eluted 
in 0.5 mL fractions of 100 mM citrate pH 4. Fractions were analysed by coomassie-stained 12% SDS-
PAGE gel. C. AC was biotinylated in vitro. The proportion of biotinylated protein was determined by a 
gel-shift assay and calculated by densitometry. Streptavidin binds biotin with very high affinity, 




Figure 5.7. AC does not interact with SapA nanodiscs 
A. Size exclusion chromatogram of SapA nanodiscs composed of PC, BMP and Chol (*) compared to 
SapB alone (^) B. Pull-down assay protocol. Biotinylated AC is immobilised on Streptavidin beads to 
test its interaction with SapA nanodiscs with different lipid compositions.  C. Coomassie-stained SDS-
PAGE gel of input and bound protein in a pull-down assay of PC-SapA and (PC, BMP, Chol)-SapA 
nanodiscs by biotinylated AC. The α subunit of AC runs at the same size as streptavidin detached 
from the resin during elution. The controls show that SapA and SapA nanodiscs do not interact non-
specifically with the resin. No SapA or SapA nanodiscs were pulled down by AC. 
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5.1.5 SapA assembly structure solution and refinement 
The structure of the SapA nanodisc crystal grown in 23.25% PEG 3350, 0.1 M Bis-Tris pH 5.64 (crystal 
shown in Fig. 5.5A, bottom left panel; diffraction dataset described in Table 5.1) was solved by 
molecular replacement using three copies of open SapA monomers (PDB ID: 4DDJ) as a search model. 
However, this solution was incomplete, as indicated by apparent but weak electron density likely 
corresponding to a fourth SapA monomer, as well as a Translation Function Z (TZF) score for this 
solution below 8 (TZF = 6.0) suggesting that the solution may be incomplete, overfilled, partly incorrect 
or completely incorrect. However, the fourth SapA chain could not be placed correctly by automated 
molecular replacement. With the help of Randy Read, this fourth monomer was successfully placed 
manually into the region of weak electron density using non-crystallographic symmetry. Although the 
electron density corresponding to the fourth SapA monomer (chain D) is very poor, it appears to have 
been placed correctly, as supported by lower Rfree after rigid body refinement of this model (Rfree = 
0.406) versus the model with three SapA monomers (Rfree = 0.465) or the incorrect automated 
molecular replacement solution with four SapA chains (Rfree = 0.466). The statistic Rfree describes how 
well the model describes a small subset of randomly selected reflections that are not used in the 
refinement of the structural model.  
 
The electron density maps of this low-resolution dataset are poorly defined, with clear density visible 
only for the backbone of α-helical segments and the side chains of some bulky residues. This makes 
model building and improvement very challenging, because the placement of most amino-acid side 
chains and flexible loops is extremely ambiguous, error-prone and difficult to achieve. The model-
building software package ISOLDE was recently developed to help guide model building into low 
resolution maps190. ISOLDE uses molecular dynamics to simulate interactions between all atoms of the 
model (or section of a large model) in real time while the model is manipulated by the user. This 
powerful approach allows refinement of atom positions based on the electron density map as well as 
interactions with neighbouring atoms. ISOLDE also provides real-time visual information on local 
deviations of the model from ideal protein geometry, informing model improvements. I ran a 
molecular dynamics simulation on the SapA tetramer model in ISOLDE, which eliminated clashes 
between atoms and corrected some Ramachandran outliers. I manually corrected obvious errors in 
the model such as Ramachandran, peptide bond and rotamer outliers and non-proline cis peptide 
bonds. These types of outliers can occur at very low frequencies; however, they are energetically 
unfavourable and require strong stabilisation by surrounding atoms. In the absence of strong density 
and stabilising interactions, these outliers are likely a consequence of erroneous modelling.  
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After model building in ISOLDE, the model was refined using the automated refinement software 
phenix.refine. Following two iterations of this cycle, Rfree started increasing, indicating that the model 
was becoming over-fitted to the data and could not be improved any further. The final refinement 
statistics are presented in Table 5.2. Selected statistics can be compared to PDB entries of similar 
resolution283 (Fig. 5.8). A typically well-refined structure should have a small and roughly equilateral 
polygon. Here, the Molprobity clashscore191 is extremely low for a structure at this resolution because 
clashes between atoms have been minimised by molecular dynamics simulations in ISOLDE. Of note, 
the average protein B-factors are unusually high for this structure. B-factors quantitate the uncertainty 
about the position of each atom. High B-factors can be caused by flexibility of certain parts of the 
molecule (if localised to specific areas), mosaicity (disorder) within the crystal, or a problem with the 
protein refinement strategy. In this case, the Wilson B-factor of the raw crystallography dataset is also 
high (Wilson B-factor= 86.6), suggesting that the crystal had high mosaicity, possibly due to the 
presence of disordered lipids within the structure. B-factors are similar across all four chains, 
indicating that mosaicity is not caused by variability in the position of the fourth SapA chain (Table 
5.2), despite the very poor electron density for this chain. 
 
Figure 5.8. SapA tetramer refinement statistics 
Histograms of the distribution of selected statistics across 1539 PDB entries of similar resolution, 
with the range specified by numbers printed in red. Statistics for the SapA tetramer structure are 
printed in black; the connecting polygon (in black) shows where these values fall in the distribution. 
Histogram bins are colored by the number of structures in each bin: 0 (blue), 385 (green), 770 (red). 
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Table 5.2. Final refinement statistics for the SapA tetramer structure. 
Resolution (Å)  52.982 - 3.154 









Chain A 139.08 
Chain B 138.10 
Chain C 144.95 
Chain D 142.16 
Ramachandran 
 
Favoured (%) 98.72 
Outliers (%) 0.32 
R.m.s deviations 
 
Bond lengths (Å) 0.003 
Bond angles (°) 0.777 
Rotamer outliers (%) 1.71 
Cis peptides (Proline) 0 
Cis peptides (General) 0 
Twisted peptides (Proline) 0 
Twisted peptides (General) 0 
Clashscore 2.70 
 
5.1.6 SapA forms a novel tetrameric structure 
In this structure, SapA forms a tetrameric assembly distinct from previously described nanodiscs. Four 
SapA molecules in an open conformation form a diamond-shaped assembly with symmetrical contacts 
(Fig. 5.9A). This is very different from the SapA nanodisc structure (Fig. 1.4E) expected based on the 
size exclusion chromatography elution profile of these nanodiscs (as detailed at the end of section 
5.1.2). It is also unlike the larger nanodiscs containing four SapA molecules for which a structure has 




Figure 5.9. Novel tetrameric SapA assembly structure 
A. Front and side view of the novel diamond-shaped tetrameric SapA assembly. SapA monomers are 
represented as ribbons and coloured by chain. B. This panel is reprinted with permission from Li et 
al.282. Top and side view of a predicted structure of a SapA nanodisc containing four SapA molecules 
(purple ribbon) forming a belt around a lipid core (lipids are represented as sticks) obtained by 
manual placement of SapA molecules around the lipid core followed by molecular dynamics 
simulations. C. This panel is reprinted with permission from Chien et al.93. Negative-stain electron 
microscopy images of SapA nanodiscs containing four SapA molecules. The scale bar represents 50 
nm. The insets show top-down views of representative nanodisc images in a 20 nm box.  
 
This tetrameric assembly is maintained by several protein-protein contacts between SapA monomers 
(Fig. 5.10A). These contacts are symmetrical and each SapA monomer participates in the same 
interactions. In particular, there are hydrophobic interactions between Trp37 on one monomer and 
Met61 and Ile58 on another monomer (Fig. 5.10A, left panel); between Tyr54 on one monomer and 
Ile38 and Leu43 on another; and between Leu2 and Ile6 on one monomer and Leu17 on another (Fig. 
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5.10A, right panel). Each SapA monomer also forms an intermolecular hydrogen bond between Tyr54 
and the backbone of Cys35 on another monomer (Fig. 5.10A, lower panel). All of the residues 
participating in these interactions are either identical between mouse and human SapA or conserved 
in terms of their hydrophobic properties (for example, Leu to Met; Fig. 5.10B). This suggests that this 
novel tetrameric assembly is not driven by interactions specific to mouse SapA.  
 
 
Figure 5.10. The tetrameric SapA assembly is maintained by protein-protein interactions 
The SapA tetramer is maintained by intermolecular protein-protein contacts, including multiple 
hydrophobic interactions (Trp37, Met61 and Ile58; Ile38, Tyr54 and Leu43; and Leu2, Ile6 and 
Leu17). In addition, Tyr54 forms an intermolecular hydrogen bond with the backbone of Cys35 
(lower panel). Each of the four symmetrical SapA monomers participates in the same interactions. B. 
Sequence alignment of mouse SapA (mSapA) and human SapA (hSapA) showing that the residues 
involved in these contacts (highlighted in yellow) are conserved (identical residues highlighted in 
yellow, conservative substitutions highlighted in pale yellow in the hSapA sequence). 
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Two structures of SapA in its open conformation have been previously published and can be compared 
to this structure. The first SapA nanodisc structure (PDB ID: 4DDJ; Fig. 1.4E) shows human SapA 
enclosing an ordered bilayer of the detergent lauryldimethylamine oxide (LDAO). Our group has also 
published a structure of mouse SapA in complex with the lipid processing enzyme GALC in the 
presence of LDAO (PDB ID: 5NXB; Fig. 1.4D). The open conformation of mouse SapA monomers within 
the novel tetrameric structure is almost identical to the open SapA conformations reported previously 
except for small loop movements (Fig. 5.11A). Human SapA within the nanodisc structure has a root 
mean square deviation (RMSD) from mouse SapA within the tetramer structure of 0.9 Å2 over 80 Cα 
atoms, with 79.7% sequence identity; GALC-associated mouse SapA has an RMSD of 1.0 Å2 over 80 Cα 
atoms, with 100% sequence identity. The dimer formed by chains A and B of the tetramer can be 
compared to the published SapA dimer structures (Fig. 5.11B). The orientation of SapA tetramer chains 
A and B relative to each other is similar to the head-to-head arrangement found in the GALC-
associated SapA dimer. Both structures are maintained by intermolecular hydrophobic contacts near 
the loop formed by residues 38-42; however, some of the residues participating in these contacts and 
the position of the SapA monomers relative to each other are different. In contrast, SapA nanodiscs 
are formed by a head-to-tail arrangement of SapA dimers without contact between monomers, the 
entire assembly being held together by the hydrophobic acyl core (Fig. 1.4E)81. 
 
Unlike SapA-LDAO nanodiscs and LDAO-solubilised, GALC-bound SapA, the electron density provides 
no evidence that this SapA tetramer structure includes detergents or lipids. However, the core of this 
structure is hollow and potentially solvent-accessible if it is not filled with amphipathic molecules (Fig. 
5.12, left panel). Considering the highly hydrophobic nature of the internal SapA surface (Fig. 5.12, 
right panel), exposure of this hollow core to solvent would be thermodynamically unfavourable. It is 
therefore likely that disordered PC and/or DDM molecules fill this internal cavity. Approximately 6 to 




Figure 5.11. Comparison of SapA structures 
A. The open conformation of mouse SapA monomers found in the novel tetrameric structure (in 
orange), human SapA-LDAO nanodiscs (in pink; PDB ID: 4DDJ) and GALC-associated, LDAO-solubilised 
dimeric mouse SapA (in blue; PDB ID: 5NXB) is almost identical, except for small movements 
indicated by (*). B. The dimer formed by chains A and B of the tetramer can be compared to the 
published dimeric SapA structures. In the tetramer, SapA monomers (orange) are arranged head-to-
head in a manner similar to GALC-associated SapA dimer (blue); however, their position and the 
protein-protein contacts involved are different. In contrast, nanodiscs are made with a head-to-tail 
arrangement of SapA monomers (pink) and do not involve any protein-protein contacts. N- and C-
termini are marked with circles. 
 
The diamond-shaped tetrameric SapA assembly observed by crystallography is unsuitable for 
structural studies with AC as it does not provide a large lipid bilayer surface for interaction with AC. 
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An important question is whether this assembly exists in solution or is an artefact of crystallisation. 
SEC-MALS showed that the average molecular mass of SapA-PC assemblies in solution is 37.1 ± 0.5 
kDa (Fig. 5.4; section 5.1.2). This is consistent with the theoretical mass of the SapA tetramer observed 
by X-ray crystallography (4 × 9.12 = 36.48 kDa). It is therefore possible that this tetrameric assembly 
was produced instead of the expected SapA nanodiscs. However, this molecular mass is also consistent 
with the mass of dimeric SapA nanodiscs with 23-29 PC molecules observed by Li et al.282. Therefore, 
it cannot be excluded that freshly prepared dimeric SapA nanodiscs underwent structural 
rearrangements in crystallisation conditions, forming the diamond-shaped tetrameric SapA assembly 
observed by crystallography. 
 
 
Figure 5.12. The core of the SapA tetramer is highly hydrophobic 
A. Surface representation of the SapA tetramer coloured based on residue hydrophobicity. The left 
panel is in the same orientation as shown in Fig. 5.10A, left panel, while the central panel is rotated 
by 90° to be in the same orientation as Fig. 5.10A, right panel. The right panel maintains the 
orientation of the central panel, with two SapA chains removed to reveal the highly hydrophobic 
core of the SapA tetramer.  
 
5.2 Can AC process glycosphingolipids? 
The work described throughout the rest of this chapter was performed prior to the publication of a 
study demonstrating in vitro activity of AC towards GalCer and involving AC in Krabbe disease 
pathogenesis284. Prior to this report, several lines of evidence indicated that AC can deacylate 
GluCer142-144, Gb3142, and potentially GalCer when these substrates are accumulated in cells deficient 
in the hydrolytic enzymes that process these glycosphingolipids to ceramide, suggesting that AC can 
deacylate these bulkier substrates; however, no in vitro activity of AC against glycosphingolipid 
substrates had yet been reported.  
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The recently published structure of AC shows a hydrophobic channel leading to the active site which 
the authors proposed to be compatible with binding of ceramide, but not the bulkier head groups of 
glycosphingolipids128. However, glycosphingolipid processing enzymes can show plasticity around 
their active site to accommodate their substrate. Indeed, structural studies by our group showed that 
the active site pocket of GALC undergoes conformational changes upon binding of a substrate 
analogue285. Such plasticity around the active site could only be observed in a crystal structure of AC 
with a glycosphingolipid substrate mimic. Therefore, I aimed to test whether AC can hydrolyse 
glycosphingolipid substrates in vitro and obtain a crystal structure capturing this process. 
 
5.2.1 AC C-terminal tag removal and autoproteolysis 
The published structure of AC showed that the C-terminus of AC is positioned near the active site and 
that the C-terminal residue (Trp395) forms part of the hydrophobic area around the active site 
essential to AC activity128. Consequently, the C-terminal H6 tag of the AC construct used in the work 
described so far (Fig. 5.1A) may obstruct the active site and hinder optimal AC function. Therefore, I 
removed the C-terminal H6 tag of AC by treatment with Carboxypeptidase A. H6-tagged AC was purified 
as documented in section 5.1.1 and incubated with carboxypeptidase A in 20 mM Tris pH 7.4, 300 mM 
NaCl for 4 or 15 hours. After 4 hours significant quantities of AC retained binding to Ni-NTA, indicating 
there was insufficient proteolysis (Fig. 5.13A), but after 15 hours, a large fraction of AC was no longer 
H6-tagged and no longer interacted with Ni-NTA beads (Fig. 5.13B). Flow-through and wash fractions 
containing untagged AC were pooled and used for subsequent experiments. To ensure complete 
autoproteolysis of AC into its active, mature form, AC was incubated in pH 4 buffer at 37 °C for 27 
hours. After this process, AC was almost fully cleaved (Fig. 5.13C). 
 
5.2.2 Activity assay of untagged AC  
I performed an AC activity assay using this untagged, mature AC sample. C12 ceramide (d18:1/12:0) 
was chosen as a substrate for this assay (Fig. 5.13D), as it has been shown to be the ceramide most 
efficiently hydrolysed by AC203. Although AC has a pH optimum of 4.5, it retains high activity at pH 4129 
therefore activity assays were performed at pH 4. 
 
Several AC activity assay protocols have been reported in the literature (reviewed by Bedia et al.286). I 
opted for a protocol using unmodified ceramide as a substrate (rather than fluorescently labelled or 
radiolabelled lipids) coupled with detection by thin layer chromatography (TLC) followed by lipid 
visualisation by charring with sulfuric acid287. Labelled lipids can be detected with more sensitivity,  
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Figure 5.13. Activity assay of AC after H6 tag removal 
A-B. The C-terminal His6 tag of AC was removed by incubation with carboxypeptidase A-agarose 
beads for 4 hours (A) or 15 hours (B). After this treatment, untagged AC was separated from His-
tagged AC and free histidine by nickel affinity chromatography with Ni-NTA beads. Flow-through (FT) 
and wash fractions containing untagged AC, and elution fractions containing His-tagged AC  were 
visualised on a Coomassie-stained 4-12% Bis-Tris gel. C. AC was incubated at pH 4 at 37 °C for 27 
hours to allow for autoproteolysis, forming mature AC. Cleavage efficiency was assessed by 
visualising the sample on a Coomassie-stained 12% SDS-PAGE gel. D. Reaction catalysed by AC in this 
activity assay. C12 Ceramide (d18:1/12:0) is hydrolysed to sphingosine (d18:1) and lauric acid (C12:0 
fatty acid). E. AC was incubated with detergent-solubilised ceramide. Lipid products were extracted 
and loaded onto the TLC plate. 10 μg of lipid standards were directly loaded onto the TLC plate for 
comparison. Sphingosine is expected to remain at the bottom of the plate with the solvent system 
used in this experiment. No formation of lauric acid or sphingosine was detected. Abbreviations: FA - 
fatty acid; Cer – ceramide. 
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facilitating enzyme kinetic studies; however, a qualitative output would be sufficient to answer 
whether AC degrades glycosphingolipids, so I chose a simpler and more economical detection method. 
I tested several TLC solvent systems for their ability to resolve ceramide. 80:10:1 (v/v/v) chloroform, 
methanol, water was found to be optimal287. 
 
Lipids must be solubilised for this activity assay, and a variety of detergents or detergent mixtures 
have been used previously (including Triton X-100 (TX-100), Tween 20, NP-40 and Sodium cholate286). 
Based on the literature, I tested several detergent mixtures for ceramide solubilisation. Visual 
inspection of the detergent-solubilised lipid solution showed that 1% TX-100 resulted in the clearest 
lipid solution, but it still remained somewhat cloudy even after sonication, indicating that ceramide 
was not fully solubilised. To promote lipid solubilisation prior to the activity assay, I followed the 
protocol I had used to solubilise lipids for SapA nanodiscs: lipids were vortexed and sonicated in 
activity assay buffer without detergent to promote liposome formation, then TX-100 was added to the 
solution, which was vortexed and sonicated further. Even with this protocol, ceramide did not fully 
solubilise. 
 
Untagged, mature AC (4.8 μM) was incubated with TX-100-solubilised ceramide (at a concentration of 
370 μM if ceramide was fully solubilised) at 37 °C for 4 hours. The reaction was stopped, and lipids 
were extracted and analysed by TLC as described above (Fig. 5.13E). Ceramide and the fatty acid 
reaction product lauric acid were used as standards. Although a broad detergent band overlaps with 
the ceramide and lauric acid positions and may disturb the separation of these species, I observed no 
formation of the hydrolysis products fatty acid and sphingosine, which is expected to remain at the 
bottom of the plate in this experiment. The lack of detectable AC activity may be the consequence of 
poor lipid solubilisation, making too little substrate available to AC, or blockage of the active site of 
the enzyme by additional residues at the C-terminal, even after H6 tag cleavage. Indeed, this 
recombinant enzyme contains a leucine and a lysine residue between the end of the native human AC 
sequence and the H6 tag.  
 
5.2.3 N-terminally tagged AC expression, purification and tag removal 
To overcome the potential problem of AC active site hindrance by a C-terminal tag, I used a different 
AC construct for subsequent structural studies and activity assays (Fig. 5.14A). N-terminally tagged AC 
is active and crystallisable128, so I used a construct with a cleavable N-terminal Protein A (ProtA) tag. 
The tag is separated from AC by a Tobacco Etch Virus (TEV) protease site, allowing removal of the tag 
by digestion with TEV protease. The residues immediately following the signal sequence on the N-
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terminus of AC (residues 22-26) were disordered in our group's preliminary low-resolution structure 
of AC (obtained by Dr Sam Spratley, Dr Janet Deane and Dr Stephen Graham), as well as the published 
structure128. These residues were not included in this AC construct (ProtA-AC27) intended for 




Figure 5.14. ProtA-AC27 tag removal optimisation 
A. Recombinant AC was expressed in HEK293F cells. The construct encoded AC (residues 27-395) 
preceded by a cleaved secretion signal peptide, Protein A and a TEV cleavage sequence. B. ProtA-
AC27 was captured from the media by IgG affinity purification. This was followed by on-bead TEV 
protease digest to cleave the tag. Small-scale test were performed to identify optimal conditions for 
TEV cleavage. Samples from each condition were analysed on a Coomassie-stained 12% SDS-PAGE 
gel. The indicated condition was chosen for subsequent experiments based on the high amount of 
untagged AC27 eluting after TEV cleavage in this condition.  
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A stable cell line expressing ProtA-AC27 was established by Dr Janet Deane using the PiggyBac 
expression system. I purified ProtA-AC27 from the media by IgG affinity purification. After protein 
capture from the media, ProtA-AC27 was subjected to on-beads digestion with TEV protease. I 
optimised the TEV cleavage step by changing the digestion time, temperature and pH of the reaction 
buffer. The best yield was obtained by overnight cleavage at 34 °C (Fig. 5.14B). 
 
I performed a large-scale preparation of this construct using this cleavage protocol (Fig. 5.15A). After 
tag removal, AC27 was eluted from the beads by gravity flow. TEV protease is tagged with a H6 tag, 
allowing its separation from AC27 by nickel affinity chromatography. After TEV removal, AC27 was 
further purified by size exclusion chromatography (Fig. 5.15B-C). The final yield of untagged AC27 was 
3 mg from 500 mL conditioned media. AC was then allowed to self-cleave at pH 4 for a further 27 
hours at 37 °C (Fig. 5.15D) prior to crytallisation trials (section 5.2.4) and activity assays (section 5.2.5). 
 
5.2.4 Crystallisation trials of AC27 with psychosine 
I hypothesised that AC may be able to accommodate the head group of GalCer in its active site pocket 
and deacylate this substrate to psychosine. I hoped to obtain a crystal structure of AC showing the 
conformational changes permitting this potential reaction. For these crystallisation trials, AC was 
mixed with the proposed reaction product psychosine because psychosine is soluble in aqueous 
buffer, whereas GalCer is not. Although enzymes have a stronger affinity for their substrate than their 
product, they do have some affinity for the product and can bind it at high enough product 
concentrations.  
 
For crystallisation trials, AC27 was concentrated to its solubility limit in pH 4 buffer (4.1 mg/mL) and a 
psychosine stock was made in the same buffer with a concentration close to its solubility limit (2 mM). 
Equal volumes of the protein and psychosine solutions were mixed for a 20-fold molar excess of 
psychosine. This mixture was incubated for an hour to allow binding of psychosine to AC, then the 
mixture was concentrated until AC27 was at a concentration of 4.1 mg/mL based on protein 
absorbance at 280 nm. This mixture was then used in high-throughput crystallisation screens. 
Although approximately 400 crystallisation conditions were tested, no diffraction-quality crystals grew 




Figure 5.15. Large scale AC27 preparation 
A. ProtA-AC27 was captured from the media by IgG affinity purification.  The tag was then removed 
by on-bead TEV digestion. Samples from each step were analysed on a Coomassie-stained 12% SDS-
PAGE gel. B. AC27 was further purified by size exclusion chromatography on a Superdex 200 16/600 
column. C. SEC elution fractions were analysed on a Coomassie-stained 12% SDS-PAGE gel. The 
indicated fractions were pooled and concentrated. D. AC27 was incubated at pH 4 at 37 °C for 27 
hours to allow for autoproteolysis, forming mature AC. Cleavage efficiency was assessed by 
visualising the sample on a Coomassie-stained 12% SDS-PAGE gel.  
 
 168
5.2.5 Activity assay of AC27 
I repeated the AC activity assay with untagged AC27 after N-terminal ProtA tag removal with 
improvements to the lipid solubilisation protocol. Ceramide was resuspended in activity assay buffer 
with 1% TX-100. I heated the lipid solution at 85 °C for 30 seconds, followed by sonication for 30 
seconds and vortexing for 10 seconds. This cycle was repeated 4 times. This resulted in clear lipid 
solution with very little particulate matter visible, indicating that the lipids were almost fully 
solubilised. After incubation of AC27 (3 µM) with ceramide (250 µM) at 37 °C for 4 hours, the lipids 
were extracted and analysed by TLC (Fig. 5.16). However, once again, no fatty acid and sphingosine 
reaction products were detected. 
 
 
Figure 5.16. Activity assay of AC27 
AC27 was incubated with detergent-solubilised ceramide. Lipid products were extracted and loaded 
onto the TLC plate. 10 μg of lipid standards were directly loaded onto the TLC plate for comparison. 
Sphingosine is expected to remain at the bottom of the plate with the solvent system used in this 
experiment, similarly to phytosphingosine (PhytoSph). No formation of lauric acid or sphingosine 
was detected in this assay. Abbreviations: FA - fatty acid; Cer – ceramide. 
 
The difficulty in establishing a viable AC activity assay to test the hypothesis that AC deacylates 
glycosphingolipids combined with the absence of structural insights into the potential mechanism of 
glycosphingolipid deacylation led me to focus on a different, cell-based way to investigate whether AC 
contributes to Krabbe disease by processing GalCer to psychosine.  
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5.3 Role of AC in Krabbe disease 
The pathogenesis of Krabbe disease is thought to be caused by accumulation of the cytotoxic 
sphingolipid psychosine in oligodendrocytes, causing their apoptosis and subsequent demyelination 
of neurons108,109. I hypothesised that in Krabbe disease, AC deacylates accumulated GalCer to 
psychosine, contributing to oligodendrocyte cell death. I aimed to test this hypothesis by looking at 
the effect of AC inhibition on apoptosis levels of GALC knock-out (KO) oligodendrocytes. Our lab has 
generated a GALC KO MO3.13 oligodendrocyte cell line by CRISPR/Cas9. Loss of GALC in this cell line 
was validated by sequencing and activity assays (Dr Stuart Fawke and Dr Janet Deane). 
 
First, I sought to establish robust apoptosis assays in this cell line. Apoptosis of GALC knock-down 
MO3.13 oligodendrocytes288 or MO3.13 oligodendrocytes fed with exogenous psychosine214 has been 
observed by caspase-3 (Casp-3) activation assays, Terminal Deoxynucleotidyl Transferase dUTP Nick 
End Labelling (TUNEL) and DNA laddering assays 3 days after differentiation of these cells. I attempted 
to replicate these assays to assess the extent of oligodendrocyte apoptosis after differentiation of 
GALC KO MO3.13 oligodendrocytes with phorbol 12-myristate 13-acetate (PMA). I assayed Casp-3 
activation, an early marker of apoptosis, by Western blotting with an antibody specifically recognising 
cleaved (active) Casp-3. No Casp-3 activation was detected in wild-type (WT) or GALC KO 
oligodendrocytes, 3 or 7 days after differentiation (Fig. 5.17). As a positive control, differentiated WT 
oligodendrocytes were treated with the non-selective kinase inhibitor staurosporine at 2 µM for 24 h, 
which has previously been shown to induce some Casp-3 activation in this cell line289, but I did not 
detect any Casp-3 activation in this positive control, suggesting that antibody staining not be optimal.  
 
TUNEL is an alternative method for the quantification of apoptotic cells. During apoptosis, genomic 
DNA is cleaved into 200 base pair (bp) fragments that can be labelled by TUNEL. I detected late 
apoptotic cells by TUNEL followed by flow cytometry in WT and GALC knockout oligodendrocytes 7 
days after differentiation (Fig. 5.18). WT oligodendrocytes were treated with staurosporine as a 
positive control. Detached cells were included in the experiment because apoptosis often causes cell 
detachment. WT oligodendrocytes did not undergo significant apoptosis during this assay (1.05%). 
Following treatment with staurosporine, 13% of WT cells were apoptotic, indicating that the assay 
could detect apoptosis. However, levels of apoptosis similar to WT control were observed in GALC KO 
cells. DNA fragments can also be extracted from apoptotic cells and visualised by agarose 
electrophoresis. The DNA of apoptotic cells forms a ladder, whereas the DNA of necrotic cells presents 
as a smear due to non-specific cleavage. I followed a protocol previously used to detect apoptosis in 
differentiated MO3.13 oligodendrocytes after GALC knock-down214. I extracted DNA from WT and 
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GALC KO oligodendrocytes before differentiation and 1, 2, 3, 6 and 7 days after differentiation. No 
DNA laddering was detected in WT (data not shown) or GALC KO oligodendrocytes (Fig. 5.19), before 
or after differentiation. However, no DNA laddering was observed in the staurosporine-treated 
positive control, indicating that this assay is not sensitive enough to detect low levels of apoptosis or 
that staurosporine-treated MO3.13 cells undergo necroptosis rather than apoptosis, as suggested by 
the presence of a faint smear in this sample.  
 
 
Figure 5.17. Casp-3 activation was not detected in WT or GALC KO oligodendrocytes 
Casp-3 activation was assayed by Western blotting in WT and GALC KO oligodendrocytes, 3 and 7 
days after differentiation. WT oligodendrocytes were treated with the kinase inhibitor staurosporine 




Figure 5.18. No apopotosis was detected in GALC KO oligodendrocytes by TUNEL assay 
DNA fragmentation was assayed in WT and GALC KO oligodendrocytes 7 days after differentiation. 
WT oligodendrocytes were treated with the kinase inhibitor staurosporine as a positive control. Cells 
were labelled by TUNEL and stained with AlexaFluor488 for analysis by flow cytometry. A. 
Representative gating strategy (WT cells): singlets were gated through the forward scatter height 
(FSC-H) vs forward scatter area (FSC-A) plot, then cells were defined on side (SSC-H) vs forward 
scatter height (FSC-H) plots to exclude small debris. B. Apoptotic cells are detected by fluorescence 
at 488 nm. Only cells with very high fluorescence intensity were gated, because MO3.13 
oligodendrocytes used in this assay are highly autofluorescent at 488 nm, as shown in C. The 
percentage of apoptotic cells is indicated. C.Unstained WT oligodendrocytes (gated as in A.) are 
autofluorescent at 488 nm. The voltage of the fluorescence detector was set higher than in B. 
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Interestingly, these results suggest that despite loss of GALC activity and accumulation of lipid 
substrates in GALC KO oligodendrocytes (verified by Dr Janet Deane and collaborators), there is no 
evidence of significant cell death contrary to expectations based on previously published work. 
Consequently, inhibiting psychosine production through AC inhibition in GALC KO cells would not 
result in detectable changes in cell death levels. 
 
 
Figure 5.19. No DNA fragmentation was detected in GALC KO oligodendrocytes 
DNA fragmentation was assayed by gel electrophoresis of DNA extracted from undifferentiated and 
differentiated GALC KO oligodendrocytes, 1 to 7 days after differentiation. WT oligodendrocytes 
were treated with the kinase inhibitor staurosporine as a positive control. 
 
5.4 Discussion 
How AC interacts with lipid bilayers to access its membrane-embedded substrate is a key unresolved 
question in our understanding of the mechanism of AC function. I probed the interaction of AC with 
membranes using a recently developed technique exploiting the lipid-binding properties of SapA to 
form lipoprotein nanodiscs93,94. Unfortunately, AC did not co-crystallise or interact with nanodisc-
enclosed lipid bilayers. Several factors may have hindered this interaction. The recombinant AC 
protein used in these experiments included a C-terminal H6 tag. When the coordinates of the first 
published AC structure became available, these showed that the C-terminus of AC is close to the active 
site and part of the hydrophobic area essential for AC activity128. It is therefore possible that the 
addition of histidine residues, charged and hydrophilic at pH 4, would disrupt the hydrophobic 
association of AC with membranes. An N-terminally tagged AC construct would be more suited to 
study the interaction of AC with membranes. Moreover, although I produced SapA nanodiscs in a 
manner similar to published protocols, I obtained an unexpected tetrameric SapA assembly very 
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different from the dimeric SapA-lipid nanodisc I was aiming to produce. This assembly does not 
present a membrane surface available for interactions with AC.  
 
The production of a tetrameric SapA assembly instead of SapA nanodiscs could be explained by two 
differences between my protocol and the original protocols for nanodisc formation. (1) Previous 
protocols use human SapA for nanodisc formation, whereas mouse SapA was used in this study. 
However, these orthologs are highly similar, and the residues involved in the interactions maintaining 
this tetrameric assembly are identical or similar in their hydrophobic properties between human and 
mouse SapA. It is therefore unlikely that this deviation accounts for the difference in the final product. 
(2) I prepared SapA nanodiscs at pH 4, which promotes the interaction between AC and membranes, 
whereas SapA nanodiscs were formed at pH 4.8 to 7.5 in previous publications93,94,282. Li et al.282 
observed that the oligomeric state of SapA within nanodiscs is dependent on the final pH of the 
nanodisc solution, rather than the pH at which these were formed. This supports the idea that SapA 
assemblies are highly dynamic, adopting distinct oligomeric states depending on the buffer condition. 
In fact, I could not conclusively show that freshly prepared nanodiscs in solution adopted the 
tetrameric conformation observed by crystallography rather than the expected dimeric nanodisc 
conformation, since the predicted molecular mass of both assemblies is similar making them 
indistinguishable by SEC-MALS. It is therefore possible that freshly prepared nanodiscs initially 
adopted a dimeric SapA nanodisc conformation, then underwent a structural rearrangement in 
various crystallisation conditions to form the tetrameric SapA assembly observed by X-ray 
crystallography. Alternatively, the initial mixture may have contained both dimeric SapA nanodiscs 
and SapA tetramers, but only the latter self-assembled into crystals. The ability of SapA to form 
variable oligomeric assemblies may have relevance for its function as a lipid transfer protein in the 
lysosome. 
 
Besides SapA nanodiscs, other lipoprotein and polymer systems have been developed for the study of 
membrane proteins, such as apolipoprotein A-based nanodiscs290 and styrene maleic acid lipid 
particles (SMALPs)291, but these methods are not adapted to the low pH stimulating the interaction of 
AC with membranes. However, recently developed technologies such as acid-compatible SMALPs292 
can function at low pH and may hold promise for the elucidation of the mechanism of AC function.  
 
The metabolic pathway involved in the formation of psychosine in Krabbe disease oligodendrocytes 
has long remained a mystery. Based on recent reports showing that AC can deacylate the 
glycosphingolipids glucosylceramide (GluCer) and Gb3142-144, I hypothesised that AC can also deacylate 
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accumulated GalCer. To demonstrate this, I attempted to implement an AC activity assay using a 
simpler, less expensive but less sensitive lipid detection method than previously described AC activity 
assays286. Unfortunately, this method was unsuccessful, and a more sensitive detection method may 
have been necessary to detect the lipid products, for example through the use of fluorescently labelled 
substrate. It is possible that the enzyme I used in these assays is not functional: the first recombinant 
AC protein used in these assays is likely to possess at least one additional hydrophilic residue at the C-
terminal even after tag removal, potentially disrupting the essential hydrophobic surface near the 
active site of AC128. The second recombinant AC protein tested was intended for structural studies and 
did not include the first five residues of AC. Both of these changes could have disrupted AC activity. A 
recently published study did in fact show activity of AC against fluorescently labelled, detergent 
solubilised GalCer in vitro284. In support of the role of AC in the production of psychosine and its 
importance for the pathogenesis of Krabbe disease, AC was shown to be necessary for psychosine 
accumulation in Twitcher mice, a mouse model of Krabbe disease, and genetic ablation of AC 
eliminated Krabbe disease symptoms in this model284. Inhibition of AC activity is therefore a promising 
therapeutic target for Krabbe disease. The AC inhibitor carmofur, approved for clinical use as a 
chemotherapeutic agent, alleviates disease in Twitcher mice if one allele of the gene encoding AC 
(ASAH1) is knocked-out. However, carmofur is not sufficient to alleviate symptoms in Twitcher mice 
with normal AC expression, and carmofur is associated with significant drug toxicity140. Therefore, an 
improved AC inhibitor targeting the hydrolysis of GalCer but not ceramide could specifically reduce 
psychosine formation, alleviate Krabbe disease symptoms and present a lower toxicity profile. 
Published AC structures and the proposed catalytic mechanism of AC128,141 cannot explain its activity 
on glycosphingolipid substrates with a bulky head group because of clashes between the proposed 
catalytic residues and the head groups of glycosphingolipids modelled into the active site by molecular 
docking128. It is therefore likely that plasticity of the active site allows AC to accommodate lipids with 
bulky head groups and/or that AC employs an alternative catalytic mechanism for the hydrolysis of 
glycosphingolipids. A structure of glycosphingolipid-bound AC would be valuable for structure-based 
design of inhibitors specifically targeting deacylation of glycosphingolipids.  
 
Such a therapeutic approach may be beneficial for other diseases because AC has been involved in 
deacylation of several glycosphingolipid substrates. AC promotes formation of lyso-Gb3 in Fabry 
disease142, a sphingolipidosis caused by loss of α-galactosidase A associated with neuropathy and 
organ failure. Lyso-Gb3 has been identified a risk factor for complications of Fabry disease293 and 
shown to sensitise nociceptive neurons, possibly causing or contributing to Fabry-disease associated 
neuropathy294. Moreover, AC promotes formation of glucosylsphingosine in the sphingolipidosis 
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Gaucher disease caused by loss of glucocerebrosidase (GCase)142-144. Mutations in the gene encoding 
GCase are the highest risk factor for Parkinson’s disease295 and glucosylsphingosine is thought to 
promote α-synuclein aggregation296, a hallmark of Parkinson's disease. AC inhibition has been shown 
to reduce the accumulation of α-synuclein in neurons derived from a patient with Gaucher disease143. 
Considering the ability of AC to process glycosphingolipids with distinct head groups, such as GalCer, 
GluCer and Gb3 (Fig. 1.9), AC may also contribute to the formation of other lysosphingolipid species, 
such as lyso-sulfatide and lyso-sphingomyelin. It is currently unknown whether AC processes 
glycosphingolipid substrates only when these are accumulated to abnormal levels, or if this is a process 
occurring at low levels under normal conditions, facilitating the formation of small quantities of 
bioactive lyso-glycosphingolipids playing a role in normal cell function. 
 
The accumulation of psychosine in GALC-deficient oligodendrocytes is thought to cause 
oligodendrocyte cell death, driving the demyelination and neurodegeneration observed in Krabbe 
disease108,109. This hypothesis is strongly supported by studies showing that GALC knock-down or 
feeding of extracellular psychosine directly causes apoptosis in differentiated MO3.13 
oligodendrocytes214,288. In contradiction with these results, I did not detect any apoptosis of 
differentiated GALC KO MO3.13 oligodendrocytes with the apoptosis assays used in previous studies. 
Exogenous psychosine feeding experiments may not reflect GALC loss-of-function phenotypes, 
because psychosine concentration and cellular localisation may differ. However, the phenotype of 
GALC KO cells should be similar to or more severe than GALC knock-down cells. It is conceivable that 
lentiviral knock-down of GALC in the reference study288 resulted in off-target effects increasing 
susceptibility to cell death. It has certainly been our experience that the generation of cell lines by 
lentiviral transduction frequently results in severe off-target effects, as illustrated in Chapter 4. 
Alternatively, knocking out GALC by transient transfection of Cas9 and gRNA may have introduced off-
target Cas9 effects reducing susceptibility to cell death in our cell line. However, a second GALC KO 
MO3.13 oligodendrocyte cell line generated using a distinct gRNA against GALC also did not show 
noticeably elevated cell death levels, based on regular trypan blue staining of this cell line. It remains 
unclear why our observations differ from published results. 
 
The absence of spontaneous cell death in GALC KO oligodendrocytes lead us to ask how loss of GALC 
results in oligodendrocyte cell death and demyelination. This has been a key area of focus in our lab 
and some of this work will be described in Chapter 6.  
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6 Understanding the interaction of PTPRM with lipids 
 
Previous work and summary 
 
The causes of demyelination and oligodendrocyte cell death in Krabbe disease are still unelucidated. 
It has been hypothesised that psychosine accumulation due to loss of GALC activity is cytotoxic and 
directly causes oligodendrocyte cell death. However, as shown in Chapter 5, genetic ablation of GALC 
in the MO3.13 oligodendrocyte cell line does not trigger cell death. The myelin sheath is formed by 
wrapping of oligodendrocyte membranes around nerve axons, a process dependent on adhesion 
molecules and other plasma membrane proteins. Aberrant accumulation of galactosphingolipids in 
GALC-deficient oligodendrocytes may disrupt this process by changing the expression, stability or 
trafficking of plasma membrane proteins, leading to defective myelination and subsequent 
oligodendrocytes cell death. Our group has investigated the consequences of galactosphingolipid 
accumulation on the plasma membrane proteome of GALC KO oligodendrocytes following the 
approach described in Chapter 4. Plasma membrane profiling was combined with whole cell 
proteomics and RNA sequencing to identify proteins down-regulated at the plasma membrane of 
GALC KO oligodendrocytes. This approach revealed that the adhesion protein Protein Tyrosine 
Phosphatase Receptor Type μ (PTPRM) is specifically down-regulated at the plasma membrane of 
GALC KO oligodendrocytes while its total cellular levels and RNA levels are unchanged. This suggests 
that aberrant galactosphingolipid accumulation hinders normal trafficking of PTPRM to the plasma 
membrane. We hypothesised that PTPRM specifically interacts with galactosphingolipid headgroups, 
leading to its intracellular retention in GALC-deficient oligodendrocytes. In support of this hypothesis, 
recent work in the Deane lab has shown that purified PTPRM Fn3-4 (the membrane proximal 
fibronectin III domains 3 and 4 of the extracellular domain) interacts with nitrocellulose-immobilised 
sulfatide on a sphingolipid array (Fig. 6.1A). Sulfatide is a galactosphingolipid formed by sulfatation of 
galactosylceramide and is a major myelin component103. Accumulation of sulfatide occurs in 
metachromatic leukoystrophy, a sphingolipidosis with very similar clinical features to Krabbe 
disease297. As sulfatide lies upstream of GalCer in the degradative pathway (Fig. 1.3) it may also 
accumulate in GALC KO oligodendrocytes. Potential interactions with lipid headgroups are likely to be 
mediated by the membrane-proximal fibronectin III domain 4 (Fn4) of PTPRM. A structure of the 
extracellular domain of PTPRM is available298 but the Fn4 domain was not observed in this structure 
(Fig. 6.1B). Our group has recently obtained a first structure of the membrane-proximal Fn4 domain 
(Fig. 6.1C). This structure revealed an atypical fibronectin III fold with large membrane-oriented loops 
possibly involved in interactions with lipid headgroups. To probe the details of this potential 
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interaction, I aimed to obtain a crystal structure of the membrane-proximal domains of PTPRM 
interacting with a galactosphingolipid analogue. Although I was not successful in obtaining a structure 
of ligand-bound PTPRM, I solved and refined a second structure of the Fn3-4 domains of PTPRM which 
provided intriguing preliminary insights into its function and regulation. Additionally, I tested a 
microscopy-based approach to monitor PTPRM trafficking in GALC KO oligodendrocytes. 
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informing the discussion of this chapter. Iain Hay has provided valuable knowledge about R2B family 
phosphatases. Finally, Dr David Gershlick (Cambridge Institute for Medical Research) provided the 
reagents and protocols for RUSH experiments.  
 
6.1 Purification of PTPRM Fn3-4 
PTPRM forms trans homophilic interactions between opposite membranes at adherens junctions. The 
rigid, ruler-like ectodomain of PTPRM allows it to act as a sensor of intercellular distances and stabilise 
the distance between membranes298. This locks the intracellular phosphatase activity at adherens 
junctions, where PTPRM can dephosphorylate substrates such as cadherins and catenins299. PTPRM 
possesses one MAM (meprin/A5/μ), one immunoglobulin-like and four fibronectin III domains 
combined with an uncharacterized intracellular juxtamembrane domain, an active phosphatase 
domain (D1) and an inactive phosphatase domain (D2) (Fig. 6.2A). The membrane-proximal Fn4 
domain hypothesised to interact with lipid headgroups is unstable when expressed on its own (Radu 
Aricescu, MRC Laboratory of Molecular Biology, personal communication). We therefore expressed 
the Fn3 and Fn4 domains of PTPRM (residues 478-723) with an N-terminal secretion sequence and a 
C-terminal His6 tag (Fig. 6.2B) by transient transfection in HEK293F cells. The cloning and first 
preparations of this construct were performed by Eve Caroe. Following the same purification protocol, 
I purified PTPRM Fn3-4 from expression media by nickel affinity purification (Fig. 6.2C) followed by 
size exclusion chromatography (Fig. 6.2D-E). This construct appears as a 35-45 kDa smear of higher  
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Figure 6.1. The membrane-proximal domain of PTPRM may interact with lipids 
Figure courtesy of Dr Janet Deane, reused with permission. A. Purified PTPRM Fn3-4 was used to 
probe a sphingolipid array (work performed by Eve Caroe). PTPRM interacts with sulfatide in this 
assay. B. Schematic representation of the structure of PTPRM. The published structure of the 
extracellular domain of PTPRM without the membrane-proximal domain is shown as a purple and 
blue ribbon (PDB ID: 2V5Y). The structure of one of the two intracellular tyrosine phosphatase (Tyr 
Phos) domains is shown as an orange ribbon (PDB ID: 1RPM). C. The crystal structure of the 
membrane-proximal fibronectin III 3 and 4 domains obtained by our group is shown as a ribbon, 
rainbow-coloured from the N-terminus (blue) to the C-terminus (red). A 22 amino-acid linker from C-
terminus of this construct to the transmembrane region of PTPRM, not included in this construct, is 
represented as a red dashed line. A second protein chain present in the crystal is shown in grey. 
Glycans are shown in stick representation (oxygen, red; nitrogen, blue). A membrane-embedded 
galactosylceramide molecule modelled in an interaction with PTPRM Fn3-4 is shown in stick 
representation.  
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molecular weight than predicted based on its sequence (29 kDa) on SDS-PAGE gels due to the 
presence of at least two potentially heterogeneous N-linked glycans.  
 
During endogenous expression of PTPRM, a fraction of PTPRM molecules is normally cleaved by the 
proprotein convertases furin and PC5300. This processing event occurs within the Fn4 domain and both 
proteolytic fragments remain associated after cleavage301. Furin and PC5 are isozymes cleaving at the 
furin cleavage site Arg-X-[Arg/Lys/X]-Arg-↓-X, where X can be any amino-acid302. In PTPRM, this motif 
corresponds to the sequence Arg-Pro-Arg-Arg-Thr, with the cleavage occurring between Arg632 and 
Thr633. Although there are potential N-glycosylation sites on the C-terminal cleavage fragment298, the 
preliminary structure of PTPRM Fn3-4 obtained in our lab suggests the absence of N-linked glycans on 
this fragment, which is therefore expected to have a molecular weight of 11 kDa calculated from its 
protein sequence. A faint band likely corresponding to the C-terminal fragment is indeed visible 
around 11 kDa (Fig. 6.2E). Based on the apparent molecular weight of uncleaved PTPRM (37 kDa), the 
glycosylated N-terminal fragment is expected to have a molecular weight of approximately 26 kDa and 
a faint band of this size is also apparent. An additional faint band is visible at 18 kDa, possibly 
corresponding to a glycosylated fraction of the C-terminal fragment (Fig. 6.2E). Altogether, this 
suggests that a very small fraction of PTPRM expressed in HEK293F cells is proteolytically processed 
by furin/PC5. This small proportion is expected since the Fn3-4 construct is expressed at much higher 
levels than endogenous levels and directly secreted by the cell instead of remaining embedded within 
the plasma membrane.  
 
A significant amount of protein was lost when PTPRM-bound Ni-NTA beads were washed prior to 
protein elution (Fig. 6.2C, "Wash" lane), possibly because the His6 tag is partially buried, reducing the 
affinity of the construct for Ni-NTA. The wash buffer contains 20 mM imidazole to outcompete binding 
of contaminant proteins weakly interacting with the resin through histidine residues. Unfortunately, 
the wash buffer appears to also outcompete binding of PTPRM to the beads, resulting in loss of some 
protein during washes. However, reducing the imidazole concentration significantly reduced the 
purity of the final product, so I chose to maintain a concentration of 20 mM imidazole in the wash 
buffer despite the reduced yield. Despite these losses, I obtained an excellent yield of 1 mg of highly 





Figure 6.2. Human PTPRM Fn3-4 expression and purification 
A. The ectodomain of PTPRM includes a MAM and Ig-like domain, followed by four fibronectin III 
(Fn) domains and a transmembrane (TM) region. The intracellular region of PTPRM includes a 
juxtamembrane domain, an active phosphatase D1 domain and an inactive D2 domain. B. The Fn3-4 
domains (residues 480-723) of PTPRM were expressed with a C-terminal hexahistidine (H6) tag in 
HEK293F cells. An N-terminal signal peptide targets this construct for secretion into the media and is 
cleaved off during expression. C. PTPRM Fn3-4 was captured from the media with Ni-NTA agarose 
and eluted with 300 mM imidazole in TBS. Fractions were analysed on a Coomassie-stained 12% 
SDS-PAGE gel. D. Eluted fractions were pooled, concentrated, and PTPRM Fn3-4 was further purified 
by size exclusion chromatography (SEC) using a Superdex 75 16/600 column. E. SEC elution fractions 
were analysed on a Coomassie-stained 4-12% Bis-tris SDS-PAGE gel. The indicated fractions were 
pooled, concentrated, and used in downstream experiments. Potential fragments formed by 
proprotease convertase cleavage (discussed in the text) are indicated. 
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6.2 X-ray crystallography  
I aimed to obtain a crystal structure of PTPRM with a galactosylceramide or sulfatide headgroup 
analogue. Sulfatide is formed by addition of a sulfate group to the 3-position of the galactose moiety 
of galactosylceramide (Fig. 6.3A-B). Unfortunately, synthetic 3-O-sulfated galactose (Gal-3S) is 
prohibitively expensive for use in structural studies. Therefore, I used galactose and the Gal-3S 
structural isomer 4-O-sulfated galactose (Gal-4S; Fig. 6.3C) as galactosylceramide and sulfatide 
analogues. Crystal structures of ligand-bound protein can be obtained in two ways. (1) If diffraction-
quality protein crystals have been grown and are reproducible, these can be soaked with ligand prior 
to crystal freezing and data collection. This simple method allows to screen for binding of several 
ligands but depends on the accessibility of the ligand-binding site through solvent channels within the 
crystal. (2) Co-crystallisation screens can be set up with protein and ligand mixed prior to plating. This 
approach is less efficient because new crystals are of unknown quality and may require optimisation, 
however it allows the formation of different crystal forms which may not be obtainable using the first 
method, especially if the ligand binding site is inaccessible or ligand binding causes large 




Figure 6.3. PTPRM may interact with galactosphingolipids including sulfatide 
A. Skeletal formula of galactosylceramide. B. Skeletal formula of sulfatide. Sulfatide is formed by 3-
O-sulfation of galactosylceramide. C. 4-O-sulfated galactose is a structural isomer of the sulfatide 
head group. 
 
6.2.1 Optimisation of the previously obtained crystal 
A crystal of PTPRM Fn3-4 diffracting to 2.89 Å was previously grown by Eve Caroe against a reservoir 
condition containing 20% (w/v) PEG 3350, 0.2 M ammonium nitrate (Fig. 6.4A). However, Eve Caroe's 
attempts to reproduce and optimise these crystals in optimisation screens, as well as in the original 
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crystallisation condition, were unsuccessful. Instead, these optimisation trials yielded drops with a 
multitude of microcrystals (Fig. 6.4B). This suggests that the latter crystallisation condition permitted 
too many crystal nucleation events, yielding many small crystals, whereas crystal nucleation in the 
original crystallisation condition was a fortuitous event possibly dependent on an unpredictable factor 
such as the presence of a contaminant in the crystallisation condition.  
 
 
Figure 6.4. Attempts to reproduce crystals 
A. Original crystal diffracting to 2.89 Å grown by Eve Caroe against a reservoir condition containing 
20% PEG 3350, 0.2 M ammonium nitrate. B. Microcrystals grown by Eve Caroe while attempting to 
reproduce the crystal shown in B. These microcrystals were used in a subsequent microseeding 
experiment. C. The crystal form shown in A was reproduced against a reservoir condition containing 
16% PEG 3350, 0.23 M ammonium nitrate. Scale bar: 100 μm. 
 
Crystallisation depends on the formation of a nucleus followed by ordered growth of a crystal lattice 
around the nucleus. Crucially, the optimal conditions for both events may be different. De-coupling 
nucleation from crystal growth can help overcome crystallisation issues. This can be done by using 
previously obtained crystals as seeds in a new screen of crystallisation conditions179. I produced a seed 
stock by crushing the microcrystals obtained by Eve Caroe (Fig. 6.4B) with a Teflon bead and set up a 
high-throughput crystallisation screen with various dilutions of this seed stock added to several 
dilutions of the original crystallisation condition. Unfortunately, no crystals grew in this experiment.  
 
In parallel, I attempted to reproduce and optimise the original crystal by screening around the 
precipitant and ammonium nitrate concentration of the original crystallisation condition. I succeeded 
in growing large crystals (Fig. 6.4C) which were used in subsequent soaking experiments (section 
6.2.3). 
 
6.2.2 Co-crystallisation screens of PTPRM Fn3-4 with galactose 
As an alternative approach to obtain a structure of galactose-bound PTPRM, I set up co-crystallisation 
screens of PTPRM Fn3-4 with galactose. PTPRM Fn3-4 was incubated with a 5-fold molar excess of 
galactose (2 mM) and the mixture was used in high-throughput crystallisation screens. Encouragingly, 
crystals and microcrystals were grown in several conditions where crystal growth was not observed in 
previous crystallisation experiments without galactose (Fig. 6.5A and B), suggesting that galactose 
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might be contained within the crystal and contributing to crystal contacts. Intriguingly, some of these 
conditions also contained sulfate, which may mimic sulfatide. I optimised these microcrystals and 
obtained crystals of sufficient size to harvest for data collection (Fig. 6.5C and D). 
 
 
Figure 6.5. Crystals grown in the presence of galactose 
A-B. Crystals obtained in high-throughput crystallisation screens of PTPRM Fn3-4 with a 5-fold molar 
excess of galactose. C-D. Crystals grown after optimisation of the conditions shown in A-B. The 
reservoir condition is detailed below each picture. Scale bar: 100 μm. 
 
6.2.3 Crystal soaks 
Several of the crystallisation condition described in sections 6.2.1 and 6.2.2 contained multiple crystals 
of similar appearance. Some crystals were harvested in their native state, whereas others were soaked 
in 10 mM galactose or Gal-4S for 10 to 30 min prior to harvesting. Soaked crystals belonging to the 
crystal form first obtained by Eve Caroe did not diffract sufficiently well for a dataset to be collected. 
I was able to collect a full dataset of diffraction images from a native crystal, but it was of lower 
resolution (3.4 Å) than the original dataset, and since these crystals did not differ from the original, 
this dataset was not of any use.  
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Data were collected to 2.83 Å from a galactose-soaked crystal grown in co-crystallisation experiments 
of PTPRM Fn3-4 with galactose (Table 6.1). This crystal was grown against a reservoir containing 0.1 
M MES/imidazole pH 6, 8% (w/v) PEG 20 000, 15% (v/v) PEG MME 550, 17 mM sodium nitrate, 17 mM 
disodium hydrogen phosphate and 17 mM ammonium sulfate and soaked with 10 mM galactose for 
10 min prior to harvesting (Fig. 6.5C). Processing of these data identified that this was a new crystal 
form. The presence of galactose and sulfate in the crystallisation condition combined with a galactose 
soak provided our best chance for observing an interaction with galactose or sulfate.  
 
Table 6.1. Data collection statistics for PTPRM Fn3-4. Values in parentheses are for the highest-
resolution shell. 
Beamline i03 
Wavelength (Å) 0.976254 
Processing package xia2 dials 
Space group P 32 2 1 
Cell dimensions  
a,b,c (Å) 87.5, 87.5, 311.2 
α,β,γ (°) 90, 90, 120 
Resolution (Å) 77.81 – 2.83 
(2.88 – 2.83) 
Rmerge 0.2019 
(12.9024) 
Rpim 0.069 (4.564) 
CC1/2 0.9928 (0.2628) 
I/sI 6.30 (0.08) 
Completeness (%) 100 (100) 
Redundancy 9.66 (8.96) 
Wilson B-factor 80.1 
 
6.2.4 PTPRM Fn3-4 model building and refinement 
The crystal structure of PTPRM Fn3-4 was solved by molecular replacement using the model of PTPRM 
Fn3-4 previously obtained by Eve Caroe, Dr Janet Deane and Dr Stephen Graham as a search model. 
The asymmetric unit contained four PTPRM Fn3-4 molecules related by non-crystallographic 
symmetry (NCS). NCS restraints were therefore used during refinement. At this resolution, the 
backbone electron density was unambiguous except for flexible loops, and side chain conformations 
were interpretable for many residues. The entire model could be built into the electron density. 
Molecular dynamics simulations and model geometry validation in ISOLDE greatly improved the 
model. Ambiguous features of the model are discussed below.  
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Continuous 2Fo-Fc electron density suggestive of a disulfide bond was visible between Cys642 and 
Cys716 in all four PTPRM Fn3-4 chains (Fig. 6.6A). Surprisingly, some negative difference density was 
also visible at the location of the bond, as well as positive difference density corresponding to a 
different conformation for the side chain of Cys642, suggesting that the disulfide bond was broken in 
a fraction of protein copies within the crystal or during data collection. These effects were most 
pronounced for chain C. Disulfide bonds are particularly sensitive to radiation damage during X-ray 
diffraction data collection303. It is therefore likely that this disulfide bond was present in the crystal 
and broken during data collection, so that the first part of the dataset describes an oxidised structure, 
whereas the second part describes a reduced disulfide bond resulting in electron density for both 
conformations. Accordingly, in a model of this structure with a reduced disulfide bond, positive 
difference density at the disulfide bond location suggests that this bond is missing (Fig. 6.6B). The 
oxidised and the reduced model both appear partially correct and have a similar Rfree, suggesting that 
both models describe the data equally well. Since the reduced form appears to be the product of 
radiation damage, and this bond is likely to be oxidised in the native state of this protein, I chose to 
model this disulfide bond in its oxidised state in the final structure model.  
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Figure 6.6. The disulfide bond between Cys642 and Cys716 is partially reduced 
A. Electron density (2Fo-Fc, in blue) and difference density (Fo-Fc, in green for positive and red for 
negative) maps showing continuous electron density between Cys642 and Cys716 strongly 
suggesting the existence of a disulfide bond. The presence of negative difference density at the 
modelled disulfide bond location and positive difference density corresponding to an alternative 
conformation for the side chain of Cys642 in all PTPRM Fn3-4 chains, particularly in chain C, indicate 
that the modelling of a disulfide bond between Cys642 and Cys716 is partially incorrect. B. Modelling 
the side chains of Cys642 and Cys716 in the reduced, free dithiol form in chain C results in positive 
difference density which can be explained by the presence of a disulfide bond in a fraction of the 
molecules in the crystal. 
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Clear electron density corresponding to N-linked glycans could be seen on Asn544 (Fn3 domain) and 
Asn598 (Fn4 domain) on all chains, except at position 598 in chain A (Fig. 6.7A-F). All N-linked glycans 
have a common core pentasaccharide composed of two N-Acetylglucosamine residues and three 
mannose residues (Man3GlcNAc2; Fig. 6.7G)304. Several of these sugar residues could be built into the 
electron density (Fig. 6.7C and 6.7F). For both N-linked glycans, additional electron density was 
observed corresponding to fucosylation of the innermost N-Acetylglucosamine, a common post-
translational modification305 (Fig. 6.7H). The most extensive electron density for the glycan at position 
544 was observed in chain B, and in chain D for the glycan at position 598. In other chains, there was 
less electron density. Therefore, for each chain, I built glycan residues into visible electron density, 
using the best-defined glycan as a template when the glycan conformation was ambiguous. This 
difference in the extent of visible electron density is most likely caused by differences in glycan 
flexibility within the crystal304. Indeed, the best electron density is visible for glycan residues 
positioned close to a symmetry molecule restricting their movement (Fig. 6.7C and F). Conversely, at 
position 598 in chain A, where no reliable electron density corresponding to a glycan is visible, a 
potential glycan would have space for flexible movement within the crystal, therefore not yielding 
consistent electron density. Importantly, the restriction of glycan movement due to crystal packing 
interactions means that the conformations observed in this structure represent one of potentially 
many conformations in solution, where glycans are likely to be very flexible. No electron density 
corresponding to glycans at the remaining predicted N-linked glycosylation sites in the Fn3 and Fn4 
domains of PTPRM (Asn534, Asn651 and Asn681)298 was observed. 
 
The final refinement statistics are shown in Table 6.2. and compared to the refinement statistics of 
deposited structures at a similar resolution (Fig. 6.8A). The clashscore191 and outlier statistics are 
excellent as a result of the molecular dynamics simulations performed in ISOLDE. Average B-factors 
are unusually high; however, these are high throughout the structure, with expected increases around 
flexible loops with poorly defined electron density (Fig. 6.8B). These high B-factor values throughout 
the structure suggest that there is disorder or mosaicity within the crystal. This may arise from glycan 
flexibility and heterogeneity within the crystal as well as radiation damage303. As discussed above, 
chain C appears to have suffered more X-ray radiation damage absorbed by the disulfide bond 
between Cys642 and Cys716, which may explain why this chain has higher B-factors than the other 
three chains.  
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Figure 6.7. Building of N-linked glycans 
Ribbon representation of each chain in the final PTPRM Fn3-4 structure showing N-linked glycans in 
stick representation (oxygen, red; nitrogen, blue). A. N-linked glycans on chain A (in blue). B. N-
linked glycans on chain B (in red). C. Electron density (2Fo-Fc, in blue) and difference density (Fo-Fc, 
in green for positive and red for negative) maps of the glycan linked to Asn544 on chain B (stick 
representation, in red). The neighbouring symmetry molecule is shown (stick representation, in light 
green). D. N-linked glycans on chain C (in yellow). E. N-linked glycans on chain D (in green). F. 
Electron density and difference density maps of the glycan linked to Asn598 on chain D (stick 
representation, in red). The neighbouring symmetry molecule is shown (stick representation, in light 
green). G. Schematic representation of the common core pentasaccharide Man3GlcNAc2. H. 
Fucosylated core pentasaccharide.  
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Table 6.2. Refinement statistics for PTPRM Fn3-4. 
Resolution (Å) 75.804 - 2.832 
No. reflections 30183 
Rwork/Rfree 0.2448/0.2952 







Chain A 116.63 
Chain B 116.44 
Chain C 120.97 
Chain D 116.56 
Ramachandran  
Favoured (%) 98.14 
Outliers (%) 0 
R.m.s deviations  
Bond lengths (Å) 0.006 
Bond angles (°) 1.023 
Rotamer outliers (%) 0.72 
Cis peptides (Proline) 0 
Cis peptides (General) 0 
Twisted peptides (Proline) 0 
Twisted peptides (General) 0 
Clashscore 2.35 
 
Due to the presence of NCS and the use of NCS restraints during refinement, all four copies of PTPRM 
are very similar (RMSD ≤ 0.6 Å) but show small, localised differences. Chain A possessed the best-
quality electron density and this model will be discussed throughout the rest of this chapter. 
  
Unfortunately, no unexplained electron density corresponding to galactose was observed in the 
refined PTPRM Fn3-4 structure. Although I did not succeed in obtaining a structure elucidating how 




Figure 6.8. PTPRM Fn3-4 refinement statistics 
A. Histograms of the distribution of selected statistics across 1854 PDB entries of similar resolution, 
with the range specified by numbers printed in red. Statistics for the PTPRM Fn3-4 structure are 
printed in black; the connecting polygon (in black) shows where these values fall in the distribution. 
Histogram bins are colored by the number of structures in each bin: 0 (blue), 519 (green), 1038 (red). 
B. B-factors of PTPRM Fn3-4 chain A residues. A similar pattern is observed in all chains.  
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6.2.5 Structural features of the Fn3 and Fn4 domains of PTPRM 
The structure of the Fn3 domain has been reported previously within the context of the ectodomain 
of PTPRM298. In this structure, the Fn4 domain was not modelled. A key feature of the ectodomain of 
PTPRM is its rigid extended architecture posited to be essential for its function as a sensor of inter-
cellular distances. This rigidity is provided by a network of interactions stabilising the interface 
between consecutive domains298. This holds true for the interface between the Fn3 and Fn4 domains, 
which is similarly stabilised by a network of hydrophobic and hydrogen bonding interactions (Fig. 
6.9A). The structure of the Fn3 domain in the context of the Fn3-4 domains or the ectodomain of 
PTPRM are very similar (RMSD 1.1 Å over 80 Cα atoms) except for some small loop movements (Fig. 
6.9B). The loop including Tyr510 is highly disordered in the Fn3-4 structure, as indicated by extremely 
poor electron density and high B-factors around this residue (Fig. 6.8B). This is because Tyr510 forms 
part of the interface between the Fn2 and Fn3 domains298 and is therefore stabilised in a different 
conformation in the PTPRM ectodomain structure (Fig. 6.9B). Similarly, the loop including Asp527, 
Pro528 and Glu529 is destabilised in the ectodomain structure due to the absence of an ordered Fn4 
domain in this structure, because these three residues are involved in interface contacts between the 
Fn3 and Fn4 domains (Fig. 6.9A). Finally, the loop bearing the glycan linked to Asn544 appears flexible. 
The presence of a symmetry molecule in close proximity to this loop in the Fn3-4 crystal suggests that 
crystal packing interactions drive this alternative loop conformation. Overall, these observations 
suggest that the Fn3 domain of PTPRM has a rigid, compact structure with limited flexibility and 




Figure 6.9. Interface between the Fn3 and Fn4 domains 
A. The interface between the Fn3 (blue) and Fn4 (lilac) domains of PTPRM is stabilised by a network 
of interactions. The protein backbone is shown as liquorice, with key residues drawn in stick 
representation (oxygen, red; nitrogen, blue). The protein surface is shown as a transparent surface. 
The left panel shows potential hydrogen bond interactions, represented as blue dashes. The right 
panel shows residues potentially involved in hydrophobic interactions. B. Structural alignment of the 
Fn3 domain within the context of the Fn3-4 construct (liquorice backbone representation, in blue) 
and of the published structure of the extracellular domain (ECD) without the Fn4 domain (in grey; 
PDB ID: 2V5Y). An unmodelled disordered loop is represented as dashes. Residues discussed in the 
text are drawn in stick representation (oxygen, red; nitrogen, blue). Termini are marked as circles. 
 
This is in contrast with the Fn4 domain of PTPRM, which has intriguing features suggestive of 
additional functions for this domain. The secondary structure of the Fn4 domain differs from the 
classical fibronectin III fold composed of two β-sheets with 3 and 4 β-strands forming a β-sandwich306 
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(Fig. 6.10A-B). In the Fn4 domain of PTPRM, the first β-sheet is replaced by three loops which are not 
organised as β-strands. The second β-sheet formed by the β-strands C, D, F and G is maintained in the 
Fn4 domain. Profile-profile alignment to distantly related fibronectin III domains using the Fold and 
Function Assignment System (FFAS) server197 and structure based-alignment using the Dali server198 
show that the Fn4 domain of PTPRM has unusual insertions in its sequence (Fig. 6.10C-D). Structural 
alignment of the Fn4 domain of PTPRM with the closest structural homolog for which a structure is 
available, the A74 fibronectin III domain of Titin307, demonstrates that in addition to the compact 
fibronectin III-like fold, a large loop is protruding out of the main fold of the Fn4 domain of PTPRM 
(residues 628-642; Fig. 6.10E). This loop, labelled the F-loop, appears to be flexible, adopting different 
conformations in each structure of the Fn3-4 domains (Fig. 6.11). Structural alignment of the two 
chains of the Fn3-4 structure previously obtained in our lab with the new Fn3-4 structure shows a 
similar overall conformation (chain A RMSD 0.8 Å over 220 Cα atoms; chain B RMSD 1.3 Å over 241 Cα 
atoms), with the exception of two membrane-proximal loops including the F-loop (Fig. 6.11). The F-
loop was found in different conformations in two models and was disordered and unmodelled in the 
third model. The electron density for this loop is very clear in the new Fn3-4 structure and in chain B 
of the previous structure because in both cases, this loop forms contacts with another protein chain 
in the asymmetric unit. Likewise, a loop equivalent to the A strand in a classical fibronectin III fold (Fig. 
6.10A-B), named the A-loop (residues 590-600), was found in different conformations in two 
structures, and disordered in the third (Fig. 6.11, right panel). The presence of flexible loops near the 
membrane-proximal end of the domain suggests they may facilitate interactions with lipids or other 
membrane proteins. The A-loop carries the glycan linked to Asn598 (Fig. 6.11). This glycan may protect 




Figure 6.10. The Fn4 domain of PTPRM has an unusual structure 
A. Schematic diagram showing the secondary structure for a typical fibronectin III fold. β-strands 
(shown as arrows) form two β-sheets arranged as a β-sandwich. B. Secondary structure of the Fn4 
domain of PTPRM. Several β-strands are replaced by loops. A long loop labelled the F-loop and a 
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short α-helix (shown as a cylinder) are inserted between strands C and D. C. FFAS profile-profile 
alignment of the Fn4 domain of PTPRM with fibronectin III domains with distant homology. D. 
Sequence alignment of the Fn4 domain of PTPRM with the closest structural homologs deposited in 
the PDB (PDB IDs are indicated in parentheses) identified using the DALI server. Uppercase means 
structurally equivalent positions with PTPRM. Lowercase means insertions relative to PTPRM. The 
most frequent amino acid is coloured in each column. E. Structural alignment of Fn4 and its closest 




Figure 6.11. The Fn4 domain possesses flexible loops 
Structural alignment of the PTPRM Fn3-4 structure described in this chapter (blue liquorice) with the 
unpublished Fn3-4 structures previously obtained in our lab (chain A: green liquorice, with 
unmodelled, disordered loops represented as dashes, chain B: pink liquorice). The F-loop and A-loop 
(circled) are flexible and adopt different conformations in each structure. Asn598 is drawn in stick 
representation. The linked glycan is not shown for clarity. The N-terminus is marked as a circle. 
 
PTPRM is cleaved by the proprotein convertases furin and PC5 between Arg632 and Thr633. After 
cleavage, the ectodomain fragment remains associated with the transmembrane fragment301. The 
structure of the Fn4 domain reveals that this cleavage event occurs in the unusual F-loop extending 
away from the Fn4 domain (Fig. 6.12), hence the name F-loop for Furin-loop. Both proteolytic 
fragments form part of the main fibronectin III fold and the extensive interactions contributing to this 
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fold are expected to maintain this fold intact after furin/PC5 cleavage, explaining why both fragments 
remain together after cleavage. It has been hypothesised that cleavage by proprotein convertases 
introduces some flexibility in the membrane-proximal region of PTPRM298 but this seems unlikely 
based on this observation. However, proteolytic fragments of the F-loop are likely to undergo large 
conformational changes after cleavage. These conformational changes may underlie the currently 
unknown effects of proprotein convertase cleavage on PTPRM function. Interestingly, the longest loop 
fragment is covalently bonded to the surface of the fibronectin III fold via a disulfide bond between 
Cys642 and Cys716, the sole disulfide bond within the Fn4 domain (Fig. 6.12). This bond does not 
tether the ectodomain fragment to the C-terminal transmembrane fragment after proprotein 
convertase cleavage. Instead, it appears to restrict the movement of this unusual loop before and 
after cleavage, stabilising this flexible region in a specific orientation likely to be important for cleaved 
and/or uncleaved PTPRM function.  
 
The R2B family of receptor-type protein tyrosine phosphatases includes PTPRM, PTPRT, PTPRK and 
PTPRU. These proteins share a common domain architecture, including the membrane-proximal Fn4 
domain. Like PTPRM, PTPRK is cleaved by proprotein convertases and is expressed on the cell surface 
as a mixture of cleaved and uncleaved protein308. PTPRU is also expressed as a mixture of cleaved and 
uncleaved forms (Iain Hay, personal communication), whereas proteolytic cleavage of PTPRT has not 
been reported. Multiple sequence alignment of the Fn4 domain across human R2B family proteins 
shows that the unusual insertion corresponding to the F-loop is conserved in R2B family members (Fig. 
6.13A, in contrast with distantly related fibronectin III domains (Fig. 6.10C-D). Despite the presence of 
this loop in other R2B family members, the loop sequence is poorly conserved (Fig. 6.13A-B). The furin 
cleavage site is also found in the F-loop region of PTPRK and PTPRU, although the exact position and 
sequence is not conserved (Fig. 6.13A). PTPRU appears to have two overlapping furin cleavage sites, 
with the first potential site at the same position as the PTPRM cleavage site, and a second site three 
residues downstream, at the same position as the PTPRK cleavage site. PTPRT does not possess a 
canonical furin cleavage site. Interestingly, the disulfide bond between Cys642 and Cys716 described 
above is conserved across all four proteins. Altogether, this comparison suggests that all R2B family 
members possess a long membrane-proximal loop anchored to the main fold of the Fn4 domain by a 
conserved disulfide bond. This loop is cleaved by proprotein convertases in all R2B family members 




Figure 6.12. Furin cleavage occurs on a long membrane-proximal loop 
Ribbon representation of the PTPRM Fn3-4 structure showing the furin cleavage site indicated by the 
symbol (>). After cleavage, the transmembrane fragment (pink) remains associated with the 
ectodomain fragment (lilac). The disulfide bond indicated by (*) drawn in stick representation 
(sulfur, yellow) anchors the loop to the main Fn4 fold. Glycans are shown in stick representation 
(oxygen, red; nitrogen, blue).  
 
I have solved and refined a structure of the Fn3-4 domains of PTPRM structure, revealing intriguing 
aspects of PTPRM structure potentially relevant for its function or regulation by proprotein 
convertases. These findings may be applicable to other R2B family receptor phosphatases. 
Unfortunately, my attempts to elucidate how PTPRM interacts with galactosphingolipids through 
crystallisation experiments with the headgroup analogues galactose or Gal-4S did not yield a structure 
of ligand-bound PTPRM. Subsequent isothermal titration calorimetry experiments performed by Alex 
Nicholson showed that PTPRM Fn3-4 does not interact with galactose. Furthermore, Gal-4S is not an 
ideal sulfatide headgroup analogue because protein-ligand interactions are often isomer-specific. We 
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have since initiated a collaboration with Prof Henrik Jensen (Department of Chemistry, Aarhus 
University) to synthesise the sulfatide headgroup Gal-3S. Future work in our lab will use this sulfatide 
analogue for interaction assays and structural studies with PTPRM. The refined structure described in 
this chapter will facilitate structural studies by providing a good quality molecular replacement model 
for the Fn3-4 domains of PTPRM.  
 
6.3 PTPRM trafficking in GALC KO oligodendrocytes 
Previous work in our lab showed that PTPRM is specifically down-regulated at the plasma membrane 
of GALC KO oligodendrocytes, but total expression levels and mRNA levels remain unchanged. 
Therefore, we hypothesised that the interaction of PTPRM with accumulated galactosphingolipid 
headgroups leads to its mistrafficking or intracellular retention in GALC-deficient oligodendrocytes. I 
aimed to test this hypothesis by monitoring PTPRM trafficking in GALC KO cells.  
 
PTPRM expression levels are extremely low in MO3.13 oligodendrocytes, rendering its detection by 
immunofluorescence challenging. Our lab has attempted endogenous GFP tagging of PTPRM without 
success. Subsequently, I set out to monitor the trafficking of recombinant GFP-labelled PTPRM 
constructs by microscopy with the “retention using selective hooks” (RUSH) technique309,310. This 
method allows one to monitor target protein trafficking through the secretory pathway after 
synchronous release from the ER. The target protein is fused to a streptavidin-binding peptide (SBP) 
and GFP and co-expressed with a "hook" protein, streptavidin fused to the ER retrieval signal peptide 
KDEL (Strep-KDEL). The target protein therefore remains in the ER until biotin is added to the cells, 
outcompeting the SBP-streptavidin interaction and allowing the synchronous release of the target 




Figure 6.13. The F-loop is conserved among R2B family receptor phosphatases 
A. Multiple sequence alignment of the membrane-proximal Fn4 domain across human R2B family 
members (PTPRM, PTPRT, PTPRK and PTPRU), coloured by percentage identity (gradient from dark 
purple for conserved residues to white for non-conserved residues). Potential furin cleavage sites 
are highlighted in orange, with red dashes indicating the peptide bond subject to hydrolysis. PTPRU 
has two overlapping furin cleavage sites. The conserved cysteines participating in a disulfide bond 
are indicated with the yellow symbol (*). B. Structure of the Fn4 domain of PTPRM (top panel: 
ribbon representation; bottom panel: surface representation) showing residue conservation. 
Residues are coloured using the same colour scheme as in A. 
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The trafficking of several PTPRM truncations including the transmembrane region was tested. Full-
length PTPRM, the extracellular domain (ECD) or the membrane-proximal Fn3-4 domains were fused 
to SBP and GFP by Eve Caroe (Fig. 6.14A). I tested the expression and trafficking of these constructs in 
HeLa cells stably expressing the hook peptide Strep-KDEL. Full-length PTPRM accumulated in 
intracellular puncta and was not released to the plasma membrane upon biotin addition, suggesting 
that this recombinant construct forms aggregates of misfolded protein (Fig. 6.14B). In contrast, the 
ECD accumulates in the ER prior to the addition of biotin (Fig. 6.14C, 0 min), and addition of biotin 
leads to its release and transport to the Golgi (Fig. 6.14C, 10 min), then to the plasma membrane, 
where it accumulates at cell-cell contact sites (Fig. 6.14C, 60-150 min) through homophilic interactions 
with the ECD on adjacent cells298. In the absence of contact with neighbouring cells overexpressing the 
ECD, the ECD is internalised as documented previously301,311 (Fig. 6.14D). Finally, the Fn3-4 domain of 
PTPRM also successfully traffics from the ER (Fig. 6.14E, 0 min) to the Golgi after biotin addition (Fig. 
6.14E, 10 min), eventually diffusing throughout the plasma membrane (Fig. 6.14E, 150 min). This 
diffuse plasma membrane localisation is expected since the Fn3-4 domains do not participate in 
homodimeric cell junction contacts298. 
 
To understand whether PTPRM is mistrafficked to an intracellular compartment instead of the plasma 
membrane in GALC KO cells, PTPRM localisation in GALC KO oligodendrocytes was assessed in a pilot 
experiment. I overexpressed the PTPRM ECD and Fn3-4 constructs described above (Fig. 6.14A) in 
GALC KO and EV control MO3.13 oligodendrocytes in the absence of the Strep-KDEL hook peptide. 
Thus, PTPRM constructs were not retained in the ER but trafficked directly towards their destination 
compartments. Although this experimental set up does not facilitate the study of trafficking kinetics, 
it may allow the comparison of PTPRM destination compartments in GALC KO cells versus EV control 
cells. As observed in HeLa cells, the ECD accumulated at cell-cell junctions when this construct was 
expressed by neighbouring cells or internalised into intracellular compartments in the absence of 
homophilic contacts in EV as well as GALC KO oligodendrocytes (Fig. 6.15, left panel). The Fn3-4 
domain was expressed diffusely at the cell surface as well as in intracellular compartments in both EV 
and GALC KO oligodendrocytes (Fig. 6.15, right panel). Overall, no difference was observed in the 




Figure 6.14. PTPRM trafficking in HeLa cells 
A. Full-length (FL) PTPRM, the extracellular domain (ECD) including the transmembrane (TM) region 
or the Fn3-4 domain including the TM region were fused to an ER targeting signal peptide (SP), an N-
terminal Streptavidin-binding peptide (SBP) and a C-terminal GFP tag. These constructs were 
transiently expressed in HeLa cells stably expressing a Streptavidin-KDEL hook peptide, retaining the 
SBP-fused constructs in the ER. At t=0, biotin was added to the cells, causing the synchronous 
release of the SBP-fused constructs from the ER. (B-E) Trafficking of these constructs was monitored 
at the indicated time points by fluorescence microscopy. Nuclei were stained with DAPI. Scale bar: 
10 μm. 
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Establishing GALC KO and EV MO3.13 cell lines stably expressing the hook peptide Strep-KDEL will 
allow synchronous release and trafficking of PTPRM constructs and may permit detection of time-
dependent differences in PTPRM trafficking. A caveat of this experiment is that PTPRM is 
overexpressed at variable levels much higher than endogenous levels, which prevents quantitative 
analysis and may mask subtle changes in protein localisation. Alternatively, immunofluorescence 
microscopy may be used to observe the localisation of endogenous PTPRM, however this will be 
dependent on antibodies sensitive enough to detect minute amounts of PTPRM. This work will 
continue to be pursued by our group.  
 
 
Figure 6.15. PTPRM localisation in GALC KO oligodendrocytes 
GFP-tagged extracellular domain (ECD) and Fn3-4 PTPRM transmembrane constructs described in 
Fig. 6.14A were transiently expressed in EV control and GALC KO MO3.13 oligodendrocytes in the 
absence of the Streptavidin-KDEL peptide, allowing GFP-tagged PTPRM constructs to traffic towards 
their destination compartments, observed by fluorescence microscopy. Nuclei were stained with 




Following up on previous work in our lab showing a specific interaction between the membrane-
proximal Fn3-4 domains of PTPRM and sulfatide, I attempted to identify the molecular determinants 
of this interaction by co-crystallisation and crystal soaking with the GalCer and sulfatide analogues 
galactose and Gal-4S. This approach did not yield the desired structure of ligand-bound PTPRM, and 
subsequent experiments performed by Alex Nicholson showed that PTPRM Fn3-4 does not interact 
with galactose. Further work in our lab will be performed with Gal-3S, a closer analogue of the 
sulfatide head group produced by our collaborators. Future interaction and structural studies will be 
essential to understand how PTPRM interacts with sulfatide. 
Fibronectin III domains are a common modular domain in the ectodomain of adhesion molecules312. 
Intriguingly, the fibronectin III domains of the adhesion proteins Ephrin A2 (EphA2) and Sidekick-1 and 
-2 (SDK1 and SDK2) have been shown to mediate binding to lipids313,314. EphA2 is a receptor tyrosine 
kinase binding to Ephrin A ligands on the apposed cell membrane. The membrane-proximal 
fibronectin III domain of EphA2 binds anionic lipids and stabilises this domain in a "sideways on" 
conformation at an angle to the remainder of the ectodomain protruding away from the 
membrane313,315 (Fig. 6.16A). The residues mediating this interaction have been identified by 
molecular dynamics simulations and validated by liposome pull-down assays313. SDK1 and SDK2 
participate in homophilic interactions. Both membrane-proximal and membrane-distal fibronectin III 
domains of SDK1 and SDK2 interact with lipids, allowing the entire ectodomain to "lie down" on the 
membrane to reduce intermembrane spacing of adhesion interfaces314 (Fig. 6.16B). This indicates that 
lipid binding can help orient and stabilise adhesion molecules for optimal function. The published 
structure of the ectodomain of PTPRM did not have continuous electron density for the Fn4 domain298, 
suggesting that this domain may have some flexibility relative to the rest of the ECD. However, our 
structures of the Fn3-4 domains of PTPRM shows that the interface between the Fn3 and Fn4 domain 
is stabilised by a network of hydrogen bond and hydrophobic interactions, suggesting that the entire 
ectodomain of PTPRM adopts a rigid rod-like structure (Fig. 6.16C). It is currently unclear whether lipid 
binding may alter the orientation of the PTPRM ectodomain relative to the membrane.  
Considering the striking specificity of PTPRM binding to sulfatide, but not other negatively charged 
lipids such as lysophosphatidic acid and GM1 (Fig. 6.1A), it is likely that lipid binding of PTPRM has 
roles beyond orienting this protein relative to the membrane. Based on data obtained in our group 
showing loss of PTPRM at the plasma membrane of GALC-deficient oligodendrocytes, it appears likely 
that lipid binding controls the trafficking or localisation of PTPRM. Pilot validation experiments showed 
no depletion of overexpressed, GFP-tagged PTPRM from the plasma membrane of GALC KO 
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oligodendrocytes. However, overexpression of recombinant PTPRM is expected to be variable across 
cells and this may mask any subtle changes in PTPRM localisation. Future experiments using RUSH 
microscopy in GALC KO oligodendrocytes or immunofluorescence microscopy of endogenous PTPRM 
will be key to identify changes in PTPRM trafficking caused by loss of GALC. These experiments must 
be supplemented with staining for organelle markers to determine the localisation of mistrafficked 
PTPRM. Alternatively, loss of endogenous PTPRM at the cell surface of GALC-deficient 
oligodendrocytes may be validated by flow cytometry, a more sensitive technique than 
immunofluorescence microscopy, and the localisation of mistrafficked PTPRM may be probed by 
subcellular protein fractionation and Western blotting.  
 
Figure 6.16. Lipid-binding adhesion molecules 
Schematic representations of the lipid-binding adhesion molecules EphA2, SDK1, SDK2 and PTPRM. 
Lipid bilayers are represented in orange. Fibronectin III domains are coloured in blue. Lipid-binding 
domains or regions are highlighted by a red (*) symbol. A. EphA2 binds ephrin A ligands on the 
apposed cell membrane. The membrane-proximal fibronectin III domain is stabilised in a “sideways 
on” conformation by binding to anionic lipids. B. SDK1 and SDK2 form trans homodimers. The 
fibronectin III domains 1-6 and 7-13 bind lipids, allowing SDK1/2 to lie on the membrane to reduce 
the distance between lipid bilayers. C. PTPRM forms trans homodimers in a rigid rod conformation. 
 
The membrane-proximal Fn4 domain of PTPRM has an unusual structure including a large, flexible 
loop protruding away from the main fibronectin III fold. This loop appears to be present in all receptor 
protein tyrosine phosphatases of the R2B family, but not in other fibronectin III domains based on 
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distant homology and structure-based alignments. The structure described in this chapter is the first 
available structure of the Fn4 domain of an R2B receptor. Interestingly, furin/PC5 cleavage of PTPRM 
and other R2B members occurs on this loop, thus named the F-loop. The functional consequences of 
proprotein convertase cleavage are unclear. Approximately half of PTPRM molecules endogenously 
expressed at the cell surface are present the cleaved form301, a proportion increased at high cell 
densities300. The Fn3 and Fn4 domains do not participate in cell-cell adhesion homodimer formation298 
and F-loop cleavage is therefore not expected to modify the affinity of this interaction. An intriguing 
hypothesis based on our data is that proprotein convertase cleavage regulates lipid binding affinity or 
specificity. This may allow dynamic targeting of PTPRM to specific membrane domains, perhaps acting 
as a regulatory mechanism of PTPRM function by driving PTPRM near or away from substrates. Future 
work in our lab will investigate the effect of proprotein convertase cleavage on the lipid-binding 
properties of PTPRM.  
Cleavage at the furin site is a necessary pre-condition for the initiation of a proteolytic cascade 
involving cleavage of the extracellular domain of PTPRM by ADAM family metalloproteinases, 
resulting in shedding of a soluble extracellular domain fragment, and intramembrane cleavage by γ-
secretases, potentially leading to internalisation of the intracellular phosphatase fragment316. An 
alternative hypothesis explaining the specific loss of PTPRM at the surface of GALC-deficient 
oligodendrocytes is that that ADAM activity might be enhanced in GALC KO cells, resulting in increased 
shedding of PTPRM. However, this would also result in increased shedding of PTPRK316, which is not 
down-regulated at the plasma membrane of GALC KO oligodendrocytes. Nonetheless, this hypothesis 
should be considered if further results do not support for our initial hypothesis that loss of GALC 
results in mistrafficking of PTPRM.  
 206
7 Conclusions and open questions 
 
How sphingolipids are extracted from membranes and passed from one protein to another are 
fascinating questions that I have tried to address during my PhD. A second key focus has been the 
impact of sphingolipid imbalances on immune cell function and cell death. Finally, I investigated how 
interactions with sphingolipids may regulate protein trafficking and function. The model systems I 
used to study these questions were sphingolipid hydrolases, their helper proteins saposins and the 
lysosomal storage diseases caused by loss of function of these proteins. These diseases are powerful 
models because they are monogenic and tractable, and may provide insights into more complex, late-
onset neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease also associated 
with mutations in sphingolipid hydrolases104,317. However, considerable uncertainty remains regarding 
the pathological mechanisms underlying sphingolipidoses. Several areas I have been investigating 
involve questions that have conflicting evidence in the literature and hypotheses that have raised 
some controversy, including the validity of the psychosine hypothesis and the definition of lipid rafts. 
 
In Chapter 3, I aimed to understand how SapB loads lipids onto CD1d. Using structural and biochemical 
methods, I attempted to characterise the interaction between CD1d and SapB facilitating the transfer 
of lipids between these two proteins. Surprisingly, I did not detect an interaction between CD1d and 
SapB using several sensitive biochemical methods, despite evidence from cell-based and in vitro 
experiments showing that SapB directly loads lipids onto CD1d165,166,169. Although the reasons for these 
inconsistencies are still unclear, my findings strongly suggest that another component is necessary for 
lipid transfer between CD1d and SapB. The identification of this component will be an exciting 
challenge. The interaction between CD1d, SapB and any partner protein(s) occurs in the lumen of 
endolysosomal compartments, limiting the direct use of available techniques such as proximity 
labelling methods. However, the development of such methods for use in the acidic and degradative 
environment of endolysosomal compartments may be possible. This may allow the identification of 
the protein complex facilitating lipid loading onto CD1d, which could then be investigated through 
structural studies. Furthermore, a lysosomal proximity labelling method would provide a tool to 
investigate other aspects of lysosomal biology, for example to validate whether sphingolipid-
degrading enzymes form multi-enzyme complexes facilitating the sequential transfer of substrate 
from one enzyme to the next in the lysosome129,318.  
 
Sphingolipidoses are often accompanied by inflammation61. The mechanisms of immune 
dysregulation by accumulated sphingolipids are still largely undefined. Many non-exclusive factors 
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may contribute to inflammation, including inflammatory cell death, tissue damage and stress, 
defective immune signalling, inflammasome activation, as well as aberrant lipid presentation. The 
consequences of sphingolipidoses on lipid presentation by CD1 molecules have been scarcely 
investigated. In a recent study by Pereira et al., antigen presenting cells from patients with lysosomal 
storage diseases were shown to retain their capacity to present CD1d and CD1b antigens exogenously 
added to these cells319. Investigating the changes in the self-lipid repertoire presented by CD1 
molecules in the context of sphingolipidoses may yield new insights into the immune pathologies of 
these diseases.  
 
Several immune receptors are known to be dependent on the correct lipid environment for their 
function and trafficking. Due to the immune abnormalities observed in Krabbe disease, including the 
formation of globoid phagocytic cells and elevated levels of pro-inflammatory cytokines, I 
hypothesised that accumulation of galactosphingolipids may cause changes in the membrane 
proteome of GALC-deficient monocytes/phagocytes. This was investigated in Chapter 4. Generating 
the cell lines for this study proved more challenging than expected due to wide-ranging off-target 
effects in the control cell lines, likely caused by lentiviral transduction or off-target Cas9 activity in 
these cells. This illustrates that genetic modification of cell lines can cause substantial and 
unpredictable changes, which may only be detected through extensive control experiments. As a 
consequence of these complications, I could not draw firm conclusions about the effect of GALC loss 
on the plasma membrane proteome of monocytes. However, I observed that loss of GALC alone was 
not sufficient to induce a globoid phenotype in monocyte/macrophage cells. This was confirmed in a 
study published by Weinstock et al. showing that globoid cell formation is triggered by accumulation 
of undigested myelin debris in GALC-deficient macrophages276. This demonstrates the complex 
interplay of different cell types in the pathology of Krabbe disease.  
 
Prior to the start of this project, there was some uncertainty about whether monocytes and 
macrophages synthesise galactosphingolipids due to the technical difficulties in quantifying these 
lipids. I observed that the expression of GALC and the enzyme UGT8 responsible for GalCer synthesis 
is dynamically regulated by differentiation and stimulation of monocyte/macrophage cells, suggesting 
that galactosphingolipids are present in these cells and that their levels are regulated to adapt for 
different cell functions required in these states. Weinstock et al. showed that no detectable amounts 
of GalCer are present in mouse bone-marrow derived macrophages, but small amounts of psychosine 
are detectable276. This suggests that some GalCer may be synthesised but processed to psychosine in 
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these cells. Whether psychosine plays an active role in normal monocyte/macrophage function 
remains an open question that could be investigated by knockout of UGT8.  
 
Abnormal accumulation of psychosine in oligodendrocytes is thought to drive Krabbe disease 
pathogenesis, but the enzyme metabolising GalCer to psychosine has long remained elusive108,109. 
Recent evidence showing that the enzyme AC can process substrates other than ceramide142-144 
prompted me to investigate whether AC deacylates GalCer to psychosine, thus contributing to Krabbe 
disease pathogenesis. This hypothesis formed the basis of the preliminary investigations described in 
Chapter 5 and was proved to be correct in a study published by Li et al.284. Genetic ablation of AC in a 
mouse model of Krabbe disease eliminates psychosine accumulation as well as the clinical symptoms 
of Krabbe disease. This provides strong support for the idea that psychosine accumulation drives the 
pathogenesis of Krabbe disease and opens up an exciting therapeutic avenue for this disease.  
 
AC inhibition holds promise for Krabbe disease treatment as well as cancer therapy139. However, 
current AC inhibitors are associated with high toxicity. An improved understanding of AC function may 
facilitate the design of improved inhibitors. The fundamental mechanism of membrane-embedded 
substrate access by AC is still unknown and was investigated in Chapter 5. I performed structural 
studies with SapA lipoprotein nanodiscs providing a membrane environment for interaction with AC. 
However, instead of SapA nanodiscs, my protocol yielded a different type of tetrameric SapA assembly 
never observed previously. Unfortunately, this assembly did not provide a lipid bilayer surface suitable 
for interactions with AC. Other lipid nanodiscs systems have been recently developed, including 
polymer-based systems suitable for use in the acidic conditions necessary for the interaction of AC 
with membranes. These tools may help determine the mechanism of substrate access by AC. 
Furthermore, it is still unclear how SapD promotes this mechanism. A structure of lipid nanodisc-
bound AC and SapD would be very informative to understand this process. Finally, the catalytic 
mechanism of GalCer hydrolysis by AC is currently unknown. I attempted to obtain a crystal structure 
illustrating this mechanism. Although this aim was not reached, such a structure would be extremely 
valuable for structure-based design of inhibitors specifically targeting psychosine formation. 
 
Psychosine accumulation in GALC-deficient oligodendrocytes is thought to directly cause cell death 
and subsequent demyelination108-110. I aimed to determine whether loss of AC reduces the levels of 
psychosine-mediated cell death in GALC KO oligodendrocytes. In contradiction with previously 
published observations214,288, I observed that the GALC KO oligodendrocyte cell line generated by our 
lab did not present increased levels of cell death compared to WT. This challenges our current 
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understanding of the psychosine hypothesis and opens questions about how loss of GALC in 
oligodendrocytes causes demyelination. This work highlights that it is likely the interplay between 
oligodendrocytes, neurons and other cell types in the brain that drives demyelination and cell death.  
 
The formation and maintenance of myelin is dependent on interactions between neurons and 
oligodendrocytes, as well as interactions between myelin layers104. Loss of adhesion molecules at the 
cell surface of oligodendrocytes may be a mechanism contributing to the demyelination observed in 
Krabbe disease. Work performed by our group showed that the adhesion protein PTPRM is lost at the 
surface of GALC-deficient oligodendrocytes but not intracellularly, suggesting that sphingolipid 
imbalances may cause dysregulation of PTPRM trafficking. Our group showed that the membrane-
proximal fibronectin III domain of PTPRM directly and specifically interacts with sulfatide. This 
suggests that the sphingolipid-binding properties of PTPRM result in dysfunctional trafficking of this 
protein in GALC-deficient cells. In Chapter 6, I attempted to obtain a structure of the membrane-
proximal domains of PTPRM associated with a sulfatide analogue to identify the molecular 
determinants of this interaction. The sulfatide analogues used in these experiments did not yield a 
structure of lipid head group-bound PTPRM; future work in our lab will be performed using a better 
sulfatide analogue synthesised by our collaborators. Nonetheless, I was able to improve our structure 
model of PTPRM. I observed that the membrane-proximal domain has a unique arch-like loop cleaved 
in its middle by proprotein convertases. The function of this loop and the effect of cleavage are 
unknown. An intriguing hypothesis is that this loop may contribute to sulfatide binding and its cleavage 
may alter the lipid-binding properties of PTPRM, thereby regulating its localisation. Future work in our 
group will address the interaction of PTPRM with sulfatide and the consequences of sulfatide binding 
for PTPRM function. These investigations may reveal a role for sphingolipid-protein interactions in 
Krabbe disease pathogenesis. 
 
Taken together, the work presented in this thesis challenges the current understanding of the 
fundamental molecular mechanisms of sphingolipid metabolism and presentation to the immune 
system. This work sets the foundation for new insights into these mechanisms, leading towards 
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The presentation of antigenic molecules is fundamental to 
host defence and immune regulation. The MHC class I and II 
molecules present peptide antigens to T cells and the molecular 
mechanisms of peptide loading and editing are relatively well 
understood1–3. However, the mechanism by which lipid antigens 
are loaded onto the CD1 family of antigen-presenting molecules 
remains poorly understood. CD1 molecules have structural 
similarity to MHC class I, including association with B-2- 
microglobulin (B2m), but unlike MHC molecules, CD1 mol-
ecules are non-polymorphic and the antigen-binding grooves of 
CD1 molecules are extremely hydrophobic, allowing the binding 
of most classes of lipids including phospholipids, glyceroli-
pids, lysolipids and glycolipids possessing a huge variety of 
glycosylated head groups4.
Of the five CD1 family members, antigen presentation by CD1d 
is best characterised. CD1d undergoes complex cellular traf-
ficking in a manner similar to that of MHC class II. Following 
synthesis in the endoplasmic reticulum, CD1d traffics via the 
Golgi apparatus to the plasma membrane, and is then internal-
ised and trafficked through early and late endocytic compart-
ments before being returned to the plasma membrane5, where 
CD1d-lipid complexes are recognized by the T cell receptor 
(TCR) of natural killer T (NKT) cells. Invariant NKT (iNKT) 
cells, which bear an invariant TCR and are characteristically 
potently activated by recognition of CD1d loaded with the 
synthetic glycolipid A-galactosylceramide (A-GalCer), are innate-
like T cells involved in the orchestration of immune responses6.
Lipid antigens are embedded in cellular membranes7 and 
thus are not directly accessible to the lumenal, lipid-binding 
groove of CD1 molecules. The loading of lipid antigen onto 
CD1 molecules therefore requires the action of lipid transfer 
proteins (LTPs) for efficient antigen presentation. The loading 
of lipids onto CD1d can occur in the ER, at the cell surface and 
in endocytic compartments. Relatively little is known about 
how lipid specificity is determined, and studies using secreted 
or recycling, surface-cleavable human CD1d found differences 
in the lipid repertoire bound to CD1d, reflecting the lipids 
present in the compartments through which it had trafficked8–10. 
Different LTPs are present in the different cellular locations 
where lipid antigen loading occurs and are likely to determine 
the lipid repertoire bound to CD1 molecules11. Interestingly, 
the late endocytic/lysosomal compartment is the site of both 
glycolipid catabolism and lipid loading of CD1d and the resident 
LTPs function in both these processes. Importantly, the anti-
genicity of glycolipids can be regulated by processing of their 
glycan headgoups prior to presentation to T cells, highlighting 
the complex interplay between these two pathways12,13.
The LTPs present in the lysosomal compartments include 
ganglioside monosialic 2 activator (GM2A), Niemann-Pick 
type C 2 (NPC2) and four saposin (Sap) proteins. SapA, SapB, 
SapC and SapD are the products of the proteolytic cleav-
age of a prosaposin (PSAP) precursor and are each small, 
non-enzymatic proteins possessing three disulphide bonds that 
stabilise an extremely heat-resistant helical structure. The 
saposins can exist in a “closed” monomeric, globular confor-
mation or, at low pH, adopt a more “open” conformation, form-
ing higher-order oligomers enclosing a hydrophobic cavity into 
which lipid acyl chains can be buried14–19. Each saposin functions 
in conjunction with specific hydrolases to facilitate the degra-
dation of different glycosphingolipids and the loss of saposin 
function phenotypically resembles the loss of the associated 
hydrolases20–25. There are two proposed mechanisms for how 
saposins assist in lipid presentation to hydrolases: the “solu-
biliser” model, whereby saposins encapsulate lipids within a 
hydrophobic oligomeric complex for presentation to soluble 
enzymes, and the “liftase” model, where saposins bind directly 
to membranes destabilising them, allowing membrane-associated 
hydrolases access to lipid substrates. Structural and cell-based 
evidence exists to support both these models19,26–29. These 
two models are also relevant for the proposed mechanisms 
by which saposins load lipids onto CD1 molecules30. SapB is 
thought to behave as a “solubiliser”, forming protein-lipid 
complexes that enhance lipid loading of CD1 molecules, while 
SapC associates with membranes and may facilitate lipid 
loading at the membrane surface.
The evidence for saposin-mediated lipid loading of CD1 mol-
ecules comes from animal knockout studies, cell-based assays 
and in vitro assays. Knockout of PSAP in mice results in the 
dramatic loss of presentation of endogenous iNKT cell ligands 
by CD1d31. The presentation of exogenous lipid antigens, such 
as A-GalCer, is impaired in PSAP knockout or knockdown 
cells31–34. In vitro assays have identified that all the saposins, as 
well as the other lysosomal LTPs, GM2A and NPC2, are capa-
ble of transferring lipids onto CD1 molecules31,35. However, 
some LTPs appear to be more efficient than others at loading 
specific lipid antigens onto different CD1 molecules30,33,36. 
Specificity within the saposin family in this process has been 
explored via in vitro assays identifying SapB as the dominant 
saposin for the loading of lipid antigens onto CD1d. Specifi-
cally, incubation of CD1d with SapB and A-GalCer has been 
shown to enhance the stimulation of iNKT cells33,34 and SapB 
      Amendments from Version 1
We thank the reviewers for their insightful comments. We have 
revised the manuscript following their helpful suggestions as 
follows:
We acknowledge that the lack of a detectable interaction does 
not necessarily mean that there is no interaction. We have 
edited the abstract and discussed why an interaction too weak 
to be detected by the assays used in this study is unlikely to be 
physiologically relevant. This is supported by the fact that strong 
direct protein-protein interactions are crucial for several different 
lipid transfer pathways as detailed in the Discussion.  
We have performed an additional equilibrium binding experiment 
where SapB was pre-loaded with the lipid A-GalCer while CD1d 
remained loaded with the endogenous human lipids with which 
it co-purifies. In agreement with our earlier results, no interaction 
was detected in this new experiment. This additional data is now 
included as part of Figure 2.
We have clarified the nature and relevance of the lipids expected 
to be associated with CD1d and SapB in the experiments 
reported in this manuscript and clarified that glycosylation of 
SapB is not required for lipid loading of CD1d.
Any further responses from the reviewers can be found at the 







can mediate lipid binding to CD1d in T cell independent assays33 
suggesting a direct role for this specific saposin in lipid load-
ing of CD1d. The ability of SapB to facilitate and enhance lipid 
exchange on CD1d has also been monitored in vitro via iNKT 
TCR binding to CD1d following incubation with lipids alone 
or lipids plus SapB34. These in vitro assays implicate SapB as a 
“lipid editor” that facilitates the loading and unloading of lipid 
antigens onto CD1d.
Due to the hydrophobic property of lipids, their exposure to 
aqueous solutions is thermodynamically unfavourable. There-
fore, lipid transfer between hydrophobic lipid-binding cavities 
of proteins requires direct interaction of the protein components 
to provide continuous shielding of the lipid from the aqueous 
phase37. This hypothesis is supported by the fact that other 
known lipid transfer proteins directly interact with the protein 
receiving the lipid38–40. However, several publications report 
a failure to detect a direct interaction between saposins and 
human CD1d11,33,34. Unfortunately, these reports do not show 
any data or detail the approaches used to monitor binding and 
the implication is that these interactions exist but are weak and 
very transitory. Therefore we have used a number of robust 
and sensitive biochemical and structural techniques to moni-
tor direct interactions between SapB and CD1d. Using multiple 
approaches in a range of conditions we do not observe any 
evidence of a direct interaction between CD1d and SapB.
Methods
Cloning and cell line production
Codon-optimised cDNA was synthesized (GeneArt) encoding 
human B2m (residues 21-119, Uniprot P61769) and the extra-
cellular domain of human CD1d (residues 20-301, Uniprot 
P15813) with a C-terminal hexahistiding tag (CD1d-H6). A modi-
fied version of the piggyBac target protein plasmid PB-T-PAF41 
was constructed retaining the N-terminal secretion signal but 
with the Protein A fusion removed. CD1d-H6 and B2m were 
individually cloned into this modified vector, using SpeI and 
AscI restriction-endonuclease sites, to produce PB-T-CD1d-H6 
and untagged PB-T-B2m. For production of an inducible, stable 
co-expression cell line, HEK293F cells were quadruple- 
transfected with PB-T-CD1d-H6, PB-T-B2m, PB-RN and PBase 
using a DNA mass ratio of 5:5:1:1 and transfected cells were 
selected with geneticin using the established protocol for the 
piggyBac expression system41.
Codon-optimised cDNA was synthesized (GeneArt) encod-
ing the segment of human PSAP corresponding to SapB 
(residues 195-274, Uniprot P07602) and subcloned into the bac-
terial expression vector pET-15b using NcoI and XhoI restriction 
endonuclease sites to produce untagged protein. SapB was also 
subcloned into the mammalian expression vector pHLsec42 using 
the restriction enzymes AgeI and KpnI to encode a C-terminally 
H6-tagged protein.
Protein expression and purification
Protein expression of CD1d-B2m complex in the HEK293F 
co-expression cell line was induced with 2 µg/mL doxycycline 
and expression media was collected over a 2 month period. 
CD1d-H6 was purified from conditioned media by nickel affinity 
chromatography in phosphate-buffered saline (PBS) pH 7.4 
and eluted using PBS containing 300 mM imidazole. CD1d-B2m 
was further purified by size exclusion chromatography on 
a Superdex 200 column (GE Healthcare) equilibrated in 
cross-linking buffer (20 mM HEPES pH 7.0, 150 mM NaCl) for 
interaction assays or distinct buffers (described below) for crys-
tallisation experiments. CD1d-B2m was concentrated to 2 mg/mL 
and stored at 4 °C for up to one month.
To produce deglycosylated CD1d-B2m, cells were treated with 
5 µM kifunensine at the same time as protein expression was 
induced. CD1d-B2m was purified by nickel affinity purifica-
tion and eluted with 100 mM citrate pH 4. CD1d-B2m protein 
was buffer exchanged into 100 mM citrate pH 5.5, using 
repeated rounds of dilution and concentration using a centrifugal 
concentrator, concentrated to 2 mg/mL and incubated with 
3125 units of Endoglycosidase H (Endo H; New England Biolabs) 
per milligram of protein for 3 hours at room temperature. 
Deglycosylated CD1d-B2m was purified by size exclusion 
chromatography (as described above).
Untagged SapB was expressed in Escherichia coli Origami 
(DE3) cells and purified as described previously43. Briefly, 
cleared lysate was heat-treated, precipitated proteins were 
cleared by centrifugation and supernatant containing SapB was 
dialysed overnight in the presence of 20 µg/mL DNAse 
against anion exchange buffer (50 mM Tris pH 7.4, 25 mM NaCl). 
SapB was further purified by anion exchange chromatography 
(HiTrap QSepharose column) followed by size-exclusion chro-
matography (HiLoad 16/600 Superdex 75 column) in 50 mM 
Tris pH 7.4, 150 mM NaCl. Purified SapB was concentrated 
to 16 mg/mL and stored at 4 °C.
His6-tagged SapB was expressed in HEK293F cells by poly-
ethylenimine-based transient transfection. After 4 days, 
SapB-H6 was purified from conditioned media by nickel affinity 
and size exclusion chromatography with a Superdex 75 column 
(GE Healthcare) in cross-linking buffer. Prior to crystallisation 
trials (but not cross-linking assays), the tag was removed by 
incubation with 1.2 U/mL Carboxypeptidase A-agarose at 
25°C overnight followed by incubation with Ni-NTA resin to 
remove tagged protein. The supernatant containing untagged 
SapB was separated from Carboxypeptidase A-agarose and 
Ni-NTA agarose by passing through a gravity flow column.
A-GalCer loading
Endogenously purified lipids were exchanged for the lipid 
A-GalCer (Avanti Lipids) based on a protocol used to obtain 
crystal structures of A-GalCer-loaded CD1d44,45. Lipid was 
resuspended in DMSO at 1 mg/mL and dissolved by heating 
the solution at 80°C for 10 min, with brief sonication and 
vortexing every 3 minutes. CD1d-B2m and SapB were incu-
bated with a 3-fold molar excess of A-GalCer in PBS overnight 
at room temperature. A-GalCer-loaded proteins were then sepa-
rated from free A-GalCer by size exclusion chromatography 
with a Superdex 200 10/300 column equilibrated in 20 mM 
HEPES pH 7.0, 150 mM NaCl. A-GalCer-loaded proteins were 
used within 24 hours after size exclusion chromatography 







Ni-NTA agarose beads were loaded with a saturating amount 
of CD1d-B2m, and complete capture of CD1d-B2m was veri-
fied by measuring the absorbance of the supernatant at 280 nm. 
Saturated beads were washed three times in equilibrium assay 
buffer (50 mM HEPES pH 7.0, 150 mM NaCl, 0.05% digitonin, 
2.5 mM CaCl2, 2.5 mM MgCl2). Serial dilutions (1:1) of 
CD1d-B2m-saturated beads were made in equilibrium assay 
buffer supplemented with unloaded Ni-NTA beads to equalize 
the bead volume across all samples. SapB was added at a final 
concentration of 680 nM in equilibrium assay buffer. The reac-
tion was incubated with shaking at room temperature for 1 hour. 
The supernatant containing unbound SapB was separated from 
the beads by centrifugation (800g, 2 min) followed by sepa-
ration with a Micro-Spin column (Pierce) (800g, 2 min) to 
remove all beads. The supernatant was analysed by SDS-PAGE 
followed by staining with SYPRO Ruby. For analysis of bead 
samples, these were boiled in SDS-PAGE loading dye, separated 
by SDS-PAGE and detected by Coomassie staining.
Cross-linking assay
Amine-reactive cross-linking agents disuccinimidyl sulfox-
ide (DSSO) and PEGylated bis(sulfosuccinimidyl)suberate 
(BS(PEG)5) were dissolved in DMSO and added to 10 µM 
CD1d-B2m alone, 20 µM SapB alone or 10 µM CD1d + 20 µM 
SapB with final cross-linker concentrations of 0, 200 µM or 1 mM 
in cross-linking buffer. The reaction was incubated for 30 min 
at room temperature and terminated by incubation with 20 mM 
Tris pH 8 for 15 min. The reaction products were analysed by 
SDS-PAGE followed by Coomassie staining.
Crystallography
Crystallization experiments were performed in 96-well nanolitre- 
scale sitting drops (200 nL protein plus 200 nL of precipitant) 
equilibrated at 20°C against 80 µL reservoirs of precipitant. 
The crystals reported here were grown in drops containing the 
following components:
Crystal form (i) (Figure 4B) contained glycosylated CD1d-H6-B2m 
(13.5 mg/mL) + 2-fold molar excess of unglycosylated SapB 
(4.7 mg/mL) in 150 mM NaCl, 50 mM Tris pH 7.4 and 
grew against a reservoir containing 20% w/v polyethylene 
glycol (PEG) 6000, 0.1 M HEPES pH 7 and 0.2 M calcium 
chloride.
Crystal form (ii) (Figure 4B) contained glycosylated 
CD1d-H6-B2m (12.4 mg/mL) + 2-fold molar excess of 
glycosylated SapB (after tag removal) (4.3 mg/mL) in 20 mM 
HEPES pH 7.0, 150 mM NaCl and grew against a reservoir 
containing 20 mM 1,6-hexanediol, 20 mM 1-butanol, 20 mM 
1,2-propanediol, 20 mM 2-propanol, 20 mM 1,4-butanediol, 
20 mM 1,3-propanediol, 0.1 M bicine/Trizma base pH 8.5, 
12.5% w/v PEG 1000, 12.5% w/v PEG 3350 and 12.5% v/v 
2-methyl-2,4-pentanediol.
Crystal form (iii) (Figure 4B) contained A-GalCer-loaded 
glycosylated CD1d-H6-B2m (11.9 mg/mL) + 2-fold molar excess 
of A-GalCer-loaded unglycosylated SapB (4.2 mg/mL) in 50 mM 
Tris pH 7.4, 150 mM NaCl and grew against a reservoir 
containing 0.1 M sodium acetate pH 5.0, 20% w/v PEG 6000 
and 0.2 M ammonium chloride.
Crystal form (iv) (Figure 4B) contained deglycosylated CD1d-
H6-B2m (13.3 mg/mL) + 2-fold molar excess of unglycosylated 
SapB (4.7 mg/mL) in 20 mM citrate pH 6, 150 mM NaCl, and 
grew against a reservoir containing 16% v/v PEG 500 mono-
methylether, 8% w/v PEG 20000, 0.1 M bicine/Trizma base 
pH 8.5, 30 mM sodium nitrate, 30 mM sodium phosphate 
dibasic and 30 mM ammonium sulfate.
Crystal form (v) (Figure 4D) contained deglycosylated 
CD1d-H6-B2m (6.5 mg/mL) + 2-fold molar excess of unglyco-
sylated SapB (2.3 mg/mL) in 100 mM citrate pH 6.0, 150 mM 
NaCl and grew against a reservoir containing 20% w/v 
PEG 3350, 0.1 M bis-Tris propane pH 7.5 and 0.2 M di-sodium 
malonate.
X-ray data collection and molecular replacement
Crystals were cryoprotected in reservoir solution supple-
mented with 20% v/v glycerol and flash-cooled by plunging 
into liquid nitrogen. Diffraction data were recorded at Dia-
mond Light Source (DLS) on beamlines I03, I04 and I04-1. 
Diffraction data were indexed and integrated using the automated 
data processing pipelines at DLS46 implementing XIA2 DIALS47, 
XIA2 3dii or autoPROC and STARANISO48 depending on the 
extent of anisotropic diffraction, then scaled and merged using 
AIMLESS49. Version numbers for crystallography data process-
ing software are detailed in Table 1. The model for molecu-
lar replacement was generated using the published structure of 
CD1d-B2m bound to lysophosphatidylcholine50 (PDB ID 3U0P, 
chains A and B), using phenix.sculptor (Phenix v1.14-3260)51,52 
to remove the lipid ligand from the model and revert the 
glycosylation site mutations present in this structure. Molecu-
lar replacement was performed using phenix.phaser53 and was 
Table 1. Crystallography data processing software.
Crystal (iii) Crystal (iv) Crystal (v)
Processing 
software
autoPROC (v1.0.5) and STARANISO 
(v1.10.15)
XIA2 (v0.5.771) 3dii (version January 
26, 2018)
XIA2 (v0.5.764) DIALS 
(v1.12.2)






followed by rigid body refinement using phenix.refine54. Molecu-
lar replacement into the highly anisotropic data (Crystal form 
(iii)) was carried out using both the isotropic and anisotropi-
cally processed data, resulting in the same solution. Maps were 
inspected using COOT (v0.8.9)55. Structure figures were rendered 
using PyMOL (v2.1.0, Schrödinger LLC).
SDS-PAGE analysis of crystals
For each crystallisation condition tested, several crystals were 
harvested from the crystallisation drop and washed by trans-
ferring to a drop of reservoir solution to remove uncrystal-
lised protein components. Crystals were then transferred to a 
second drop of reservoir solution and dissolved in SDS-PAGE 
loading buffer. Alternatively, large crystals from which data had 
been collected at the synchrotron were recovered into SDS-
PAGE loading buffer from the crystal-mounting loop. Individual 
crystal components were analysed by SDS-PAGE followed by 
Coomassie staining.
Results
Purification of CD1d-β2m complex from a human cell line
Several strategies have been developed previously for the 
purification of CD1d including refolding from E. coli inclusion 
bodies56, baculovirus-insect cell expression50 and mammalian 
expression systems57. An important consideration for CD1d pro-
tein expression and purification is the inclusion of the essential 
partner protein B2m. In a manner similar to the heavy chain of 
MHC class I, CD1d non-covalently associates with B2m and this 
association is required for maturation of its four glycan chains58. 
In order to obtain high quality, near-native CD1d protein for 
in vitro studies, we chose to co-express human CD1d with 
B2m in the mammalian suspension cell line HEK293F as 
this would confer correct folding, native post-translational 
modification and full glycosylation of CD1d. Initial trials 
using polyethylenimine-based transient co-transfection of 
CD1d and B2m resulted in very low yields. Thus we used a 
piggyBac-expression system41 to establish stable and inducible 
co-expression of full-length, untagged B2m with the ectodo-
main of CD1d possessing a C-terminal hexahistidine tag (H6) 
(Figure 1A). Both proteins were expressed with an N-terminal 
secretion signal sequence targeting synthesis to the endoplas-
mic reticulum, resulting in protein secretion into the media. This 
expression strategy results in CD1d molecules that are bound to 
endogenous human lipids acquired during folding in the endo-
plasmic reticulum and trafficking through the Golgi apparatus. 
CD1d-H6 was purified from conditioned media by nickel affin-
ity chromatography followed by size exclusion chromatography 
(Figure 1B and C). Untagged B2m co-purified with CD1d, 
indicating that both proteins are correctly folded and form 
a stable complex. Although some CD1d alone was puri-
fied, we were able to separate this from CD1d-B2m following 
size exclusion (Figure 1C). Using this expression system, 
we obtained a high yield (1 mg/100 mL media) of very pure 
CD1d-B2m protein. The yield was over 10 times higher than 
that obtained with transient co-transfection in the same 
cell line.
Purification of SapB
The four saposin proteins (SapA-D) are produced from the 
proteolytic cleavage of the precursor protein PSAP which 
normally occurs upon delivery to the lysosome. To produce 
recombinant SapB alone, the segment of human PSAP corre-
sponding to SapB (Figure 1D) was expressed in E. coli. Untagged 
SapB was purified following a well-established protocol43 
that exploits the heat stability of saposins followed by anion 
exchange and size exclusion chromatography (Figure 1E and F). 
Previous structural studies with E. coli-expressed SapB 
identified that it exists as a tight dimer that co-purifies with 
E. coli phosphatidylethanolamine14.
CD1d binding to SapB is not detectable using in vitro 
interaction assays
Classical pull-down experiments involve the capture and immo-
bilisation onto resin of a tagged bait protein followed by incuba-
tion with prey protein. Subsequent wash steps remove unbound 
protein leaving behind protein complexes for detection. How-
ever, as the concentration of free prey protein is reduced 
at each wash, the equilibrium is pushed towards complex 
dissociation, meaning this method is not well suited for the cap-
ture of weak or transient interactions. Using this approach, no 
interaction was detectable between immobilised CD1d-B2m 
and SapB. Therefore, an alternative approach was adopted 
to overcome the limitations of prey-depletion by using an 
in vitro equilibrium binding assay (Figure 2A). In this assay, the 
bait is bound to beads at a range of concentrations and the prey 
is added at a low, limiting concentration. Following incubation, 
and no wash steps, the supernatant is separated from the beads and 
unbound prey is detected using the sensitive protein dye SYPRO 
Ruby. Monitoring the depletion of prey from the supernatant by 
the large excess of bait protein, rather than monitoring complex 
formation directly, represents a more sensitive measure of binding 
and thus is optimised for weak or transient interactions59.
Equilibrium binding assays were carried out using CD1d-B2m 
as bait at a concentration range of 0-40 µM and with SapB as 
the prey at 680 nM. Previous in vitro studies have identified 
that SapB can load A-GalCer onto CD1d at a pH range between 
5 and 833. Although this exchange appears to be most effi-
cient at pH 6, this pH causes partial dissociation of the CD1d 
His-tag from the Ni-NTA resin. Therefore, the equilibrium 
binding assay was performed at pH 7. Previous work, and our 
preliminary experiments, showed that B2m dissociates from 
CD1d in the presence of detergent60. However, the gentle deter-
gent digitonin was found to cause minimal disruption of the 
CD1d-B2m complex60 and was used in this assay. Despite the 
use of this optimised approach, no binding of SapB to CD1d 
could be detected (Figure 2B). In these conditions, at high 
CD1d-B2m concentrations, a small amount of B2m is detectable 
in the supernatant due to dissociation from CD1d (Figure 2B). 
By comparing how little appears to be lost based on the 
Coomassie-stained bead samples this highlights the sensitivity 







Figure 1. Purification of CD1d-β2m and SapB. A. A His-tagged construct encoding the extracellular domain of CD1d (CD1d-H6) was 
co-expressed with untagged full-length B2m in mammalian cells. B. Size exclusion chromatography (SEC) showing co-purification of 
CD1d-H6 with B2m. C. SDS-PAGE of SEC fractions. The indicated fractions containing B2m-associated CD1d were used in subsequent 
experiments. D. Untagged SapB (residues 195-274 of the precursor protein PSAP) was expressed in E. coli. E. SEC of SapB after 
multi-step purification. F. SDS-PAGE of SEC fractions. The indicated fractions were used in subsequent experiments.
Figure 2. Equilibrium binding assay of CD1d-β2m and SapB. A. Schematic diagram illustrating the equilibrium binding assay protocol. 
B. Increasing concentrations of CD1d-B2m were bound to beads and detected by Coomassie-stained SDS-PAGE. After incubation with 
SapB, unbound SapB was detected in supernatants by SYPRO Ruby-stained SDS-PAGE. The lipids bound to CD1d-B2m and SapB in this 
experiment are the endogenous lipids they co-purify with following expression in human cells and E. coli, respectively. C. As for panel B but 






Previous studies have shown that the ectodomain of CD1d 
co-purifies with a broad range of cellular lipids following 
synthesis and trafficking through the secretory pathway, but is 
likely to be primarily loaded with sphingomyelin8–10. SapB co- 
purifies with E. coli phosphatidylethanolamine14, a lipid 
species that has also been shown to bind CD1d61. Although it 
seems likely that this lipid composition for SapB and CD1d 
should be compatible with protein-protein interactions required 
for lipid exchange, lipid loading onto CD1d has only been for-
mally demonstrated in vitro for a few lipids, and in particular 
A-GalCer33,34. Therefore, both proteins were pre-loaded with 
A-GalCer prior to performing the equilibrium binding assay. 
However, this variation also did not result in a detectable inter-
action between SapB and CD1d (Figure 2C). To exclude 
the possibility that a strong interaction between CD1d and SapB 
only occurs when SapB exchanges a lower affinity antigen 
for A-GalCer, we repeated the equilibrium binding assay where 
SapB was pre-loaded with A-GalCer while CD1d retained 
the co-purified endogenous lipids (Figure 2D). Again, there was 
no substantial depletion of SapB from the supernatant in this 
assay. These results strongly suggest that CD1d and SapB 
do not directly interact in vitro, or that their interaction is 
extremely weak with a Kd > 40 µM.
In vitro cross-linking does not capture an interaction 
between CD1d and SapB
Cross-linking of proteins using short chemical tethers that react 
with surface-exposed lysine side-chains can be used to capture 
transient or weak interactions. Both CD1d and SapB have 
several surface-exposed lysines, and of particular importance, 
lysine residues are present near the lipid-binding groove of 
CD1d where we would predict SapB to bind (Figure 3A and B). 
Therefore, it is possible that CD1d and SapB interact in a way 
that is amenable to intermolecular cross-linking of surface 
lysines by amine-reactive cross-linkers. We used cross-linkers 
of different lengths to maximise the chances of capturing an inter-
action: DSSO, with a 10.3 Å spacer arm, and BS(PEG)5, with a 
21.7 Å spacer arm. CD1d-B2m and SapB were incubated with 
these cross-linkers either alone or following mixing (Figure 3C). 
For the CD1d-B2m samples alone, cross-linking between CD1d 
and B2m is clearly evident, as expected. There is also some 
evidence of additional higher order oligomers, probably due to 
the large number of surface lysines on both CD1d and B2m. How-
ever, no additional cross-linking products were observed when 
CD1d-B2m and SapB were incubated together with the cross-
linkers. This indicates that CD1d-B2m and SapB do not interact 
together in a conformation that is amenable to cross-linking.
Figure 3. In vitro cross-linking of CD1d-β2m and SapB. A. Ribbon diagram of the structure of CD1d (beige) and B2m (pink)(PDB ID 3U0P) 
with the lipid antigen groove labelled (arrow). Surface-accessible lysine residues available for cross-linking are highlighted (red sticks). 
B. Ribbon diagram of the structure of a SapB dimer (yellow and orange, PDB ID 1N69) with bound lipid (in gray). Lysine residues are 
highlighted as in panel A. The N-linked glycosylation site of SapB is highlighted (blue sticks). C. Coomassie-stained SDS-PAGE of 
CD1d-B2m and unglycosylated SapB samples following incubation with cross-linkers of different lengths: DSSO (10.3 Å) or BS(PEG)5 






SapB possesses one N-linked glycosylation site on residue Asn21 
(Figure 3B), which remains unglycosylated when expressed 
in E. coli. Although unglycosylated SapB loads lipids onto 
CD1d33,34, it is possible that this glycan on SapB may increase 
its affinity for CD1d. Therefore, we repeated the cross-linking 
experiment following expression of His-tagged SapB 
in mammalian HEK293F cells, enabling the purifica-
tion of glycosylated protein. Following purification, two 
SapB-H6 species were present, with molecular weights of 
approximately 10 and 13 kDa, likely corresponding to ungly-
cosylated and glycosylated SapB-H6 (Figure 3D). It was not 
possible to separate these two SapB species, likely due to SapB 
dimerization, and so cross-linking experiments were carried out 
using this mixed sample (Figure 3D). However, we again did 
not observe formation of any additional cross-linked products 
when CD1d-B2m was incubated with glycosylated SapB-H6. 
We note that although the same amount of unglycosylated SapB 
(Figure 3C) and glycosylated SapB (Figure 3D) were used in 
cross-linking assays, the Coomassie-stained bands corresponding 
to glycosylated SapB appear much stronger. This increased 
staining may be due to the additional histidine residues in 
the affinity tag increasing the amount of Coomassie reagent 
binding to this small protein.
CD1d-β2m and SapB do not co-crystallise
An alternative method to capture weak, transient protein-protein 
interactions is to attempt co-crystallisation. In this experiment 
both protein components are mixed together at a range of 
concentrations and different molar ratios, then subjected to 
crystallisation trials. The benefit of using the sitting-drop vapour 
diffusion approach is that during the experiment the drop 
containing protein and precipitant gradually equilibrates with 
the reservoir, generally resulting in reduced drop volume and the 
progressive increase in concentration of the drop components. 
In this way, the protein components are steadily concen-
trated together with the aim of capturing an interaction that is 
otherwise extremely hard to measure using biochemical and 
biophysical assays62.
Extensive crystallisation trials containing both CD1d-B2m and 
SapB were performed, varying the following parameters: (1) 
protein concentration (6-13 mg/mL CD1d-B2m, 2-6 mg/mL 
SapB), (2) molar ratio of SapB to CD1d, taking into account the 
predicted dimeric state of SapB (2:1-3:1 SapB to CD1d); (3) full 
glycosylation or deglycosylation of protein components; and 
(4) lipid exchange for A-GalCer. Figure 4A shows an example 
of the high purity of the protein components that went into crys-
tallisation trials. These experiments yielded several different 
crystals in a range of conditions, a subset of which are 
shown in Figure 4B. To determine the composition of these 
crystals, two approaches were used depending on the quality of the 
crystals grown. The first approach, which can be used for any 
protein crystal, involves harvesting and washing the crystals 
in reservoir solution to remove residual uncrystallised 
components, then separating the proteins by SDS-PAGE followed 
by detection using Coomassie staining (Figure 4C, each gel lane 
corresponds to the above crystal in panel 4B). This revealed 
that both SapB and CD1d-B2m were capable of forming 
crystals but in none of the crystals grown did both compo-
nents crystallise together. The second approach used was to 
collect diffraction data for any crystals that diffracted to 5 Å 
resolution or better, then use molecular replacement to 
confirm the contents of the asymmetric unit (Table 2). Three 
crystal forms satisfied this criteria, including two that had also 
Figure 4. Crystallisation trials of CD1d-β2m and SapB. A. Coomassie-stained SDS-PAGE example of the purified protein sample used 
in crystallisation trials. B. Examples of four crystals (i)–(iv) grown in a range of conditions using different protein compositions. Scale bar 
represents 100 µm. C. Coomassie-stained SDS-PAGE of harvested and washed crystals shown in panel B. D. Image of the crystal that 
diffracted to highest resolution as described in Table 2. Scale bar represents 100 µm. Abbreviations: gCD1d-glycosylated CD1d, dgCD1d-






Table 2. Data collection statistics and molecular replacement solutions. For Crystal 4B (iii) statistics 
have been included for data from a single crystal before (isotropic) and after anisotropic truncation and 
scaling using STARANISO. Values in parentheses are for the highest-resolution shell.
Data collection Crystal Fig 4B (iii) Crystal Fig. 4B (iv) Crystal Fig. 4D (v)
Beamline I04 I04-1 I03
Wavelength (Å) 0.9999 0.9159 0.9793
Processing package autoPROC + STARANISO XIA2 3dii XIA2 DIALS
Space group C 2 P 21 C 2
Cell dimensions
a,b,c (Å) 273.3, 88.0, 127.9 123.8, 122.9, 159.9 186.2, 57.1, 129.2
],^,c (°) 90, 114, 90 90, 95, 90 90, 100, 90
Isotropic Anisotropic
Resolution (Å) 124.71 – 4.97 
(5.05 – 4.97)
124.71 – 4.55 
(5.00 – 4.55)
123.27 – 3.49 
(3.55 – 3.49)
54.53 – 2.52 
(2.56 – 2.52)
Rmerge 0.438 (2.187) 0.198 (0.507) 0.161 (1.572) 0.072 (2.438)
Rpim 0.279 (1.366) 0.127 (0.323) 0.067 (0.663) 0.031 (1.028)
CC1/2 0.967 (0.322) 0.987 (0.704) 0.992 (0.714) 0.999 (0.813)
I/SI 1.9 (0.5) 3.4 (1.8) 6.9 (1.0) 10.9 (0.8)
Completeness (%) 99.8 (99.8) e* 80.0 (56.7) 
s* 39.2 (8.1)
99.8 (99.9) 99.8 (98.0)
Redundancy 3.4 (3.5) 3.4 (3.4) 6.9 (6.6) 6.7 (6.6)
Molecular replacement
# CD1-B2m/ASU 4 6 2
*ellipsoidal (e) and spherical (s) completeness are quoted for anisotropic data processing using STARANISO.
been tested using SDS-PAGE (Figure 4B (iii) and (iv) and 4D 
(v)). These three samples all contained CD1d-B2m only as 
confirmed by molecular replacement trials using multiple 
copies of all potential components as well as manual inspection 
of maps. In all datasets additional density was observed for 
unmodelled glycans on CD1d (deglycosylation of CD1d using 
Endo H leaves a residual acetylated glycosamine), confirming the 
validity of the molecular replacement solution. For several CD1d 
molecules, additional unmodelled density near the lipid-binding 
groove was evident that likely corresponds to partially-ordered 
lipid components. Further inspection of electron density maps 
revealed no evidence for the presence of SapB. For most 
molecules of CD1d in all three different crystal forms the pre-
dicted binding site for SapB (over the lipid-binding groove) was 
occupied by another copy of CD1d. The use of both SDS- 
PAGE analysis of all grown crystals and molecular replace-
ment solution of higher quality crystals confirmed that, despite 
extensive efforts with a broad range of CD1d-B2m/SapB 
combinations, these do not form a stable, crystallisable complex.
Discussion
Using highly purified components we have been unable to iden-
tify a direct interaction between CD1d-B2m and SapB in vitro. 
Several biochemical and structural approaches were imple-
mented that have the capacity to capture weak and transient 
interactions, including binding equilibrium assays, protein cross-
linking, and co-crystallisation trials. Various factors that may 
influence the strength or specificity of these interactions were 
tested, including different pH and buffer systems, exchange of 
the lipids loaded onto both protein components, and 
changing the glycosylation state of each protein. None of these 
variants resulted in the detection of a direct interaction. Our 
previous work studying saposin interactions with lysosomal 
hydrolases showed that although these interactions are sensitive 
to pH and salt concentrations, they were always detectable, and 
while detergent/lipid was required, neither the nature of the 
lipid/detergent nor the glycosylation state mattered19.
Direct protein-protein interactions are crucial for several differ-
ent lipid transfer pathways. The lipopolysaccharide (LPS) trans-
fer cascade resulting in Toll-like receptor 4 (TLR4) activation 
involves several lipid transfer steps. LPS binding protein (LBP) 
extracts LPS and transfers it onto the receptor CD14. CD14 then 
transfers LPS to the TLR4 co-receptor MD-2. A direct, high 
affinity (Kd  = 5.52 nM) interaction between LBP and CD14 is 
necessary for lipid transfer, and lipid transfer promotes rapid 
dissociation of CD14:LPS from LBP. Similarly, a direct 
interaction between CD14 and the TLR4:MD-2 complex is 
required for lipid transfer38. The transfer of lipids between 






(apoB)-containing lipoproteins. Microsomal Triglyceride Transfer 
protein assists this process by binding to apoB with high affin-
ity (Kd 10-30 nM)
63 and transferring lipids onto apoB through an 
unknown mechanism. Both functions are required for lipopro-
tein assembly39. As another example, Niemann–Pick C1 (NPC1) 
and Niemann–Pick C2 (NPC2) proteins collaborate to export 
cholesterol from the lysosome. Soluble NPC2 binds choles-
terol in the lysosomal lumen, interacts with the middle lume-
nal domain of the multipass transmembrane protein NPC1 
and transfers cholesterol to NPC1 via a transfer tunnel linking 
the cholesterol-binding pockets of both proteins. The interac-
tion between NPC2 and NPC1 (Kd 0.4-2 µM) is required for 
cholesterol export40. In all cases, a high-to-medium affinity direct 
interaction between proteins engaged in lipid transfer is detect-
able. In this study, we were unable to detect a direct interaction 
between CD1d and SapB despite the assays being capa-
ble of detecting very weak interactions. Specifically, the 
equilibrium assay used in this study can detect protein inter-
actions where the dissociation constant is as weak as 40 µM. In 
the absence of avidity effects, interactions weaker than 40 µM 
are unlikely to be physiologically relevant. Furthermore, the 
cross-linking assay can detect short-lived, transient interactions 
and the co-crystallography technique uses very high concen-
trations of protein components allowing for the detection of 
very weak interactions. It therefore seems unlikely that an 
interaction that is undetectable by these methods could 
permit direct lipid exchange between SapB and CD1d.
The study of lipid loading of CD1 molecules is technically 
challenging as biochemical methods often require the inclu-
sion of detergents, which may interfere with lipid solubilisa-
tion and binding. Also, the detection of changes to CD1d-lipid 
complexes is limited by available reagents including specific 
antibodies and iNKT TCRs. However, the inability to identify 
a direct interaction between CD1d and SapB raises a number of 
important questions regarding the role of saposins in lipid antigen 
presentation.
It is well established that knockout of the saposin precursor 
protein PSAP results in impaired presentation of lipid antigens 
by CD1d. Due to the dual role of saposins in lipid loading and 
lipid processing, the absence of PSAP will not only alter CD1d 
lipid loading, but will also significantly alter the composition 
of the lysosomal lipidome. Indeed, the loss of a single saposin 
results in the cellular accumulation of multiple, different GSLs. 
For example, loss of SapB alone, in mice or in humans, results 
in the accumulation of sulfatides, globotriaosylceramide, and 
lactosylceramide64,65. Therefore, in saposin knockout and rescue 
models, the effects on antigen processing and the changes to 
local lipid concentrations may have indirect and unpredict-
able effects on CD1d loading in the lysosome. Similarly, 
cell-based assays that involve recognition of CD1d-lipid com-
plexes by NKT cells are complicated by the requirement of 
some glycolipid headgroups to be processed by lysosomal 
hydrolases12, a process that is itself dependent upon 
saposins.
In vitro assays testing the role of different saposins in 
facilitating lysosomal hydrolase activity identify some of the 
difficulties in determining specificity of saposin-lipid binding. 
For example, in vitro assays have identified that SapC and SapA 
are both able to enhance the activity of B-galactosylceramidase 
(GALC) to promote degradation of the galactosphingolipids66,67. 
However, this does not reflect the specificity of saposins in 
whole organisms as loss of SapA causes Krabbe disease, 
similar to that of loss of GALC, while mutations in SapC 
do not20,21,23–25. Why these in vitro assays do not recapitulate the 
specificity of saposins in a whole organism remains unclear 
but may suggest a non-specific detergent-like effect of saposins 
when present at relatively high concentrations. It is unclear 
whether a similar effect may be partially confounding the inter-
pretation of SapB influence on CD1d lipid loading. While 
in vitro studies demonstrating the ability of SapB to enhance 
CD1d stimulation of iNKT cells or binding to iNKT TCRs are 
very compelling regarding the importance of SapB in this proc-
ess, these do represent an indirect way of monitoring how SapB 
may be involved in lipid exchange33,34. In light of our data show-
ing no detectable interaction between CD1d and SapB, the 
question remains: how can SapB facilitate lipid editing 
without directly binding CD1d? Modelling of how SapB might 
facilitate lipid exchange identified a role for SapB in enhanc-
ing the kinetics of lipid exchange in a manner similar to that 
of Tapasin in peptide exchange on MHC class I molecules34. 
This comparison is driven by the crucial roles that Tapasin and 
SapB play in the binding and exchange of peptides or lipids, 
respectively, to the antigen-binding grooves of MHC class I 
or CD1d molecules. In order for Tapasin to carry out this role, 
it binds directly to MHC class I but as part of a larger complex 
including additional proteins2,68. Although the in vitro assays 
demonstrating the importance of SapB for CD1d lipid presenta-
tion did not require other proteins, it is possible that there may 
be additional factors involved in enhancing the affinity of SapB 
for CD1d in cells.
Additional factors may influence the efficiency of lipid load-
ing onto CD1d in cells. For example, the relative abundance 
of different LTPs in the lysosome may influence the lysosomal 
lipid composition, altering exchange kinetics. Therefore, it 
may be important that SapA-D exist in equimolar concentra-
tions in the endolysosome, as ensured by their production from a 
common precursor. If this is the case, studies involving indi-
vidual saposins or partial PSAP rescues will be difficult to 
interpret, potentially explaining some experimental inconsist-
encies. The lysosomal lipidome is not only influenced by the 
activity of saposins and sphingolipid processing hydrolases 
but also by the careful balance of other membrane components 
such as cholesterol and bis(monoacylglycero)phosphate that are 
crucial for endosomal vesicle formation. Lipid loading of CD1 
in endolysosomal compartments is highly complex, requiring the 
delicate interplay of lipid binding, lipid processing and lipid 
exchange. For now, the mechanism of transfer of lipids onto CD1 









Figshare: Original data used in Figure 1, https://doi.org/10.6084/
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Proteins significantly changed more than 2-fold at the plasma membrane of GALC KO1 and KO2 versus 
EV1 control THP-1 cells, quantified by plasma membrane profiling-mass spectrometry (Benjamini-
Hochberg adjusted q-value < 0.05).  
 
Gene ID Log2 (fold change KO1/EV1) q-value 
Log2 (fold change 
KO2/EV1) q-value 
IL18R1 3.35 7.16E-04 1.98 5.56E-03 
SLC7A11 3.22 8.89E-04 2.69 2.06E-03 
FAS 2.85 8.89E-04 1.98 5.10E-03 
TRHDE 2.61 2.34E-04 2.85 6.82E-05 
GGT5 2.55 2.34E-04 1.40 3.82E-03 
ANPEP 2.49 2.34E-04 1.66 1.65E-03 
EPHB1 2.21 8.89E-04 1.48 6.19E-03 
CIB1 2.20 2.16E-03 2.63 9.25E-04 
SDK1 2.19 1.57E-03 1.92 2.73E-03 
SDC2 2.10 8.18E-04 1.47 4.34E-03 
SLC40A1 2.09 2.76E-03 1.90 5.22E-03 
JAG1 1.83 2.34E-04 1.76 4.11E-04 
TMC8 1.81 8.89E-04 2.10 4.22E-04 
ACE 1.72 2.71E-03 2.22 9.25E-04 
PROCR 1.63 8.89E-04 1.54 9.61E-04 
SLC7A7 1.62 6.17E-03 1.74 4.18E-03 
TMC6 1.62 9.05E-04 1.83 7.46E-04 
MCEMP1 1.39 1.95E-03 1.39 2.04E-03 
CD244 1.38 1.95E-03 1.64 9.61E-04 
PCDH20 1.34 6.17E-03 1.42 4.34E-03 
IL2RB 1.22 5.67E-03 1.11 9.37E-03 
LPAR4 1.10 8.84E-03 1.11 8.12E-03 
ICAM2 -1.08 9.10E-03 -1.17 5.56E-03 
DLL1 -1.30 7.05E-03 -1.63 2.04E-03 
FLT3 -1.31 6.60E-03 -1.27 6.14E-03 
ITGAL -1.61 1.46E-03 -1.57 1.66E-03 
TMEM158 -1.62 3.70E-03 -1.97 1.52E-03 
ALB -2.01 3.09E-03 -1.99 3.89E-03 
CNTN4 -2.16 6.17E-03 -2.01 8.12E-03 
AXL -2.52 1.57E-03 -1.81 8.91E-03 
LILRB4 -2.65 2.34E-04 -1.47 5.00E-03 




Proteins significantly changed more than 2-fold in lysates of GALC KO1 and KO2 versus EV1 control 
THP-1 cells, quantified by whole cell proteomics (Benjamini-Hochberg adjusted q-value < 0.05) 
 
Gene ID Log2 (fold change KO1/EV1) q-value 
Log2 (fold change 
KO2/EV1) q-value 
SLC7A11 2.93 5.75E-04 2.37 1.14E-03 
HSD11B1 2.86 5.37E-03 4.57 1.46E-03 
MSRB3 2.48 4.42E-04 3.02 2.10E-04 
MARCKS 2.01 1.04E-03 3.75 2.10E-04 
OAS3 2.01 5.42E-04 3.30 2.04E-04 
MNDA 2.00 1.15E-03 2.52 6.51E-04 
MYO6 1.88 3.98E-04 1.20 1.09E-03 
H1F0 1.63 1.50E-03 1.40 2.49E-03 
OCLN 1.55 1.17E-02 1.91 6.57E-03 
CKAP4 1.46 4.58E-04 1.57 3.15E-04 
AKR1C2 1.41 2.78E-03 1.62 2.13E-03 
ARHGAP31 1.30 2.77E-03 1.20 6.42E-03 
MT2A 1.27 4.37E-03 1.39 4.39E-03 
SASH3 1.24 2.11E-03 1.19 2.18E-03 
PLS1 1.24 3.98E-04 1.43 2.48E-04 
RAB20 1.23 3.51E-03 1.04 5.27E-03 
RNASE2 1.22 3.51E-03 1.53 1.46E-03 
AP3S2 1.16 2.13E-03 1.11 2.55E-03 
TNIK 1.16 1.12E-03 1.10 1.42E-03 
ISG20 1.11 4.11E-03 1.84 1.03E-03 
MCEMP1 1.09 6.33E-03 1.07 8.37E-03 
HSPA4L 1.05 9.49E-04 1.10 8.16E-04 
SLC9A7 -1.37 1.92E-02 -1.35 1.42E-02 
FHL1 -1.53 2.64E-03 -1.01 1.38E-02 






Differentially expressed genes in GALC KO1 and KO2 versus EV1 control THP-1 cells quantified by RNA 
sequencing (> 2-fold change, False discovery rate adjusted q-value < 0.05) 
 
Gene ID Log2 (fold change KO1/EV1) q-value 
Log2 (fold change 
KO2/EV1) q-value 
MSRB3 2.98 1.01E-13 4.14 6.33E-14 
OAS3 2.67 1.01E-13 4.38 6.33E-14 
IFI6 2.07 1.01E-13 4.20 6.33E-14 
H2BU1 1.98 1.01E-13 1.63 6.33E-14 
SESN3 1.98 3.07E-11 2.51 1.88E-11 
OAS2 1.86 1.01E-13 3.90 6.33E-14 
ENC1 1.78 5.25E-08 1.74 1.46E-04 
SLC7A11 1.74 1.01E-13 2.01 6.33E-14 
CACNA1E 1.74 4.37E-12 1.97 3.20E-10 
MAP4K1 1.73 2.18E-05 1.60 1.40E-02 
CKAP4 1.72 1.01E-13 1.91 6.33E-14 
CX3CR1 1.69 3.76E-11 1.40 1.80E-04 
NLRC3 1.68 1.15E-07 1.62 4.38E-04 
TRHDE 1.59 4.65E-03 2.67 4.36E-03 
OAS1 1.56 3.85E-06 3.01 6.33E-14 
C3orf80 1.56 1.01E-13 1.31 1.94E-07 
SDK1 1.54 2.62E-05 1.38 1.78E-02 
CTSG 1.54 2.00E-06 1.88 6.74E-06 
H2AW 1.52 1.01E-13 1.12 7.54E-07 
NEGR1 1.49 2.94E-03 1.61 4.30E-02 
SYNE1 1.45 2.10E-04 1.32 4.07E-02 
H3-2 1.44 1.01E-13 1.50 2.31E-11 
MYO6 1.44 1.88E-05 1.15 3.59E-02 
DGKH 1.42 7.89E-12 1.43 2.46E-08 
TSPAN5 1.41 6.30E-04 1.80 3.41E-03 
TRIM22 1.40 4.93E-05 2.58 3.45E-11 
ABCA1 1.40 1.60E-10 1.40 1.60E-06 
IRS2 1.38 4.31E-05 1.39 3.76E-03 
PDGFD 1.34 3.14E-04 1.19 4.47E-02 
TSC22D1 1.33 1.81E-05 1.34 1.78E-03 
CMPK2 1.31 1.77E-05 3.48 6.33E-14 
MNDA 1.31 5.18E-04 2.69 1.42E-10 
ISG15 1.31 3.95E-06 3.18 6.33E-14 
ANPEP 1.30 1.13E-11 1.22 2.19E-06 
NPTXR 1.27 5.82E-04 1.47 3.38E-03 
 246
Gene ID Log2 (fold change KO1/EV1) q-value 
Log2 (fold change 
KO2/EV1) q-value 
IFIT5 1.23 3.51E-04 2.43 1.74E-11 
HOXA13 1.21 1.65E-04 1.32 2.02E-03 
JAG1 1.20 2.32E-03 1.28 3.55E-02 
NTNG2 1.20 5.00E-03 1.64 9.03E-03 
GBP5 1.19 4.34E-03 1.70 3.54E-03 
HELZ2 1.19 5.82E-08 2.33 6.33E-14 
IFIT3 1.18 2.60E-05 2.90 6.33E-14 
IRF9 1.16 8.53E-06 1.61 2.30E-08 
SASH3 1.11 4.58E-06 1.18 1.12E-04 
IFIT1 1.11 2.30E-03 3.20 6.33E-14 
LACC1 1.10 3.06E-03 1.11 4.27E-02 
MT2A 1.09 5.10E-07 1.48 6.09E-10 
DUSP16 1.09 6.47E-03 1.24 3.24E-02 
HSD11B1 1.09 1.36E-02 2.56 9.83E-05 
IFITM1 1.09 4.59E-02 3.01 4.75E-03 
DDX60L 1.06 1.77E-11 1.70 6.33E-14 
PARP14 1.06 2.98E-09 2.21 6.33E-14 
PARP9 1.05 8.45E-05 2.25 6.33E-14 
KIAA0408 1.05 7.93E-03 1.43 4.64E-03 
CYP1B1 1.03 2.91E-08 1.10 4.90E-07 
JCAD 1.02 6.32E-03 1.29 6.25E-03 
TCF23 1.01 7.63E-05 1.76 2.45E-11 
NFATC2 1.00 3.97E-03 1.35 1.41E-03 
DDX60 1.00 1.31E-04 1.97 3.44E-13 
TENT5A 1.00 5.37E-04 1.79 2.62E-09 
ARRDC3 -1.02 7.85E-07 -1.65 1.11E-10 
DLL1 -1.21 1.38E-03 -1.22 2.03E-02 
SLC9A7 -1.25 1.88E-04 -1.88 3.64E-05 
KCNQ3 -1.34 8.86E-06 -2.09 2.15E-07 
RASA1 -1.42 1.01E-13 -1.49 1.20E-13 
AFAP1 -1.51 3.74E-07 -2.04 1.40E-07 






Proteins significantly changed more than 2-fold in lysates of Cas9 versus WT THP-1 cells, quantified by 







MAGEA4 3.00 5.50E-11 
RPS19BP1 2.89 1.06E-09 
SCD 2.53 6.36E-09 
C19orf53 2.49 4.93E-08 
CCND3 2.46 6.35E-06 
CNTNAP4 2.46 2.70E-07 
BYSL 2.41 2.02E-09 
TFEB 2.35 5.50E-11 
MAP1B 2.34 1.89E-07 
RRP36 2.29 1.91E-09 
HIF1AN 2.19 1.93E-09 
PACSIN1 2.17 2.90E-07 
RPL22L1 2.17 2.03E-07 
ASNS 2.14 9.14E-06 
IGF2BP3 2.10 3.17E-09 
GMPR 2.10 9.48E-08 
PHGDH 2.08 4.70E-06 
C16orf72 2.07 7.45E-08 
ARRB2 2.06 2.02E-09 
BCAT1 1.97 1.06E-09 
AMOT 1.97 1.10E-09 
OARD1 1.94 4.20E-10 
DPYSL3 1.84 4.78E-08 
FAM49A 1.82 1.23E-08 
FOXP4 1.80 1.96E-08 
MEF2C 1.76 2.18E-06 
KCNK5 1.75 3.52E-06 
BARX1 1.74 1.21E-06 
SAYSD1 1.67 1.21E-06 
YBX3 1.66 3.68E-09 
CHPT1 1.65 3.50E-06 
CFAP97 1.64 1.66E-05 
ENKD1 1.62 3.47E-06 






FAM234B 1.58 1.06E-09 
NOP53 1.54 2.98E-07 
SLC7A5 1.53 2.77E-07 
PHKA1 1.52 1.25E-07 
SENP6 1.50 5.36E-09 
SLITRK5 1.49 1.54E-07 
SCD5 1.48 2.58E-07 
SLC38A1 1.47 2.60E-07 
NPM3 1.47 5.00E-06 
GLUL 1.46 5.24E-07 
PLA2G4A 1.46 6.09E-08 
HK2 1.44 2.02E-09 
NOB1 1.43 2.44E-08 
C1QBP 1.42 1.11E-07 
GSTM4 1.42 1.49E-07 
RAB33A 1.41 1.93E-06 
CDCA7L 1.40 2.91E-07 
STX10 1.40 5.21E-08 
REEP5 1.39 7.63E-08 
GOT1 1.38 4.96E-07 
MATK 1.38 3.47E-06 
NDUFB8 1.38 1.16E-05 
PHF23 1.36 2.68E-08 
PSRC1 1.35 4.43E-06 
FAIM 1.34 3.27E-07 
MPHOSPH10 1.33 1.54E-08 
RRP1 1.32 6.72E-09 
FAM32A 1.32 1.64E-06 
MAPT 1.30 4.88E-09 
MSI2 1.30 1.37E-08 
AKAP10 1.30 4.08E-08 
SLF2 1.29 1.26E-09 
ALKBH2 1.29 2.48E-06 







LTV1 1.27 3.43E-09 
PCLAF 1.27 1.40E-04 
ZNF280A 1.27 1.45E-07 
RCN3 1.27 1.48E-08 
LCOR 1.26 4.17E-07 
GCSH 1.25 1.41E-07 
CD109 1.25 7.93E-08 
KCTD15 1.25 6.21E-07 
FAM204A 1.24 5.48E-05 
CCDC7 1.24 8.41E-06 
CCDC137 1.23 9.92E-09 
DESI2 1.23 2.27E-03 
NUP42 1.21 5.19E-07 
CEP72 1.21 3.88E-08 
BIN2 1.20 1.57E-07 
PSAT1 1.20 3.40E-05 
NOP2 1.19 1.75E-09 
UTP11 1.19 8.16E-09 
PDLIM1 1.18 8.06E-08 
PHB 1.18 1.01E-08 
TENM3 1.17 2.12E-07 
SLC16A1 1.16 3.68E-06 
PRKAR1B 1.16 3.14E-07 
PHB2 1.14 2.91E-07 
CCDC86 1.14 1.61E-08 
OTX1 1.14 9.29E-05 
PTPRN2 1.14 1.68E-06 
MYO10 1.13 1.20E-07 
ALAS1 1.13 3.87E-07 
HENMT1 1.13 5.29E-06 
CCNB1 1.12 6.30E-06 
OSBPL10 1.12 7.22E-05 
NR2F1 1.12 3.11E-06 
STAR 1.12 2.26E-05 
AEBP2 1.11 2.50E-06 
CWF19L1 1.11 2.12E-08 
SDHAF1 1.11 6.74E-04 
TPI1 1.11 8.93E-09 






RAD18 1.11 2.68E-08 
ZFAND5 1.10 7.37E-04 
MLXIPL 1.10 5.47E-05 
PCMTD2 1.10 3.01E-07 
CD320 1.10 8.43E-06 
WWP1 1.10 3.08E-03 
ZNF697 1.10 2.14E-07 
HMGN5 1.10 9.00E-08 
NQO1 1.09 6.10E-07 
REXO2 1.09 9.92E-06 
CD55 1.09 2.26E-08 
ADAT2 1.09 9.57E-06 
SDHAF2 1.09 2.27E-05 
ASS1 1.08 4.61E-04 
RRM2 1.08 1.41E-04 
AGPAT4 1.08 1.50E-05 
SYNPO 1.07 8.14E-07 
MTHFD1L 1.07 2.54E-08 
UBE2S 1.07 2.69E-05 
BBX 1.07 1.01E-06 
NAP1L5 1.07 1.21E-06 
CLCC1 1.06 1.10E-09 
HPDL 1.06 3.66E-08 
CEBPG 1.05 2.50E-04 
PTMS 1.05 9.93E-04 
MARCKS 1.05 2.58E-07 
C14orf93 1.04 3.48E-03 
NFATC2IP 1.04 1.83E-06 
LBR 1.04 2.99E-08 
ICE1 1.04 1.94E-07 
CDK4 1.04 1.18E-06 
MTRR 1.04 9.23E-08 
ARHGAP11A 1.03 1.68E-06 
STRAP 1.03 1.68E-08 
GPT2 1.03 7.55E-04 
GALK2 1.03 1.34E-08 
COX15 1.03 6.98E-07 
GSTM1 1.02 5.83E-07 







PARVB 1.02 1.44E-05 
TSR3 1.02 1.44E-05 
TRAF3IP3 1.02 4.58E-06 
C7orf50 1.02 2.32E-08 
SCO1 1.02 7.18E-08 
LARP4 1.02 1.53E-05 
CTTN 1.02 1.76E-05 
FOXM1 1.01 9.93E-06 
PLEKHF1 1.01 5.62E-07 
C12orf45 1.01 3.35E-05 
XPO5 1.00 1.64E-08 
SFT2D3 -1.00 2.10E-07 
MFSD1 -1.00 4.95E-07 
RAB2A -1.01 2.12E-08 
FAM174B -1.01 1.07E-05 
CTBS -1.01 1.80E-06 
PACS1 -1.01 2.46E-07 
MYO6 -1.01 1.21E-08 
DENND4B -1.01 4.08E-08 
HGSNAT -1.01 3.11E-07 
MAP3K20 -1.02 1.02E-07 
PTK2B -1.02 1.38E-06 
PHLPP1 -1.02 2.68E-08 
LAMC1 -1.02 1.25E-05 
RAB3IL1 -1.02 1.78E-06 
ITGB2 -1.02 3.82E-08 
ZBTB34 -1.02 1.48E-06 
POMP -1.02 4.32E-03 
NAGA -1.03 6.26E-09 
SYNJ2BP -1.03 8.59E-07 
APLP2 -1.03 7.81E-08 
IGSF10 -1.03 7.16E-04 
SRSF11 -1.03 3.91E-06 
GNAQ -1.04 6.13E-09 
GAMT -1.04 3.24E-05 
CHCHD7 -1.04 1.71E-04 
TALDO1 -1.05 8.87E-08 
DOCK1 -1.05 2.54E-06 






PBXIP1 -1.05 2.10E-07 
CTSV -1.05 3.74E-08 
VAT1L -1.06 3.19E-05 
GSTM3 -1.06 6.21E-08 
MAN2B1 -1.07 4.93E-08 
WDFY2 -1.08 4.51E-08 
NIPA2 -1.08 6.45E-05 
PTPRJ -1.08 3.92E-08 
EPB41L3 -1.09 3.25E-07 
PEX11B -1.09 3.90E-06 
DDAH2 -1.10 3.43E-09 
TTC28 -1.10 9.01E-04 
DACH1 -1.10 9.50E-08 
P2RY2 -1.10 4.28E-04 
ALYREF -1.11 8.38E-07 
SLC22A18 -1.11 6.03E-07 
FKBP9 -1.11 7.01E-09 
PLD4 -1.11 1.48E-07 
OSTC -1.11 3.96E-05 
PCYOX1L -1.11 3.60E-08 
ARC -1.11 2.86E-02 
BASP1 -1.11 3.26E-07 
PARVA -1.12 2.46E-07 
AGK -1.12 1.54E-09 
MYO1G -1.12 3.48E-04 
TNFAIP8 -1.12 2.33E-06 
TRMT2A -1.13 1.41E-08 
ORMDL1 -1.13 9.38E-05 
NUDT18 -1.13 1.10E-06 
UBA7 -1.14 1.08E-05 
KIAA1755 -1.14 1.33E-04 
FHL1 -1.15 1.52E-05 
FGD2 -1.15 1.80E-05 
GNPTG -1.15 1.69E-06 
MCOLN2 -1.15 1.02E-06 
SIPA1 -1.16 2.41E-08 
CSTB -1.16 1.97E-07 
CRYBG1 -1.16 7.60E-04 







RCSD1 -1.17 2.27E-06 
CD84 -1.17 6.09E-06 
SYK -1.17 1.70E-09 
TDRD7 -1.17 3.56E-07 
ANXA2 -1.18 2.51E-05 
SSH3 -1.18 3.54E-08 
SAMHD1 -1.18 8.15E-06 
MANBA -1.19 1.02E-07 
S100A6 -1.19 1.12E-03 
ALDH6A1 -1.19 2.70E-07 
GPR158 -1.19 1.15E-05 
IGFBP7 -1.19 1.06E-07 
AIF1 -1.19 8.89E-05 
SLC17A5 -1.20 3.59E-06 
SLC25A1 -1.20 9.25E-09 
ARHGEF10L -1.20 9.58E-07 
LGALS3 -1.20 2.45E-08 
PGD -1.20 3.85E-07 
NCOA4 -1.21 5.24E-04 
MICAL1 -1.21 1.79E-07 
SERPINB1 -1.21 1.36E-09 
SIRPB1 -1.22 1.14E-06 
AHNAK -1.22 1.16E-05 
PPT1 -1.23 1.77E-08 
ARHGAP26 -1.24 2.82E-06 
ECM1 -1.24 5.22E-06 
SLC27A3 -1.24 3.29E-07 
VPS35L -1.24 6.03E-09 
CYFIP2 -1.25 5.70E-06 
ARSD -1.25 4.63E-08 
CAPZA2 -1.26 3.77E-08 
DDT -1.26 2.68E-07 
NUDT7 -1.26 3.66E-08 
CCNE2 -1.27 1.55E-03 
PLBD1 -1.27 1.03E-04 
SDSL -1.27 9.08E-05 
HDAC9 -1.27 7.51E-07 
IRS2 -1.28 3.16E-06 






OTULINL -1.29 2.96E-07 
A2M -1.29 1.98E-05 
TRIM32 -1.30 2.34E-08 
PUDP -1.30 3.16E-08 
SIRT7 -1.31 2.23E-08 
EDEM1 -1.31 3.97E-07 
DPP7 -1.31 4.36E-08 
ANXA1 -1.31 3.82E-08 
ROBO1 -1.32 1.09E-06 
CD82 -1.32 3.87E-07 
CCNYL1 -1.32 8.38E-07 
RNH1 -1.33 1.01E-07 
EIF4A2 -1.33 1.12E-07 
NME3 -1.33 5.36E-09 
FMNL1 -1.33 1.24E-05 
COMT -1.35 6.13E-09 
TPM2 -1.36 4.68E-07 
HSP90AA4P -1.36 4.12E-05 
HSD17B8 -1.36 4.18E-05 
ARHGAP9 -1.36 2.26E-08 
MRC2 -1.36 3.68E-09 
PSTPIP2 -1.37 1.96E-08 
RUNX2 -1.37 4.95E-04 
BLVRA -1.37 2.68E-08 
IRF7 -1.38 2.59E-03 
TMEM59 -1.38 4.50E-06 
CPM -1.38 5.70E-08 
C8orf82 -1.39 2.33E-02 
NAXE -1.39 2.02E-09 
GCA -1.41 5.79E-05 
SGK3 -1.41 7.99E-09 
LAPTM5 -1.41 2.08E-04 
GATM -1.41 9.35E-08 
RUBCNL -1.41 6.55E-07 
FBXO6 -1.42 6.21E-08 
TGFBI -1.42 4.18E-09 
ERMP1 -1.43 8.60E-09 
ARSB -1.44 6.22E-09 







SDCBP -1.45 4.49E-09 
CAP1 -1.46 3.46E-09 
CAMK2D -1.46 4.20E-10 
HEXB -1.47 1.04E-08 
ENPP4 -1.47 5.99E-09 
CD1D -1.47 8.39E-05 
SRRM1 -1.49 4.88E-09 
GAA -1.49 1.65E-08 
ARHGAP1 -1.50 2.12E-09 
CHKB -1.50 3.46E-09 
KCTD12 -1.51 3.17E-07 
LRRC8C -1.51 3.01E-09 
NOMO1 -1.51 1.46E-06 
ITGAX -1.52 2.14E-05 
ZNF408 -1.52 5.36E-09 
STK32C -1.55 2.33E-04 
SERPINB10 -1.57 5.37E-07 
EMB -1.57 7.65E-09 
SHARPIN -1.58 4.77E-08 
TNFAIP8L2 -1.60 1.32E-07 
TLR2 -1.60 4.88E-09 
ERLIN2 -1.61 5.82E-10 
F13A1 -1.62 8.93E-09 
NAPRT -1.63 4.28E-10 
TBXAS1 -1.63 1.21E-06 
HCK -1.64 4.66E-06 
RET -1.64 1.05E-08 
NCF2 -1.65 1.60E-07 
GPX1 -1.65 3.21E-07 
FTL -1.67 3.81E-07 
GRN -1.67 6.13E-09 
AZU1 -1.67 8.67E-07 
HSD11B1 -1.68 2.93E-05 
HBE1 -1.68 1.17E-02 
PRTN3 -1.70 1.34E-05 
OCLN -1.70 3.91E-09 
LILRB4 -1.70 7.09E-07 
CTNNB1 -1.71 1.69E-07 






GLUD2 -1.71 6.94E-08 
DDAH1 -1.72 5.36E-09 
PRSS12 -1.72 1.48E-08 
GLO1 -1.72 3.83E-09 
THEMIS2 -1.73 2.24E-08 
TMOD2 -1.74 3.32E-03 
CBR4 -1.75 2.89E-08 
CD70 -1.75 7.41E-07 
MNDA -1.76 4.05E-08 
NDRG2 -1.76 2.16E-04 
CHID1 -1.77 4.20E-10 
S100A4 -1.77 6.44E-06 
FRY -1.78 3.44E-09 
RNASE2 -1.80 1.16E-06 
TYMP -1.81 1.56E-07 
MVP -1.81 1.52E-06 
RBKS -1.82 1.20E-08 
PECAM1 -1.82 1.08E-08 
IGF2BP2 -1.84 5.50E-11 
TSPO -1.85 1.03E-05 
TPP1 -1.85 2.45E-08 
PALM -1.85 1.26E-08 
WDFY1 -1.85 3.91E-09 
TRIM21 -1.88 2.63E-08 
CNN3 -1.88 2.03E-07 
ALDH3B1 -1.91 5.36E-09 
IFI16 -1.94 8.92E-06 
FILIP1L -1.95 6.03E-09 
HYAL3 -1.96 3.25E-06 
ACP3 -1.98 2.77E-07 
CA2 -2.00 2.27E-08 
RIPK3 -2.00 1.78E-07 
EGFL7 -2.01 3.45E-09 
NCAM2 -2.02 5.36E-09 
COL10A1 -2.04 2.32E-06 
GRAMD4 -2.06 2.02E-09 
SDC2 -2.08 1.06E-09 
LGALS1 -2.10 4.93E-08 







CTNND1 -2.13 1.42E-08 
LILRB2 -2.15 2.93E-06 
RASSF4 -2.19 1.68E-08 
NAIP -2.22 6.44E-07 
AKR1C2 -2.23 1.50E-05 
DSG2 -2.27 4.93E-08 
SLC44A1 -2.34 4.20E-10 
DOK3 -2.36 1.54E-08 
SERPINB8 -2.39 1.34E-08 
FBP1 -2.40 9.05E-10 
CD68 -2.40 2.79E-07 
CD38 -2.47 1.03E-09 
PRXL2A -2.49 2.98E-07 
NMNAT3 -2.54 5.84E-08 
CLEC4M -2.58 4.11E-06 
TSPYL5 -2.61 7.17E-09 
ALDH2 -2.62 8.16E-09 
COL9A2 -2.65 1.64E-08 
CKB -2.67 1.71E-08 






FCER1G -2.70 9.50E-08 
CEACAM6 -2.78 7.62E-09 
RENBP -2.83 6.26E-09 
DMRTA2 -2.85 2.70E-08 
NCAM1 -2.93 6.53E-08 
EPHX2 -2.99 1.06E-09 
ITGAL -3.02 1.88E-08 
KYNU -3.06 2.98E-07 
HK3 -3.10 2.42E-07 
VIM -3.33 2.58E-07 
S100A9 -3.42 1.39E-06 
CAV1 -3.45 1.22E-07 
ANXA6 -3.60 2.41E-08 
S100A8 -3.61 2.11E-07 
CGREF1 -3.79 1.83E-07 
CRABP1 -3.86 1.13E-06 






Proteins significantly changed more than 1.4-fold in lysates of GALC KO1 and KO2 versus mixed 
population EV control (EVm) THP-1 cells, quantified by whole cell proteomics (Benjamini-Hochberg 
adjusted q-value < 0.05)
 
Gene ID Log2 (fold change KO1/EVm) q-value 
Log2 (fold change 
KO2/EVm) q-value 
MSRB3 1.17 6.59E-03 1.11 3.63E-03 
ANPEP 1.02 1.46E-05 0.33 1.21E-02 
H1-0 0.97 1.07E-02 0.67 3.29E-02 
RASSF4 0.80 6.59E-03 0.70 5.85E-03 
MNDA 0.75 5.00E-03 0.62 6.17E-03 
NDST2 0.70 5.48E-03 0.38 4.29E-02 
CKAP4 0.61 2.19E-03 0.60 1.29E-03 
OCLN 0.55 4.38E-03 0.49 3.91E-03 
SASH3 0.51 7.65E-03 0.30 4.94E-02 
HDAC9 -0.51 3.01E-02 -0.75 2.50E-03 
NUDT12 -0.51 1.23E-03 -0.23 3.23E-02 
PRKACB -0.54 2.35E-04 -0.33 2.50E-03 
ISOC1 -0.54 2.78E-04 -0.21 3.13E-02 
PAIP2 -0.57 3.59E-02 -0.51 2.85E-02 
TSPYL5 -0.60 2.77E-02 -0.58 1.91E-02 
DDAH1 -0.66 1.37E-03 -0.69 7.75E-04 
SMN1 -0.74 3.40E-02 -0.74 1.58E-02 
SYNPO2 -0.79 1.16E-02 -0.60 2.07E-02 
ENPP4 -0.94 4.43E-05 -0.54 1.29E-03 
GALC -1.03 9.88E-03 -0.75 2.01E-02 
 
 
